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WELCOME	ADDRESS	
	
Dear	colleagues,	
	
It	 is	 our	 great	 pleasure	 to	 welcome	 you	 to	 the	 18th	 Symposium	 on	 Radiopharmacy	 and	 Radio-
pharmaceuticals	in	Salzburg,	Austria,	located	in	equal	distance	from	the	major	Austrian	Universities	Graz,	
Innsbruck	and	Vienna.	The	symposium	is	jointly	organized	by	the	Austrian	community	of	Pharmacists	and	
Chemists	being	involved	in	Radiopharmacy,	Medicinal	Radiochemistry	and	Radiopharmaceutical	Research	
also	 representing	 different	 aspects	 of	 our	 field	 from	 CNS	 applications	 to	 therapeutic	 radio-
pharmaceuticals,	11C	and	18F-chemistry	 to	 radiometals	as	well	 as	 from	research	and	development	 to	
daily	radiopharmacy	practice.	
	
Salzburg	is	a	small	city	with	a	long	cultural	history,	being	strongly	connected	with	Mozart,	the	“Sound	of	
Music”	and	the	annual	Music	Festival.	The	famous	Fortress,	the	baroque	Cathedral	and	church	makes	it	a	
UNESCO	World	Heritage	Site,	its	attractions	being	most	famous	in	the	world.	
	
The	Symposium	Venue	is	right	in	the	centre	of	Salzburg	and	allows	you	to	stay	at	the	same	location	with	
your	colleagues	for	discussion	and	exchange.	It	is	in	walking	distance	to	all	important	sights	of	the	city,	
the	train	station	and	the	local	airport.	Excellent	train	connections	to	Munich	and	Vienna	airport	allow	you	
to	reach	our	symposium	easily	from	all	over	the	world.	Besides	an	interesting	scientific	programme	we	
will	also	surprise	you	with	some	nice	social	events	giving	you	a	flavour	of	Austrian	history,	culture	and	
food.	
	
We	invite	you	to	come	to	Salzburg	for	this	new	edition	of	ESRR	in	2016	and	are	really	looking	forward	to	
welcome	you.	
	
Clemens	Decristoforo	
Herbert	Kvaternik	
Markus	Mitterhauser	
Wolfgang	Wadsak	
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SCIENTIFIC	COMMITTEE	
Martin	Behe		 Switzerland	
Petra	Kolenc-Peitl		 Slovenia	
Valentina	Ferrari		 United	Kingdom	
Antony	Gee		 United	Kingdom	
	
LOCAL	ORGANISING	COMMITTEE	
Clemens	Decristoforo		 Medical	University	Innsbruck,	Austria		
Herbert	Kvaternik		 Medical	University	Graz,	Austria	
Markus	Mitterhauser		 Medical	University	Vienna,	Austria	
Wolfgang	Wadsak		 Medical	University	Vienna,	Austria	
	
ORGANISING	SECRETARIAT	
EANM	Executive	Secretariat	
Andreas	Felser	
Petra	Neubauer	
Schmalzhofgasse	26	
1060	Vienna,	AUSTRIA	
Tel.:		 +43-(0)	890	44	27	
Fax:		 +43-(0)890	44	27	-	9	
Email:		 office@esrr.info	
URL:		 www.esrr.info	
	
CONGRESS	VENUE	
Wyndham	Grand	Salzburg	Conference	Center	
Fanny-von-Lehnert-Str.	7	
5020	Salzburg	
Salzburg	(Austria)	
Tel.:	 +43	(0)662	4688-0	
URL:	 http://www.wyndhamgrandsalzburg.com/	
	
	
	
	
The	ESRR	is	organized	in	cooperation	with	the		
International	Atomic	Energy	Agency	
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EXHIBITORS	&	SPONSORS		
We	would	like	to	thank	all	exhibitors	and	sponsor	of	the	ESRR	2016	for	their	support!	
	
ABX	advanced	biochemical	compounds	
Biomedizinische	Forschungsreagenzien	GmbH	
Bayer	Healthcare	
DSD	Pharma	
Eckert	&	Ziegler	Europe	GmbH	
Elysia	Germany	GmbH		
GE	Healthcare			
IASON	GmbH	
IBA	SA	(ION	BEAM	APPLICATION)	
IRE	ELIT	
ITG	Isotope	Technologies	Garching	GmbH	
Jiangsu	Huayi	Technology	Co,	Ltd.		
Ridgeview	Instruments	AB	
Rotem	GmbH	
Scintomics	GmbH	
Siemens	Healthcare	GmbH	 	
Trasis	SA	
Von	Gahlen	Nederland	B.V.	
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GENERAL	INFORMATION	(A-Z)	
	
Airport	&	Arrival	Information	
The	airport	of	Salzburg	is	located	about	four	kilometers	from	the	city	center.	It	takes	15	minutes	
to	reach	the	historic	city	center	by	taxi	or	public	bus.	Salzburg	Airport	is	the	arrival	airport	for	
many	 international	airlines	and	 low-cost	 carriers.	Direct	 flights	 to	Salzburg	are	available	 from	
Berlin,	 Düsseldorf,	 Hannover,	 Hamburg,	 Cologne/Bonn,	 Frankfurt,	 Leipzig-Halle,	 Amsterdam,	
Vienna,	London,	Manchester,	Stockholm,	Zurich	and	other	cities.A	convenient	airport	shuttle	also	
takes	passengers	from	Munich	Airport	to	Salzburg.	Salzburg	Train	Station	is	a	15	minutes'	walk	
from	the	historic	city	center.	Here	you	can	transfer	to	a	trolley	bus,	regional	bus,	local	train	or	
suburban	train.	As	a	border	station	to	Germany,	Salzburg	has	outstanding	Eurocity,	Intercity	and	
ICE	connections.	Salzburg's	new	suburban	railroad	connects	the	city	with	the	surrounding	towns.	
Salzburg	is	at	the	hub	of	the	European	highway	network:	the	A1	Vienna-Salzburg,	the	A8	Munich–
Salzburg	and	the	A10	Villach–Salzburg	converge	in	Salzburg.	Please	remember	to	purchase	a	toll	
sticker	if	you	are	driving	to	Salzburg.	
	
Certificate	of	Attendance	
Upon	arrival	all	registered	delegates	will	receive	a	certificate	of	attendance.	
	
Climate	
The	daytime	temperatures	in	April	linger	between	4°	-	14°	Celsius.	
	
Credit	cards	
All	 major	 credit	 cards,	 including	 Eurocard,	 Diners,	 VISA	 and	 Mastercard	 are	 accepted	 in	
restaurants,	hotels,	shopping	centers	and	stores.	Travel	cheques	can	be	cashed	in	most	banks	
and	exchange	offices.	
	
Currency	
The	official	currency	in	Austria	is	EUR	(€).	You	can	exchange	your	currency	without	any	limits	for	
total	amount	at	all	banks	and	exchange	offices	in	Vienna.	When	exchanging	your	currency,	you	
will	need	your	passport	or	official	ID-card.	If	you	do	not	have	it	with	you,	the	bank	may	refuse	
to	exchange	your	currency	
Electricity	
The	 power	 supply	 in	 Austria	 is	 220/240	 Volt-current.	 Most	 electric	 outlets	 adhere	 to	 the	
continental	standard	(Schuko).	Appliances	from	North	America	require	a	transformer	and	British	
appliances	require	an	adaptor	for	the	two-pin	sockets	in	use	in	Austria.	
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Museums	
There	is	a	large	variety	of	museums	in	Salzburg.	For	prices	and	opening	hours	please	refer	to	the	
hotel	 reception	 or	 any	 tourist	 information.	 Museums	 and	 exhibitions	 are	 usually	 closed	 on	
Monday.	
	
Restaurants	&	Nightlife	
There	is	a	large	choice	of	restaurants	in	Salzburg,	offering	various	kinds	of	local	or	international	
dishes.	Many	of	fine	dining	establishments	are	located	in	the	city	of	Salzburg.	Salzburg	is	also	a	
trendsetter	when	it	comes	to	organic	food:	nearly	38	%	of	the	agricultural	enterprises	are	organic	
farmers.	 Even	 the	 simpler	 restaurants	 serve	 fine	 delicacies	 from	 the	 Salzburg	 region.Four	
extraordinary	breweries	in	the	city	of	Salzburg	invite	guests	to	enjoy	a	hearty	snack	in	a	convivial	
atmosphere.	Favorite	places	to	grab	a	bite	in	between	are	the	delicatessen	shops	in	Salzburg's	
Old	City,	 the	 stands	at	 the	Green	Market	or	one	of	 the	weekly	 farmers'	markets	on	Mirabell	
Square	or	Papageno	Square.	
	
Secretariat	&	Registration	desk	
The	registration	desk	will	be	open:	
Thursday,	April	07,	2016	 14:00-20:00	
Friday,	April	08,	2016		 08:30-18:00	
Saturday,	April	09,	2016	 08:00-17:30	
Sunday,	April	10,	2016	 08:30-13:30	
	
Shopping	
Salzburg	is	an	ideal	destination	to	shop	for	a	wide	variety	of	items	catering	to	everybody’s	tastes	
and	wishes.	A	unique	shopping	experience	awaits	you	in	Salzburg.	A	variety	of	shops	can	be	found	
in	the	Old	City	–	on	Getreidegasse,	Judengasse	and	in	the	traditional	passageways	–	 including	
long-established	 shops,	 international	 chains	 and	 small	 boutiques.	 Salzburg	 also	 has	 the	most	
modern	and	attractive	shopping	center	in	the	world:	the	award-winning	Europark	has	130	stores	
for	endless	shopping.	Stores	in	Salzburg	are	usually	open	from	Monday	to	Friday	from	10:00	a.m.	
to	6:00	p.m.	and	Saturdays	from	10:00	a.m.	to	5:00	p.m.		Some	already	open	at	8:00	a.m.	or	close	
for	a	1	or	2-hour	lunch	break.		A	few	shops,	such	as	souvenir	shops,	are	also	open	on	Sundays	
and	holidays.	The	shops	at	the	Europark	are	open	from	Monday	to	Thursday	from	9:00	a.m.	to	
7:30	p.m.,	on	Friday	from	9:00	a.m.	to	9:00	p.m.	and	on	Saturday	from	9:00	a.m.	to	6:00	p.m.	
	
Taxes	&	Tipping	
The	standard	tax	rate	is	20%,	however,	some	services	such	as	hotel,	food	and	transport	have	a	
reduced	 rate	 of	 10%.	 Most	 services	 do	 not	 include	 tipping.	 In	 higher	 class	 restaurants	 it	 is	
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common	to	give	up	to	10%	of	the	total.	For	any	other	services	(taxi,	restaurants,	hotel)	it	is	up	to	
you	how	much	you	want	give.	
	
Time	zone	
Salzburg	is	6	hours	ahead	of	US	–	Eastern	Standard	Time	and	1	hour	ahead	of	Greenwich	Mean	
Time	(GMT).	
	
Visa		
All	visitors	entering	Austria	must	possess	valid	passports.	For	citizens	from	the	European	Union	
Member	countries	a	valid	identity	card	is	sufficient.	
PLEASE	 CHECK	 THE	 CURRENT	 VISA	 REQUIREMENTS	 WITH	 THE	 NEAREST	 AUSTRIAN	
CONSULATE/EMBASSY	IN	YOUR	COUNTRY	BEFORE	YOUR	DEPARTURE	TO	AUSTRIA!	
	
Delegate	Registration	Fees	include:	
• Access	to	all	scientific	session		
• Access	to	poster	exhibition	
• Access	to	industry	exhibition	
• Free	copy	of	all	congress	documentation	
• Certificate	of	attendance	
• Meals	-	April	08,	09	&	10,	2016	
• Coffee	breaks	
• Invitation	to	the	opening	ceremony	and	welcome	reception	–	April	07,	2016	
• Invitation	to	the	closing	ceremony–	April	10,	2016	
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PROGRAMME	OVERVIEW	
	
THURSDAY,	APRIL	07,	2016	
19:30-19:50	 	 Opening	Ceremony	&	Welcome	Meeting		
19:50-20:25	 	 Welcome	Lecture	–	“CSI	Mozart”	
20:30-22:00	 	 Welcome	Reception		
	
FRIDAY,	APRIL	08,	2016	
08:30-10:15	 	 Session	I	–	METs	&	PEPs	
10:15-10:45	 	 Poster	Viewing	Session		
Coffee	Break	
10:45-12:45	 	 Session	II	–	1+8=9	18	9F	
12:45-14:15	 	 Lunch	Break	
14:15-15:50	 	Session	III	–	The	Need	to	Treat	
15:50–16:30	 	 Poster	Viewing	Session		
Coffee	Break	
16:30-18:00	 	 Session	IV	–	Small	Pioneers	
	
SATURDAY,	APRIL	09,	2016	
08:30-10:15	 	 Session	V	–	PET	–	Prostate	&	Endocrinology	Targeting	
10:15-10:45	 	 Poster	Viewing	Session	
	 	 	 Coffee	Break	
10:45-12:45	 	 Session	VI	–	Brain	D/Train	
12:45-13:50	 	 Lunch	Break	
13:50-14:15	 	 The	host	special:	Radiolabelled	flies	
14:15-15:50	 	Session	VII	–	Incredible	Artefacts	–	Excellent	Activities	(IAEA)	
15:50-16:30	 	 Poster	Viewing	Session	
Coffee	Break	
16:30-17:30	 	 Session	VIII	–	Inside	Strasbourg	
	
SUNDAY,	APRIL	10,	2016	
08:30-10:05	 	 Session	IX	–	Gee	m.p.	
10:30-11:00	 	 Poster	Viewing	Session	
Coffee	Break	
11:00-12:35	 	 Session	X	–	Gal-Pals	
12:35-12:45	 	 Symposium	Overview	&	Closing	Remarks	
12:45	 	 	 Farewell	Lunch	
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HIGHLIGHTS	
Invited	Lectures	
	
“CSI	Mozart”	 W.	Parson,	Austria	
The	isotope	revolution	that	can	change	imaging	and	therapy	 M.	Jensen,	Denmark	
Speed	matters!	Shortening	time	from	EOB	to	product	release	 W.	Wadsak,	Austria	
Radionuclide	therapy:	do	we	understand	what	we	are	doing?	-	
A	radiobiology	perspective	 J-P.	Pouget,	France	
Good	or	bad?	Why	ethics	in	animal	studies	matter?	 S.	Heskamp,	The	Netherlands	
Pitfalls	in	animal	studies	 M.	Martic-Kehl,	Switzerland	
PSMA-targeted	low-molecular	weight	radioligands:		
Their	design	for	diagnosis	and	therapy	of	prostate	cancer	 K.	Kopka,	Germany	
Molecular	future	in	psychiatry	 R.	Lanzenberger,	Austria	
What	you	see	is	not	what	you	should	treat:	Image	artifacts	–	The	don´ts		 T.	Beyer,	Austria	
Molecular	future	in	psychiatry	 R.	Lanzenberger,	Austria	
How	to	use	the	Eur.	Pharmacopoeia	and	how	to	contribute	 E.	Pel,	France	
New	monographs	and	chapters	in	the	Eur.	Pharmacopoeia	 T.	Kroon,	The	Netherlands	
Validation	&	Qualification:	a	GMP	burden	or	an	opportunity?	 S.	Todde,	Italy	
Extemporaneous	Preparation	of	Radiopharmaceuticals	 C.	Decristoforo,	Austria	
Why	are	investors	not	interested	in	my	radiotracers?	 R.	Zimmermann,	France	
	
Invited	Lectures	are	marked	within	the	scientific	programme	in	light	blue.		
	
	
	
	
	
	
	
	
	
	
SCIENTIFIC	PROGRAMME	
Thursday,	April	07,	2016	
19:30		Opening	Ceremony	&	Welcome	Meeting	 M.	Behe,	Switzerland	/	M.	Mitterhauser,	Austria	
19:40	 OP01		 Welcome	Lecture	 C.	Decristoforo,	Austria	
19:50	 OP01		 “CSI	Mozart”	 W.	Parson,	Austria	
	
20:30		Welcome	Reception	and	cocktail	 		
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Friday,	April	08,	2016	
08:30	 Session	I	–	METs	&	PEPs	 E.	von	Guggenberg,	Austria	/	R.	Mikolajczak,	Poland	
08:30	 OP02	 The	isotope	revolution	that	can	change	imaging	and	therapy	 M.	Jensen,	Denmark	
09:15	 OP03	 Selective	Extraction	of	Medically-Related	Radionuclides	from	Proton-	
	 	 Irradiated	Thorium	Targets	 V.	Radchenko,	USA	
09:27	 OP04	 Comparison	of	[68Ga]FSC(succ-RGD)3	and	[68Ga]NODAGA-RGD	for		
	 	 PET	imaging	of	αvβ3	integrin	expression	 C.	Zhai,	Austria	
09:39	 OP05	 A	new	NPY-Y1R	targeting	peptide	for	breast	cancer	PET	imaging	 B.	Guérin,	Canada	
09:51	 OP06	 The	influence	of	multivalency	on	CCK	2	receptor	targeting	 D.	Summer,	Austria	
10:03	 OP07	 SPECT	Imaging	of	αvβ3	Expression	by	[99mTc(N)PNP43]-		
	 	 Bifunctional	Chimeric	RGD	Peptide	not	Cross-Reacting	with	αvβ5	 C.	Bolzati,	Italy	
	
10:15	 Coffee	Break	&	Poster	Viewing	
	
10:45	 Session	II	–	1+8=9	18	9F	 M.	Jensen,	Denmark	/	T.	Mindt,	Switzerland	
10:45	 OP08	 Speed	matters!	Shortening	time	from	EOB	to	product	release	 W.	Wadsak,	Austria	
11:30	 OP09	 New	dienophiles	for	the	inverse-electron-demand	Diels-Alder		
	 	 reaction	and	for	pretargeted	PET	imaging.	 E.	Billaud,	Belgium	
11:42	 OP10	 New	complexing	agent	for	Al18F-labelling	of	heat-sensitive	biomolecules:	
	 	 Synthesis	and	preclinical	evaluation	of	Al18F-RESCA1-HSA	 F.	Cleeren,	Belgium	
11:54	 OP11	 A	novel	versatile	precursor	efficient	for	F-18	radiolabelling	via	click-chemistry	 B.	Lugatoa,	Italy	
12:06	 OP12	 A	general	applicable	method	to	quantify	unidentified	UV	impurities	
	 	 in	radiopharmaceuticals	 R.	Klok,	The	Netherlands	
12:18	 OP13	 Development	of	[18F]Fluoro-C-glycosides	to	radiolabel	peptides		
	 	 for	PET	application	 C.	Collet,	France	
12:30	 OP14	 A	Microfluidic	Approach	for	the	68Ga-labeling	of		
	 	 PSMAHBED-CC	and	NODAGA-RGD	 S.	Pfaff,	Austria	
	
12:45	 Lunch	Break	 	
	
14:15	 Session	III	–	The	Need	to	Treat	 M.	Mitterhauser,	Austria	/	K.	Kopka,	Germany	
14:15	 OP15	 Radionuclide	therapy:	do	we	understand	what	we	are	doing?		
	 	 A	radiobiology	perspective	 J-P.	Pouget,	France	
15:00	 OP16	 Surprising	reactivity	of	astatine	in	the	nucleophilic	substitution		
	 	 of	aryliodonium	salts:	application	to	the	radiolabeling	of	antibodies	 F.	Guérard,	France	
15:12	 OP17	 64Cu-NOTA-pertuzumab	F(ab')2	fragments,	a	second-generation	probe		
	 	 for	PET	imaging	of	the	response	of	HER2-positive	breast	cancer	to		
	 	 trastuzumab	(Herceptin)	 K.	Lam,	Canada	
15:24	 OP18	 Development	of	radiohalogenated	analogues	of	a	avb6-specific	peptide		
	 	 for	high	LET	particle	emitter	targeted	radionuclide	therapy	of	cancer.	 S.	Paillas,	UK	
15:36	 OP19	 Ligand	Specific	Efficiency	(LSE)	as	a	guide	in	tracer	optimization	 E.	Briard,	Switzerland	
	
15:50	 Coffee	Break	&	Poster	Viewing	Session		
	
16:30	 Session	IV	–	Small	Pioneers	 M.	Behe,	Switzerland	/	P.	Kolenc	Peitl,	Slovenia	
17:00	 OP20	 Good	or	bad?	Why	ethics	in	animal	studies	matter?	 S.	Heskamp,	The	Netherlands	
17:15	 OP21	 Pitfalls	in	animal	studies	 M.	Martic-Kehl,	Switzerland	
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Saturday,	April	09,	2016	
08:30	 Session	V	–	PET	–	Prostate	&	Endocrinology	Targeting	 P.	Elsinga	/	P.	Laverman,	The	Netherlands	
08:30	 OP22	 PSMA-targeted	low-molecular	weight	radioligands:		
	 	 Their	design	for	diagnosis	and	therapy	of	prostate	cancer	 K.	Kopka,	Germany	
09:15	 OP23	 The	radiosynthesis	of	an	18F-labeled	triglyceride,	developed		
	 	 to	visualize	and	quantify	brown	adipose	tissue	activity	 M.	Bauwens,	The	Netherlands	
09:27	 OP24	 Influence	of	the	fluorescent	dye	on	the	tumor	targeting		
	 	 properties	of	dual-labeled	HBED-CC	based	PSMA	inhibitors	 A-C.	Baranski,	Germany	
09:39	 OP25	 [18F]MEL050	as	a	melanin	PET	tracer	:	fully	automated	
	 	 radiosynthesis	and	evaluation	for	the	detection	of	pigmented		
	 	 melanoma	in	mice	pulmonary	metastases	 N.	Rizzo-Padoin,	France	
09:51	 OP26	 Design	and	Preclinical	Evaluation	of	Novel	Radiofluorinated		
	 	 PSMA	Targeting	Ligands	Based	on	PSMA-617	 J.	Cardinale,	Germany	
10:03	 OP27	 A	Novel	Radiolabeled	Peptide	for	PET		
	 	 Imaging	of	Prostate	Cancer:	64Cu-DOTHA2-PEG-RM26	 B.	Guérin,	Canada	
	
10:15	 Coffee	Break	&	Poster	Viewing	Session		
	
10:45	 Session	VI	–	Brain	D/Train	 A.D.	Windhorst,	The	Netherlands	
10:45	 OP28	 	Molecular	future	in	psychiatry	 R.	Lanzenberger,	Austria	
11:30	 OP29	 Biodistribution	of	[18F]Amylovis®,	a	new	radiotracer		
	 	 PET	imaging	of	β-amyloid	plaques	 L.	Fernández	Maza,	Spain	
11:42	 OP30	 Synthesis	and	preclinical	evaluation	of	[11C]-BA1	PET		
	 	 tracer	for	the	imaging	of	CSF-1R	 B:	Attili,	Belgium	
11:54	 OP31	 In	vivo	imaging	of	the	MCHR1	in	the	ventricular	system	via	[18F]FE@SNAP	 C.	Philippe,	Austria	
12:06	 OP32	 Synthesis	of	the	first	carbon-11	labelled	P2Y12	receptor	antagonist	for		
	 	 imaging	the	anti-inflammatory	phenotype	of	activated	microglia	 B.	Janssen,	The	Netherlands	
12:18	 OP33	 Radiosynthesis	of	a	selective	HDAC6	inhibitor		
	 	 [11C]KB631	and	in	vitro	and	ex	vivo	evaluation.	 K.	Vermeulen,	Belgium	
12:30	 OP34	 Improving	metabolic	stability	of	fluorine-18	labelled		
	 	 verapamil	analogues	 R.	Raaphorst,	The	Netherlands	
	
12:45	 Lunch	Break	
	
13:50	 The	host	special:	Radiolabelled	flies	 C.	Decristoforo	/	H.	Kvaternik,	Austria	
	
14:15	 Session	VII	–	Incredible	Artefacts	–		
	 Excellent	Activities	(IAEA)	 J.	Osso	Junior,	Austria	/	S.	Rubow,	South	Africa	
14:15	 OP35	 What	you	see	is	not	what	you	should	treat:	Image	artifacts	–	The	don´ts	 T.	Beyer,	Germany	
15:00	 OP36	 Development	of	a	novel	PET	tracer	for	the	
	 	 activin	receptor-like	kinase	5	 L.	Rotteveel,	The	Netherlands	
15:12	 OP37	 SPECT	Imaging	and	Biodistribution	Studies	of	111In-EGF-Au-PEG	Nanoparticles	In	Vivo	 L.	Song,	UK	
15:24	 OP38	 Melanoma	targeting	with	[99mTc(N)(PNP3)]-labeled		
	 	 NAPamide	derivatives:	preliminary	pharmacological	studies	 C.	Bolzati,	Italy	
15:36	 OP39	 [68Ga]NODAGA-RGD:	cGMP	synthesis	and	data	from	a	phase	I	clinical	study	 R.	Haubner,	Austria	
	
15:50	 Coffee	Break	&	Poster	Viewing	
	
16:30	 Session	VIII	–	Inside	Strasbourg	 P.	Bremer,	Norway	/	R.	Pickett,	UK	
16:30	 OP40	 How	to	use	the	Eur.	Pharmacopoeia	and	how	to	contribute	 E.	Pel,	France	
16:40	 OP41	 New	monographs	and	chapters	in	the	Eur.	Pharmacopoeia	 T.	Kroon,	The	Netherlands	
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Sunday,	April	10,	2016	
08:30	 Session	IX	–	Gee	m.p.	 A.	Gee,	UK	/	P.	Kolenc	Peitl,	Slovenia	
08:30	 OP42	 Validation	&	Qualification:	a	GMP	burden	or	an	opportunity?	 S.	Todde,	Italy	
09:00	 OP43	 Validation	Quiz	 A.	Gee,	UK	&	P.	Kolenc	Peitl,	Slovenia	
09.40	 OP44	 Implementation	of	a	GMP-grade	radiopharmacy	facility	in	Maastricht	 M.	Bauwens,	The	Netherlands	
09.52	 OP45	 Setting	up	a	GMP	production	of	a	new	radiopharmaceutical	 S.	Forsback,	Finland	
10:05	 OP46	 Extemporaneous	Preparation	of	Radiopharmaceuticals	 C.	Decristoforo	&	H.	Kvaternik,	Austria	
	
10:30	 Coffee	Break	&	Poster	Viewing	
	
11:00	 Session	X	–	Gal-Pals	 E.	Janevik,	Republic	of	Macedonia	/	J.	Sosabowski,	UK	
11:00	 OP47	 Why	are	investors	not	interested	in	my	radiotracers?	 R.	Zimmermann,	France	
11:45	 OP48	 In	Vitro	and	In	Vivo	Evaluation	of	68-Gallium	Labeled	Fe3O4-DPD		
	 	 Nanoparticles	as	Potential	PET/MRI	Imaging	Agents.	 M.	Karageorgou,	Greece	
11:57	 OP49	 Fast	PET	imaging	of	inflammation	using	68Ga-citrate	with		
	 	 Fe-containing	salts	of	hydroxy	acids	 A.S.	Lunev,	Russia	
12:09	 OP50	 68Ga	labelled	siderophore	for	detection	of	Pseudomonas	infections	 M.	Petrik,	Czech	Republic	
	
12:35	 Symposium	Overview	&	Closing	Remarks		
	
12:45	 Farewell	Lunch	 Congress	venue	
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OP03	
Selective	Extraction	of	Medically-Related	Radionuclides	from	Proton-Irradiated	Thorium	Targets	
V.	 Radchenko1,	 J.W.	 Engle1,	 C.	 Roy2,	 J.	 Griswold2,	 M.F.	 Nortier1,	 E.R.	 Birnbaum1,	 M.	 Brugh1,	 S.	
Mirzadeh2,	K.	D.	John1,	M.E.	Fassbender1	
1	Los	Alamos	National	Laboratory,	Los	Alamos,	New	Mexico,	USA	
2	Oak	Ridge	National	Laboratory,	Oak	Ridge,	Tennessee,	USA		
	
Background:	Clinicians	rely	on	nuclear	medicine	for	the	treatment	of	numerous	diseases	[1,	2]	impacting	
millions	of	patients	annually.	Recently,	Targeted	Radiotherapy	(TR)	has	been	successfully	advanced	with	
the	 US	 FDA	 approval	 of	 several	 radionuclide	 based	 drugs	 [3].	 Combinations	 of	 several	 types	 of	
radionuclide	emissions	for	therapy	(i.e.,	α-therapeutic	agent	combined	with	β-	therapeutic)	could	lead	to	
even	more	effective	treatment	options	[4].	One	of	the	limiting	factors	in	the	development	of	TR	as	a	widely	
adopted	 treatment	option	 is	 the	availability	of	 select	 radionuclides	with	optimum	emission	properties	
(both	 in	 volume	 and	 periodicity	 of	 delivery),	 which	 poses	 a	 challenge	 due	 to	 the	 fact	 that	 different	
radionuclides	 typically	 require	 different	 target	 materials	 and/or	 nuclear	 reaction	 pathways	 for	 their	
formation.	Materials	&	Methods:	We	already	published	a	successful	strategy	for	the	isolation	of	225/227Ac	
from	 irradiated	 thorium	 targets	 [5].	 We	 also	 published	 the	 recovery	 of	 Pa	 isotopes	 [6]	 from	 proton	
irradiated	thorium.	In	this	work,	we	propose	the	isolation	of	several	other	medically	related	radionuclides	
namely	 103Ru,	 223/225Ra,	 111Ag	 from	 the	 same	 target	 material.	 Results:	 Several	 methods	 based	 on	 ion	
exchange	chromatography	and	solid	phase	extraction	show	promise	for	the	co-extraction	of	103Ru	and	Ra	
isotopes	from	thorium	irradiated	targets.	Anion	exchange	in	HCl	media	proved	to	be	an	efficient	method	
for	the	isolation	of	103Ru,	while	a	combination	of	cation	exchange	resin	/	citrate	and	DGA	resin/HNO3	is	
suitable	 for	 Ra	 isotopes	 separation.	 Discussion/Conclusion:	 Production	 yields	 for	 the	 proposed	
radionuclides	were	evaluated	by	comparison	of	actual	product	yields	with	calculated	(predicted)	yields.	
Radiochemical	strategies	for	co-extraction	of	103Ru	and	223/225Ra	isotopes	based	on	ion	exchange	and	solid	
phase	extraction	chromatography	will	be	discussed.	References:	1.		Stigbrand,T.	et	al.		Springer	2008,	ISBN	
978-1-4020-8696-0.,	2.	Fahey,F.	et	al.	J.	Nucl	Med.	2014	55(2):	337.	3.www.fda.gov	4.Dash	A.,	et	al.,	Curr	
Radiopharm.	2013	6(3):	152.		5.	Radchenko	V.	et	al.,	Chromatography	A,		2014	1380:	55.6.Radchenko	V.et	
al.	accepted	Radiochimica	Acta,	Oct	2015	
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OP04	
Comparison	 of	 [68Ga]FSC(succ-RGD)3	 and	 [68Ga]NODAGA-RGD	 for	 PET	 imaging	 of	 αvβ3	 integrin	
expression	
Chuangyan	Zhai,1	Gerben	M.	Franssen,2	Milos	Petrik,3	Peter	Laverman,2	Clemens	Decristoforo1	
1	Department	of	Nuclear	Medicine,	Medical	University	Innsbruck,	Innsbruck,	Austria	
2	 Department	 of	 Radiology	 &	 Nuclear	 Medicine,	 Radboud	 University	 Medical	 Center,	 Nijmegen,	 The	
Netherlands		
3	Institute	of	Molecular	and	Translational	Medicine,	Faculty	of	Medicine	and	Dentistry,	Palacky	University,	
Olomouc,	Czech	Republic	
	
Background:	The	arginine-glycine-aspartic	(RGD)	peptide	sequence	serves	as	a	high-affinity	antagonist	of	
the	 integrin	 αvβ3	 receptor	 that	 plays	 an	 important	 role	 in	 tumor	 angiogenesis.	 Recently	we	 reported	
[68Ga]FSC(succ-RGD)3,	a	trimeric	RGD	peptide,	exhibited	excellent	targeting	properties	for	αvβ3	 integrin	
expression	and	significant	improved	tumor	uptake	compared	to	monomeric	[68Ga]NODAGA-RGD.(1)	Here	
we	report	the	PET	 imaging	properties	of	 [68Ga]FSC(succ-RGD)3	 in	different	xenograft	 tumor	model	and	
compared	 them	 with	 [68Ga]NODAGA-RGD.	 Materials	 &	 Methods:	 The	 PET	 imaging	 properties	 of	
[68Ga]FSC(succ-RGD)3	were	studied	in	nude	mice	bearing	M21	human	melanoma	xenografts	and	human	
glioblastoma	 U87MG	 xenograft	 tumor.	 A	 parallel	 PET	 imaging	 of	 68GaNODAGA-RGD	 	 in	 same	mouse	
bearing	 	 U87MG	 xenograft	 tumor	 was	 performed	 as	 a	 comparison.	Results	 :The	 static	 PET	 image	 of	
[68Ga]FSC(succ-RGD)3	 in	 nude	 mice	 showed	 highly	 visualized	 tumors	 of	 M21	 (positive)	 whereas	
nonvisualized	tumor	of	M21-L	(negative)	tumor	xenografts	1	h	post	injection	confirming	receptor-specific	
activity	 accumulation.	 The	 dynamic	 PET	 images	 of	 [68Ga]FSC(succ-RGD)3	 showed	 rapid	 clearance	 of	
[68Ga]FSC(succ-RGD)3	from	the	circulation	while	the	tumor	remained	clearly	visible.	A	direct	comparison	
of	 [68Ga]FSC(succ-RGD)3	with	 [68Ga]NODAGA-RGD	 in	nude	mice	bearing	U87MG	xenograft	 tumor	using	
PET/CT	resulted	comparable	target/background	ratio	(tumor/kidneys	ratio	=	1.3	and	1.6,	tumor/muscle	
ratio	=	4.9,	5,	respectively,	90	min	post	injection).	The	time	activity	curves	from	dynamic	PET	data	showed	
an	increase	of	the	activity	concentration	of	[68Ga]FSC(succ-RGD)3	in	tumor	firstly,	then	remained	almost	
constant	whereas	that	of	[68Ga]NODAGA-RGD	decreased	quickly.	The	significant	enhanced	tumor	uptake	
(3.8	vs.	1.6	%	ID/g)	in	addition	to	the	slower	washout	rate	from	tumor	for	[68Ga]FSC(succ-RGD)3	not	only	
allows	the	PET	imaging	at	late	time	points,	but	also	provides	the	possibility	to	achieve	the	same	image	
contrast	using	 less	radioactivity	as	well	as	detect	 low-level	 integrin	expression.	Discussion/Conclusion:	
[68Ga]FSC(succ-RGD)3	shows	the	advantages	in	the	respect	of	delayed	imaging,	reduced	radiation	dose	as	
well	 as	 monitoring	 low-level	 integrin	 expression	 in	 tissues	 in	 comparison	 to	 [68Ga]NODAGA-RGD,	
therefore	it	is	a	promising	agent	for	integrin	αvβ3	receptor	imaging.	References	:	1-	Knetsch	PA,	Zhai	C,	
Rangger	C,	et	al.	[2015]	Nucl	Med	Biol,	42:115-122.	
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OP05	
A	new	NPY-Y1R	targeting	peptide	for	breast	cancer	PET	imaging	
Ait-Mohand	Samia1,	Dumulon-Perreault	Véronique2,	Guérin	Brigitte1,2	
1	Département	de	médecine	nucléaire	et	radiobiologie,	Faculté	de	médecine	et	sciences	de	la	
santé,	Université	de	Sherbrooke,	QC,	Canada	J1H5N4	and	2	Centre	d’Imagerie	Moléculaire	de	
Sherbrooke	(CIMS),	CR-CHUS,	Sherbrooke,	QC,	Canada	J1H5N4	
	
Background:	NPY-Y1	receptor	(NPY-Y1R)	is	a	promising	target	for	breast	cancer	imaging.	Previously,	our	
group	 prepared	 and	 tested	 a	 series	 of	 truncated	 NPY	 analogs	 derived	 from	 BVD-15	 (;	 [Pro30,	 Tyr32,	
Leu34]NPY(28-36)-NH2)	for	64Cu-labeling	).	Unfortunately	the	biological	half-live	of	the	most	potent	tracer,	
[Lys(64Cu/DOTA)4]BVD15,	when	injected	in	mouse	plasma	was	shorter	than	15	minutes.	In	this	study,	we	
improved	the	design	of	BVD15	in	order	to	increase	its	stability	in	vitro	and	in	vivo	and	maintain	its	targeting	
capability.	Materials	&	Methods:	Modifications	of	the	peptide	backbone,	the	chelator	and	the	use	of	D-	
and	non-naturel	amino	acids	were	proposed	to	improve	the	peptide	tracer	stability.	The	peptides	were	
synthesized	on	solid	phase	and	conjugated	to	NOTA	chelator.	Binding	studies	on	MCF-7	human	breast	
cancer	cells	(2)	were	performed	after	each	structural	modification	to	make	sure	that	the	potency	and	the	
selectivity	of	the	new	NOTA-peptide	conjugates	to	NPY-Y1R	were	maintained.	Once	active	compounds	
were	 identified,	 they	 were	 radiolabeled	 with	 64Cu	 for	 performing	 plasma	 stability,	 cellular	 uptake,	
internalization,	and	blocking	studies	on	MCF-7	cells	in	order	to	rapidly	identify	the	promising	candidates	
for	in	vivo	studies.	Results:	A	64Cu/NOTA-BVD15	derivative	presenting	a	very	low	Ki	(9	nM)	and	showing	a	
very	high	stability	in	plasma	up	to	20	h	and	in	vivo	for	30	minutes	has	been	identified.	Cell	assays	showed	
a	constant	uptake	and	internalization	over	the	whole	experiment	(Fig.	1A).	The	internalized	fraction	after	
2h	was	~20%.	The	radiopeptide	uptake	was	blocked	in	presence	of	an	excess	of	unlabeled	peptide	(Fig.	
1B).	
	
Figure	1:	 Specific	 cell	uptake	and	 internalization	 rate	after	 incubation	of	MCF-7	cells	with	 64Cu/NOTA-
BVD15	derivative	at	37	ºC.	(A)	Cell	uptake	calculated	as	cell	surface-bound	(•)	and	internalized	fraction	
(▪).	(B)	Uptake	at	1	and	2	h	in	absence	(light	gray)	and	in	presence	of	an	excess	of	unlabeled	peptide	(dark	
gray).	Discussion/Conclusion:	We	have	identified	a	new	64Cu-labeled	peptide	presenting	a	good	stability	
and	an	excellent	affinity	to	NPY-Y1R.	On	the	basis	of	the	cellular	results,	the	64Cu/NOTA-BVD15	derivative	
appears	to	have	a	potential	for	the	targeting	of	NPY-Y1R	positive	tumors.	References:	1Balasubramaniam	
A,	Dhawan	VC,	Mullins	DE,	Chance	WT,	Sheriff	S,	Guzzi	M,	Prabhakaran	M,	Parker	EM,	[2001],	J	Med	Chem	
44:	1479-1482.	2	Guérin	B,	Dumulon-Perreault	V,	Dubuc	C,	Authier	S,	Bénard	F,	[2010]	Bioorg.	Med.	Chem.	
Lett.	20:	950-953.	 	
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OP06	
The	influence	of	multivalency	on	CCK	2	receptor	targeting	
D.Summer1,	A.	Kroess1,	C.	Rangger1,	H.	Haas2,	P.	Laverman3,	F.	Gerben3,	E.	von	Guggenberg1,	
C.Decristoforo1	
1Department	of	Nuclear	Medicine,	Medical	University	Innsbruck		
2Division	of	Molecular	Biology/Biocenter,	Medical	University	Innsbruck	
3Department	of	Nuclear	Medicine,	Radboud	University	Medical	Center,	Nijmegen,	The	Netherlands	
Background:	 Multivalency	 has	 shown	 to	 enhance	 accumulation	 of	 receptor	 targeted	
radiopharmaceuticals,	 due	 to	 the	 avidity	 effect	 and	 increased	 apparent	 tracer	 concentration.	 For	
metabolically	unstable	peptides	multimerisation	may	also	delay	metabolic	processes	like	oxidation	and	
enzymatic	cleavage	leading	to	loss	of	binding	affinity.	The	aim	of	this	study	was	to	show	the	benefit	of	
multimeristation	 on	 the	 targeting	 behaviour	 using	 a	 CCK2-receptor	 targeting,	 metabolically	 unstable	
Minigastrin	peptide	(MG11).	Materials	&	Methods:	Fusarinine	C,	a	cyclic	siderophore	bearing	three	amino	
residues,	was	chosen	as	chelating	agent	and	up	to	three	peptide	sequences	(MG11=	D-Glu1,	desGlu2-6]-
minigastrin)	were	conjugated	by	using	maleimide	chemistry.	Radiotracers	were	labelled	with	68Ga	as	well	
as	with	 89Zr	 following	 standard	 radiolabeling	 protocols.	 For	 in	 vitro	 characterisation	 stability	 studies,	
determination	of	the	partition	coefficient	and	cell	uptake	studies	were	performed.	In	vivo	experiments	
included	biodistribution	studies	(1h	p.i)	and	static	micro	PET/CT	imaging	and	were	carried	out	in	tumour	
xenograft	bearing	balb/c	nude	mice.	Results:	Peptide	conjugates	could	be	labelled	with	68Ga	(5-15min	
RT,	pH4-5)	and	89Zr	(60min,	RT,	pH7)	achieving	radiochemical	yields	of	more	than	98%.		All	complexes	
showed	 excellent	 stabilities	 in	 the	 presence	 of	 EDTA,	 DTPA,	 FeCl3	 and	 in	 human	 serum	 after	 certain	
timepoints.	Partition	coefficient	(logP)	values	ranging	from	-1	to	-3	revealed	a	hydrophilic	character	of	the	
radiotracers.	As	expected	a	decrease	of	hydrophilicity	correlated	with	increasing	grade	of	multimerisation.	
The	cell	uptake	ranged	from	10	to	15%	per	mg	protein	and	could	be	reduced	significantly	by	blocking	with	
human	minigastrin	indicating	specific	receptor	binding	of	all	conjugates.	Biodistribution	studies	showed	a	
tumour	 uptake	 ranging	 from	 5%	 (monomer)	 to	 approximately	 10%	 ID/g	 (multimer)	 one	 hour	 post	
injection.	Tumour	to	organ	ratio	was	decreased	by	multimerisation	and	especially	the	kidney	retention	
was	increased	significantly	by	the	di-	and	trimeric	radiotracers.	Static	animal	imaging	one	and	two	hours	
after	 injection	of	68Ga	 labeled	conjugates	confirmed	 the	outcome	of	 the	biodistribution	studies.	89Zr	
labeled	 counterparts	 showed	 very	 similar	 results	 but	 after	 24	 hours	 post	 injection	 the	 trimeric	
bioconjugate	 showed	much	 better	 tumour	 imaging	 ability	 than	 the	 corresponding	mono-	 and	 dimer.	
Discussion/Conclusion:	 Though	 these	 results	 are	 preliminary	multimerisation	 seems	 to	 correlate	with	
higher	tumour	uptake	leading	to	better	late	timepoint	imaging	but	high	kidney	retention	seems	to	be	a	
major	limitation.	Stability	studies	are	ongoing.	
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OP07	
SPECT	Imaging	of	αvβ3	Expression	by	[99mTc(N)PNP43]-	Bifunctional	Chimeric	RGD	Peptide	not	Cross-
Reacting	with	αvβ5	
Cristina	Bolzati1,	Nicola	Salvarese1,2,	Fiorenzo	Refosco1,	Laura	Meléndez-Alafort2,	Debora	Carpanese2,	
Antonio	Rosato2,3,	Michele	Saviano4,	Annarita	Del	Gatto5,	Daniela	Comegna5	Laura	Zaccaro5	
1IENI-CNR,	Padua,	Italy;	2DiSCOG-University	of	Padua,	Italy;	3IOV	Padua,	Italy;	4IC-CNR,	Bari,	Italy;	5IBB-
CNR,	Naples,	Italy			
	
Background:	Recently	a	new	bifunctional	chimeric	RGD	peptide	(RGDechi),	comprising	a	cyclic	Arg-Gly-
Asp	 pentapeptide	 covalently	 bound	 to	 an	 echistatin	 domain,	 has	 been	 reported1.	 In	 vitro	 and	 in	 vivo	
biological	studies	evidenced	that	this	chimeric	peptide	selectively	binds	to	αvβ3	 integrin	and	does	not	
cross-react	with	αvβ52.	In	order	to	obtain	an	optimal	SPECT	radiotracer,	a	series	of	[99mTc(N)PNP]	labelled	
peptides	 has	 been	 prepared	 and	 their	 pharmacological	 properties	 investigate.	Materials	 &	Methods:	
RGDechi-hCit	 	 (1)	 and	 three	 truncated	 peptide	 derivatives	 [RGDechi1_17	 (2),	 RGDechi1_16	 (3)	 and	
RGDechi1_14	(4)]	lacking	the	two,	three	and	five	C-terminal	amino	acids,	were	synthetized	in	solid	phase	
by	Fmoc	chemistry	and	conjugated	with	a	cysteine	linked	to	the	Lys1	side	chain	to	allow	the	labeling	with	
[99mTc(N)PNP43]-synthon	 (PNP43	 =	 (CH3)2P(CH2)2N(C2H4OCH3)(CH2)2P(CH3)2).	 In	 vitro	 stability	 and	
pharmacological	parameters	of	the	corresponding	compounds,	99mTc1-4,	were	assessed.	Challenges	with	
an	excess	of	glutathione	and	cysteine	and	Log	P	values	were	also	investigated.	Furthermore,	radiolabeled	
peptides	 (99mTc1-4)	were	 applied	 to	 study	 in	 vivo	 stability	 and	 the	pharmacokinetic	 profiles	 on	 tumor	
bearing	mice.	Results:	All	99mTc-compounds	were	obtained	with	RCY	>	90%.	Log	P	values	demonstrate	the	
hydrophilic	nature	of	the	radiolabeled	peptides	ranging	from	-2.96	to	-2.12.	No	significant	variations	in	
RCPs	of	the	complexes	were	detected	in	challenge	experiments	with	an	excess	(10	mM)	of	glutathione	
and	cysteine.		In	general,	a	high	in	vitro	stability	was	observed	after	incubation	in	human	and	mice	sera	as	
well	as	in	mice	liver	homogenate;	a	slight	degradation	of	99mTc1-4	was	found	in	kidneys	homogenate.	Cell	
uptake	 assays	 showed	 that,	 excluding	 99mTc4	 compound,	 99mTc1-3	 radiolabeled	 peptides	 accumulate	
selectively	in	cells	expressing	αvβ3	integrin	and	does	not	accumulate	in	cell	expressing	moderate	levels	of	
αvβ5	and	undetectable	levels	of	αvβ3	integrins.	In	agreement	with	in	vitro	findings,	biodistribution	studies	
showed	 that	 the	 99mTc1-3	 radiolabeled	 chimeric	 peptide	 selectively	 localizes	 in	 tumor	 xenografts	
expressing	αvβ3	and	fails	to	accumulate	in	those	expressing	αvβ5	integrin.	Discussion/Conclusion:	99mTc-
labeled	 RGDechi,	 RGDechi1_17	 and	 RGDechi1_16	 chimeric	 peptides	 can	 be	 used	 for	 highly	 selective	
αvβ3	expression	 imaging	by	SPECT	 technology.	Among	 the	 tested	compounds,	 99mTc2	possess	 the	best	
distribution	profile	and	highest	 localization	 in	 tumor	expressing	αvβ3.	This	 research	was	supported	by	
MIUR	through	PRIN	20097FJHPZ-004	and	FIRB	“RINAME”2010-RBAP114AMK,	by	Programma	Operativo	
Nazionale	Ricerca	e	Competitivita	PON	01_02388	and	by	Italian	Association	for	Cancer	Research	AIRC	IG	
13121.	References:	1.	Del	Gatto	A,	[2006]	J	Med	Chem	49:3416–20.	2.	Zannetti	A,	[2009]	Clin	Cancer	Res	
15;	5224-5233.	
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OP09	
New	 dienophiles	 for	 the	 inverse-electron-demand	 Diels-Alder	 reaction	 and	 for	 pretargeted	 PET	
imaging.	
Emilie	 Billaud1,	 Muneer	 Ahamed1,	 Frederik	 Cleeren1,	 Elnaz	 Shahbazali2,	 Tim	 Noël2,	 Volker	 Hessel2,	
Alfons	Verbruggen1	and	Guy	Bormans1	
1	Laboratory	of	Radiopharmacy,	KU	Leuven,	Leuven,	Belgium	
2	Micro	 Flow	 Chemistry	&	 Process	 Technology,	 Chemical	 Engineering	 and	 Chemistry	 Department,	 TU	
Eindhoven,	The	Netherlands	
	
Introduction:	 In	 cancer	 research,	
pretargeted	PET	imaging	has	emerged	
as	an	effective	two-step	approach	that	
combines	the	affinity	and	selectivity	of	
antibodies	 with	 the	 rapid	
pharmacokinetics	 and	 favorable	
dosimetry	 of	 smaller	 molecule	
radiolabeled	 with	 short-lived	
radionuclides.	 This	 approach	 can	 be	
based	 on	 the	 bioorthogonal	 inverse-
electron-demand	 Diels-Alder	 (IEDDA)	
“click”	 reaction	 between	 tetrazines	
and	 trans-cyclooctene	 (TCO)	
derivatives.	 Our	 project	 aims	 to	 develop	 new	 [18F]TCO-dienophiles	with	 high	 reactivity	 for	 the	 IEDDA	
reaction,	improved	in	vivo	stability	and	favorable	pharmacokinetics.	New	dienophiles			were			synthesized			
using	 an	 innovative	 continuous-flow	micro-photochemistry	 process,	 and	 their	 reaction	 kinetics	with	 a	
tetrazine	were	determined.	In	vivo	stability	studies	of	the	most	promising	18F-radiolabeled-TCO-derivative	
([18F]trans-EB-70)	was	investigated,	and	its	potential	for	pretargeted	PET	imaging	was	assessed.Materials	
and	 Methods:	 Organic	 chemistry	 Fluoro-cis-cyclooctene	 derivatives	 and	 mesylate	 precursors	 for	
radiofluorination	were	synthesized	in	5-8	steps.	Structures	of	intermediates	and	final	compounds	were	
confirmed	by	NMR	and	mass	spectrometry.	Photochemistry	Trans-for-cis	 isomerization	was	performed	
using	a	microfluidic	setup.		
	
Kinetics	Reactions	between	dienophiles	and	3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine	in	MeOH	at	25°C	were	
monitored	by	UV	spectrophotometry	at	290	nm	(pseudo-first	order	conditions).	18F-radiolabeling	(semi-
automated)	Nucleophilic	substitution	of	mesylate	trans-EB-77	using	[18F]KF,K222	was	achieved	in	MeCN	at	
90°C	for	15	min.	[18F]trans-EB-70	was	purified	by	HPLC.	In	vivo	stability	[18F]trans-EB-70	was	evaluated	in	
healthy	NMRI	mice,	by	ex	vivo	biodistribution	(2,	10,	30,	60	min	p.i.).	In	vitro	pretargeting	Prostate	tumor	
slices	 (LNCaP	 and	 PC-3	 cells)	were	 successively	 incubated	with	 a	 prostate-specific	membrane	 antigen	
(PSMA)	 inhibitor	modified	with	3-(4-(trifluoromethyl)phenyl)-6-phenyl-1,2,4,5-tetrazine,	and	 [18F]trans-
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EB-70.	Direct	incubation	with	[18F]click-PSMAi,	and	blocking	experiments	(2-(phosphonomethyl)pentane-
1,5-dioic	acid)	were	performed.		
	
Results	Fluoro-cis-cyclooctene	derivatives	 and	mesylate	 precursors	were	 synthesized	 in	 3-35%	overall	
yields.	The	 trans-for-cis	micro-photoisomerization	reached	yields	of	48%.	Reaction	kinetics	of	 the	new	
dienophiles	are	fast,	with	k2	ranging	from	475.6±32.8	to	1913.0±195.9	M-1.s-1.	Radiosynthesis	of	[18F]trans-
EB-70	was	achieved	 in	60	min,	with	12%	radiochemical	yield	 (decay-corrected),	a	radiochemical	purity	
>99%	(for	at	least	2h),	and	70-188	GBq.µmol-1	specific	activity.	Biodistribution	of	[18F]trans-EB-70	in	mice	
demonstrated	absence	of	in	vivo	defluorination	and	a	fast	clearance	via	urinary	and	hepatobiliary	systems.	
Regarding	in	vitro	experiment,	the	binding	on	LNCaP	tumor	slices	(expressing	PSMA	receptors)	subjected	
to	pretargeting	was	PSMA-specific	and	slightly	inferior	to	the	binding	of	[18F]click-PSMAi.	No	significant	
binding	was	 observed	 in	 PC-3	 cells	 (negative	 control).	Discussion/Conclusion:	We	 demonstrated	 that	
[18F]trans-EB-70	is	a	suitable	dienophile	for	the	IEDDA	“click”	reaction	and	for	pretargeting	applications.	
Therefore,	 [18F]trans-EB-70	 will	 be	 investigated	 further	 in	 pretargeted	 µPET	 experiments.	 Research	
support:	SBO	MIRIAD	(IWT	Flanders)	
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OP10	
New	 complexing	 agent	 for	 Al18F-labelling	 of	 heat-sensitive	 biomolecules:	 Synthesis	 and	 preclinical	
evaluation	of	Al18F-RESCA1-HAS	
Cleeren	F1,	Lecina	J1,	Koole	M2,	Verbruggen	A1	and	Bormans	G1	
1Laboratory	for	Radiopharmacy,	University	of	Leuven,	Belgium	
2Department	of	Nuclear	Medicine	and	Molecular	Imaging,	University	of	Leuven,	Belgium	
	
Introduction:	 The	 Al18F-labelling	 strategy	 involves	 formation	 of	 aluminium	 mono[18F]fluoride	
({Al18F}2+)	 which	 is	 trapped	 by	 a	 suitable	 chelator	 –mostly	 bound	 to	 a	 biomolecule-	 in	 aqueous	
medium.1At	this	moment	however,	the	need	for	elevated	temperatures	(100-120	°C)	limits	its	widespread	
use.	 Therefore,	 we	 designed	 new	 restrained	 complexing	 agents	 (RESCAs)	 for	 use	 of	 this	 strategy	 at	
moderate	temperature.	RESCA1	 is	an	acyclic	pentadentate	 ligand	with	a	N2O3	coordinative	set	that	 is	
able	to	complex	{Al18F}2+		efficiently	at	25	°C.	To	evaluate	the	stability	and	kinetic	inertness	of	the	chelate	
in	vivo,	RESCA1	was	conjugated	 to	human	serum	albumin	 (HSA)	and	 labelled	with	 {Al18F}.	The	Al18F-
labelled	conjugate	was	monitored	in	vivo	for	6	h	p.i..	
	
Figure	1:	Al18F-labelling	of	RESCA1-HSA,	in	vivo	biodistribution	(%ID/g)	in	healthy	rats	and	whole-body	
PET	image	of	a	healthy	rat	180	min	after	intravenous	injection		
Materials	&	Methods:	HSA	was	 reacted	with	RESCA1-TFP.	 	RESCA1-HSA	 (7.5	mg,	110	nmol)	 in	750	μl	
sodium	acetate	buffer	(0.1	M,	pH	4.5)	was	added	to	a	freshly	prepared	{Al18F}2+	solution	(1.4	GBq,	50	
nmol	AlCl3,	12	min,	RT).	The	product	was	purified	using	a	PD-10	caolumn	and	RCP	was	determined	with	
SEC-HPLC.	To	test	stability	in	serum,	Al18F-RESCA1-HSA	in	100	µl	PBS	was	added	to	rat	serum	(900	µl),	
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kept	at	37°C	and	monitored	up	to	4	h.	Ex	vivo	biodistribution	was	studied	at	1	h,	3	h	and	6	h	p.i.	of	Al18F-
RESCA1-HSA	(2-7.5	MBq)	 in	healthy	female	rats.	Small-animal	whole-body	PET	imaging	was	performed	
using	a	FOCUS	220	tomograph.	Results:	RESCA1-HSA	was	obtained	with	a	chelator-to-protein	ratio	of	3,	
estimated	 by	 ESI-TOF-HRMS	 analysis.	 Al18F-RESCA-HSA	 was	 prepared	 in	 high	 RCY	 (>70%)	 and	 purity	
(>95%)	in	<	30	min.	91%	of	product	was	still	intact	in	rat	serum	after	4	h	incubation.	Distribution	in	rats	
(figure	1)	showed	high	retention	in	blood	with	5.42	±	0.23%	ID/g,	4.93	±	0.22%	ID/g	and	3.66	±	0.06%	ID/g	
at	1h,	3h	and	6	h	respectively	 from	which	the	blood	biological	half-life	was	calculated	to	be	8.6	h.	No	
significant	increase	in	bone	uptake	was	observed,	indicating	excellent	in	vivo	stability	of	the	Al18F-labelled	
construct.	Discussion/Conclusion:	We	successfully	labelled	for	the	first	time	a	heat-sensitive	biomolecule	
via	 the	 Al18F-method	 in	 one	 radiolabelling	 step.	 Al18F-	 RESCA1-HSA	 showed	 excellent	 stability	 and	
favourable	properties	for	PET	blood	pool	imaging	applications.	References:	1.McBride,	W.	J.,	Sharkey,	R.	
M.,	and	Goldenberg,	D.	M.	[2013],	EJNMMI	Res.	3,	36.		
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OP11	
A	novel	versatile	precursor	efficient	for	F-18	radiolabelling	via	click-chemistry	
B.	Lugatoa,	S.	Stucchia,	E.A.	Turollaa,	L.	Giulianoa,	S.Toddea,	P.	Ferraboschib	
aUniversity	of	Milano-Bicocca,	Department	of	Medicine	and	Surgery,	Tecnomed	Foundation;	bUniversità	
degli	Studi	di	Milano,	Dipartimento	di	Biotecnologie	Mediche	e	Medicina	Traslazionale.	
Introduction	In	the	last	years,	the	Cu(I)-catalyzed	Huisgen	[3+2]	cycloaddition	between	terminal	alkynes	
and	azides	emerged	as	a	powerful	 tool	 in	F-18	 labelling	biomolecules	such	as	peptides,	because	of	 its	
regioselectivity,	mild	 aqueous	organic	 conditions,	 reduced	 reaction	 times,	 and	high	 yields.(1)	 	A	weak	
point	of	the	method	is	the	lack	of	suitable	commercially	available,	stable	precursors.(1)	In	this	paper	we	
report	the	synthesis	and	F-18	radiolabelling	of	a	new,	versatile,	easy	to	handle,	and	stable	azide	precursor	
useful	for	click-chemistry.	Materials	and	methods:	Reagents	and	solvents	were	purchased	from	Sigma-
Aldrich.	 [18F]Fluoride	 was	 produced	 with	 an	 IBA	 Cyclone	 18/9	 cyclotron.	 Radioactive	 syntheses	 were	
carried	 out	 on	 a	 fully	 automated	 radiosynthesis	 module	 (GE	 TracerLab	 FX-FN	 Pro),	 and	 analyzed	 by	
analytical	 RP-HPLC	 with	 UV	 and	 radiochemical	 detectors.	 Non-radioactive	 compounds	 were	 fully	
characterized	 by	 NMR,	 ESI-MS	 and	 IR.	Results:	A	 series	 of	 bifunctional	 precursors,	 bearing	 the	 azide	
moiety	and	different	leaving	groups	(e.g.	tosylate,	mesylate,	iodo),	coupled	to	a	short	polyetyleneglycol	
chain,	with	the	aim	to	improve	their	stability	and	hydrophilicity,	were	designed	and	successfully	prepared	
following	a	ten-step	synthetic	pathway.	A	protection-deprotection	strategy	of	functional	groups	achieved	
the	desired	precursors	with	good	yield	and	purity.	Fluorinated	reference	standards	were	also	prepared	
and	purified.	 Precursors	were	 radiolabelled	with	 F-18	 and	 then	 coupled	 to	propargylglycine	 as	 alkyne	
counterpart.	[18F]Fluoride	was	purified	following	standard	procedure,	and	nucleophilic	displacement	of	
the	iodo	leaving	group	took	place	at	100°	C,	in	20	min.	The	resulting	labelled	azide	was	then	successfully	
purified	using	a	Sep-Pak	tC18	cartridge,	giving	51%	radiochemical	yield	(not	decay	corrected)	and	93%	
radiochemical	 purity.	 The	 purified	 azide	 was	 then	 conjugated	 to	 propargylglycine,	 showing	 52%	
conversion	within	30	min	at	room	temperature.	Purification	and	formulation	have	still	to	be	optimized.	
Discussion/Conclusion:	A	new	optimized	precursor	useful	for	F-18	radiolabelling	and	click-chemistry	was	
prepared,	 and	 it	 demonstrated	 to	 be	 effective	 in	 radiolabelling	 non-protected	 alkynyl	 modified	
aminoacids,	by	a	fully	automated	synthetic	procedure.	Good	results,	in	terms	of	radiochemical	yield	and	
purity,	were	obtained	with	iodo-derivative	precursor.	Purification	and	formulation	of	the	final	conjugation	
product	are	in	progress.	References	(1)	Roeda	D,	Dolle	F,	[2015]	Chemistry	of	Molecular	Imaging,	55-77	(2)	
Pretze	M,	Pietzsch	D,	Mamat	C,	[2013]	Molecules,	18:	8618-8665	
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OP12	
A	general	applicable	method	to	quantify	unidentified	UV	impurities	in	radiopharmaceuticals		
R.P.	Klok1,	M.P.J.	Mooijer1,	N.H.	Hendrikse1,2,	A.D.	Windhorst1	
1	Department	of	Radiology	&	Nuclear	Medicine,	VU	University	Medical	Center,	Amsterdam,	The	
Netherlands	
2	Department	of	Clinical	Pharmacology	&	Pharmacy,	VU	University	Medical	Center,	Amsterdam,	The	
Netherlands	
	
Introduction:	 Radiopharmaceuticals	 are	 released	 for	 administration	 by	 a	 quality	 control	 procedure	
against	 pre-set	 specifications.	 One	 of	 these	 release	 specifications	 is	 the	 chemical	 purity	 of	 the	 drug	
product,	 determined	 with	 High	 Pressure	 Liquid	 Chromatography	 (HPLC)	 and	 UV	 detection.	 In	 the	
European	 Pharmacopeia	 (EP)	 hardly	 any	 specifications	 are	 given	 for	 the	 chemical	 purity	 of	 a	
radiopharmaceutical.	When	unknown	 impurities	are	present	 in	 the	 chromatogram,	 the	decision	 if	 the	
radiopharmaceutical	can	be	released,	is	very	frequently	based	on	unclear	parameters	like	‘no	unidentified	
UV	signals	present’.	There	 is	a	need	for	an	objective	specification	 in	order	 to	have	a	save	and	reliable	
release.	Aim:	The	purpose	of	 the	presented	work	 is	 to	define	a	generally	applicable	method	to	define	
tolerances	 for	 unidentified	 impurities	 in	 radiopharmaceuticals.	Materials	&	Methods:	A	 retrospective	
analysis	 was	 performed	 on	 HPLC	 analysis	 results	 of	 [11C]Flumazenil,	 [11C]PIB,	 [11C]Erlotinib,	
[11C]DPA713,	[18F]PK209	and	[18F]FES.	Quantification	of	the	carrier	signal	in	the	UV	chromatogram	was	
determined	by	use	of	calibration	curves,	utilizing	Chromeleon®	6.8.	Unidentified	impurities	were	semi-
quantified	 utilizing	 the	 surface	 area	 in	 the	UV	 chromatogram	 relative	 to	 the	 quantified	 carrier	 signal.	
Based	 on	 the	 EP.	monography	 of	 [11C]Flumazenil	 and	 [18F]FET,	 the	 specification	 for	 unidentified	UV	
impurities	was	determined	to	be	0.22	pmol/injection	volume	for	a	single	unidentified	impurity	and	0.88	
pmol/injection	volume	for	the	total	of	unidentified	impurities.	This	specification	was	tested	for	over	500	
batches	of	 the	radiopharmaceuticals	and	compared	to	the	 less	specific	parameter	 ‘no	unidentified	UV	
signals	present’.	Results:	In	a	pilot	assessment	we	encountered	in	5-10%	cases	unidentified	UV	impurities	
leading	to	rejection	of	the	batch,	based	on	the	specification	‘no	unidentified	UV	signals	present’.	Of	these	
rejected	 batches	 25%	was	 also	 rejected	with	 the	 new	 defined	 specification.	 Reason	 for	 this	 reduced	
number	 of	 rejections	 is	 that	 with	 the	 new	 specification	 the	 presence	 of	 unidentified	 impurities	 is	
evaluated	objectively.	The	analysis	of	the	full	database	is	currently	on-going.	Discussion/Conclusion:	With	
this	method	the	amount	of	unidentified	 impurities	can	be	estimated	 in	an	optimal	and	objective	way,	
utilizing	EP	 limits	of	 [11C]Flumazenil	 and	 [18F]FET,	without	operator	 variability.	References:	 European	
Pharmacopeia	8.0-8.6.	
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OP13	
Development	of	[18F]Fluoro-C-glycosides	to	radiolabel	peptides		
Collet	C.1,2,	Petry	N.1,3,	Chrétien	F.1,3,	Karcher	G.1,2,4,	Pellegrini-Moïse	N.1,3,	Lamandé-Langle	S.1,3	
1Université	de	Lorraine,	F-54500	Vandoeuvre	les	Nancy	-	France	
2NancycloTEP,	Plateforme	d’imagerie	expérimentale,	54500	Vandoeuvre	les	Nancy	-	France	
3CNRS,	UMR	7565	SRSMC,	F-54506	Vandoeuvre	les	Nancy	-	France	
4CHU	de	Nancy-Brabois,	F-54511	Vandoeuvre	les	Nancy	–	France	
	
Introduction:	The	18F-labeling	of	peptides	for	PET	applications	has	been	used	for	many	years.1	However,	
the	sensitivity	of	these	peptides	does	not	allow	their	direct	radiolabelling	under	harsh	conditions,	except	
few	 recent	 examples.	 A	 solution	 is	 to	 use	 a	 prosthetic	 group,	 an	 easily	 radiolabeled	 small	 molecule,	
subsequently	 coupled	 in	 mild	 condition	 to	 the	 peptide.	 In	 continuation	 of	 our	 previous	 work,2	 we	
therefore	 propose	 to	 develop	 and	 use	 new	 C-glycoside-based	 prosthetic	 groups.	 The	 use	 of	 sugar	
derivatives	as	prosthetic	group	would	improve	bioavailability	and	pharmacokinetic	properties	of	peptides.	
Materials	&	Methods:	These	C-glycoside	derivatives	should	have	a	good	leaving	group	thus	allowing	easy	
substitution	by	fluorine-18,	i.e.	triflate.	A	copper	catalyzed	azide	alkyne	cycloaddition	(CuAAC)	was	then	
used	for	coupling	these	carbohydrates	with	a	peptide.	Some	model	peptides	containing	a	cysteine	residue	
as	RGDC	and	c(RGDfC)	are	used.	The	high	nucleophilicity	of	the	thiol	function	can	thus	be	exploited	to	
prepare	 S-propargylated	 derivatives.	 The	 fully	 automated	 radiosynthesis	 of	 these	 [18F]fluoro-
glycopeptides	was	performed	on	an	AllInOne®	(Trasis)	synthesizer.	Results:	Triflated	precursors	of	these	
C-glucosides	prosthetic	groups	and	the	non-radioactive	references	were	synthesized	 in	alpha	and	beta	
configuration.	Fluoride-18	radiolabeling	was	optimized	and	the	automated	radiosynthesis	of	[18F]fluoro-
glycopeptides	with	some	model	peptides	(RGDC,	c(RGDfC))	was	presented.		
OHO
HO N
NN
OH
18F
OHO
HO N3OH
18F
OAcO
AcO N3OAc
TfO
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S
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S
peptide
	
	
Discussion/Conclusion:	 The	 synthesis	 and	 radiosynthesis	 of	 6-[19F/18F]fluoro-C-glycosides	 displaying	 a	
three	carbon	arm	terminated	with	an	azide	group	were	optimized.	CuAAC	of	fluoro-C-glycosides	with	RGD	
derivative	peptides	gave	[19F/18F]fluoro-glycopeptides	in	good	yields.	References:	[1]	a)	Okarvi	S.M.	[2011]	
Eur.	J.	Nucl.	Med.,	28:	929-938.	b)	Kuhnast	B.,	Dollé	F.	[2010]	Curr	Radiopharm.,	3:	174-201.	[2]	a)	Collet	
C.,	Maskali	F.,	Clément	A.,	Chrétien	F.,	Poussier	S.,	Karcher	G.,	Marie	P.-Y.,	Chapleur	Y.,	Lamandé-Langle	
S.,	 [2016],	 J.	 Label.	 Compd.	 Radiopharm.	 DOI:	 10.1002/jlcr.3362.	 b)	 Lamandé-Langle	 S.,	 	 Collet	 C.	
Hensienne	R.,	Vala	C.,	Chrétien	F.,	Chapleur	Y.,	Mohamadi	A.,	Lacolley	P.,	Regnault	V.,	[2014],	Bioorg.	Med.	
Chem.	22:	6672-6683.	c)	Lamandé-Langle	S.,	Chapleur	Y.,	Chrétien	F.,	Collet	C.	[2014],	WO	2014006022	
A1	20140109.	d)	Chapleur	Y.,	Vala	C.,	Chrétien	F.,	Lamandé-Langle	S.	[2013]	Toward	imaging	glycotools	by	
click	coupling;	Witczak	
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OP14	
A	Microfluidic	Approach	for	the	68Ga-labeling	of	PSMAHBED-CC	and	NODAGA-RGD	
Sarah	Pfaff	1,2,	Cecile	Philippe	1,	Markus	Mitterhauser	1,3,	Marcus	Hacker	1,	Wolfgang	Wadsak	1,2	
1	Department	of	Biomedical	Imaging	and	Image-guided	Therapy,	Division	of	Nuclear	Medicine,	Medical	
University	of	Vienna,	Austria	
2	Department	of	Inorganic	Chemistry,	University	of	Vienna,	Austria	
3	LBI	for	Applied	Diagnostics,	Vienna,	Austria	
	
Introduction:	In	nuclear	medicine	a	remarkably	high	demand	of	68Ga-radiotracers	has	emerged	during	the	
last	decade.	For	a	variety	of	non-68Ga-containing	radiotracers	a	microfluidic	approach	for	their	syntheses	
could	be	established,	enabling	an	enhancement	of	yields	due	to	high	surface-to-volume	ratios1,2.	In	this	
proof-of-principle	 study,	 the	 68Ga-radiolabeling	 of	 PSMAHBED-CC	 and	 NODAGA-RGD	 using	 a	 microfluidic	
approach	was	evaluated.	Furthermore,	adding	TWEEN	20	(a	surfactant	suitable	for	in	vivo	applications)	
and	its	impact	on	the	radiochemical	yield	was	explored.	Materials	and	Methods:	The	syntheses	of	68Ga-
PSMAHBED-CC	 and	 68Ga-NODAGA-RGD	 (both	 precursors	 from	 ABX)	 were	 performed	 using	 an	 Advion	
NanoTek	LF	microfluidic	device.	The	system	incorporates	a	flow-through	reactor	that	consists	of	a	silica	
capillary	(l=2	m,	Ø100	µm,	V=15.6	µL).	68Ga3+	was	obtained	from	a	68Ge/68Ga-generator	(3.7	GBq;	Obninsk)	
according	 to	 a	 fractionized	 protocol.	 The	 precursor	 and	 68Ga3+	were	 loaded	 in	 two	 storage	 loops	 and	
distinct	volumes	thereof	were	pushed	through	the	reactor	with	different	flowrates	(30,	50,	80	µL/min)	at	
different	 temperatures	 (25,	 50,	 80,	 100,	 120,	 150°C)	 using	 NaOAc	 and	 HEPES	 for	 pH	 adjustment,	
respectively.	Additionally,	the	influence	of	TWEEN	20	as	a	surfactant,	to	reduce	known	adsorption	effects	
in	microfluidic	tubing,	was	investigated.	Results:	Accomplished	experiments	revealed	feasibility	of	68Ga-
labeling	 of	 PSMAHBED-CC	and	NODAGA-RGD	using	 a	microfluidic	 device.	 All	 temperatures	 and	 flowrates	
resulted	 in	 mean	 radiochemical	 yields	 in	 a	 range	 of	 20-55%.	 Syntheses	 at	 higher	 temperatures	 and	
flowrates	proved	to	be	more	efficient.	For	instance,	HEPES	buffered	syntheses	at	100°C	and	flowrate	of	
80	µL/min	yielded	68Ga-PSMAHBED-CC	in	42.6	±	22.1	%	(n=10)	and	68Ga-NODAGA-RGD	in	49.7	±	32.5	%	(n=7).	
Applying	the	same	parameters,	TWEEN	20	could	strikingly	improve	the	yield	of	68Ga-PSMAHBED-CC	to	70.8	±	
16.8	%	 (n=13).	Discussion/Conclusion:	This	 study	 provides	 the	 proof-of-principle	 of	 68Ga-labeling	 in	 a	
microfluidic	“flow-through”	system.	The	application	of	TWEEN	20	 led	 to	drastically	 increased	yields	of	
68Ga-PSMAHBED-CC	due	to	 its	surfactant	nature.	As	a	result,	this	microfluidic	approach	will	be	pursued	to	
increase	 availability	 of	 68Ga-radiopharmaceuticals	 according	 to	 the	 dose-on-demand	 principle.	
References:	1	Lee	C,	Sui	G,	Elizarov	A,	Shu	J,	Shin	Y,	Dooley	A,	Huang	J,	Daridon	A,	Wyatt	P,	Stout	D,	Kolb	
H,	Witte	O,	 Satyamurthy	N,	Heath	 J,	 Phelps	M,	Quake	 S,	 Tseng	H,	 	 [2005]	 Science;	 310:	 1793─1796	 2	
Ungersboeck	J,	Philippe	C,	Mien	L,	Häusler	D,	Shanab	K,	Lanzenberger	R,	Spreitzer	H,	Keppler	B,	Dudczak	
R,	Kletter	K,	Mitterhauser	M,	Wadsak	W,	[2011],	Nuc	Med	Bio;	39:	1087─1092	
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OP16	
Surprising	reactivity	of	astatine	in	the	nucleophilic	substitution	of	aryliodonium	salts:	application	to	the	
radiolabeling	of	antibodies	
François	 Guérard1,	 Yong-Sok	 Lee2,	 Sébastien	 Gouard1,	 Kwamena	 Baidoo3,	 Cyrille	 Alliot1,4,	 Michel	
Chérel1,	Martin	W.	Brechbiel3	and	Jean-François	Gestin1.	
1	Centre	de	Recherche	en	Cancérologie	Nantes-Angers	(CRCNA),	Unité	INSERM	892	-	CNRS	6299,	Nantes	
44007	(France).	
2	 Center	 for	 Molecular	 Modeling,	 Division	 of	 Computational	 Bioscience,	 Center	 for	 Information	
Technology,	National	Institutes	of	Health,	Bethesda,	Maryland	20892	(USA).	
3	Radioimmune	&	 Inorganic	Chemistry	 Section,	Radiation	Oncology	Branch,	National	Cancer	 Institute,	
National	Institutes	of	Health,	Bethesda,	Maryland	20892	(USA).	
4	Arronax	GIP,	Nantes	44817	(France)	
	
Introduction:	Aryliodonium	salts	have	recently	emerged	as	versatile	precursors	for	the	synthesis	of	18F-
radiolabeled	 compounds	 for	 PET	 imaging.1,2	 However,	 little	 is	 known	 about	 the	 applicability	 of	 these	
reagents	for	labeling	with	the	heaviest	radiohalogens	iodine	and	astatine,	both	useful	for	nuclear	imaging	
and/or	therapy.3	In	this	study,	we	aimed	at	probing	the	reactivity	of	radio-iodide	(125I)	and	astatide	(211At)	
towards	diaryliodonium	salts	in	order	to	assess	their	usefulness	for	radiolabeling	biomolecules	of	interest	
in	nuclear	medicine.	Materials	&	Methods:	First,	parameters	of	radio-iodination	and	astatination	reaction	
(solvent,	 temperature,	 duration	 and	 counter-ion	 of	 iodonium)	 were	 studied	 on	 model	 compounds.	
Bifunctional	iodonium	salts	were	then	designed,	allowing	the	synthesis	of	[125I]-SIB	and	[211At]-SAB,	two	
prosthetic	groups	widely	used	for	radio-iodination	and	astatination	of	biomolecules.	Both	[125I]-SIB	and	
[211At]-SAB	were	 conjugated	 to	 the	multiple	myeloma	 targeting	mAb	 9E7.4	 (anti-CD138).	 Conjugation	
yields	 and	 resulting	 immunoreactivity	 were	 compared	 with	 the	 conventional	 arylstannane	 chemistry	
approach	(Figure	1).	
	
Figure	1:	Radio-iodination	and	astatination	of	9E7.4	IgG	from	iodonium	salts	precursors.	
Results:	Initial	reaction	parameters	studies	highlighted	a	striking	difference	of	reactivity	between	radio-
iodide	and	astatide	that	could	not	be	anticipated	from	the	trends	observed	within	the	halogen	series.	Not	
only	 the	 astatination	 reaction	was	 highly	 efficient	 at	much	 lower	 temperature	 than	 iodination,	 but	 it	
appeared	solvent	and	counter-ion	independent	(not	 iodination).	Thermochemical	studies	highlighted	a	
large	difference	of	activation	energy	between	both	halogens	with	Ea	=	23.5	kcal/mol	and	17.2	kcal/mol	
for	radio-iodination	and	astatination,	respectively.	Quantum	chemical	calculations	support	the	hypothesis	
that	astatination	occurs	via	a	monomeric	iodonium	complex	whereas	iodide	occurs	via	a	dimeric	complex	
which	 requires	more	 energy	 for	 the	 reaction	 to	 proceed.	 This	 explains	 the	 large	 reactivity	 difference	
observed.	 Radiolabeling	 of	 an	 antibody	 with	 specifically	 designed	 iodonium	 salts	 outperformed	
-OTf
I
+
Ar O
O
N
O
O
125I- or 211At-
OO N
O
O
X
1) Sep-pak purification
2) conjugation to 9E7.4 IgG 9E7.4-SIB (75%)
 or
9E7.4-SAB (78%)
Ar =
S
or O
X = 125I, SIB (RCY = 87%)
X = 211At, SAB (RCY = 93%)
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 30	
	
conventional	arylstannane	chemistry	approaches	in	terms	of	global	efficiency	(radiochemical	yields	>90%,	
conjugation	 yields	 ≈	 75%,	 and	 simpler	 purification:	 no	 HPLC	 needed)	 with	 excellent	 preservation	 of	
immunoreactivity	of	the	IgG	with	both	radionuclides	and	less	concerns	regarding	the	toxicity	of	precursors	
and	side	products.	Discussion/Conclusion:	In	comparison	with	the	conventional	arylstannane	approach,	
aryliodonium	salts	appear	as	more	efficient	precursors	for	preparation	of	radio-iodinated	and	astatinated	
compounds.	Furthermore,	they	allow	simpler	purification	procedures	(easy	transfer	to	automation),	with	
the	additional	advantage	of	a	much	lower	toxicity,	which	is	of	primary	importance	for	human	use.	Most	
of	all,	the	unexpected	reactivity	of	astatine	we	unveiled	highlights	that	a	lot	is	still	to	be	discovered	about	
the	chemistry	of	this	radioelement	which	remains	to	date	largely	unexplored.4	References:	1.	Telu	S,	Chun	
J-H,	Siméon	FG,	Lu	S	&	Pike	VW	[2011]	Org.	Biomol.	Chem.	9:	6629–6638,	2.	Moon	BS	et	al.[2011]	Org.	
Biomol.	 Chem.	 9:	 8346–8355	 (2011)	 3.	 Adam	MJ	 &	Wilbur	 DS	 [2005]	 	 Chem.	 Soc.	 Rev.	 34:	 153–163	
4.Wilbur,	DS	[2013].	Nat.	Chem.	5:	246–246		
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OP17	
64Cu-NOTA-pertuzumab	F(ab')2	fragments,	a	second-generation	probe	for	PET	imaging	of	the	response	
of	HER2-positive	breast	cancer	to	trastuzumab	(Herceptin)		
Lam	K1,	Chan	C1,	Reilly	RM1,2,3	
1Department	of	Pharmaceutical	Sciences,	University	of	Toronto,	Canada;	2Department	of	Medical	
Imaging,	University	of	Toronto,	Canada;	3Toronto	General	Research	Institute,	University	Health	
Network,	Toronto,	Canada	
Introduction:	 SPECT/CT	 imaging	 with	 111In-BzDTPA-pertuzumab	 detected	 trastuzumab	 (Herceptin)-
mediated	HER2	downregulation	in	human	breast	cancer	xenografts	in	mice	and	was	correlated	with	a	good	
response	 to	 treatment.	This	agent	 is	now	being	 studied	 in	a	Phase	 I/II	 clinical	 trial	 sponsored	by	OICR	
(PETRA;	 ClinicalTrials.gov	 identifier:	 NCT01805908).	 Our	 objective	 was	 to	 develop	 and	 characterize	 a	
second-generation	 positron-emitting	 analogue	 for	 PET/CT	 imaging,	 64Cu-NOTA-pertuzumab	 F(ab')2,	 to	
provide	greater	sensitivity,	more	accurate	radiotracer	quantitation	and	a	lower	radiation	absorbed	dose.	
Materials	&	Methods:	 To	 determine	 the	 optimal	 dose,	mice	with	 subcutaneous	 HER2-overexpressing	
tumours	were	injected	with	5,	50,	100	or	200	µg	of	64Cu-NOTA-F(ab')2	(2.2±0.6	MBq)	and	sacrificed	at	24	
h	p.i.	 for	 biodistribution.	 To	determine	 the	normal	 tissue	distribution,	 pharmacokinetics	 and	 radiation	
dosimetry	of	64Cu-NOTA-F(ab')2,	non-tumour	bearing	Balb/c	mice	were	administered	50	µg	of	64Cu-NOTA-
F(ab')2	 (2.9±0.3	 MBq)	 and	 sacrificed	 at	 select	 time	 points.	 Three	 groups	 of	 mice	 bearing	 HER2-
overexpressing	 tumours	were	 injected	with	 64Cu-NOTA-F(ab')2	 (50	 µg;	 10.6±0.4	MBq)	with	 or	without	
administration	of	pertuzumab	(1	mg)	24	h	before,	or	with	64Cu-NOTA-F(ab')2	prepared	from	nonspecific	
human	IgG	(50	µg;	8.2±1.9	MBq)	to	demonstrate	specificity.	Mice	were	imaged	with	PET/CT	at	24	and	48	
h	p.i.	and	sacrificed	for	biodistribution.	Results:	The	50	µg	dose	of	64Cu-NOTA-F(ab')2	showed	the	highest	
tumour	 to	 blood	 ratio,	 followed	 by	 the	 100,	 5,	 and	 200	 µg	 doses	 (18.2±7.2,	 15.4±0.8,	 14.0±5.0,	 and	
10.9±1.8,	 respectively).	 In	 non-tumour	 bearing	 mice,	 only	 the	 kidney	 retained	 significant	 radiotracer	
uptake	at	24	h	p.i.	(49.1±5.9	%ID/g).	Initial	estimates	for	t½α	and	t½β	were	1.2	h	and	6.0	h,	respectively.	
The	projected	total	body	radiation	absorbed	dose	to	humans	was	0.02	mSv/MBq,	half	that	estimated	for	
111In-BzDTPA-pertuzumab.	Tumour	to	normal	tissue	contrast	of	PET/CT	images	appeared	similar	between	
the	 24	 and	 48	 h	 p.i.	 imaging	 time	points.	 Tumour	 accumulation	of	 64Cu-NOTA-F(ab')2	was	 significantly	
higher	in	mice	administered	64Cu-NOTA-F(ab')2	without	pertuzumab	blocking	(8.4±3.4	%ID/g)	relative	to	
mice	pre-injected	with	1	mg	of	pertuzumab	(3.9±0.5	%ID/g;	P	<	0.05),	and	mice	administered	64Cu-NOTA-
F(ab')2	prepared	 from	non-specific	 human	 IgG	 (2.7±0.5	%ID/g;	P	 <	 0.05).	Discussion/Conclusion:	 64Cu-
NOTA-F(ab')2	is	HER2	specific	and	can	visualize	HER2-overexpressing	tumours	at	24	or	48	h	p.i.	with	PET/CT	
imaging.	The	lower	projected	radiation	absorbed	doses	for	64Cu-NOTA-F(ab')2	compared	to	111In-BzDTPA-
pertuzumab	 may	 make	 this	 a	 more	 attractive	 imaging	 agent	 to	 detect	 trastuzumab-mediated	 HER2	
downregulation	in	breast	cancer.	Supported	by	grants	from	the	OICR	Smarter	Imaging	and	High	Impact	
Clinical	Trials	(HICT)	Programs.	
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OP18	
Development	of	radiohalogenated	analogues	of	a	avb6-specific	peptide	for	high	LET	particle	emitter	
targeted	radionuclide	therapy	of	cancer.	
Salomé	Paillas	a,	,	John	Marshall	b,	Jean-Pierre	Pouget	c	and	Jane	Sosabowski	a	
aCentre	for	Molecular	Oncology,	Barts	Cancer	Institute,	Charterhouse	Square,	Queen	Mary	University	of	
London,	bCentre	for	Tumour	Biology,	Barts	Cancer	Institute,	Charterhouse	Square,	Queen	Mary	
University	of	London,	UK,	cInstitut	de	Recherche	en	Cancérologie	de	Montpellier,	Inserm	U1194,	
Montpellier,	France.	
	
Introduction:	Targeted	radionuclide	therapy	(TRT)	of	solid	tumors	has	a	limited	efficacy	mainly	because	
these	tumours	have	high	radioresistance	and	take	up	limited	amounts	of	radiolabeled	vectors.	Strategies	
to	overcome	this	include	the	use	of	small	peptides	combined	with	radionuclides	that	emit	highly	cytotoxic	
particles,	namely	high	linear	energy	transfer	(LET)	particles	such	as	alpha	particles	and	Auger	electrons.				
We	have	chosen	to	target	the	epithelial-specific	integrin	αvβ6,	which	is	weak	or	absent	on	normal	tissues	
but	is	upregulated	on	many	cancers	where	it	is	strongly	associated	with	reduced	survival.		One	targeting	
vector	is	a	20	mer	peptide,	A20FMDV2	which	we	have	previously	used	to	image	αvβ6-positive	tumours	
with	SPECT	 (In-111)	or	PET	 (F-18,	Ga-68).	 	 The	peptide	 showed	extremely	high	kidney	 retention	when	
radiolabelled	with	radiometals,	but	this	was	not	seen	with	the	F-18	analogue.		Due	to	anticipated	dose-
limiting	 toxicity	 in	 kidney	 for	 radiometal-based	 TRT,	 we	 have	 developed	 a	 peptide	 suitable	 for	
radiohalogenation	with	the	Auger	electron	emitter	I-125	and	the	alpha	particle	emitter	At-211.	Materials	
and	methods:	The	20	mer	high	affinity	αvβ6-targeting	peptide,	A20FMDV2	used	 in	previous	work	has	
been	derivatised	to	contain	a	trimethylstannyl	benzamide	moiety	so	that	it	can	be	radiolabelled	with	I-125	
and	At-211.	The	peptide	has	been	 radiolabelled	with	 I-125	and	 radioligand	binding	and	 internalization	
assays	have	been	carried	out	in	cells	that	overexpress	αvβ6	and	compared	with	that	of	the	111In-DTPA-
A20FMDV2	studied	previously.		Clonogenic	assays	have	been	carried	out	on	both	the	non-radiolabelled	
peptide	and	the	radiolabelled	analogue	in	both	αvβ6-positive	and	negative	cells	to	determine	the	effect	
of	high	LET	irradiation.	Results:	Radiolabelling	efficiency	with	I-125	was	>91	%	and	the	analogue	showed	
high	binding	affinity	and	rapid	internalisation.		Clonogenic	assays	showed	that	the	non-labelled	peptide	
alone	was	able	to	inhibit	cell	growth	and	that	this	effect	was	not	seen	on	αvβ6-negative	cells.			This	effect	
was	 enhanced	when	 radiolabelled	with	 a	 high	 LET	particle	 emitter.	Discussion/Conclusion:	The	αvβ6-
specific	 peptide	 when	 radiolabelled	 with	 a	 high-LET	 particle	 emitter	 shows	 promise	 as	 an	 agent	 for	
targeted	radionuclide	therapy.	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 33	
	
OP19	
Ligand	Specific	Efficiency	(LSE)	as	a	guide	in	tracer	optimization	
Emmanuelle	Briard1,	Yves	P.	Auberson1,	John	Reilly2,	Mark	Healy2,	David	Sykes3	
1Novartis	Institutes	for	Biomedical	Research,	Basel,	CH,	2Novartis	Institutes	for	Biomedical	Research,	
Cambridge,	USA,	3University	of	Nottingham,	UK	
Introduction:	 Successful	 radiotracers	 results	 from	 a	 favorable	 combination	 of	 target	 density,	 ligand	
affinity,	nonspecific	binding	and	permeation.	All	these	parameters	can	be	measured	independently	and	
the	 interplay	between	some	of	them	is	well	known:	for	 instance,	the	required	affinity	depends	on	the	
target	density,	a	condition	often	described	as	Bmax/Kd	>	10.	Importantly,	the	required	affinity	of	a	tracer	
is	also	correlated	to	nonspecific	binding:	An	increased	affinity	is	beneficial	only	if	the	nonspecific	binding	
remains	constant.	This	work	aimed	at	identifying	an	index	taking	into	account	the	relationship	between	
these	two	parameters,	to	guide	optimization	at	the	early	stage	of	a	tracer	development	project.	Materials	
&	Methods:	Similarly	to	the	Ligand	Efficiency	(LE)	index,	which	relates	the	affinity	of	a	drug	to	the	number	
of	its	non-hydrogen	atoms,	we	explored	the	usefulness	of	the	Ligand	Specific	Efficiency	index	(LSE),	which	
we	defined	as	the	ratio	between	affinity	(expressed	as	the	log	of	its	affinity	for	a	specific	target,	e.g.	pIC50	
or	pKd),	and	the	logarithmic	value	of	the	experimental	non-specific	binding	measurement,	CHI(IAM).[Jiang]	
LSE	provides	a	measure	of	affinity,	normalized	to	non-specific	binding.	It	shows	how	efficient	the	ligand	is	
at	binding	to	the	desired	target,	compared	to	all	other	non-specific	binding	partners.	
LSE	=	pKd	/	log(CHI(IAM))	 	 	 	
Ro1138452	
Results:	A	series	of	well	described	PET	tracers	was	evaluated	to	set	the	LSE	threshold.	This	analysis	showed	
that	an	LSE	>	5	and	preferably	LSE	>	5.4	is	required	for	a	successful	tracer.	This	concept	was	applied	to	the	
development	 of	 a	 prostacyclin	 receptor	 (IPR)	 tracer.	Our	 chemical	 starting	 point	was	 Ro1138452,[Clark]	
which	we	selected	based	on	encouraging	overall	properties,	including	a	high	affinity	for	IPR	(Ki	=	0.23	nM).	
In	contrast,	 its	CHI(IAM)	value	of	58	clearly	 indicated	a	high	tendency	for	non-specific	binding.	Despite	
such	high	non-specific	binding,	Ro1138452	has	a	LSE	value	of	5.1,	which	is	close	to	the	minimum	value	
what	would	be	expected	for	a	successful	PET	tracer.	This	raised	hope	that	some	improvement	in	binding	
specificity	would	allow	the	use	of	a	close	derivative	for	imaging	purposes.	The	use	of	LSE	during	the	IPR	
tracer	optimization	will	be	presented.	Discussion/Conclusion:	LSE	is	based	on	a	rather	intuitive	concept,	
in	the	sense	that	a	good	PET	tracer	candidate	should	have	the	optimum	balance	of	affinity	and	binding	
specificity.	It	is	a	convenient	index	to	evaluate	and	compare	molecules	based	on	measured,	rather	than	
in	 silico	 values,	 and	 is	 applicable	 independently	 of	 target	 and	 chemotype.	 It	 is	 a	 useful	 index	 at	 the	
beginning	of	a	project,	and	facilitates	the	selection	of	the	most	promising	scaffold	for	further	optimization.	
References:	 	 Jiang	Z,	Reilly	 J,	Everatt	B,	Briard	E,	 [2011],	 J	Pharm	Biomed	Anal	54:	722–729,	Clark	RD,	
Jahangir	A,	Severance	D,	Salazar	R,	Chang	T,	Chang	D,	Jett	MF,	Smith	S,	Bley	K,	[2004],	Bioorg	Med	Chem	
Lett	14:	1053-1056	
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OP23	
The	radiosynthesis	of	an	18F-labeled	triglyceride,	developed	to	visualize	and	quantify	brown	adipose	
tissue	activity	
	
Andreas	Paulus1,	Wouter	van	Marken	Lichtenbelt1	,Felix	Mottaghy2,3,	Matthias	Bauwens1,3	
1Research	School	NUTRIM,	Maastricht	University,	Maastricht,	Netherlands			
2	Division	of	Nuclear	Medicine,	Uniklinikum	Aachen,	Aachen,	Germany	
3	Department	of	Medical	Imaging,	Division	of	Nuclear	Medicine,	MUMC,	Maastricht,	Netherlands	
	
Introduction:	Brown	adipose	tissue	(BAT)	is	an	interesting	type	of	tissue	that	receives	major	interest	as	a	
target	to	combat	obesity.	It	was	(re-)discovered	in	2009,	when	PET-CT	studies	with	[18F]-FDG	showed	its	
presence	and	metabolic	activity	even	in	adult	humans	[1].	It	is	however	difficult	to	quantitatively	assess	
this	metabolic	activity	using	[18F]-FDG,	as	BAT	mainly	uses	lipids	as	an	energy	source.	Radiolabeled	fatty	
acids,	such	as	[18F]-FTHA,	can	provide	useful	information,	but	are	not	optimal	considering	the	lipid	uptake	
mechanism	BAT	is	not	based	on	singular	fatty	acids,	but	instead	triglycerides	(in	lipoproteins).	As	such,	we	
aim	to	develop	a	radiolabeled	triglyceride,	hoping	this	will	shed	more	light	on	the	lipid	burning	of	BAT,	
thus	allowing	to	calculate	the	impact	of	BAT	on	the	total	metabolism	of	the	human	body.	Methods:	A	
fatty	acid	(C16)	BODIPY-Fl	dye	is	radiolabeled	with	F-18	using	an	F-18/F-19	exchange	reaction	of	the	boron-
fluoride	core	of	the	BODIPY	dye	to	yield	a	bimodal	PET/fluorescent	imaging	tool.	BODIPY-C16	is	esterified	
with	1,3	–	Diolein	and	assistance	of	thionylchloride	yielding	the	resulting	fluorescent	triglyceride	(TG).	In	
vitro	 experiments	 with	 BODIPY-C16	 are	 conducted	 to	 investigate	 the	 applicability	 the	 dual-modality	
imaging	probe.	Results:	BODIPY-C16	could	be	radio-labeled	in	a	Lewis	Acid	assisted	F-18/F-19	exchange	
reaction	 in	 a	 reasonable	 yield	 (66%,	 not	 corrected	 for	 decay)	 and	 a	 final	 purity	 after	 C18	 Sep-Pak	
purification	of	more	than	97%.	Esterification	of	BODIPY-C16	resulted	in	a	BODIPY-TG	with	a	yield	of	more	
than	90%	within	30	minutes.	First	in	vitro	experiments	showed	specific	uptake	of	BODIPY-C16	in	BAT	and	
WAT	as	the	compound	was	located	within	the	lipid	droplets	of	the	cell.	Direct	radiolabeling	of	the	BODIPY-
TGL	 was	 also	 successful	 (60%	 yield,	 >97%	 purity).	 Discussion/Conclusion:	 First	 experiments	 implied	
radiolabeled	 BODIPY-C16	 is	 a	 promising	 BAT	 PET	 tracer	 with	 the	 opportunity	 to	 resolve	 its	 metabolic	
character	on	a	sub-cellular	level	due	to	its	dual-modality.	In	vivo	imaging	of	radiolabeled	BODIPY-C16	and	
BODIPY-TGL,	incorporation	into	micelles	as	well	as	further	in	vitro	experiments	will	be	conducted	in	the	
near	future	to	investigate	the	applicability	of	this	tracer	in	lipid	metabolism	imaging	of	BAT.	References:	
[1]	van	Marken	Lichtenbelt	WD,	et	al,	2009,	N	Engl	J	Med,	360(15):1500-8	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 35	
	
OP24	
Influence	 of	 the	 fluorescent	 dye	 on	 the	 tumor	 targeting	 properties	 of	 dual-labeled	 HBED-CC	 based	
PSMA	inhibitors	
Baranski,	 Ann-Christin1,	 Schäfer,	Martin1,	 Bauder-Wüst,	 Ulrike1,	 Haberkorn,	 Uwe2,	 Eder,	Matthias1,	
Kopka,	Klaus1	
1	Div.	of	Radiopharmaceutical	Chemistry,	German	Cancer	Research	Center	(dkfz),	Heidelberg,	Germany	
2	Department	of	Nuclear	Medicine,	University	of	Heidelberg,	Heidelberg,	Germany	
	
Introduction:	 Image-guided	 cancer	 surgery	 using	 fluorescence	 imaging	 has	 high	 clinical	 impact	 and	
already	shows	potential	to	improve	the	outcome	of	oncological	surgery	(1).	As	first	clinical	experiences	
with	the	68Ga-labeled	PSMA-targeting	inhibitor	Glu-urea-Lys-Ahx-HBED-CC	(PSMA-11)	demonstrated	high	
and	 specific	 tracer	 uptake	 in	 prostate	 cancer	 lesions	 a	 fluorescence	 dye	 conjugate	 of	 PSMA-11	might	
represent	a	promising	bimodal	tracer.	The	combination	of	preoperative	staging	by	means	of	PET/CT	and	
PET/MRI,	followed	by	image-guided	surgery	will	further	improve	the	accuracy	of	detecting	PSMA-positive	
tumor	 lesions	by	merging	 the	 strengths	of	both	 techniques.	 Therefore,	 various	 fluorescent	dyes	were	
conjugated	to	the	inhibitor	PSMA-11	to	determine	the	impact	of	the	dye	conjugation	on	the	ligand’s	in	
vitro	and	 in	vivo	characteristics.	Materials	&	Methods:	The	optical-dye	 labeled	tracer	PSMA-HBED-CC-
FITC,	PSMA-HBED-CC-AlexaFluor488	and	PSMA-HBED-CC-IRDye800CW	were	synthesized	based	on	PSMA-
11.	The	binding	properties	were	analyzed	in	a	competitive	cell	binding	assay	followed	by	internalization	
experiments	 in	human	PSMA	expressing	LNCaP	cells.	Biodistribution	studies	were	performed	 in	LNCaP	
tumor-bearing	mice	(BALB/c	nu/nu)	to	determine	specific	tumor	uptake	and	pharmacokinetic	properties.	
Results:	Comparative	cell	binding	experiments	revealed	a	high	affinity	to	PSMA	expressing	cell	lines	for	
all	 conjugates,	 which	 is	 in	 line	 with	 the	 values	 obtained	 with	 the	 reference	 68Ga-PSMA-11.	 The	
radiolabeled	fluorescent-dye	conjugates	showed	specific	cell	uptake	and	were	effectively	internalized	into	
the	 PSMA	 expressing	 cell	 line	 LNCaP.	 First	 in	 vivo	 results	 indicated	 slightly	 varying	 pharmacokinetic	
properties	depending	on	the	fluorescent	dye.	The	FITC-	and	AlexaFluor488-conjugates	revealed	a	higher	
tumor	uptake	compared	to	68Ga-PSMA-11,	while	a	minor,	but	still	satisfying	uptake	was	detected	for	the	
IRDye800CW-conjugate.	Discussion/Conclusion:	Conjugation	of	a	fluorescent	dye	to	the	well-established	
imaging	agent	PSMA-11	showed	rather	minor	dye-dependent	impact	on	cell	binding	properties,	tumor	
uptake	and	the	pharmacokinetic	characteristics.	In	order	to	further	improve	the	biodistribution	profile	of	
the	IRDye800CW-conjugate,	structural	optimization	will	be	done.	These	first	preclinical	results	emphasize	
the	potential	of	a	dual-labeled	PSMA	inhibitor	to	serve	as	a	multimodal	imaging	agent,	enabling	sensitive	
pre-,	 intra-	 and	 post-therapeutic	 identification	 of	 metastases	 with	 one	 and	 the	 same	 molecule.	
References:	(1)	Brouwer	O.	R.,	et	al.	[2014],	Eur	Urol	65:	600-609		
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OP25	
[18F]MEL050	as	a	melanin	PET	tracer	:	fully	automated	radiosynthesis	and	evaluation	for	the	detection	
of	pigmented	melanoma	in	mice	pulmonary	metastases	
1,2Chaussard	M,	 1,2,4Hosten	 B,	 1,2,4Vignal	 N,	 1,2Tsoupko-Sitnikov	 V,	 1,5Hernio	 N,	 1,5Hontonnou	 F,	
1,2,5Merlet	P,	3,5Poyet	JL,	1,2,5Sarda-Mantel	L,1,2,4Rizzo-Padoin	N.	
1	Unité	Claude	Kellershohn,	IUH,	Hôpital	Saint-Louis,	Paris,	F-75010,	France.	
2	GH	Saint-Louis	Lariboisière	F.	Widal	AP-HP,	Paris,	F-75010,	France.	
3	Inserm	U1160,	Hôpital	Saint-Louis,	Paris,	F-75010	France.	
4	Université	Paris	Descartes,	Faculté	de	Pharmacie,	Paris,	F-75006,	France.	
5	Université	Paris	Diderot,	Faculté	de	médecine,	Paris,	F-75010	France.	
	
Introduction:	 Melanoma	 is	 a	 highly	 malignant	 cutaneous	 tumor	 of	 melanin-producing	 cells.	 Early	
detection	of	melanoma	is	the	best	way	to	reduce	mortality.	Several	radiolabeled	 imaging	probes	have	
been	 evaluated	 for	 melanoma	 imaging.	 MEL050	 is	 a	 synthetic	 benzamide-derived	 molecule	 that	
specifically	binds	to	melanin	with	high	affinity.	Our	aim	was	to	implement	a	fully	automated	radiosynthesis	
of	 [18F]MEL050,	 including	 HPLC	 purification	 and	 formulation,	 using	 for	 the	 first	 time,	 the	 AllInOne	
radiosynthesis	 platform	 (Trasis,	Ans,	Belgium),	 and	 to	 validate	 this	 PET	 radiotracer	 in	 vivo	 in	 a	mouse	
model	of	melanoma.	Materials	&	Methods:	[18F]MEL050	was	synthesized	using	a	one-step	bromine-for-
fluorine	 nucleophilic	 heteroaromatic	 substitution.	 Briefly,	 [18F]MEL050	 was	 prepared	 from	 a	 bromo-
precursor,	using	no-carrier-added	18F-KF-Kryptofix	222	(dimethylformamide,	150°C,	6	min),	followed	by	
preparative	HPLC	purification	(C18	column	(300x7.8	mm,	7	μm),	isocratic	elution	with	acetonitrile/20	mM	
ammonium	 bicarbonate	 (20:80,	 v/v),	 3.0	 ml/min)	 and	 cartridge-reformulation	 (Sep-Pak®	 Plus	 C18	
environmental)	of	the	collected	fraction.	Radiochemical	and	chemical	purity,	stability	and	specific	activity	
measurements	 were	 monitored	 using	 analytical	 HPLC.	 Chemical	 identity	 of	 the	 labeled	 compound	
[18F]MEL050	was	assessed	by	co-injection	with	non-radioactive	standard	MEL050.	Experimental	model	of	
pulmonary	metastatic	melanoma	was	obtained	by	IV	injection	of	B16-F10	cells	in	NMRI	mice.	Mice	(n=8)	
were	imaged	15	days	after	inoculation,	using	INVEON	microPET/CT	device	(Siemens),	after	IV	injection	of	
0.36±0.04MBq/g	of	[18F]MEL050.	Dynamic	and	static	acquisitions	were	acquired	from	time	of	injection	to	
2h	after	 tracer	 injection.	 The	maximum	percentage	of	 [18F]MEL050	 Injected	Dose	per	 g	of	 lung	 tissue	
(%ID/g	Max)	was	determined	using	ROIs	manually	drawn	on	1h-post	injection	PET	images,	and	correlated	
to	 ex-vivo	 findings.	 Results:	 The	 fully	 automated	 radiosynthesis	 of	 [18F]MEL050	 required	 an	 overall	
radiosynthesis	time	of	60	min,	with	an	end-of-synthesis	yield	of	20-26%	(n=12).	Isocratic	semi-preparative	
HPLC	 allowed	 efficient	 separation	 of	 [18F]MEL050	 from	 the	 reaction	 mixture.	 The	 radiotracer	 was	
consistently	produced	with	radiochemical	purity	higher	than	99%.	The	specific	activity	was	in	the	range	of	
177-325GBq/µmol	 and	 the	 product	 stability	 was	 maintained	 at	 RCP>98%	 over	 6	 h.	 PET/CT	 images	
retrieved	known	biodistribution	of	 [18F]MEL050	 in	mice,	and	allowed	clear	visualization	of	<1mm	 lung	
tumours	 with	 [18F]MEL050	 %/ID/g	 Max	 of	 4.7±2.6%.	 Discussion/Conclusion:	 We	 successfully	
implemented	 the	 radiosynthesis	of	 [18F]MEL050	using	 the	AllInOne	 radiosynthesis	platform	 ,	 including	
HPLC	separation	and	formulation.	In	vivo	PET/CT	validation	of	the	radiotracer	was	obtained	in	a	mouse	
model	of	metastatic	pigmented	melanoma,	showing	high	specific	[18F]MEL050	uptake	in	sub-millimetric	
lung	tumours.	
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OP26	
Design	and	Preclinical	Evaluation	of	Novel	Radiofluorinated	PSMA	Targeting	Ligands	Based	on	PSMA-
617	
J.	Cardinale1,	M.	Schäfer1,	M.	Benešová1,	U.	Bauder-Wüst1,	O.	Seibert2,	F.	Giesel2,	U.	Haberkorn2,	M.	
Eder1,	K.	Kopka1	
1DKFZ,	 Division	 of	 Radiopharmaceutical	 Chemistry,	 Heidelberg,	 Germany;	 2DKFZ,	 Clinical	 Cooperation	
Unit	Nuclear	Medicine,	Heidelberg,	Germany	
	
Introduction:	Urea-based	inhibitors	of	the	prostate-specific	membrane	antigen	(PSMA)	are	well	known	
and	promising	candidates	for	the	diagnosis	(1,	2)	and	therapy	of	prostate	cancer.	The	aim	of	the	project	
was	the	development	of	F-18	labeled	PSMA	ligands	based	on	the	theranostic	compound	PSMA-617.	The	
compounds	evaluated	during	 the	preliminary	experiments	showed	a	high	uptake	 in	non-target	organs	
caused	by	their	relatively	high	lipophilicity.	Therefore	we	currently	reduce	this	lipophilicity	by	the	addition	
of	charged	amino	acids	to	the	linker	region	of	our	PSMA	inhibitors	(3).	Materials	&	Methods:	The	PSMA	
binding	motif	 Glu-NH-CO-NH-Lys	was	 synthesized	 by	 a	well-established	method	 (4)	 using	 solid	 phase	
chemistry	and	subsequently	an	amino	acid	linker	was	built	up	by	fmoc-based	solid	phase	peptide	synthesis	
(SPPS).	 The	 non-radioactive	 reference	 compounds	 were	 also	 prepared	 analogically	 and	 eventually	
conjugated	 by	 6-fluoronicotinic	 acid.	 After	 separation	 from	 the	 resin	 and	 deprotection	 the	
peptidomimetics	were	labeled	using	the	TFP-ester	of	6-[18F]fluoronicotinic	acid	as	prosthetic	group.	The	
Ki	values	of	all	compounds	were	determined	by	competitive	binding	assays	on	PSMA-positive	LNCaP	cells	
against	 68Ga-PSMA-10	 (5)	 using	 the	 respective	 cold	 reference	 compounds.	 Additionally,	 the	 cellular	
internalization	of	the	radiofluorinated	ligands	was	determined.	Results:	All	18F-labeled	PSMA-inhibitors	
presented	 in	 this	 study	 showed	 low	 nanomolar	 affinities	 towards	 PSMA,	 usually	 paired	 with	 high	
internalization	 ratios	 of	 more	 than	 15	 %,	 shown	 in	 vitro.	 Among	 those	 PSMA-1007	 showed	 an	
outstandingly	high	internalization	ratio	of	about	70	%	while	the	Ki	was	in	the	typical	range	(6	nM).	Hence	
PSMA-1007	was	further	evaluated	in	vivo.	The	organ	distribution	showed	a	high	and	specific	tumor	uptake	
of	 8.0±2.4	 %ID/g.	 Finally,	 the	 PSMA-targeting	 potential	 of	 PSMA-1007	 was	 further	 demonstrated	 by	
dynamic	 µPET	 experiments.	 Discussion/Conclusion:	 Based	 on	 our	 experience	 with	 PSMA-617	 and	
preliminary	 results	we	developed	a	 series	of	 radiofluorinated	PSMA	 inhibitors	with	high	affinities	 and	
internalization	ratios.	Among	those	a	promising	candidate	for	further	translation	into	the	clinic	has	already	
been	 found.	 This	 candidate	 –	 namely	 PSMA-1007	 –	 is	 currently	 transferred	 into	 first-in-man	 studies.	
Nevertheless	further	optimization	of	the	lead	compound	is	still	ongoing.	References:	(1)	Afshar-Oromieh	
A.	et	al.,	[2013],	Eur.	J.	Nucl.	Med.	Mol.	Imaging	40,	486-495.	(2)	Szabo	Z.	et	al.,	[2015],	Mol.	Imaging	Biol.	
17,	565-574.	(3)	Cardinale	J.	et	al.,	EP	15002800.9.	(4)	Eder	M.	et	al.,	[2012],	Bioconjugate	Chem.	23,	688-
697.	(5)	Schäfer	M.	et	al.,	[2012],	EJNMMI	Res.	2,	23.	
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OP27	
A	Novel	Radiolabeled	Peptide	for	PET	Imaging	of	Prostate	Cancer:	64Cu-DOTHA2-PEG-RM26	
Mansour	 Nematallah,	 Paquette	 Michel,	 Ait-Mohand	 Samia,	 Dumulon-Perreault	 Véronique,	 Lecomte	
Roger,	Guérin	Brigitte.	
Introduction:	 The	 Gastrin-Releasing	 Peptide	 Receptor	 (GRPR)	 is	 overexpressed	 in	 a	 wide	 variety	 of	
prostate	 cancers,	 hence	 its	 interest	 as	 a	 potential	 biomarker.	 As	 such,	 previous	 work	 used	 different	
radiolabeled	GRPR-binding	peptides	to	specifically	target	tumors	in	vivo	(1,	2).	Recently,	we	synthesized	a	
novel	 bifunctional	 chelator	 bearing	 hydroxamic	 acid	 arms,	 called	 DOTHA2,	 for	 which	 our	 group	
demonstrated	 fast	and	stable	complexation	 to	 64Cu	 (3).	The	goal	of	 this	 study	was	 to	develop	a	GRPR	
antagonist,	D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2	(RM26),	conjugated	to	the	novel	[64Cu]-DOTHA2	to	
visualize	prostate	tumor	by	PET	imaging.	Material	&	Methods:	DOTHA2-PEG-RM26	was	conveniently	and	
efficiently	assembled	on	solid	support	with	good	yield.	The	inhibition	constant	(Ki)	was	measured	on	PC3	
cells	as	previously	described	(1).	Dynamic	PET	images	were	acquired	during	60	minutes	on	nu/nu	male	
mice	bearing	PC3	tumors.	Biodistribution	studies	were	performed	using	balb/c	male	mice	and	nu/nu	male	
mice	bearing	PC3	tumors	at	time	points	of	30,	60	and	120	minutes.	To	assess	specific	binding,	a	cohort	
received	500	nmol/kg	of	unlabeled	peptide	15	minutes	prior	tracer	injection	for	both	PET	and	dissection	
studies.	 Results:	 DOTHA2-PEG-RM26	 complexed	 64Cu	 with	 fast	 kinetics	 at	 room	 temperature.	 The	
radiopeptide	showed	high	stability,	 low	residual	activity	in	various	tissues	and	fast	clearance	in	normal	
mice.	The	Ki	of	Cu-DOTHA2-PEG-RM26	was	in	the	low	nanomolar	range	(0.68	±	0.19	nM).	[64Cu]-DOTHA2-
PEG-RM26	in	vivo	pharmacokinetics	demonstrated	rapid	blood	and	renal	clearance.	Small	animal	blocking	
experiments	showed	a	significant	uptake	drop	compared	to	tracer	alone	(p	<	0.05	from	20	to	60	min)	in	
PET	imaging	and	by	biodistribution	in	the	GRPR-rich	pancreas	for	both	balb/c	and	nu/nu	mice	(respectively	
p<	 0.05	 and	 p	 <	 0.01	 at	 30	 min).	 Discussion	 /	 Conclusion:	 The	 use	 of	 [64Cu]-DOTHA2-PEG-RM26	 is	
promising	for	visualizing	prostate	tumors.	These	preliminary	data	suggest	that	DOTHA2	can	be	used	to	
develop	 many	 other	 peptide-	 and	 protein-derived	 PET	 tracers.	 References:	 1.	 Fournier	 P,	 Dumulon-
Perreault	V,	Ait-Mohand	S,	Tremblay	S,	Bénard	F,	 Lecomte	R,	Guérin	B,	 [2012].	Bioconjug.	Chem.	23	 :	
1687-1693,	2.	Fournier	P,	Dumulon-Perreault	V,	Ait-Mohand	S,	Langlois	R,	Bénard	F,	Lecomte	R,	Guérin	
B,[2012]	Eur	J	Nucl	Med	Mol	Imaging	Research,	2:	1-15,	3.	Ait-Mohand	S,	Denis	C,	Tremblay	G,	Paquette	
M,	Guérin	B,	[2014]	Org	Lett	16:	4512-4515	
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OP29	
Biodistribution	of	[18F]Amylovis®,	a	new	radiotracer	PET	imaging	of	β-amyloid	plaques	
Fernandez-Maza	 L1,	 Rivera-Marrero	 S2,	 Prats	 Capote	 A3,	 Parrado-Gallego	 A1,	 Fernandez-Gomez	 I1,	
Balcerzyk	 M1,	 Sablon-Carrazana	 M2,	 Perera-Pintado	 A3,	 Merceron-Martinez	 D2,	 Acosta-Medina	 E4,	
Rodriguez-Tanty	C2.	
1.	Centro	Nacional	de	Aceleradores.	Universidad	de	Sevilla,	CSIC,	Junta	de	Andalucia.	Spain.	
2.	Centro	de	Neurociencias	(CNEURO),	La	Habana.	Cuba.	
3.	Centro	de	Isótopos	(CENTIS),	Mayabeque.	Cuba.	
4.	Centro	de	Estudios	Avanzados	de	Cuba	(CEAC),	La	Habana.	Cuba.	
	
Aim:	[18F]-2-(3-fluoropropyl)-6-methoxynaphtalene	([18F]Amylovis®)	is	a	new	naphthalene-derivative	for	
detecting	β-amyloid	plaques	in	Alzheimer’s	disease.	The	aim	of	the	study	is	the	assessment	of	the	animal	
biodistribution	 of	 this	 new	 radiotracer.	 Material	 and	 methods:	 [18F]Amylovis®	 was	 synthesized	 by	
nucleophilic	substitution	of	the	tosyl	group	of	the	precursor.	Thirty	five	healthy	male	Balb/C	mice	of	10-
12	weeks	were	divided	into	6	groups	of	5	animals	each	and	injected	with	similar	doses	of	[18F]Amylovis®	
through	a	lateral	tail	vein.	Blood	samples	were	collected	and	the	animals	were	sacrificed	at	5,	15,	30,	45,	
70	and	180	minutes.	Organs	of	 interest	were	removed	and	washed	with	saline.	Radioactivity	of	blood,	
plasma,	urine,	faeces,	brain,	cerebellum,	heart,	liver,	stomach,	spleen,	bowel,	colon,	left	kidney,	muscle,	
bone	and	tail	was	measured	in	a	well	counter.	To	assess	protein	binding,	plasma	samples	were	diluted	
with	acetonitrile	and	centrifuged	at	4000	g.	Pellets	of	proteins	and	supernatants	were	separated	and	their	
radioactivity	measured	 in	 a	 well	 counter.	 RadioTLC	 analysis	 of	 plasma	were	 performed	 for	 the	 same	
purpose	 in	 silicagel	 60	 and	mobile	 phase	 of	 acetonitrile/water	 (95/5).	 20µL	 of	 each	 supernatant	was	
analysed	 by	 HPLC-RP	 using	 a	 C18	 column	 and	 acetonitrile/water	 (75/25)	 as	mobile	 phase	 to	 identify	
plasma	metabolites.	 Pharmacokinetic	 parameters	 (AUC,	 t1/2,	 Cmax,	 Cl,	 Vss)	 were	 calculated	 using	 non-
compartmental	analysis	(NCA).	Dynamic	PET/CT	images	of	healthy	and	transgenic	APPSwe/PS1dE9	mice	
were	acquired	for	2.5	h	after	i.v.	administration.	Immunohistochemistry	of	control	and	transgenic	mice	
brains	were	performed	to	identify	β-amyloid	plaques.	Results:	[18F]Amylovis®	crossed	blood	brain	barrier.	
Renal	and	hepatic	pathways	were	the	main	excretion	routes.	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 40	
	
OP30	
Synthesis	and	preclinical	evaluation	of	[11C]-BA1	PET	tracer	for	the	imaging	of	CSF-1R	
Bala	Attili,	Muneer	Ahamed	and	Guy	Bormans,	Laboratory	for	Radiopharmacy,	Department	of	
Pharmaceutical	and	Pharmacological	Sciences,	KU	Leuven,	Leuven,	Belgium.	
Introduction:	Colony	stimulating	factor-1R	(CSF-1R)	also	called	Feline	McDonough	Sarcoma	(FMS),	is	a	
type-III	kinase	receptor.	FMS	is	widely	expressed	and	considered	to	regulate	development,	maintenance	
and	functioning	of	mononuclear	phagocyte	lineage	such	as	monocytes,	macrophages,	dendritic	cells,	
langerhans	cells,	microglia	and	osteoclasts1.Overexpression	of	FMS	has	been	implicated	in	a	number	of	
disease	states	including	cancer,	rheumatoid	arthritis,	Crohn’s	disease	and	bone	disorders.	FMS	is	also	
known	to	play	a	key	role	in	microglia	differentiation	and	activation	and	it	is	assumed	to	be	a	key	
mediator	in	neuroinflammation2.	
	
Figure	 1.	 Radiochemical	 synthesis	 followed	 by	 biodistribution	 baseline	 and	 blocking	 and	 time	 activity	
curves	of	microPET	scans	in	rats.	
Materials	 and	 Methods:	 Synthesis	 of	 5-cyano-N-(4-(4-methylpiperazine-1-yl)-2-(4-methylpiperidin-1-
yl)phenyl)furan-2-carboxamide	 and	 5-cyano-N-(2-(4-methylpiperidine-1-yl)-4-(piperazine-1-
yl)phenyl)furan-2-carboxamide	were	 done	 according	 to	 literature	methods	with	 slight	modifications	3.		
[11C]-methyl	triflate	reacts	with	the	precursor	in	presence	of	a	base	at	room	temperature	for	2	minutes	
providing	carbon-11	radiolabeled	[11C]BA-1	(Figure	1)	which	was	purified	by	using	reversed-phase	high	
pressure	 liquid	 chromatography	 (RP-HPLC).	 The	 peak	 corresponding	 the	 reference	 compound	 was	
collected	and	checked	for	purity	using	analytical	RP-HPLC.		Baseline	biodistribution	study	was	performed	
at	2,	10,	30	and	60	min.	respectively.	Blocking	experiment	(10	mg/kg	cold	compound)	was	performed	at	
30	min	time	point	 in	healthy	female	adult	mice	n=3	and	compared	with	vehicle	treated	batch.	 In	vitro	
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autoradiography	experiments	were	 carried	out	on	 rat	 brain	 slices	by	 incubating	 tracer	 in	 presence	or	
absence	of	cold	reference	compound	(40	µM/ml).	MicroPET	imaging	studies	were	performed	on	a	Focus™	
220	microPET	scanner	with	female	rats.	Results:	Reference	and	precursor	molecules	were	synthesized	
with	comparable	purities	and	yields	reported	in	the	literature,	the	alkylation	yield	(relative	to	[11C]CH3I	
activity)	was	60	%	and	radiochemical	purity	was	98	%	with	average	specific	activity	(n=5)	of	250	GBq/µmol.	
Biodistribution	 study	 shows	 high	 tracer	 uptake	 in	 brain	 (4	 %	 ID	 4	 at	 2	 min),	 with	 both	 renal	 and	
hepatobiliary	excretion.	High	lung	uptake	was	observed	with	(14	%	ID	at	2	min	p.i.).	Blocking	with	cold	
compound	did	not	result	in	any	blocking	effect	in	brain	but	we	observed	blocking	in	peripheral	organs	like	
liver	 and	 spleen,	 and	 also	 observed	 slight	 blocking	 in	 pancreas	 and	 kidneys.	We	 did	 not	 observe	 any	
blocking	with	in	vitro	autoradiography	experiments	on	rat	brain	slices.	Baseline	microPET	scans	suggests	
good	uptake	of	tracer	into	brain	with	(SUV	1.2	at	3	min	pi)	and	blocking	resulted	in	a	higher	brain	uptake	
(SUV	2).	Discussion/Conclusion:	We	successfully	synthesized,	[11C]-BA1.	In	preclinical	evaluation	we	did	
not	observe	any	significant	blocking	effect	 in	the	brain,	we	are	currently	 looking	for	other	high	affinity	
molecules	for	CSF-1R.	References:	1.	Y.	Nakamichi	et	al.,	(2013),	J	Bone	Miner	Metab	31,	486–495.	2.	M.	
I.	El-Gamal	et	al.	FMS	Kinase	Inhibitors:	Current	Status	and	Future	Prospects,	(2013),	Medicinal	Research	
Reviews,	 33,	 No.	 3,	 599-636.	 3.	 C.	 R	 Illig	 et	 al,	 Discovery	 of	 novel	 FMS	 Kinase	 inhibitors	 as	 anti-
inflammatory	agents	(2008),	Bioorganic	&	Medicinal	Chemistry	Letters,	18,	1642-1648.	
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OP31	
In	vivo	imaging	of	the	MCHR1	in	the	ventricular	system	via	[18F]FE@SNAP	
C.	Philippe1,	M.	Zeilinger1,	T.	Scherer2,	C.	Fürnsinn2,	M.	Dumanic1,	W.	Wadsak1,	M.	Hacker1,	
M.	Mitterhauser1,3	
1Dept	of	Biomedical	Imaging	and	Image-guided	Therapy,	Division	of	Nuclear	Medicine,	Radiopharmacy	
and	Experimental	Nuclear	Medicine,	Medical	University	of	Vienna,	Austria	
2Dept	of	Medicine	III,	Division	of	Endocrinology	and	Metabolism,	Medical	University	of	Vienna,	Austria	
3Ludwig	Boltzmann	Institute	for	Applied	Diagnostics,	Vienna,	Austria	
	
Introduction:	The	melanin	concentrating	hormone	receptor	1	(MCHR1)	is	predominately	expressed	in	the	
lateral	hypothalamus	and	is	playing	a	key	role	in	energy	homeostasis	and	obesity.	Recently,	it	has	been	
shown	that	the	MCHR1	is	expressed	in	the	ependymal	cells	of	the	3rd	ventricle	where	it	is	involved	in	the	
regulation	of	cilia	beat	frequency	[1].	This	beating	facilitates	cerebrospinal	fluid	circulation,	which	is	crucial	
for	brain	function,	as	defects	in	ventricular	cilia	result	in	hydrocephalus.	Our	aim	was	to	investigate	the	
potential	of	the	MCHR1	ligand	[18F]FE@SNAP	[2]	for	PET-imaging	of	the	MCHR1	in	the	ventricular	system.	
Materials	&	Methods:	In	vivo	experiments	were	conducted	in	naïve	male	Sprague	Dawley	rats.		For	small-
animal	 PET/CT/MR	 experiments,	 rats	 were	 anesthetized	 by	 isoflurane.	 25min	 after	 [18F]FE@SNAP	 iv	
injection	 (47.8±1MBq;	 SA:	 19.7±6GBq/µmol),	 vehicle	 (baseline	 group,	 n=3)	 or	 15mg/kg	 SNAP-7941	
(blocking	group,	n=3)	were	administered	through	the	tail	vein.	75min	after	tracer	injection,	the	rats	were	
sacrificed.	Radioactivity	concentrations	in	brain	were	calculated	and	expressed	as	SUVs.	In	another	set	of	
experiments,	[18F]FE@SNAP	(51.3±26MBq;	SA:	36.1±28GBq/µmol)	as	well	as	vehicle	(baseline	group,	n=3)	
or	 15mg/kg	 SNAP-7941	 (blocking	 group,	 n=3)	 were	 injected	 into	 conscious	 freely	 moving	 rats	 via	 a	
permanent	catheter	implanted	into	the	jugular	vein,	thus	excluding	an	influence	of	anaesthesia.	45min	
after	tracer	application,	rats	were	sacrificed,	the	brain	was	removed	and	cut	for	ex	vivo	autoradiography.	
Subsequently,	brain	slices	were	put	on	Phosphor	Imager	plates	for	exposure	and	analyzed	with	a	Cyclone	
Phosphor	Imager	the	following	day.	Regions	of	interest	(ROIs)	were	drawn	for	the	hypothalamic	region,	
the	ventricle	and	a	non-target	region.	ROIs	resulted	 in	normalized	DLU/	mm2);	ratios	of	ventricle/non-
target	were	calculated.	Results:	PET/CT/MR	experiments:	the	SUV	in	the	ventricular	system	was	0.73±0.11	
for	the	baseline	group	and	0.34±0.07	for	the	blocking	group,	which	represents	a	significant	reduction.	Ex	
vivo	autoradiography	showed	a	distinct	uptake	in	the	ventricular,	which	was	significantly	reduced	in	the	
blocking	group	(Table	1).		
RATIO	 Baseline	 Blocking	 P-values	
ventricle/non-target	 2.20	±	0.4	 1.38	±	0.2*	 <0.0001	
Table	1.	Calculated	ratios	of	the	ROIs	(DLU/mm2).	*	indicates	significant	blocking.	
	
Conclusion:	[18F]FE@SNAP	evinced	specific	uptake	in	the	ventricular	system	of	naïve	rats	regardless	their	
state	of	consciousness	and	is	therefore	a	suitable	imaging	agent	for	cilia	beat	function.	References:	[1]	
Conductier	G,	Martin	AO,	Risold	P-Y,	et	al.	[2013],	Front.	Endocrinol.	4:	182	[2]	Philippe	C,	Nics	L,	Zeilinger	
M,	et	al.	[2013],	Sci.	Parm.	81:	625-639	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 43	
	
OP32	
Synthesis	of	the	first	carbon-11	labelled	P2Y12	receptor	antagonist	for	imaging	the	anti-inflammatory	
phenotype	of	activated	microglia		
B.	 Janssen1,	 D.J.	 Vugts1,	 G.T.	 Molenaar1,2,	 U.	 Funke1,2,	 P.S.	 Kruijer2,	 F.	 Dollé3,	 G.	 Bormans4,	 A.A.	
Lammertsma1,	A.D.	Windhorst1	
1Department	of	Radiology	&	Nuclear	Medicine,	Neuroscience	Campus	Amsterdam,	VU	University	Medical	
Center,	Amsterdam,	The	Netherlands;	2BV	Cyclotron	VU,	Amsterdam,	The	Netherlands;	3CEA,	 Institut	
d’Imagerie	 BioMédicale,	 Service	 Hospitalier	 Frédéric	 Joliot,	 Orsay,	 France;	 4Laboratory	 for	
Radiopharmacy,	Dept.	of	Pharmaceutical	and	Pharmacological	Sciences,	KU	Leuven,	Leuven,	Belgium	
Introduction:	Activated	microglia	are	a	hallmark	of	neuroinflammation	(NI),	which	in	turn	is	associated	
with	neurodegenerative	diseases	[1].	The	P2Y12	receptor	(P2Y12R)	is	upregulated	in	the	anti-inflammatory	
phenotype	 of	 activated	 microglia,	 and	 is	 not	 expressed	 on	 macrophages	 and	 other	 brain	 cells	 [2].	
Therefore,	 P2Y12R	 could	 be	 an	 interesting	 new	 target	 for	 PET	 imaging	 of	 microglial	 activation	 in	 NI.	
Recently,	a	series	of	P2Y12R	antagonists	with	high	binding	affinity	was	reported	[3].	Based	on	this	series,	
the	purpose	of	the	present	study	was	to	label	urea	derivative	5	(IC50	=	6	nM)	with	carbon-11.	Materials	&	
Methods:	The	synthesis	of	5,	as	reference,	and	compounds	3	and	6,	as	precursors	for	the	radiosynthesis	
of	 [11C]-5,	 is	 depicted	 below.	 Carbon-11-labelling	 was	 performed	 via	 a	 rhodium(I)-mediated	 [11C]CO	
carbonylation	reaction	[4,5].	[11C]5	was	evaluated	using	in	vitro	autoradiography	of	healthy	mouse	brains	
and	ex	vivo	biodistribution	and	radiometabolite	analyses	in	healthy	male	Wistar	rats.	
	
Results:	Compound	5	 and	precursors	3	and	6	were	 successfully	 synthesised.	 [11C]5	was	obtained	 in	 a	
radiochemical	 yield	 of	 10±2	 %	 (corrected	 for	 decay,	 calculated	 from	 [11C]CO2	 (n=6)),	 and	 high	
(radio)chemical	purity	(≥98%)	and	specific	activity	(79±32	GBq·µmol-1	(n=6)).	In	in	vitro	autoradiography	
studies	 of	 the	 healthy	mouse	 brain,	 [11C]5	 could	 be	 blocked	 (81%)	with	 ticagrelor,	 indicating	 specific	
binding	to	P2Y12R.	However,	rapid	metabolism	in	rat	plasma	was	observed	with	only	30±4%	(n=3)	of	[11C]5	
left	 at	45	min	p.i..	 In	addition,	ex	vivo	 biodistribution	 revealed	 that	 [11C]5	 did	not	enter	 the	 rat	brain.	
Discussion/Conclusion:	[11C]5	is	not	suitable	for	in	vivo	studies,	but	can	still	be	used	in	vitro	to	validate	
P2Y12R	as	a	target	for	imaging	the	anti-inflammatory	phenotype	of	activated	microglia.	
Acknowledgement:	This	research	has	received	funding	from	the	European	Union's	Seventh	Framework	
Programme	(FP7/2007-2013)	under	grant	agreement	n°	HEALTH-F2-2011-278850	(INMiND).	References:	
1.	Jacobs	AH	&	Tavitian	B,	[2012],	J.	Cereb.	Blood	Flow	Metab.	32:	1393.	2.	Hickman	SE	et	al.	[2013],	Nat.	
Neurosci.	16:	 1896;	 Butovsky	O	et	 al.	 [2014],	Nat.	Neurosci.	 17:	 131;	Moore	CS	et	 al.	 [2015],	Neurol.	
Neuroimmunol.	Neuroinflamm.	2:	e80.	3.	Bach	P	et	al.	[2013],	Eur.	J.	Med.	Chem.	65:	360.	4.	Eriksson	J	et	
al.	[2012],	J.	Labelled	Compd.	Radiopharm.	55:	223.	5.	Åberg	O	&	Långström	B	[2011],	J.	Labelled	Compd.	
Radiopharm.	54:	38.	 	
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Radiosynthesis	of	a	selective	HDAC6	inhibitor	[11C]KB631	and	in	vitro	and	ex	vivo	evaluation	
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Introduction:	HDAC6	has	been	reported	as	a	regulator	in	numerous	diseases	ranging	from	different	kinds	
of	 cancers	 (ovarian,	 breast,	 prostate,..)	 to	neurological	 deficiencies	 (Alzheimer’s	 disease,	Huntington’s	
disease,	 amyotrophic	 sclerosis,..)	 [1,2].	 Still	 many	 characteristics	 and	 functions	 of	 HDAC6	 in	 these	
pathologies	 are	 unrevealed.	 Hence,	we	 aim	 to	 develop	 a	 selective	 HDAC6	 PET	 tracer	 to	 visualize	 the	
dynamics	of	HDAC6	in	normal	and	disease	states.	Recently,	Lu	and	coworkers	synthesized	[11C]KB631,	a	
highly	 potent	 (IC50=1.4	 nM)	 and	 selective	 (3700-fold	 selectivity	 against	 HDAC1)	 PET	 tracer	 for	 HDAC6	
imaging	 in	 the	 brain,	which	 showed	 similar	 pharmacokinetic	 properties	 as	 tubastatin	A	 [3].	 However,	
[11C]KB631	 showed	 low	 brain	 bioavailability	 [4].	 In	 this	 regard	we	 opted	 to	 use	 this	 tracer	 as	 a	more	
peripheral	imaging	agent.	The	radiosynthesis	was	redesigned	and	preliminary	results	were	obtained	with	
a	biodistribution	study	and	autoradiography	experiments	in	brain	and	tumor	slices.	Materials	&	Methods:	
[11C]KB631	was	synthesized	through	methylation	of	the	corresponding	precursor	(300	µg)	with	[11C]-MeI	
in	anhydrous	DMSO	(250	µL)	at	100	°C	for	4	min	(Fig.	1).	The	biodistribution	was	studied	in	NMRI-mice	at	
2,	10,	30	and	60	min	 (n	=	3	 /	 time	point)	post	 injection	 (p.i.).	Organs	and	 tissues	were	harvested	and	
radioactivity	was	counted	in	a	gamma-counter.	Autoradiography	studies	were	carried	out	with	[11C]KB631	
on	wild-type	Wistar	rat	brain	tissue	and	PC3/LNCaP	prostate	tumor	slices.	Slices	were	incubated	with	18.5	
MBq/400µL	 (brain)	 or	 18.5	 MBq/250	 µL	 (tumor)	 of	 tracer	 with/without	 100	 µM	 of	 cold	 authentic	
reference	compound	(KB631)	or	non-structural	related	pan-HDAC	inhibitor	Suberoylanilide	hydroxamic	
acid	(SAHA)	[5].		
N NH
O
HN
OH
N N
O
HN
OH
11CH311CH3I, DMSO
4 min 100 °C
	
	
Results:	Based	on	prep	HPLC	integration,	the	methylation	yield	was	55	%	with	a	radiochemical	purity	of	
97	%	and	a	specific	activity	of	48	GBq/µmol.	Biodistribution	studies	indicated	low	brain	uptake	(<0.1	%ID	
at	 2,	 10,	 30	 and	 60	min)	 and	 renal	 and	 hepatobiliary	 excretion	 (Fig	 2).	 Autoradiography	 experiments	
showed	regional	binding.	Binding	in	brain/tumor	slices	was	highly	displaceable	in	the	presence	of	100	µM	
non-labeled	reference	KB631	(up	to	90%	for	brain,	PC3	and	LNCaP)	or	100	µM	SAHA	(73%	brain,	39%	PC3	
and	59%	LNCaP)	(Fig	3).	
Fig.1	Radiosynthesis	of	[11C]KB631	
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Discussion/Conclusion:	 We	 successfully	 radiolabeled	 and	 evaluated	 a	 potential	 carbon-11	 labeled	
radiotracer	for	in	vitro	and	ex	vivo	visualization	of	HDAC6.	However,	biodistribution	studies	indicated	low	
brain	uptake,	peripheral	potency	 still	 needs	 to	be	 further	examined.	Autoradiography	 studies	 showed	
regional	 and	 displaceable	 binding.	 Furthermore,	 radiometabolite	 studies	 followed	 by	 µPET	 on	 a	mice	
tumor	model	will	be	performed.	References:	1.	Sakamoto	KM,	Aldana-Masangkay	GI,	[2011],	JBB.	2011:	
875824,	2.	Helleputte	L,	Benoy	V,	Bosch	L,	[2014],	RRB,	5:	1–13.	3.	Butler	KV,	Kalin	J,	Brochier	C,	Vistoli	G,	
Langley	B,	Kozikowski	AP,	[2011],	JACS,	132:	10842–6.	4.	Lu	S,	Zhang	Yi,	Kalin	J,	Liow	JS,	Gladding,	RL,	Innis	
RB,	Kozikowski,	AP,	Pike	VW,	[2013],	JLCR,	56:	S1-S492.	5.	Wagner	FF,	Weїwer	M,	Lewis	MC,	Holson	EB.	
[2013],	NT,	10:	589–604.		
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Fig.2	Biodistribution	study	in	NMRI-mice	[11C]KB631	at	2,	10,	30	and	60	min	p.i.		
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Improving	metabolic	stability	of	fluorine-18	labelled	verapamil	analogues	
Raaphorst	RM1,	Luurtsema	G2,	Lammertsma	AA1,	Elsinga	PH2,	Windhorst	AD1,		
1	 Department	 of	 Radiology	 &	 Nuclear	 Medicine,	 Neuroscience	 Campus	 Amsterdam,	 VU	 University	
Medical	Center,	Amsterdam,	The	Netherlands,	2	Department	of	Nuclear	Medicine	and	Molecular	Imaging,	
University	Medical	Center	Groningen,	University	of	Groningen,	Groningen,	The	Netherlands	
	
Introduction:	 (R)-[11C]verapamil	 is	 widely	 used	 as	 a	 PET	 tracer	 for	 investigating	 P-glycoprotein	 (P-gp)	
function	 in	 patients	 with	 epilepsy,	 Alzheimer´s	 disease	 and	 other	 neurodegenerative	 diseases	 [1].	
Recently,	we	 have	 developed	 the	 fluorine-18	 analogues	 (R)-N-[18F]fluoroethylverapamil	 (1)	 and	 (R)-O-
[18F]fluoroethylnorverapamil	(2),	potentially	enabling	P-gp	studies	in	centres	without	an	on-site	cyclotron.	
These	analogues	showed	specific	P-gp	substrate	behaviour,	but	metabolic	stability	was	poor	(Fig	1b).	The	
purpose	of	the	present	study	was	to	assess	whether	deuterated	analogues	would	have	better	metabolic	
stability.	Materials	&	Methods:	To	a	dried	18F/K2.2.2/K2CO3	complex,		2-bromoethyl-d4-tosylate	in	DMF	was	
added	and	reacted	for	10	min	at	90°C	to	obtain	2-bromo-[18F]fluoroethane-d4.	This	was	distilled	at	100	°C	
through	an	AgOTf	column	at	200	°C	into	a	cooled	(0	°C)	vial	containing	1.5	mg	of	(R)-normethyl	verapamil	
(1a)	and	3	mg	of	K2CO3	in	ACN.	While	stirring,	this	reaction	mixture	was	heated	at	120	°C	for	15	min	and	
purified	by	HPLC,	resulting	in	1b.	Tracer	2b,	3b	and	4b	were	obtained	by	direct	fluorination	of	precursors	
2a,	3a	and	4a	and	only	2b	 required	 final	Boc-deprotection	with	TFA.	1b	and	2b	were	administered	 to	
Wistar	rats,	and	the	level	of	labelled	metabolites	was	measured	in	blood	plasma	and	brain	samples.	
	
Fig	1.	a)	Labelling	scheme	for	PET	tracers	1b,	2b,	3b	and	4b.	Reagents	and	conditions:	i)	[18F]fluoroethyl-
d4-triflate,		
	
MeCN,	120	°C,	15	min	ii)	18F/K2.2.2/K2CO3,	MeCN,	90	°C,	15	min.	Only	for	2b,	TFA;	b)	results	of	metabolite	
analysis	 for	1	and	2	 (non-deuterated	analogues)	and	1b	and	2b	 (deuterated	analogues)	 in	plasma	and	
brain.	Results:	1b,	2b,	3b	and	4b	were	obtained	in	a	radiochemical	yield	of	3,	6,	5	and	10%,	respectively,	
a	purity	>98%	and	a	specific	activity	>80	GBq·µmol-1.	Results	of	the	metabolite	analysis	are	presented	in	
Fig.	 1b.	 The	 deuterated	 analogues	 showed	 improved	 metabolic	 stability	 compared	 with	 the	 non-
deuterated	compounds.	Discussion/Conclusion:	Labelling	of	tracers	1b-4b	was	successful.	Although,	both	
1b	and	2b	showed	significantly	increased	metabolic	stability,	total	intact	tracer	levels	at	15	min	are	still	
lower	than	desired.	The	resulting	effect	of	increased	metabolic	stability	for	PET	imaging	will	be	evaluated	
in	P-gp	KO	mice.	To	determine	the	effect	of	a	deuterated	N-methyl	group,	tracer	3b	and	4b	were	designed	
and	still	need	 to	be	evaluated	 for	metabolic	 stability.	Reference:	 [1]	Raaphorst	RM	et	al.,	 [2015],	Clin	
Pharmacol	 Ther	 97	 (4):	 362-371	Acknowledgements:	 This	 project	 is	 supported	 by	 STW	 (OTP-project	
11741)	
OP36	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 47	
	
OP36	
Development	of	a	novel	PET	tracer	for	the	activin	receptor-like	kinase	5	
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Windhorst1	
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Introduction:	Pulmonary	arterial	hypertension	(PAH)	is	a	disease	in	which	pulmonary	arterial	
obstruction	increases	vascular	resistance,	leading	to	right	ventricular	failure	[1].	Inhibition	of	
transforming	growth	factor-β	(TGF-β)	signalling	via	activin-receptor-like	kinase	5	(ALK5)	prevents	
progression	and	development	of	pulmonary	hypertension	[2].	To	further	understand	the	role	of	ALK5	in	
PAH,	the	purpose	of	this	study	was	to	synthesize	[11C]2	(IC50	=	5.5	nM)	[3]	and	to	assess	its	potential	as	a	
positron	emission	tomography	(PET)	ligand	for	measuring	ALK5	expression	and	activity	in	vivo.	Materials	
&	Methods:	[11C]2	was	synthesized	according	to	scheme	1.	[11C]2	was	evaluated	using	biodistribution	
and	metabolite	studies	in	Wistar	rats	(n=4	per	time	point	at	15	and	60	min).	In	addition,	specific	binding	
was	assessed	using	autoradiography	on	ALK5	expressing	MDA-MB-231	tumor	sections.		
	
	
Scheme	1:	synthesis	of	[11C]2	
a
	
	
b	
	
	
	
	
	
	
	 Intact	tracer		 15	min	 60	min	[11C]2	 74	±	5	%	 46	±	2	%	
c	 A:	[11C]2	B	(Blocking):	[11C]2	+	EW-7197		C	(Blocking):	[11C]2	+	SB-431542	D	(Blocking):	[11C]2	+	2	
											A																												B																						C																										D	
		
Figure	1:	a)	Ex	vivo	biodistribution	of	[11C]2	in	Wistar	rats.	b)	Parent	fractions	of	[11C]2	in	Wistar	rats	at	2	
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different	time	points.	c)	Autoradiograms	of	MDA-MB-231	tumor	sections	using	[11C]2	 in	5	mM	Tris-HCl	
buffer.	
Results:	[11C]2	was	synthesized	using	a	[11C]carboxylation	reaction	with	a	yield	of	18±6	%,	a	specific	activity	
of	116±31	GBq·μmol-1	and	a	purity	of	>	95	%.	The	tracer	showed	a	normal	biodistribution	ex	vivo	(Figure	
1a)	and	a	moderate	stability	 in	vivo	(Figure	1b).	The	autoradiograms	presented	binding	of	[11C]2	to	the	
tumor	sections.	Pretreatment	of	the	tumor	sections	with	ALK5	blocking	agents	(EW-7197,	SB-431542	and	
2)	decreased	the	binding	of	[11C]2	significantly	(Figure	1c).	Conclusion:	[11C]2	was	synthesized	successfully,	
and	initial	in	vitro	and	ex	vivo	studies	indicate	its	potential	as	a	putative	tracer	of	ALK5,	warranting	further	
in	 vivo	 evaluation.	 Acknowledgment:	 CVON	 is	 acknowledged	 for	 funding	 of	 this	 project	 and	 the	 BV	
Cyclotron	VU	for	providing	[11C]CO2.	References:	[1]	Archer	S.	et	al.,	[2010],	Circ.	121(18):	2045-66.		[2]	
Harms	HJ	et	al.,	[2013],	TRM	1	(16):	1-7	[3]	 Amada	H.	et	al,	[2012]	BMC	20(24):	7128-38.	
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OP37	
SPECT	Imaging	and	Biodistribution	Studies	of	111In-EGF-Au-PEG	Nanoparticles	In	Vivo	
Lei	Song,	Sarah	Able,	Nadia	Falzone,	Veerle	Kersemans,	Katherine	Vallis	
CR-UK/MRC	Oxford	Institute	for	Radiation	Oncology,	Department	of	Oncology,		
University	of	Oxford,	Oxford,	UK	
	
Introduction:	 Radiolabelled	 antibodies	 and	peptides	 hold	promise	 for	molecular	 radiotherapy	but	 are	
often	limited	by	low	payload	resulting	in	delivery	of	inadequate	amounts	of	radioactivity	to	tumour	tissue	
and,	therefore,	modest	therapeutic	effect.	We	have	developed	PEGylated	epidermal	growth	factor	(EGF)-
gold	nanoparticles	(NP)	with	a	high	indium-111	(111In)	payload	(111In-EGF-Au-PEG	NPs)	as	a	prototypic	NP-
based	theranostic	radiopharmaceutical.	Materials	and	methods:	EGF-Au-PEG	NPs	were	prepared	via	an	
interaction	between	gold	and	the	disulphide	bonds	of	EGF	followed	by	PEGylation	by	mPEG-thiol	(MW:	
800,	2000,	6000)	and	characterised	by	SEC-HPLC,	DLS	and	zeta	potential.	The	targeting	property	of	NPs	
with	various	PEG	MWs	was	investigated	by	confocal	imaging	following	exposure	of	MDA-MB-468	(1.3	x	
106	 EGFR/cell)	 and	MDA-MB-231/H2N	 (105	 EGFR/cell)	 cells	 to	 Cy3-EGF-Au-PEG	NPs.	 111In-EGF-Au-PEG	
(MW:	6000)	and	111In-EGF-Au	NPs	were	chosen	for	SPECT	imaging	and	biodistribution	studies	using	MDA-
MB-468	xenograft-bearing	mice.	Results:	Successful	PEGylation	was	confirmed	by	DLS	and	zeta	potential	
measurements,	 showing	 the	 hydrodynamic	 sizes	 of	 NPs	were	 18.5,	 19.4,	 24.8	 and	 32.5	 nm;	 the	 zeta	
potentials	in	water	were	-24,	-15,	-14	and	-9	mV	for	EGF-Au	and	EGF-Au-PEG	with	MWs	of	800,	2000	and	
6000,	respectively.	SEC-HPLC	showed	that	the	retention	time	of	EGF-Au-PEG	NPs	was	shorter	than	EGF-
Au	NPs	as	PEGylation	resulted	in	larger	NPs.	Confocal	imaging	demonstrated	that	both	EGF-Au	and	EGF-
Au-PEG	NPs	were	efficiently	bound	and	internalised	by	MDA-MB-468	cells.	In	vivo	SPECT	studies	in	mice	
bearing	MDA-MB-468	xenografts	revealed	high	tumour	uptake	in	animals	that	received	111In-EGF-Au-PEG	
(MW:	6000)	compared	to	111In-EGF-Au.	The	tumour/muscle	radioactivity	ratios	for	111In-EGF-Au-PEG	and	
111In-EGF-Au	were	7.2	and	2.5.	Conclusion:	An	111In-labelled	EGF-Au-PEG	nanosystem	was	developed.	It	
enabled	targeted	delivery	of	a	high	111In	payload	to	an	EGFR-positive	cancer	model	that	can	be	potentially	
exploited	for	molecularly	targeted	radiotherapy.	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 50	
	
OP38	
Melanoma	 targeting	 with	 [99mTc(N)(PNP3)]-labeled	 NAPamide	 derivatives:	 preliminary	
pharmacological	studies	
Davide	Carta1,	Nicola	Salvarese2,	Wiebke	Sihver3,	Feng	Gao3,	Hans	Jürgen	Pietzsch3,	Barbara	Biondi4,	
Paolo	Ruzza4,	Fiorenzo	Refosco2,	Cristina	Bolzati2		
1DSF,	University	of	Padua,	Via	Marzolo	5,	35131	Padova,	Italy	
2IENI-CNR,	Corso	Stati	Uniti	4,	35127	Padova,	Italy		
3Institute	of	 Radiopharmaceutical	 Cancer	Research,	HZDR,	Bautzner	 Landstrasse	 400,	 01328	Dresden,	
Germany;	
	4ICB-CNR,	Via	Marzolo	1,	35131	Padova,	Italy	
	
Introduction:	 Malignant	 melanoma	 is	 the	 most	 lethal	 form	 of	 skin	 cancer	 and	 the	 most	 commonly	
diagnosed	malignancy	among	young	adults	with	an	increasing	incidence.	Hence,	the	development	of	new	
melanoma-specific	pharmaceutical	for	diagnosis	and/or	therapy	is	a	subject	of	great	interest	and	intense	
research.	The	purpose	of	this	study	was	to	examine	the	effect	of	cyclization	on	the	biological	profile	of	
[99mTc(N)(PNP3)]-labeled	 α-MSH	 peptide	 analogs	 (PNP3	 =	 N,N-
bis(dimethoxypropylphosphinoethyl)methoxyethylamine).	Method:	A	lactam	bridge-cyclized	H-Cys-Ahx-
βAla3-c[Lys4-Glu-His-D-Phe-Arg-Trp-Glu10]-Arg11-Pro-Val-NH2	(NAP―NS2)	and	the	corresponding	linear	H-
Cys-Ahx-βAla-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH2	(NAP-NS1)	peptide	were	synthetized,	characterized	by	
ESI-MS	spectroscopy	and	their	MC1R	binding	affinity	were	determined	in	B16/F10	melanoma	cells.	In	vitro	
stability	 and	 pharmacological	 parameters	 of	 [99mTc(N)(NAP―NS1)(PNP3)]+	 (1)	 and	
[99mTc(N)(NAP―NS2)(PNP3)]+	(2)	were	assessed.	Challenges	with	an	excess	of	glutathione	and	cysteine	
and	Log	P	values	were	also	investigated.	Furthermore,	1	and	2	were	applied	to	study	in	vivo	stability	and	
the	pharmacokinetic	profiles	on	healthy	rats.	Results:	1	and	2	were	obtained	in	high	yield	(RCY	>	90%).	
Log	P	values	demonstrate	the	hydrophilic	nature	of	the	radiolabelled	peptides:	-1.43	for	1;	-	2.087	for	2.	
No	significant	variations	in	RCPs	of	both	the	complexes	were	observed	in	challenge	experiments	with	an	
excess	(10	mM)	of	glutathione	and	cysteine.	A	high	 in	vitro	stability	was	observed	for	both	complexes	
after	 incubation	in	human	and	rat	sera	as	well	as	 in	rat	 liver	homogenate;	a	fast	degradation	of	2	was	
detected	in	kidneys	homogenate.	1	retains	a	high	receptor	affinity	(Kd=7.1	±	0.5	nM).	Biodistribution	data	
of	1	display	a	favorable	pharmacokinetic	profiles	characterized	by	a	fast	blood	clearance	and	elimination	
from	 normal	 tissues.	 A	 rapid	 excretion	 via	 the	 renal	 pathway	 was	 observed	 according	 to	 the	 high	
hydrophilic	character	of	the	radio-conjugate.	The	effect	of	the	cyclization	on	the	pharmacokinetic	profile	
of	2	was	reflected	in	a	reduction	of	the	blood	clearance	and	of	the	elimination	from	the	other	organs,	in	
particular,	from	excretory	organs	such	as	liver	and	kidneys.	Conclusion:	Compared	with	the	linear	peptide,	
cyclization	negatively	affects	the	biological	properties	of	NAP-NS2	peptide	by	reducing	its	binding	affinity	
for	MCR1R	(Ki:	0.9±0.3	nM	for	NAP_NS1;	7.1±2.4	nM	for	NAP_NS2)	and	decreasing	the	overall	excretion	
rate	of	the	corresponding	[99mTc(N)(PNP3)]-labeled	peptide	from	the	body	as	well	as	its	stability.	Thus	only	
the	linear	[99mTc(N)(PNP3)-labeled	peptide	is	suitable	for	further	investigations	in	tumor	bearing	animals.	
This	 research	 was	 supported	 by	 MIUR	 through	 PRIN	 20097FJHPZ-004	 and	 FIRB	 “RINAME”2010-
RBAP114AMK.	
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OP39	
[68Ga]NODAGA-RGD:	cGMP	synthesis	and	data	from	a	phase	I	clinical	study	
Roland	Haubner1,	Armin	Finkensted2,	Armin	Stegmair1,3,	Christine	Rangger1,	Clemens	Decristoforo1,	
Heinz	Zoller2,	Irene	J.	Virgolini1	
1Department	 of	 Nuclear	Medicine,	Medical	 University	 of	 Innsbruck,	 Austria;	 2Department	 of	 Internal	
Medicine,	Medical	University	of	Innsbruck,	Austria;	3FH	Gesundheit	/	University	of	Applied	Sciences	Tyrol,	
Innsbruck,	Austria.	
Introduction:	Preclinical	studies	demonstrated	that	[68Ga]NODAGA-RGD	allows	imaging	of	integrin	avb3	
expression	 using	 PET.	 Here	 we	 present	 all	 data	 (quality	 control,	 toxicological	 study,	 and	 dosimetry	
estimation)	necessary	to	initialize	clinical	studies,	the	establishment	of	the	remote	controlled	synthesis,	
and	 data	 from	 the	 phase	 I	 clinical	 study.	Methods:	 Labelling	 was	 carried	 out	 in	 a	 remote	 controlled	
synthesis	 unit	 under	 clean	 room	 conditions.	 Quality	 control	 included	 TLC,	 HPLC,	 GC,	 pH	 control,	 Ge-
breakthrough,	half-life,	endotoxin	content,	and	control	of	sterility.	Storage	stability	after	4	h	was	studied	
and	dose	estimations	based	on	animal	data	were	carried	out	using	OLINDA.	Sprague-Dawley	rats	were	
used	 for	 an	 extended	 single	 dose	 toxicity	 study.	 The	 phase	 I	 clinical	 study	 included	 9	 patients	 with	
hepatocellular	carcinoma	(HCC).	Static	scans	at	5,	30,	and	60	min	p.i.	including	5	bed	positions	each	were	
performed	using	the	Discovery	690	PET/CT.	Blood	was	sampled	30	and	60	min	p.i.	and	urine	60	min	p.i.	
and	 used	 for	 stability	 studies	 via	 HPLC.	 Results:	 [68Ga]NODAGA-RGD	 could	 be	 produced	 in	 high	
radiochemical	yield	and	 radiochemical	purity	 (HPLC	and	TLC	>99%).	The	pH	 in	 the	 final	 isotonic	 saline	
formulation	 was	 approx.	 6.	 Ethanol	 content	 was	 between	 2.5	 and	 3.0%	 v/v.	 No	 detectable	 68Ge-
germanium	was	 found.	 LAL	 test	 revealed	 0.7	 EU/ml.	 Sterility	 tests	 showed	 that	 all	 samples	 met	 the	
specifications	according	to	Ph.	Eur..	No	radiolysis	of	the	tracer	was	found	in	the	formulated	solution.	The	
single	dose	toxicity	study	showed	that	the	compound	was	well	tolerated	in	animals.	This	was	confirmed	
by	 the	 clinical	 study	 where	 no	 severe	 side	 effects	 were	 observed.	 High	 metabolic	 stability	 of	
[68Ga]NODAGA-RGD	was	found	based	on	the	analysis	of	blood	and	urine	samples.	The	static	scans	showed	
rapid	tracer	elimination	from	the	body	with	low	background	activity	in	almost	all	organs.	The	calculated	
effective	dose	was	21.5±5.4	µSv/MBq.	Unfortunately,	 the	 investigated	 tumors	did	not	show	 increased	
tracer	accumulation	indicating	no	or	low	integrin	αvβ3 expression.	Conclusion:	This	study	revealed	that	
[68Ga]NODAGA-RGD	can	be	easily	produced	under	GMP	conditions	 and	met	 the	 requirements	 for	 the	
clinical	use.	The	phase	I	clinical	study	with	patients	bearing	HCC	did	not	allow	identification	of	the	lesions	
but	demonstrated	rapid	elimination	from	the	body,	high	metabolic	stability	and	low	radiation	burden.	The	
low	tracer	accumulation	in	the	tumor	might	be	related	to	low	receptor	expression,	thus	further	studies	
are	needed	to	verify	the	integrin	αvβ3 imaging	properties.		
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 52	
	
OP44	
Implementation	of	a	GMP-grade	radiopharmacy	facility	in	Maastricht	
Ivo	Pooters1,	Maartje	Lotz1,	Roel	Wierts1,	Felix	Mottaghy1,2,	Matthias	Bauwens1,3	
1	Department	of	Radiology	and	Nuclear	Medicine,	MUMC+,	Maastricht,	The	Netherlands	
2	Nuclear	Medicine,	Uniklinikum	Aachen,	Aachen,	Germany	
3	Research	School	NUTRIM,	Maastricht	University,	Maastricht,	The	Netherlands		
	
Introduction:	In	the	Netherlands,	a	modified	“light”	version	of	the	European	GMP,	i.e.	GMP-z,	for	the	(kit-
)	production	of	registered	radiopharmaceuticals	for	individual	patients	in	hospital	pharmacies	is	in	effect.	
However,	 GMP-z	 does	 not	 allow	 to	 synthesize	 radiopharmaceuticals	 for	 clinical	 trials	 or	 therapeutic	
applications,	in	which	case	the	European	GMP	applies.	At	the	MUMC,	a	growing	interest	in	performing	in-
house	clinical	trials	with	new	radiopharmaceuticals	and	in	the	synthesis	of	radiotherapeuticals	led	to	the	
decision	 of	 upgrading	 the	 current	 Radiopharmacy	 facility.	 Several	 restrictions	 applied:	
radiopharmaceuticals	will	not	be	sold	to	third	parties	and	the	surface	area	of	the	entire	facility	is	limited	
to	55	m2	(including	the	production	lab,	QC	lab	and	separate	sluices	for	personnel	and	goods).	Additionally,	
the	 facility	 had	 to	 allow	 both	 preparation	 of	 routine	 99mTc-compounds	 as	 well	 as	 GMP-grade	
radiopharmaceuticals.	This	study	examines	the	time	line	of	implementation	for	such	a	small	scale	facility	
and	may	be	relevant	to	other	hospitals	considering	to	comply	with	this	regulation.	Materials	&	Methods:	
A	team	was	founded	 late	2012,	 including	a	radiochemist,	QA	officer,	 radiopharmacist,	 radiation	safety	
officer,	clinical	physicist	and	a	construction	project	 leader	(totaling	nearly	5	fulltime-equivalents).	User	
requirements	for	the	facility,	hotcells	and	laboratory	equipment	were	determined.	Preliminary	building	
plans	were	drawn	up	and	several	expert	companies	chosen,	specialized	in	HVAC,	cleanroom	construction	
and	area	and	radiation	monitoring.	Results:	For	the	hotcells,	a	successful	Factory	Acceptance	Test	was	
performed	in	February	2015.	Construction	of	the	new	facility	started	end	of	May	2015,	starting	with	the	
planned	installation	of	the	hotcells	for	which	removal	of	a	section	from	the	outer	wall	was	necessary.	The	
second	 phase	 of	 the	 reconstruction	 (setting	 up	 of	 a	GMP-compliant	 cleanroom)	 is	 scheduled	 to	 start	
January	2016,	 leading	 to	 full	operability	 in	April	2016	and,	upon	 inspection	by	 the	Dutch	 Inspectorate	
(IGZ),	GMP-compliant	production	is	expected	by	the	end	of	2016.Discussion/Conclusion:	It	is	essential	to	
have	a	high	degree	of	 in-house	expertise	when	starting	a	 radiopharmacy	building	project.	Completely	
documented	construction	planning,	based	on	a	solid	list	of	requirements,	takes	2-3	years	to	build	up	and	
is	a	necessity	to	allow	timely	and	high-quality	construction.		
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OP45	
Setting	up	a	GMP	production	of	a	new	radiopharmaceutical	
Forsback,	Sarita1;	Bergman	Jörgen1;	Kivelä	Riikka2		
1Radiopharmaceutical	 Chemistry	 Laboratory,	 Turku	 PET	 Centre,	 University	 of	 Turku,	 Turku,	 Finland;	
2Turku	University	Hospital,		Hospital	Pharmacy,	Turku,	Finland	
Introduction:	 Good	 Manufacturing	 Practice	 (GMP)	 sets	 strict	 requirements	 for	 the	 manufacturing	
conditions,	synthesis	and	quality	of	radiopharmaceuticals.	Robust	production	and	quality	control	methods	
for	radiopharmaceuticals	are	essential	 for	diverse	and	effective	clinical	utilization	of	Positron	Emission	
Tomography	 (PET).	This	presentation	describes	 the	set	up	procedure	of	a	new	radiopharmaceutical	 in	
Turku	 PET	 Centre	 (TPC).	 All	 issues	 other	 than	 directly	 related	 to	 GMP	 such	 as	 toxicology,	 labeling	
chemistry,	analytical	methods	or	documentation	for	the	authorities	(i.e.	IMPD)	are	not	discussed	here.	
Materials	 &	 Methods:	 Quality	 standards	 and	 product	 specification	 are	 expressed	 in	 EU	 (Annex	 15	
Qualification	and	Validation,	revision	into	operation	1	Oct	2015)	and	Europ.	Pharmacopoeia	(8th	Edition).	
The	setup	of	a	new	radiopharmaceutical	at	TPC	requires	existence	of	the	following:	
• Established	quality	system	
• Documentation	system	
• Competent	personnel	
• Classified	clean	rooms	
• Qualified	equipment	
• System	for	material	management	
	
Initially	 the	 specifications	 for	 critical	 materials	 and	 primary	 packing	 materials	 of	 the	 new	
radiopharmaceutical	must	be	defined.	At	TPC	specifications	for	new	radiopharmaceutical	are:		
•	 Appearance	
•	 Identification	
•	 Radioactivity	
•	 Radionuclidic	identity	
•	 Radionuclidic	purity	
•	 Radiochemical	purity	
•	 Chemical	purity	
•	 Residual	solvents	
•	 Content	of	ethanol	
•	 pH	
•	 Sterility	
•	 Bacterial	endotoxins	
•	 Shelf	life
	
Results:	After	ensuring	that	the	production	of	a	new	radiopharmaceutical	is	robust	and	repeatable	and	
all	analytical	methods	including	sterility	and	endotoxin	tests	are	validated,	the	process	can	be	validated	
according	 to	 a	 written	 validation	 plan.	 In	 addition	 bioburden	 (number	 of	 bacteria	 living	 on	 the	 drug	
solution	 before	 sterilization)	 must	 be	 determined.	 The	 aseptic	 processing	 of	 operators	 must	 also	 be	
confirmed	by	performing	media	 fills	 (the	performance	of	 an	aseptic	manufacturing	procedure	using	a	
sterile	 microbiological	 growth	 medium	 in	 place	 of	 the	 drug	 solution).	 At	 TPC	 the	 process	 validation	
includes	 three	consecutive	process	validation	batches	which	 shall	 fulfill	 all	 specifications	 for	 the	given	
radiopharmaceutical.	This	also	qualifies	the	operator	for	production.	Additional	batches	must	be	done	in	
order	 to	 qualify	 more	 operators.	 Finally,	 process	 validation	 and	 documentation	 is	 compiled.	 Process	
validation	report,	method	description	for	preparation	and	quality	control	and	master	batch	record	are	
written.	 Discussion/Conclusion:	 After	 all	 documentation	 has	 been	 accepted	 by	 QA,	 the	 new	
radiopharmaceutical	is	ready	for	clinical	production	and	all	changes	to	the	process	must	be	performed	via	
change	control	process.	
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OP48	
In	Vitro	and	In	Vivo	Evaluation	of	68-Gallium	Labeled	Fe3O4-DPD	Nanoparticles	as	Potential	PET/MRI	
Imaging	Agents.		
M.	 Karageorgou1,	 M.	 Radović2,	 C.	 Tsoukalas1,	 B.	 Antic2,	 M.	 Gazouli3,	 M.	 Paravatou-Petsotas1,	 S.	
Xanthopouls1,	M.	Calamiotou4,	D.	Stamopoulos4,5,	S.	Vranješ-Durić2,	P.	Bouziotis1.	
1.	Radiochemical	Studies	Laboratory,	INRASTES,	NCSR	“Demokritos”,	Athens,	Greece.		
2.“Vinča”	Institute	of	Nuclear	Sciences,	Laboratory	for	Radioisotopes,	University	of	Belgrade,	Belgrade,	
Serbia.	
3.	Department	of	Basic	Medical	Science,	Laboratory	of	Biology,	School	of	Medicine,	NKUA,	Athens,	Greece	
4.	Department	of	Solid	State	Physics,	NKUA,	Athens,	Greece.	
5.	INN,	NCSR	“Demokritos”,	Athens,	Greece.		
	
Introduction:	The	combination	of	different	imaging	modalities	has	received	increasing	interest	over	the	
past	decade,	as	it	enables	to	overcome	the	limitations	of	a	single	imaging	modality	and	ensures	enhanced	
interpretation	 of	 diseases	 and	 abnormalities	 in	 vivo.	 Dual	modality	 PET/MRI	 imaging	 agents,	 such	 as	
radiolabeled	 magnetic	 nanoparticles,	 are	 promising	 candidates	 for	 a	 number	 of	 diagnostic	 and	
therapeutic	applications	(i.e.	MRI-magnetic	hyperthermia	and	radiotherapy).	The	aim	of	the	present	study	
is	 to	evaluate	 the	efficacy	of	 68Ga	 labeled	 Fe3O4	 superparamagnetic	 iron	oxide	nanoparticles	 (SPIONs)	
coated	 with	 DPD	 phosphonate,	 as	 potential	 PET/MRI	 imaging	 agents.	Materials	 &	Methods:	 SPIONs	
coated	with	 biocompatible	DPD-phosphonate	were	 radiolabeled	with	 positron-emitting	Gallium-68	 to	
quantify	the	accumulation	of	the	nanoparticles	in	vivo.	In	vitro	stability	studies,	in	PBS,	saline	and	human	
serum,	were	 performed	 to	 evaluate	 their	 aqueous	 solubility	 in	 vivo.	 In	 vivo	 biodistribution	 study	was	
performed	in	9	healthy	mice	at	30,	60	and	120	min	post-injection.	Results:	
68Ga-Fe3O4-DPD	SPIONs	presented	high	radiolabeling	yield	(95%)	and	proved	stable	in	vitro.	The	 in	vivo	
study	exhibited	significant	liver	and	spleen	uptake	at	all	examined	time	points	in	healthy	mice,	whereas	
minor	fractions	attained	in	other	organs.	A	small	fraction	of	radiolabeled	nanoparticles	presented	in	bones	
is	 indicative	of	high	affinity	of	phosphonate	to	bone	tissue.	The	biodistribution	profiles	between	 68Ga-
Fe3O4-DPD	 SPIONs	 and	 free	 68Ga-acetate	 were	 also	 compared,	 indicating	 different	 pharmacokinetic	
behavior	for	68Ga-acetate,	with	no	target	tissue	and	excretion	via	 the	kidneys.	Conclusion:	 68Ga-Fe3O4-
DPD	 SPIONs	 demonstrated	 high	 radiolabeling	 efficiency	 and	 in	 vitro	 stability	 and	 satisfactory	 in	 vivo	
behavior.	 Cytotoxicity	 studies	 to	 explore	 the	 potential	 toxic	 effects	 of	 the	 nanoparticles,	 as	 well	 as	
biodistribution	studies	in	tumor	models,	are	in	progress.	References:	1.	Bouziotis	P,	Psimadas	D,	Tsotakos	
T,	Stamopoulos	D,	Tsoukalas	C,	2012,	CTMC,	12:	1-9.	
2.	Burke	B,	Baghdadi	N,	Clemente	G,	Camus	N,	Archibald	S,	2014,	RSC,	175:	59-71.	
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OP49	
Fast	PET	imaging	of	inflammation	using	68Ga-citrate	with	Fe-containing	salts	of	hydroxy	acids	
A.	S.	Lunev1,2,	A.	A.	Larenkov1,	K.A.	Petrosova1,	O.	E.	Klementyeva1,	G.	E.	Kodina1	
1	Burnasyan	Federal	Medical	Biophysical	Center	of	FMBA	Russia,	Moscow,	Russia,		
2	Moscow	State	Academy	of	Veterinary	Medicine	and	Biotechnology,	Moscow,	Russia	
	
Introduction:	68Ga-citrate	is	one	of	the	radiotracers	for	PET	imaging	of	inflammation/infection.	Gallium	
(like	 iron)	 has	 high	 affinity	 to	 blood	 transport	 proteins	 (e.g.	 transferrin)	 due	 to	 their	 similar	
physical/chemical	properties	[1].	One	of	the	functions	of	transport	proteins	is	delivery	iron	(gallium	too)	
to	inflammation/infection	foci	for	inclusion	in	metabolic	pathways	related	with	eradication	of	pathology	
[2].	But	excessive	gallium	bindings	with	proteins	are	cause	of	slow	blood	clearance,	 long	accumulation	
time	in	foci	(24-72	h)	and	exception	of	application	possibility	of	the	short-lived	68Ga	(T½	=	1,13	h)	unlike	
67Ga	(T½	=	78,26	h).	Injection	of	additional	nonradioactive	chemical	agents	(e.g.	Fe3+	containing	salts	of	
hydroxy	acids:	citrate,	tartrate,	lactate,	etc.)	competing	with	gallium	to	the	protein	joining	(blocking	of	its	
metal	binding	capacity)	is	one	of	the	ways	to	solve	formulated	problem.	It	can	be	used	for	correction	of	
68Ga-citrate	pharmacokinetics	for	increasing	of	the	blood	clearance,	accumulation	in	foci	and	fast	imaging.	
Materials	&	methods.	68Ga-citrate	without/with	extra	injection	of	Fe3+	containing	salts	(citrate,	tartrate,	
lactate,	malate,	and	ascorbate)	was	injected	mice	with	modeled	lung	infection	(was	got	using	intra	lung	
injection	of	 cell	 suspension	of	 E.	 coli;	 acute	phase	of	 infection	was	evoluted	 for	 3-4	days).	 PET/X-RAY	
Genisys4	(Sofie	Bioscience,	USA)	was	used	for	noninvasive	PET	imaging	with	subsequent	reconstruction	
of	 imaging	 and	 their	 analysis	 (value	 of	 clearance,	 distribution	 volume).	 Scanning	 time	 is	 10	 min.	
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Figure	1	–	PET	images	of	mice	with	modeled	lung	infection	(arrow	indicates)	
Results:	 I.	v.	 injection	of	Fe3+	containing	salts	of	hydroxy	acids	blocked	the	metal-binding	capability	of	
transferrin	serum	and	others	and	allowed	decreasing	gallium-68	radioactivity	in	blood	significantly	and	
increasing	accumulation	in	inflammation	(3-5	time).	It	allowed	receiving	more	informative	PET-images	of	
inflammation	 early	 (for	 30-60	 min	 after	 injection).	 Pharmacokinetic	 parameters	 proved	 it.	
Discussion/Conclusion.	 There	 was	 no	 statistically	 significant	 difference	 between	 68Ga-citrate	
accumulation	 for	 different	 inflammation	 model	 because	 PET	 imaging	 is	 indication	 of	 pathological	
processes	and	isn't	their	identification.	References:	1.	Harris	WR,	Pecoraro	VL,	[1983],	Biochem.	22:	292–
299.	2.	Green	MA,	Welch	MJ,	[1989],	Int.	J.	Rad.	Appl.	Instrum.	16:	435–438.	
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Installation	and	validation	of	11C-methionine	synthesis	
Kvernenes,	O.H.1;	Adamsen,	T.C.H.1,2	
1	Centre	for	Nuclear	Medicine/PET,	Department	of	Radiology,	Haukeland	University	Hospital,	Jonas	Lies	
Vei	65,	5021	Bergen,	Norway,		
2	Department	of	Chemistry,	University	of	Bergen,	Allégaten	41,	5007,	Bergen,	Norway	
Introduction:	 In	 the	 installation	 of	 methionine	 as	 our	 latest	 tracer	 we	 chose	 the	 Eckert	 and	 Ziegler	
Modular-Lab	 PharmTracer	 as	 production	module,	 utilizing	 the	 so	 called	 «wet-method»	 for	 producing	
methyl	iodide.	After	complete	installation	in	the	hot	cell,	a	simplified	version	of	Ph.Eur	(Ph	Eur	monograph	
1617)	release	criterions	was	used,	and	the	product	was	found	to	pass.	HPLC	showed	excellent	radio	purity	
and	the	installation	was	completed.	Materials	&	Methods:	Homocysteine	thiolactone,	iodic	acid,	0.1M	
lithium	aluminum	hydrid	in	THF,	potassium	dihydrogen	phosphate	were	used	in	the	C11-Met	synthesis,	
Methods	used	are	described	in	Ph.Eur,	with	the	exception	of	chiral	HPLC,	in	which	an	Astec	Chirobiotic	T	
column	with	 70:30:0.02,	MeOH:H2O:HCOOH	 eluent	 was	 employed.	Results:	During	 later	 analyses	 for	
residual	solvents	 in	connection	with	a	GC-PQ,	THF	was	 found	present	 in	 the	product,	3-4	 times	above	
recommended	level.	The	HPLC	method	in	the	Ph.Eur	 is	10	minutes,	however,	by	 increasing	acquisition	
time,	a	radio	peak	appeared	at	about	18	minutes	in	the	chromatogram.	This	peak	was	about	10-15%	of	
total	 radio	 signal,	meaning	 the	 required	 radio	purity	 limit	 in	 Ph.Eur	was	not	met.	When	analysing	 for	
enantiomeric	purity,	which	was	not	initially	done,	about	12%	of	the	d-enantiomer	was	found,	not	meeting	
the	 Ph.Eur	 limit.	 Increasing	 the	 flow	 of	 helium	 during	 the	 azeotropic	 distillation	 decreased	 residual	
solvent,	and	subsequently	the	ICH	residual	solvent	limits	was	met.	The	radio	peak	in	the	HPLC	was	found	
to	be	methyl	iodide	(MeI)	which	is	adsorbed	and	co-eluted	from	the	C-18	Sep-Pak	cartridges.	Eckert	and	
Ziegler	proposed	a	rearrangement	of	the	module	tubing	and	a	new	synthesis	template	program	enabling	
direct	helium	flushing	of	the	C-18	Sep-Pak.	By	the	use	of	this	new	configuration,	removing	excess	MeI	was	
achieved	 and	 the	 radio	 purity	 limits	 described	 by	 the	 Ph.Eur	 monograph	 was	 finally	 met.	 Different	
protocols	 are	 called	 for	 in	 the	 initial	 phase	 dissolving	 the	 precursor	 in	 ethanol	 and	 NaOH	 solution,	
however,	tweaking	these	had	little	effect	of	the	enantiomeric	purity.	Different	batches	of	precursor	was	
later	analysed	for	enantiomeric	purity.	Large	discrepancies	were	found	between	batches	which	directly	
influenced	 the	enantiomeric	 ratio	of	 the	 final	 product.	Conclusion:	Great	 care	 should	be	 taken	 in	 the	
installment	of		new	synthesis	systems,	and	all	available	tests	should	be	run	before	system	installation	is	
approved.	The	Ph.Eur.	methods	may	not	always	be	sufficient	to	prove	radio	or	chemical	purity,	even	if	a	
monograph	exist.		
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Fully	automated	synthesis	of	68Ga-labelled	peptides	using	the	IBA	Synthera®	and	Synthera®	Extension	
modules	
René	Martin*,a	Sebastian	Weidlich,a	Anna-Maria	Zerges,a	Cristiana	Gameiro,b	Neva	Lazarova,b	Marco	
Müllera	
a	ABX	GmbH,	Radeberg,	Germany	
b	IBA	RadioPharma	Solutions,	Louvain-La-Neuve,	Belgium	
Introduction:	The	interest	 in	68Ga-tracers	has	been	growing	strongly	over	the	last	years,	mainly	due	to	
new	 developments	 in	 prostate	 cancer	 imaging	 and	 therapy.1,2	 In	 collaboration	 with	 IBA,	 we	 have	
established	 an	 automated	 synthesis	 of	 68Ga-labelled	 peptides	 including	 68Ga-DOTA-TATE/-NOC,68Ga-
PMSA-11	and	68Ga-PSMA-617	on	Synthera®.	Materials	&	Methods:	During	the	tests,	an	IBA	Synthera®	and	
the	new	Synthera®	Extension	module	were	used.	68Ga	was	obtained	initially	from	an	old	iGG	100	generator	
in	5	mCi.	The	 final	 tests	were	carried	out	 in	combination	with	a	new	GalliaPharm	68Ge/68Ga	generator	
loaded	with	50	mCi.	A	modified	standard	nucleophilic	IFPTM	(IFP™	FDG)	was	designed	for	the	synthesis	
process.	 Synthera®	 Extension	was	 used	 for	 the	 elution	 of	 the	 generator.	 The	 eluate	was	 loaded	 on	 a	
Chromafix	PS-H+		cartridge	and	the	hydrochloric	acid	waste	 -	which	contains	most	of	 the	 68GeCl4	 -	was	
transferred	into	the	waste	container.	The	activity	was	eluted	from	the	cation	exchange	cartridge	using	a	
solution	of	5	M	sodium	chloride	in	0.1	N	hydrochloric	acid3	and	transferred	directly	into	the	reaction	vessel	
which	was	pre-loaded	with	precursor	 in	 1.5	M	HEPES	buffer.	 Labelling	was	 carried	out	 at	 95	 °C	 for	 7	
minutes.	Purification	was	performed	using	a	Sep-Pak®	Light	C18	cartridge.	The	product	was	eluted	with	a	
1:1-mixture	of	ethanol/water	and	dispensed	into	the	final	vial	through	a	sterile	filter.	Further	dilution	was	
performed	with	0.9%	saline	by	passing	through	the	sterile	filter.	The	peptides	were	synthesized	in	a	GMP-
compliant	qualified	area	at	ABX.	For	the	DOTA-peptides,	stock	solutions	were	prepared	(1	mg/ml)	and	
freezed.	For	PSMA-11,	vials	with	10	µg	of	precursor	were	used.		Results:	With	50	µg	of	DOTA-TATE,	DOTA-
NOC	and	PSMA-617,	the	final	radiolabelled	products	were	obtained	in	>60%	uncorrected	yield.	For	PSMA-
11,	only	10	µg	of	precursor	were	used.	The	radiochemical	purity	was	>98%	in	all	cases.	The	Ph.	Eur.	spot	
test	for	HEPES	was	performed	and	showed	HEPES	<	200	µg	/	V	with	V	being	12	to	14	ml.	The	pH	of	the	
final	 solution	was	5	 to	5.5.	Ethanol	 content	was	<	10%.	Discussion/Conclusion:	We	have	developed	a	
dedicated	disposable	IFP	cassette	for	the	IBA	Synthera®	and	Synthera®	Extension	modules,	which	delivers	
all	 common	 68Ga-tracers	 in	 high	 yield.	 	 The	 use	 of	 dedicated	 single	 -use	 Gallium-68	 IFPTM	 allows	 for	
production	of	18F-FDG	on	the	same	module	with	no	cross-contamination.	References:	1	Afshar-Oromieh	
A,	Hetzheim	H,	Kratochwil	C,	Benesova	M	et	al.,	[2015],	JNM	56:	1697-1705.	2	Benešová	M,	Schäfer	M,	
Bauder-Wüst	 U,	 Afshar-Oromieh	 A	 et	 al.,	 [2015],	 JNM	 56:	 914-920.	 3	Mueller	 D,	 Klette	 I,	 Baum	 R	 P,	
Gottschaldt	M	et	al.,	[2012],	BC	23:	1712-1717	
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PP03	
GMP	compliant	production	of	15O-labeled	water	using	IBA	18	MeV	proton	cyclotron		
Gert	 Luurtsema1,	Michèl	de	Vries1,	Michel	Ghyoot2,	Gina	van	der	Woude1,	Rolf	 Zijlma1,	Rudi	Dierckx1,	
Hendrikus	H.	Boersma1	&	Philip	H.	Elsinga1.	
1. Department	 of	 Nuclear	 Medicine	 and	 Molecular	 Imaging,	 University	 Medical	 Center	 Groningen,
University	of	Groningen,	The	Netherlands.	
2. IBA	RadioPharma	Solutions,	Louvain-la-Neuve,	Belgium.
Introduction	:	The	most	common	tracer	used	for	measuring	brain	perfusion	is	[15O]H2O.	In	general	[15O]	
is	produced	using	a	cyclotron	 that	accelerates	deuterons	onto	a	 target	 filled	with	 14N2	with	a	 trace	of	
oxygen.		Nowadays,	cyclotrons	have	been	developed	that	are	only	capable	of	accelerating	protons.	This	
abstract	 describes	 the	 performance	 of	 Cyclone	 18	 twin	 from	 IBA,	 which	 accelerate	 only	 protons,	 for	
production	and	administration	of	 [15O]H2O.	Methods:	The	Cyclone	18	 twin	 from	 IBA	 is	 a	 fixed	energy	
cyclotron	using	18	MeV	protons	 in	which	H-	particles	are	accelerated	and	converted	 into	protons	 (H+).	
Bombardment	with	protons	of	the	special	designed	target	filled	to	25	bar	takes	place,	initiating	the	nuclear	
reaction:	 15N(p,n)15O.	 [15O]H2O	was	 produced	 by	 conversion	 of	 the	 [15O]O2	 using	 a	 new	 designed	 IBA	
chemistry	module	 and	 placed	 in	 a	 shielded	 class	 A	 foam	 hood	 located	 in	 the	GMP	 laboratory.During	
preparation,	15O	gas	flows	from	the	cyclotron	into	the	IBA	chemistry	module	and	is	mixed	with	hydrogen	
gas	and	passed	through	a	palladium	column.	The	produced	[15O]H2O	is	collected	in	a	sterile	0.9%	saline	
solution	to	obtain	a	final	product	suitable	for	patient	administration.	Validation	of	the	production	process	
included:	 (1)	 assessment	 of	 practical	 yields,	 (2)	 check	 on	 pharmaceutical	 requirements	 and	 (3)	
reproducibility	of	performance	of	both	cyclotron	and	water	module.	Results:	
According	to	our	knowledge	,	this	is	the	first	time	that	GMP-production	of	15O	labeled	water	using	IBA	18	
MeV	proton	cyclotron	is	described.	The	method	was	validated	and	met	all	pharmacopeia	specifications,	
and	was	subsequently	approved	for	patient	studies.	The	practical	production	yield	of	15O	labeled	water	
using	this	method	was	ranged	between	1300-1700	MBq	measured	in	the	syringe.	This	method	is	suitable	
for	multiple	batches	within	a	time	frame	of	8	minutes.	After	validation	more	than	50	patient	runs	were	
performed	with	a	reliability	of	>	99	%.	Conclusion:	A	new	production	method	for	15O-labeled	water	using	
Cyclone	18	 and	dedicated	 chemistry	module	 from	 IBA	was	described	and	qualified	 according	 to	GMP	
regulations.	It	was	demonstrated	to	be	suitable	for	clinical	use.		
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PP04	
In	vitro	Nuclear	Imaging	Potential	of	New	Subphthalocyanine	and	Zinc	Phthalocyanine	
Fatma	Yurt	Lambrecht	a,	Ozge	Era,	Mine	Inceb,	Cıgır	Biray	Avcic,	Cumhur	Gunduzc,	Fatma	Aslihan	Sarid	
A	Department	of	Nuclear	Applications,	Institute	of	Nuclear	Science,	Ege	University,	Bornova,	35100,	Izmir,	
Turkey;	B	Department	of	Energy	Systems	Engineering,	Faculty	of	Technology,	Mersin	University,	TR-33480	
Tarsus,	Mersin,	Turkey;	C	Department	of	Medical	Biology,	Faculty	of	Medicine,	Ege	University,	Bornova,	
35100,	Izmir,	Turkey;	D	Advanced	Technology	Research	&	Application	Center,	Mersin	University,	Ciftlikkoy	
Campus,	TR-33343	Yenisehir,	Mersin,	Turkey.	
Introduction:	Cancer	caused	by	abnormal	cell	proliferation	has	become	a	very	common	disease	in	recent	
years.	Nuclear	imaging	has	a	significant	place	in	cancer	diagnosis.	Photosensitizers	(PS)	such	as	chlorine,	
phthalocyanine,	 porphyrin	 and	 tetraprol	 derivatives	 are	 come	up	PDT	applications.	 	 Furthermore,	 PSs	
accumulate	 selectively	 in	 the	 tumor	 tissue	compared	 to	normal	 tissue.1,	2	 	Therefore,	 such	compounds	
labeled	with	a	radionuclide	can	be	used	as	a	probe	for	nuclear	imaging.	In	present	study,	we	synthesized	
a	 new	 Subphthalocyanine	 (SubPc)	 and	 Zinc	 phthalocyanine	 [Zn(II)Pc]	 and	 determined	 in	 vitro	 nuclear	
imaging	potential.	Materials	&	Methods:	SubPc	and	Zn(II)Pc	 (Figure	1)	were	 synthesized	according	 to	
published	methods	of	 Ince	et	al.3-5	The	radiolabeling	with	131I	via	 iodogen	method	was	carried	out	and	
optimization	conditions	(pH,	amount	of	iodogen	and	reaction	time)	were	determined.	We	will	use	EMT6/P	
(mouse	mammary	carcinoma),	HeLa	(human	cervix	adenocarcinoma)	Hep	G2	(human	liver	hepatocellular	
carcinoma),	HT-29	(human	colon	colorectal	adenocarcinoma),	WI38	(human	normal	lung	fibroblast)	cell	
lines	 for	 the	 intracellular	 uptake	 studies.	 The	 intracellular	 uptake	 efficiency	 of	 131I	 labeled	 Pcs	 are	
determined	according	to	published	study	of	Ocakoglu	et	al.	in	mentioned	cell	lines.6	
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Figure	1:	Molecular	structure	of	SubPc	and	Zn(II)	Pc.	
Results:	We	observed	 that	 the	 radiolabeling	 efficiencies	 of	 SubPc	 and	 Zn(II)Pc	were	 significantly	 high	
(91.9±3.1%	and	97.2±1.4%,	 respectively).	The	optimization	conditions	were	determined	as	pH	9,	1	mg	
amount	of	 iodogen	and	30	minutes	of	reaction	time	for	SubPc;	pH	7,	1	mg	amount	of	 iodogen	and	45	
minutes	of	reaction	time	for	Zn(II)Pc.	In	vitro	cell	line	studies	are	in	progress.	References:	1.	Brown	SB,	
Brown	EA,	Walker	I,	[2004],	LO	5:	497-508.	2.	Dolmans	DE,	Fukumura	D,	Jain	RK,	[2003],	NRC	3:	380-387.	
3. Ince	M,	Medina	A,	Yum	JH,	Yella	A,	Claessens	CG,	Martínez-Díaz	M,	Torres	T,	[2014],	C-AEJ	20:	2016-
2021.	4.	Ince	M.,	Martinez-Diaz	MV,	Barbera	J,	Torres	T,	[2011],	JMC	2011:	1531-1536.	5.	Ince	M,	Cardinali	
F,	 Yum	 JH,	 Martínez-Díaz	 M,	 Nazeeruddin	 MK,	 Grätzel	 M,	 Torres	 T,	 [2012]	 C-AEJ	 18:	 6343-6348.	 6.	
Ocakoglu	K,	Er	O,	Yurt	Lambrecht	F,	Yılmaz	Süslüer	S,		Kayabasi	C,	Gündüz	C,	Yılmaz	O,	[2014],	JDT	18:	1-
7.*Acknowledge:	 The	 authors	 gratefully	 acknowledge	 financial	 support	 by	 The	 Scientific	 and	
Technological	Research	Council	of	Turkey,	TUBITAK	(Grant	no:	114Z430).	
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Synthesis,	Photodynamic	Therapy	Efficacy	and	Nuclear	Imaging	Potential	of	Zinc		Phthalocyanines	
Kasim	Ocakoglu	a,b,	Ozge	Er	c,	Onur	Alp	Ersoz	c,	Fatma	Yurt	Lambrecht	c,	Mine	Ince	b,	Cagla	Kayabasi	d,	
Cumhur	Gunduz	d	
A	Advanced	Technology	Research	&	Application	Center,	Mersin	University,	Ciftlikkoy	Campus,	TR-33343	
Yenisehir,	Mersin,	Turkey.	
B	Department	of	Energy	Systems	Engineering,	Faculty	of	Technology,	Mersin	University,	TR-33480	Tarsus,	
Mersin,	Turkey.	
C	Department	of	Nuclear	Applications,	Institute	of	Nuclear	Science,	Ege	University,	Bornova,	35100,	Izmir,	
Turkey	
D	Department	of	Medical	Biology,	Faculty	of	Medicine,	Ege	University,	Bornova,	35100,	Izmir,	Turkey.	
Introduction:	 In	 recent	 years,	 photodynamic	 therapy	 (PDT)	 gained	 speed	 in	 cancer	 treatment.	 This	
method	is	based	on	two	steps.	Firstly,	a	photosensitizer	(PS)	is	accumulated	in	cancer	tissue	then	flowed	
by	light	irradiation.	During	a	photoreaction	Type	II,	energy	transfer	occurs	between	the	PS	and	molecular	
oxygen	(O2),	the	exposed	photosensitizers	produce	highly	toxic	singlet	oxygen	(1O2).	The	singlet	oxygen	
is	responsible	for	the	cell	damage.1-3	Pthalocyanines	have	high	tumor	uptake	efficiencies.	This	property	
allows	 them	 to	 be	 used	 as	 bifunctional	 agents	 for	 PDT	 and	 nuclear	 imaging.	 In	 the	 present	 study,	
symmetrical	Zn(II)Pc	1	and	unsymmetrically	substituted	Zn(II)Pc	2	were	synthesized	and	examined	as	a	
bifunctional	 agent	 for	 nuclear	 imaging	 and	 PDT.Materials	 &	 Methods:	 Zn(II)Pcs	 were	 synthesized	
according	to	a		published	procedure.4	The	Zn(II)Pcs	were	radiolabeled	with	131I	by	using	iodogen	method.	
Optimization	conditions	of	radiolabeling	(pH,	amount	of	 iodogen	and	reaction	time)	were	determined.	
Biodistribution	studies	were	performed	with	Albino	Wistar	female	healthy	rats.	The	radiolabeled	Zn(II)Pcs	
were	injected	into	the	tail	vein	of	each	rats	and	then	the	rats	were	sacrificed	at	30,	60	and	120	min	post	
administration.	 Tissue	 samples	 were	 collected	 and	 counted	 using	 a	 Cd(Te)-RAD-501	 single	 channel	
analyzer.	In	vitro	the	photodynamic	therapy	studies,	EMT6/P	(mouse	mammary	carcinoma),	HeLa	(human	
cervix	adenocarcinoma)	cell	lines	were	used.	Zn(II)Pc	1	and	Zn(II)Pc	2	were	exposed	to	red	light	(650	nm)	
at	the	doses	of	10-30	J/cm2.	Results:	The	Zn(II)Pc	1	and	Zn(II)Pc	2	were	radiolabeled	with	131I	with	high	
efficiency	 (93.4±1.6%	 and	 91.4±1.6%,	 respectively).	 The	 results	 of	 biodistribution	 study	 showed	 that	
radiolabeled	Zn(II)Pc	1	has	high	uptake	on	lung,	large	intestine,	ovary	and	pancreas.	However,	the	uptake	
of	radiolabeled	Zn(II)Pc	2	was	determined	as	to	be	statically	significant	in	pancreas	and	large	intestine.	
Zn(II)Pc	1	was	showed	no	phototoxic	effect	in	both	cell	lines	although	PDT	activity	of	Zn(II)Pc	2	in	HeLa	cell	
line	was	determined.	Conclusion:	In	conclusion	the	radiolabeled	Zn(II)Pc	1	might	be	a	promising	imaging	
agent	 for	 lung,	 ovary	 pancreas,	 and	 colon	 tumors.	 However,	 the	 radiolabeled	 Zn(II)Pc	 2	 might	 be	 a	
promising	nuclear	 imaging	agent	for	colon	and	pancreas	tumors,	also	promising	PDT	agent	for	cervical	
tumors.	References:	1.Castano	AP,	Demidova	TN,	Hamblin	MR,	[2004],	PPT	1(4):	279-293.	2.	Juarranz	A,	
Jaen	P,	 Sanz-Rodriguez	F,	Cuevas	 J,	Gonzalez	 S	 [2008],	CTO	10(3):	 148-154.	3.	Plaetzer	K,	Krammer	B,	
Berlanda	 J,	 Berr	 F,	 Kiesslich	 T,	 [2009],	 LMS	 24(2):	 259-268.	 4.	Maya	 EM,	 Vazquez	 P,	 Torres	 T,	 [1999],	
Chemistry	5(7):	2004-2013.	
*Acknowledge:	The	authors	gratefully	acknowledge	financial	support	by	The	Scientific	and	Technological
Research	Council	of	Turkey,	TUBITAK	(Grant	no:	112T565).	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
Page 62	
PP06	
Radio-U(H)PLC	–	the	Search	on	the	Optimal	Flow	Cell	for	the	γ-Detector	
Torsten	Kniess,	Sebastian	Meister,	Steffen	Fischer,	Jörg	Steinbach	
Helmholtz-Zentrum	 Dresden-Rossendorf,	 Institute	 of	 Radiopharmaceutical	 Cancer	 Research,	
01314	Dresden,	Germany	
Introduction:	Radio-HPLC	is	routinely	used	for	analysis	and	quality	control	of	radiopharmaceuticals.	The	
introduction	of	U(H)PLC	enabled	decreased	detection	levels,	improved	resolution	and	significant	shorter	
analysis	times;	crucial	parameters	for	radiotracer	analysis.	Despite	these	benefits	only	a	few	examples	of	
radio-U(H)PLC	have	been	reported	[1-3];	one	reason	may	be	the	absence	of	a	suitable	γ-detector	with	a	
flow	cell	which	is	compatible	to	UPLC	conditions.	We	used	a	commercial	γ-detector	in	combination	with	
different	 flow	 cell	 inserts	 and	 report	 on	 their	 effect	 on	 the	 sensitivity	 and	 resolution	 of	 the	 γ-signal.	
Materials	&	Methods:	An	ACQUITY	UPLC	H-Class	System	(Waters)	was	used	with	a	GABI	Star	γ-detector	
(Raytest)	equipped	with	a	2”x	2”	pinhole	scintillation	crystal	in	combination	with	three	different	flow	cells.	
UPLC	was	performed	on	an	ACQUITY	HSS	C18	column	(2.1	x	100	mm,	1,8	µm)	with	a	flow	rate	of	0.65	
mL/min	 and	 a	 3	 min	 gradient	 of	 30/70	 acetonitrile/0.1%	 TFA.	 The	 sigma-1	 receptor	 imaging	 probe	
[18F]fluspidine	 [4]	 served	 as	 analyte	 with	 2	 µL	 injection	 volume,	 containing	
8	–	400	kBq	of	[18F]fluspidine.	Results:	For	best	resolution	and	avoiding	an	excessive	back-pressure	to	the	
PDA	cell	 (<	70	bar)	 the	capillary	between	PDA	and	γ-detector	should	be	as	short	as	possible.	This	was	
realized	by	placing	the	γ-detector	in	30	cm	distance	to	the	PDA-detector	on	a	special	table.	Three	different	
flow	cells	were	applied	(Figure	1):	
a) Raytest	standard	flow	cell	(5	µL),
b) Raytest	2”	capillary	holder	equipped	with	a	UPLC	capillary	0.004”	ID	(9/5/2	nL),
c) self-build	lead	insert	with	a	5	mm	hole	and	UPLC	capillary	(2	nL).
By	 injecting	400	kBq	of	 [18F]fluspidine	and	using	 the	different	 flow	cells,	γ-signals	having	a	peak	width	
between	0.13	and	0.20	mm	and	a	peak	intensity	750	-	4400	cps	were	obtained.	The	capillary	holder	(5	nL)	
and	 the	 self-build	 insert	 (2	 nL)	 showed	 a	 comparable	 peak	 width,	 but	 differentiated	 sensitivity.	 To	
determine	 the	minimum	detectable	 level	 samples	between	170	kBq	and	8	kBq	of	 [18F]fluspidine	were	
injected;	with	15	kBq	of	[18F]fluspidine	a	good	signal	to	background	ratio	of	6:1	was	achieved.	
Figure	 1:	 standard	 flow	 cell	 (left);	 capillary	 holder	 (middle);	 self-build	 lead	 insert	 (right)	
Conclusion:	By	performing	radio-U(HPLC)	with	a	GABI	Star	γ-detector	equipped	with	a	Raytest	2”	capillary	
holder	(5	nL),	γ-signals	with	good	sensitivity	and	peak	width	can	be	obtained.	In	addition,	the	self-build	
flow	cell	insert	(2	nL)	gave	the	highest	sensitivity	and	the	best	signal	to	background	ratio.	
References:	[1]	Franck	D,	Nann	H,	Davi	P,	Schubiger	PA,	Ametamey	SM,	[2009],	Appl	Radiat	Isot	67:	1068-
1070.	[2]	Maas	B,	Zijlma	R,	Bannink	A,	Lub-de	Hooge	M,	Elsinga	PH,	Dierckx	RAJO,	Boersma	HH,	Luurtsema	
G,	[2013],	Eur	J	Nucl	Med	Mol	Imaging	40	(S2):	S322-S323.	[3]	Kryza	D,	Janier	M,	[2013],	Appl	Radiat	Isot	
78:	72-76.	[4]	Maisonial-Besset	A,	Funke	U,	Wenzel	B,	Fischer	S,	Holl	K,	Wünsch	B,	Steinbach	J,	Brust	P,	
[2015],	Appl	Radiat	Isot	84:	1-7	
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PP07	
Radiolabeling,	Characterization	&	Biodistribution	study	of	Cysteine	and	its	derivatives	with	Tc99m.	
Rabia	Ashfaq	1	&	2*,	Saeed	Iqbal	Dr2,	Atiq-ur-Rehman1,	Irfan	ullah	Khan	Dr3	
1. Nuclear	 Medicine	 Department,	 Shaukat	 Khanum	 Cancer	 Hospital	 and	 Research	 Centre,	 Lahore.	 2.
Forman	Christian	College,	Lahore.	3.Institute	of	Nuclear	medicine	and	Oncology,	Lahore,	Pakistan	
Introduction:	Several	studies	are	available,	which	highlight	the	use	of	Schiff	base	ligands	for	radio-labeling,	
but	very	 little	work	has	been	reported	which	has	used	Marcepto	compounds,	although	 it	 is	desired	to	
include	such	compounds	in	the	design	of	radiopharmaceuticals	due	to	their	importance	in	the	biological	
system.	Materials	and	methods:	Equimolar	L	–	cysteine	and	salicylaldehyde	in	distilled	water	and	ethanol	
were	heated	at	40°C	 to	 form	a	white	colored	 ligand.	The	product	 formed	was	analyzed	using	FT	–	 IR,	
thermo	 gravimetric	 analysis	 and	 elemental	 analysis	 at	 Fc	 College.	 Radiolabeling	 of	 the	 ligand	 was	
performed	at	SKMCH&RC	using	99mTc	from	99Mo	generator.	SnCl2.H2O	was	used	as	a	reducing	agent	at	
STP.	Radio	TLC	was	performed	using	SG	plates	and	0.9%	NaCl	and	acetone	as	the	mobile	phases.	Geiger	
Muller	 counter	 detected	 the	 counts	 on	 the	 SG	plates	 and	 radiolabeling	 efficiency	 of	 the	 product	was	
achieved.	Quality	 control	 results	 of	 the	 radiolabeled	 product	were	 performed	 before	moving	 further.	
During			Biodistribution	study,	product	was	injected	IV	into	the	animal	ear.	Scanning	was	performed	under	
the	gamma	camera.	Results:	Ligand	synthesis	was	verified	from	IR	indicating	the	presence	of	the	closed	
ring	structure	Thiozolidine	ring	1	(Fig.	1).	IR	showed	absence	of	chromophore	group	hence	the	ligand	was	
colorless.	DSC	peaks	indicated	the	reaction	type	as	endothermic.	Ligand	appeared	to	be	stable	in	DMSO.	
After	 optimizing	 various	 parameters	 effective	 radiolabeling	 up	 to	 88	 %	 was	 achieved	 at	 pH	 5,	 using	
lyophilized	 tin	 chloride	 pyrophosphate	 cold	 kit	 in	 NaCl	 (0.9%).	 Animal	 study	 was	 carried	 out	 for	 Bio	
distribution	 of	 the	 radiopharmaceutical.	 99mTc	 –	 ligand	 uptake	 was	 highlighted	 in	 the	 soft	 organs	
immediately	after	injection.	The	areas	showing	higher	radiotracer	uptake	were	kidney	(20	%),	liver	(35	%),	
bones	(15%)	and	brain	(10	%)	(Fig.	2).	Delayed	images	showed	the	radiotracer	retention	in	the	soft	organs	
as	well	as	in	the	spine	of	the	animals	(Fig	3,	4).	Comparative	study	was	performed	using	99mTc	–	MDP	and	
99mTc	 PHYTATE.	 Conclusion:	 Salicylaldicysteine	 is	 efficiently	 labeled	 with	 99mTc	 and	 is	 suitable	 in	
simultaneous	scanning	of	liver,	kidney	and	brain.	In	this	study,	significant	uptake	is	highlighted	in	brain	in	
addition	to	soft	tissues	in	dynamic	flow	followed	with	delay	images,	which	is	worth	consideration.	This	
indicates	the	ability	of	drug	in	crossing	the	blood	brain	barrier.		This	study	also	highlights	the	importance	
of	sulfur	containing	ligands	in	brain	scanning.				
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Fig. 2 
Fig. 3 Fig. 4 
Reference:	1.	MacDonald,	L.	G.,	Brown,	D.	H.,	Morris,	J.	H.,	&	Smith,	W.	E.	(1982).	Copper	Schiff	base	
complexes	with	polyfunctional	amino	acids.	Inorganica	Chimica	Acta,	67,	7-12.	
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PP08	
Radiolabelling	of	poly	(lactic-co.glycolic	acid)	(PLGA)	nanoparticles	with	99mTC	
R.	Iglesias-Jerez1,		M.D.	Cayero-Otero2,	L.	Martín-Banderas2,	A.	Perera-Pintado3,	I.	Borrego-Dorado1	
1Servicio	de	Medicina	Nuclear.	Hospital	Universitario	Virgen	del	Rocío.	Avda	Manuel	Siurot	s/n.	41013.	
Seville.	Spain	
2Dpt.	Farmacia	y	Tecnología	Farmacéutica.	Facultad	de	Farmacia.	Universidad	de	Sevilla.	c/Prof.	Gracía	
González	nº2,	41012,	Seville,	Spain.	
3Dirección	de	Investigaciones	Clínicas,	Centro	de	Isotopos,	34	No.	4501	e/	45	y	47,	Kohly,	Playa,	La	
Habana,	CP	11300,	Cuba	
Introduction:	Radiolabelled	 nanoparticles	 have	 gained	 a	 widespread	 application	 in	 the	 diagnosis	 and	
therapy	 of	 several	 diseases	 (inflammation/infection,	 cancer,	 and	 others).	 	 PLGA	 Nanoparticles	 (NPs)	
prepared	by	 solvent	 emulsion	evaporation	method	 [1]	 have	 shown	more	 suitable	 characteristics	with	
regard	 to	 those	 produced	 by	 nanoprecipitation:	 better	 size,	 a	 higher	 homogeneity	 and	 higher	
encapsulation	 efficiency.	 The	 combination	 of	 99m	 Tc	 +	 PLGA	 nanoparticles	 (platforms	 with	 excellent	
biodegradability	and	biocompatibility)	could	allow	obtaining	a	suitable	nanosystem	for	theranosis.	The	
aim	of	the	present	work	is	to	optimize	the	radiolabelling	of	PLGA	nanoparticles	with	99mTc.	Materials	and	
Methods:	PLGA	 nanoparticles	were	 prepared	 using	 the	 nanoprecipitation	method	 [1].	 Then,	 5	mg	 of	
lyophilized	NPs	were	dispersed	 in	1	mL	0.9%	NaCl	and	stored	 in	a	vacuum	vials.	Different	amounts	of	
stannous	chloride	dehydrate	in	aqueous	solution	(30,	20,	4,	2,	1	and	0,1	μg)	were	added.	Then,	was	added	
≈74	MBq	(2	mCi)	of	99mTc	in	1	mL	of	0.9%	NaCl.	Finally,	the	suspension	was	incubated	for	10	min.	99mTc	-
NPs	suspensions	were	analyzed	by	thin	layer	chromatography	(TLC)	with	silica	gel	strips	(10	x2,5	cm).	With	
0.9%	NaCl	as	the	mobile	phase,	free	pertechnetate	ran	with	the	front,	meanwhile	particles	stayed	in	the	
start.	 Using	 a	 solution	 of	 pyridine:	 acetic	 acid:	 water	 (3:	 5:	 15),	 radiocolloids	 remained	 at	 start,	 NPs	
migrated	 with	 Rf	 =	 0.3	 and	 free	 pertechnetate	 moved	 with	 Rf	 =	 0.7-0.8	 [2].	 Results:	Using	 1	 μg	 of	
SnCl2*2H2O	as	a	reducing	agent,	PLGA	nanoparticles	(without	surface	modification)	were	labeled	with	99m	
Tc	with	 a	 yield	 ≥	 90	%.PLGA	nanoparticles	 size	 ranged	 from	160-180	nm	 in	 diameter	with	 an	 electric	
surface	of	-36	mV.	After	radiolabelling,	particles	increased	in	size	up	to	a	diameter	≈	380	nm.	Conclusions:	
Results	obtained,	indicate	that	the	procedures	of	nanoparticle	synthesis,	radiolabelling	and	quality	control	
were	 reproducible	 and	 right	 to	 design	 a	 biodegradable	 nanosystem	 suitable	 for	 in	 vivo	 theranosis.	
References:	 [1]	 Martín-Banderas	 L,	 Sáez-Fernández	 E,	 Holgado	 MÁ,	 Durán-Lobato	 MM,	 Prados	 JC,	
Melguizo	C,	Arias	JL.	Int	J	Pharm.	2013	Feb	25;443(1-2):103-9.	[2]	Snehalatha	M,	Kolachina	V,	Saha	RN,	
Babbar	AK,	Sharma	N,	Sharma	RK.	J	Pharm	Bioallied	Sci.	2013	Oct;5(4):290-7.	
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Development	of	[18F]PD-410	as	a	Non-Peptidic	PET	Radiotracer	for	Gastrin	Releasing	Peptide	Receptors	
Ines	 Farinha-Antunes,b	 Chantal	 Kwizera,b	 Enza	 Lacivita,a	 Ermelinda	 Lucente,a	Mauro	Niso,a	 Paola	De	
Giorgio,a	Roberto	Perrone,a,c	Nicola	A.	Colabufo,a,c	Philip	H.	Elsinga,b	Marcello	Leopoldo	a,c	
aDipartimento	di	Farmacia	–	Scienze	del	Farmaco,	Università	degli	Studi	di	Bari	“Aldo	Moro”,	Bari,	Italy	
bDepartment	 of	 Nuclear	 Medicine	 and	 Molecular	 Imaging,	 University	 Medical	 Center	 Groningen,	
University	of	Groningen,	Groningen,	The	Netherlands	
cBIOFORDRUG	s.r.l.,	Spin-off,	Università	degli	Studi	di	Bari	“Aldo	Moro”,	Bari,	Italy	
Introduction:	The	Gastrin	Releasing	Peptide	(GRP)	receptor	has	high	expression	on	prostate	cancer	cells.	
Consequently,	bombesin,	a	14-amino	acid	peptide	that	binds	with	high	affinity	to	GRP	receptors,	has	been	
widely	 studied	 for	 the	 development	 of	 radiopeptides	 for	 application	 in	 prostate	 cancer	 imaging.	 To	
overcome	 some	 limitations	 of	 radiolabelled	 peptides,	 we	 developed	 a	 small	 molecule	 non-peptidic	
radiotracer	targeting	GRP	receptors.	Small	molecules	offer	various	advantages	over	peptides	since	they	
can	be	suitably	designed	to	modulate	potency,	selectivity,	lipophilicity,	and	cell	permeability	and	do	not	
suffer	from	poor	tissue	penetration,	poor	serum	stability,	and	quick	elimination.	The	aim	of	the	present	
study	is	to	develop	a	non-peptidic	fluorine-18	PET	radioligand	with	antagonist	properties,	for	visualization	
of	GRP	receptors.	PD-410	((S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-
methyl-2-[3-(4-nitrophenyl)ureido]propionamide)	 was	 selected	 as	 potent	 compound	 for	 18F-
radiolabelling	(Ki	was	38	±	2	nM).	Methods:	[18F]PD410	was	synthesized	by	reaction	of	[18F]fluoroethyl	
tosylate	with	the	corresponding	phenol	precursor	in	presence	of	NaH	followed	by	HPLC-purification.	Cell	
experiments	were	carried	out	with	PC3	cells	to	determine	cell	uptake,	efflux	and	in	vitro	binding	affinity.	
Chemical	structure	of	[18F]PD410	
Results:	In	contrast	to	other	[18F]fluoroethylation	reactions,	RCY	was	low	(<5%)	because	of	substantial	
defluorination.	 The	 uptake	 of	 [18F]PD410	 in	 PC3	 prostate	 cancer	 cells	 gradually	 increased	 within	 60	
minutes	of	incubation,	thereafter	reaching	a	plateau.	The	maximum	cellular	associated	radioactivity	was	
found	to	be	70%.	Non-specific	binding	accounted	for	40%.	The	efflux	kinetics	of	[18F]PD410	showed	rapid	
dissociation	of	the	tracer,	remaining	only	6%	of	the	tracer	within	120	min.	This	radioactivity	decreased	
exponentially	with	a	half-life	of	13	minutes.	In	vitro	binding	affinity	of	[18F]PD410	was	plotted	as	sigmoid	
curves	for	the	displacement	of	[18F]PD410	as	a	function	of	increasing	concentrations	of		the	GRP	receptor	
specific	inhibitor	Glu[Aca-BN(7-14)]2.	The	IC50	value	was	0.10	nM	for		Glu[Aca-BN(7-14)]2.	Conclusions:	
[18F]PD410	displayed	high	affinity	for	GRP	receptor	and	the	in	vitro	results	warrant	further	in	vivo	PET-
studies.	
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An	improved	nucleophilic	synthesis	of	2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy)	benzothiazole	
([18F]FEDMBT),	potential	diagnostic	agent	for	breast	cancer	imaging	by	PET	
V.V.	Vaulina1,	O.S.	Fedorova1,	V.V.	Orlovskaja1,	С.L.	Chen2,	G.Y.	Li2,	F.C.	Meng2,	R.S.	Liu2,3,	H.E.	Wang2,	
R.N.	Krasikova1.		
1N.P.	 Bechtereva	 Institute	 of	 Human	 Brain,	 Russian	 Academy	 of	 Science,	 Saint-Petersburg,	 Russian	
Federation;	2Department	of	Biomedical	Imaging	and	Radiological	Sciences,	National	Yang-Ming	University	
Taipei,	Taiwan;	3National	PET/Cyclotron	Center,	Veterans	General	Hospital,	Taipei,	Taiwan.	
	
Introduction:	Substituted	benzotiazoles	(BT)	are	a	class	of	compounds	with	high	affinity	and	selectivity	to	
aryl	hydrocarbon	receptor	(AhR),	a	receptor	often	expressed	in	breast	cancer	tissue.		Among	them	2-(3,4-
dimethoxyphenyl)-5-fluorobenzothiazole	 (PMX	 610)	 exhibited	 very	 potent	 (GI50	 <	 0.1	 nM)	 antitumor	
properties	in	vitro	in	human	breast	cancer	cell	lines.	Based	on	that	scaffold	we	recently	suggested	18F-
fluoroethylated	 analogue	 of	 PMX	 610,	 the	 2-(3,4-dimethoxyphenyl)-6-(2-
[18F]fluoroethoxy)benzothiazole	([18F]FEDMBT)1.	Preliminary	studies	showed	high	accumulation	of	the	
radiotracer	 in	MCF-7,	MDA-MB468	and	MDA-MB231	breast	cancer	cells.	Here	we	report	an	 improved	
synthesis	and	purification	of	[18F]FEDMBT	for	preclinical	trials.	
	
		
Materials	and	methods:	The	extent	of	18F-fluorination	was	followed	via	radioTLC	(EtAc:hexane	1:4).	The	
HPLC	purification	was	performed	using	Waters	C18	XBridge	250	x	10	mm	column,	0.05M	NH4OAc:EtOH,	
50:50,	3	ml/min,	UV	254	nm.	For	SPE	purification	1.2	mL	of	aqueous	25%	EtOH	was	added	to	the	reaction	
mixture	(5	mg	of	precursor,	0.6	mL	of	DMF)	to	prevent	precipitate	formation.	The	resulting	solution	was	
passed	through	the	Sep-Pak	tC18	Plus	Long	cartridge.	The	cartridge	was	then	rinsed	with	2	mL	of	50%	aq.	
EtOH	 allowing	 for	 complete	 removal	 of	 the	 precursor.	 The	 product,	 [18F]FEDMBT,	was	 recovered	 by	
successive	elution	of	the	cartridge	with	2	and	1	mL	of	55%	aq.	EtOH.		
Results	 Under	 optimal	 reaction	 conditions	 (see	 figure)	 a	 high	 18F-incorporation	 rate	 of	 80-85%	 was	
achieved.	The	HPLC	purification	afforded	the	product	in	>99%	radiochemical	purity	and	RCY	of	55%	(decay	
corrected).	 Isolated	product	 fraction	was	mixed	with	 phosphate	 buffered	 saline	 to	 adjust	 the	 pH	 and	
ethanol	concentration,	without	final	re-formulation	step.	Fractionated	SPE	purification	afforded	product	
with	>99%	RCP	and	60%	RCY	(decay	corrected).	While	SPE	technique	allowed	for	complete	removal	of	
precursor,	a	minor	chemical	 impurity	 (not	 identified)	 remained	 in	 the	 final	 formulation.	Work	 is	being	
undertaken	now	to	resolve	this	 issue.	 	Discussion/conclusion:	An	optimized	synthesis	of	[18F]FEDMBT	
afforded	product	with	radiochemical	purity	and	high	yield.	It	can	be	easy	automated	using	TracerLab	FX-
N	 Pro	 platform.	 The	 suggested	 “HPLC	 free”	 SPE	 purification	 can	 be	 applied	 in	 the	 production	 of	
[18F]FEDMBT	for	ongoing	in	vitro	cell	lines	experiments	and	preclinical	trials.	This	study	was	supported	
by	RFBR	grant	15-54-52026/15	and	MOST	104-2923-B-010-001-MY2.	
1.Chen	CL	et	al,	[2015],		EJNMMI,	42,	Suppl.1,	S481	
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PP11	
Internal	Radiation	Dose	Assessment	of	Radiopharmaceuticals	Prepared	with	Accelerator-Produced	
99mTc	
Laura	Meléndez-Alafort1,	Mohamed	Abozeid1,	Guillermina	Ferro-Flores2,	Anna	Negri3,	Michele	Bello4,	
Nikolay	Uzunov5,6,	Martha	Paiusco3,	Juan	Esposito6,	Antonio	Rosato1,3,		
1DiSCOG-University	 of	 Padua,	 Italy;	 2ININ,	 Ocoyoacac,	México;	 3IOV	 Padua,	 Italy;	 4DFA-University	 of	
Padua,	Italy;	5Faculty	of	Natural	Sciences,	University	of	Shumen,	Bulgaria;	6INFN-LNL,	Legnaro,	Italy.	
	
Introduction:	99mTc	is	the	radionuclide	most	widely	used	in	diagnostic	nuclear	medicine.	It	is	available	
from	99Mo/99mTc	generators,	where	99Mo	is	obtained	by	a	fission	reaction	in	nuclear	reactors.	Direct	
reactions	using	proton	beams	[e.g.	100Mo(p,2n)99mTc]	are	a	reliable	and	relatively	cost-effective	method	
to	fulfill	the	shortage	of	this	isotope	given	the	imminent	closure	of	the	existing	old	reactors.	However,	the	
results	of	LARAMED	project	from	the	LNL-INFN	showed	that	the	extracted	solution	of	99mTc	from	the	
proton-bombarded	100Mo-enriched	target	contains	small	quantities	of	several	technetium	radioisotopes	
(93Tc,	94Tc,	95Tc,	95mTc	and	96Tc)[1].	 	The	aim	of	this	work	was	to	estimate	the	total	contribution	of	
technetium	 radioisotopes	 to	 the	 patient	 radiation	 absorbed	 dose	 after	 administration	 of	 four	
radiopharmaceuticals	prepared	with	 technetium-99m	obtained	 from	 the	100Mo(p,2n)99mTc	 reaction.	
Methods:	 The	 internal	 radiation	 absorbed	 doses	 of	 pertechnetate,	 sestamibi,	
hexamethylpropyleneamine	 oxime	 (HMPAO),	 and	 disodium	 etidronate	 (HEDP)	 radiopharmaceuticals,	
were	assessed	considering	both	technetium-99m	prepared	from	the	100Mo(p,2n)99mTc	reaction	as	well	
as	from	generators.	Time-integrated	activity	in	the	main	source	organs	[Ã(rs,TD)]	for	each	radioisotope	
was	 calculated	 using	 the	 radiopharmaceutical	 biokinetic	 models	 published	 by	 the	 International	
Commission	 on	 Radiological	 Protection	 (Publication	 53	 and	 80,	 ICRP).	 OLINDA/EXM	 1.1	 software	was	
applied	for	dose	calculations	using	an	adult	male	phantom	as	a	program	input	and	the	above	Ã(rs,TD)	
calculated	values.	The	total	absorbed	dose	in	the	target	organs,	produced	by	the	mixture	of	technetium	
radioisotopes,	was	calculated	for	3	time	periods	after	100Mo	irradiation.	Results:	The	amounts	of	other	
technetium	radioisotopes	in	the	99mTc-radiopharmaceuticals	produced	a	low	increase	of	radiation	doses.	
Bone	marrow	 is	 the	organ	 that	exhibited	 the	highest	difference	between	 the	dose	obtained	 from	 the	
generator-produced	99mTc	and	the	accelerator-produced	one.	For	example,	HEDP	bone	marrow	dose	
(4.41E-03	mSv/MBq)	showed	an	increase	in	the	of	8.5%	(4.79E-03	mSv/MBq),	11.8%	(4.93E-03	mSv/MBq)	
and	 17.7%	 (5.19E-03	 mSv/MBq)	 using	 99mTc	 obtained	 at	 9,	 14,	 and	 19	 h	 after	 100Mo	 irradiation,	
respectively.	The	corresponding	differences	for	sestamibi,	pertechnetate	and	HMPAO	were	less	than	8%,	
10%	and	14%	for	the	same	irradiation	times.	Conclusion:	The	increase	of	radiation	doses	caused	by	93Tc,	
94Tc,	95Tc,	95mTc	and	96Tc,	compared	with	the	dose	from	99mTc	is	relatively	low.	However,	its	impact	
should	not	be	underestimated.	Administering	the	labeled	radiopharmaceuticals	at	least	nine	hours	after	
the	target	irradiation	is	advisable	to	reduce	the	irradiation	caused	by	the	other	technetium	radioisotopes.	
References:	1.	Uzunov	N,	Bello	M,	et	al,	[2015],	INFN	LNL	Report,	ISSN	1828-8561,	241:52-53.	
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A	specialized	Five-Compartmental	Model	Software	for	Pharmacokinetic	Parameters	Calculation	
Laura	Meléndez-Alafort1,	Cristina	Bolzati2,	Guillermina	Ferro-Flores3,	Nicola	Salvarese1,	Debora	
Carpanese1,	Mohamed	Abozeid1,	Antonio	Rosato1,4,	Nikolay	Uzunov5.	
1DiSCOG-University	of	Padua,	Italy;	2IENI-CNR,	Padua,	Italy;	3	ININ,	Ocoyoacac,	México;	4IOV	Padua,	
Italy;		5Faculty	of	Natural	Sciences,	University	of	Shumen,	Bulgaria.	
	
Introduction:	 The	 use	 of	 pharmacokinetics	 modeling	 in	 preclinical	 nuclear	 medicine	 is	 very	 limited	
although	 it	 is	 well	 known	 that	 such	 models	 could	 be	 valuable	 tools	 to	 study	 radiopharmaceutical-
properties1.	Nowadays,	 the	preclinical	evaluation	of	new	radiopharmaceuticals	 is	 still	 focused	only	on	
biodistribution	 studies,	 mainly	 because	 of	 the	 lack	 of	 currently	 available	 user-friendly	 specialized	
programs	to	assist	 researchers	 in	calculating	radiopharmacokinetic	parameters.	Methods:	A	dedicated	
spreadsheet	software	to	calculate	pharmacokinetic	parameters	such	as	tracer-biological	half-life	(T1/2),	
mean	 residence	 time	 (MRT)	 for	 each	 compartment,	 as	 well	 as	 the	 fraction	 of	 the	 tracer	 leaving	 the	
compartments	 per	 unit	 time	 (transfer	 rate	 constant,	 TRC),	 has	 been	 developed.	 The	 menu-driven	
spreadsheet	software	is	based	on	five-Compartment	Kinetic	Model	(CoKiMo).	CoKiMo	was	used	to	study	
pharmacokinetic	parameters	of	11	99mTc-nitrido	complexes,	reported	as	potential	myocardial	perfusion-
imaging	agents	(MPIAs),	of	general	formula	[99mTcN(DTC-Ln)(PNP)]+	(DTC-Ln=	alicyclic	dithiocarbamates;	
PNP=	diphosphinoamine)2,	and	the	results	were	compared	with	those	of	99mTc-Sestamibi	and	99mTc-
Tetrofosmin.	Biodistribution	studies	for	all	MPIAs	have	been	performed	in	Sprague-Dawley	rats	(n	=	312)	
to	determine	organ	uptake.	Results:	MPIAs	time-activity	curves	have	been	obtained	using	CoKiMo	for	5	
compartments,	by	interpolation	of	organ	activity	values	measured	at	different	time	points.	Curves	have	
been	 integrated	to	calculate	T1/2	and	MRT	 in	 the	studied	organs	of	all	MPIAs.	Subsequently	software	
employs	a	module	with	 implemented	optimization	procedure,	dedicated	to	calculate	the	values	of	the	
TRCs.	Finally,	CoKiMo	calculations	were	validated	by	comparison	with	two	different	software:	Olinda/Exm	
and	 SAAM	 II.	 [99mTcN-(PNP)]+-complexes	 showed	 a	 faster	 blood	 and	 liver	 clearance	 as	 compared	 to	
99mTc-Sestamibi	and	99mTc-Tetrofosmin,	in	agreement	with	some	previous	reported	studies2.	However,	
it	 was	 found	 that	 when	 CoKiMo	 pharmacokinetic	 data	 were	 used,	 a	 wide	 quantitative	 comparison	
between	all	MPIAs	was	possible,	which	in	fact,	was	not	possible	using	only	the	biodistribution	data.	The	
analysis	of	the	results	showed	that		99mTcN-PDTC3	turned	out	to	be	the	best	candidate	for	translation	
into	 clinical	 practice	 due	 to	 its	 rapid	 and	 high	 heart	 uptake,	 and	 fast	 liver	 and	 lung	 clearance,	which	
enabled	an	early	visualization	of	myocardial	tissue.	Conclusion:	CoKiMo	proved	to	be	an	easy	to	use	and	
flexible	specialized	software	to	study	the	kinetic	of	a	great	number	of	pharmaceuticals	labeled	with	an	
unlimited	 number	 of	 radionuclides.	 Therefore,	 it	 can	 be	 a	 useful	 tool	 for	 an	 extensive	 preclinical	
characterization	of	new	radiopharmaceuticals.	References:	1.-	Rescigno	A,	[2010],	AAPS	J	12:61-72.		2.-	
Bolzati	C,	Cavazza-Ceccato	M,	et	al,[2010],	Bioconjug	Chem	21:928-939	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 71	
	
PP13	
Molecular	imaging	of	the	pharmacokinetic	behavior	of	low	molecular	weight	18F-labeled	PEtOx	in	
comparison	to	89Zr-labeled	PEtOx	
Palmieri	L1,2.,	Verbrugghen	T1,	Glassner	M3,	Hoogenboom	R2,	Staelens	S1,	wyffels	L1,2	
1Molecular	Imaging	Center	Antwerp,	University	of	Antwerp,	Antwerp,	Belgium;	2Department	of	Nuclear	
Medicine,	Antwerp	University	Hospital,	Antwerp,	Belgium;	3Supramolecular	Chemistry,	Ghent	
University,	Ghent,	Belgium	
	
Introduction:	 PEGylation	 is	 a	 methodology	 that	 is	 commonly	 used	 to	 improve	 the	 PK	 profile	 of	
radiotracers.	In	recent	years	biocompatible	poly(2-alkyl-2-oxazoline)s	(PAOx)	gained	a	lot	of	attention	as	
alternative	to	PEG	because	of	their	much	higher	chemical	versatility.	PAOx	can	be	equipped	with	side-
chain	functionalities,	allowing	loading	multiple	targeting	molecules,	while	the	chain-end	can	be	selectively	
radiolabeled.	We	previously	evaluated	the	PK	behavior	of	89Zr-labeled	poly(2-ethyl-2-oxazoline)s	(89Zr-
PEtOx)	in	a	molecular	weight	(MW)	range	of	5-110kDa	using	µPET	imaging.	While	we	found	the	expected	
increase	 of	 circulation	 time	 with	 increasing	 MW,	 the	 5kDa	 [89Zr]-PEtOx	 demonstrated	 unusual	 high	
kidney	retention.	We	now	developed	[18F]-PEtOx	5kDa	and	compared	its	pharmacokinetic	behavior	to	
[89Zr]-PEtOx	5kDa.Materials	and	Methods:	PEtOx	was	radiolabeled	with	18F	using	SPAAC.	For	this,	PEtOx	
was	first	derivatized	with	bicyclononyne	(BCN).	Automated	18F-labeling	of	BCN-PEtOx	was	performed	by	
reaction	of	azidoethyl	tosylate	with	azeotropically	dried	18F-	followed	by	distillation	of	the	formed	[18F]-
fluorethylazide	into	a	second	reactor	for	reaction	with	BCN-POX.	The	reaction	mixture	was	purified	using	
a	PD-10	cartridge	and	QC	was	performed	using	a	Zenix-C	80Å	column.	To	evaluate	the	PK	profile,	C57BL/6	
mice	(n=4)	were	intravenously	injected	with	[18F]-BCN-PEtOx	(16.47±1.68Mbq,	~100µg)	and	dynamically	
scanned	over	the	first	2h.	Volumes	of	interest	were	delineated	for	heart,	liver	and	kidneys	to	calculate	
standard	uptake	values	(SUV).	Results:	[18F]-BCN-PEtOx	was	obtained	with	a	RCY	of	4.30%	(n=4,	decay	
corrected	to	EOB)	and	a	RCP	of	100%	after	PD-10	purification.	As	was	previously	demonstrated	for	[89Zr]-
PEtOx	 5kDa,	 µPET	 imaging	 revealed	 rapid	 and	 complete	 blood	 clearance	 of	 [18F]-PEtOx	 5kDa	
(SUV=2.42±0.16	 at	 10min	pi	 and	 SUV=0.27±0.08	 at	 1h	pi).	 Peak	 liver	 uptake	 related	 to	perfusion	was	
reached	 within	 1min	 pi	 (SUV=2.92±0.18)	 and	 quickly	 decreased	 (SUV=0.50±0.03	 at	 10min	 pi	 and	
SUV=0.07±0.00	at	1h	pi)	 indicating	only	minor	contribution	of	the	liver	 in	the	clearance	of	[18F]-PEtOx	
5kDa.	 The	 kidneys	 displayed	 a	 high	 initial	 uptake	 (SUV=5.67±0.87	 at	 3.75min	 pi	 versus	 7.58±2.54	 at	
3.75min	pi	for	[89Zr]-Df-PEtOx	5kDa)	but	where	[89Zr]-Df-PEtOx	5kDa	was	not	cleared	from	the	kidneys	
(SUV=2.36±0.84	 at	 24h	 pi),	 [18F]-PEtOx	 5kDa	 showed	 a	 fast	 and	 almost	 complete	 clearance	
(SUV=0.27±0.08	at	1h	pi	and	SUV=0.12±0.05	at	2h	pi).	Conlusions:	 [18F]-PEtOx	5kDa	 is	quickly	cleared	
from	the	body	and	does	not	display	high	kidney	 retention.	The	unusual	kidney	 retention	of	 [89Zr]-Df-
PEtOx	5kDa	is	therefore	most	likely	related	to	endocytosis	and	lysosomal	degradation	of	the	radiolabeled	
polymer	followed	by	trapping	of	radiometal	89Zr	in	the	proximal	tubules.	
	 	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 72	
	
PP14	
Towards	Nucleophilic	Synthesis	of	the	α-[18F]fluoropropyl-L-dihydroxyphenylalanine		
V.	V.	Orlovskaja1,	O.	F.	Kuznetsova1,	O.	S.	Fedorova1,	V.	I.	Maleev2;	Yu.	N.	Belokon2;	A.	Geolchanyan3;	
A.	S.	Saghyan3;	L.	Mu4,	R.	Schibli4;	S.	M.	Ametamey4;	R.	N.	Krasikova1	
1	N.P.	Bechtereva	Institute	of	Human	Brain,	RAS,	St.-Petersburg,	Russia;	2A.N.	Nesmeyanov	Institute	of	
Organoelement	Compounds,	RAS,	Moscow,	Russia;	3SPC	Armbiotechnology	NAS,	Yerevan,	Republic	of	
Armenia;	4Center	for	Radiopharmaceutical	Sciences	of	ETH,	PSI	and	USZ,	Zurich,	Switzerland	
	
Introduction:	The	interest	towards	use	of	6-[18F]fluoro-L-DOPA	as	a	PET	radiotracer	for	the	evaluation	of	
dopaminergic	system’s	state	and	also	as	tumor	diagnostic	agent	has	been	steadily	increasing	during	the	
last	decade.	Considerable	work	is	being	undertaken	to	overcome	the	practical	difficulties	encountered	in	
the	 production	 of	 6-[18F]fluoro-L-DOPA	 and	 other	 ring-fluorinated	 amino	 acids	 via	 nucleophilic	
substitution	route.	Aromatic	amino	acids	carrying	monofluoro	methyl	group	in	the	α-position	have	also	
been	considered	as	potential	PET	radiotracers,	with	nucleophilc	synthesis	of	racemic	α-[18F]fluoromethyl	
phenylalanine	using	cyclic	sulfamidate	precursor	already	reported1.	Recently	our	group	has	suggested	a	
route	towards	enantiomerically	pure	α-[18F]fluoromethyl-p-tyrosine	via	direct	nucleophilic	fluorination	
of	a	NiII	complex2.	However,	18F-fluorination	of	the	precursor	bearing	α-MeSO3	(mesyloxy)	leaving	group	
was	inefficient,	possibly	due	to	the	steric	hindrance	at	the	α-carbon	of	the	tyrosine	moiety.	In	continuation	
of	 that	 previous	work	we	 have	 investigated	 the	 synthesis	 of	 the	 α-[18F]fluoropropyl-L-DOPA	 via	 18F-
fluorination	of	a	similar	precursor	(I,	Fig.1).		
	
Materials	 and	 methods:	 Radiofluorination	 of	 I	 was	 performed	 in	 the	 presence	 of	 kryptofix/K2CO3	
(acetone,	10	min,	85oC,	10	mg	of	precursor).	The	extent	of	18F-fluorination	was	followed	by	radioTLC	
(EtAc:CHCl3:CH3COOH	4:1:1).	After	solvent	removal	the	18F-fluorinated	intermediate	was	treated	with	
6M	aq.	HCl	at	140oC	for	10	min.	The	product	was	analyzed	by	radioTLC	(EtOH:n-Butanol:CH3COOH	4:1:1)	
and	HPLC	(Lichrosphere	100-RP-18,	250	x	4	mm,	0.1%	CH3COOH).		Results	The	precursor,	NiII	complex	of	
Schiff	base	of	(2S)-1-benzyl-N-(2-formylphenyl)pyrrolidine-2-carboxamide	(BBA)	with	(S)-2-amino-2-(3,4-
bis((methylsulfonyl)oxy)benzyl)-5-((methylsulfonyl)oxy)pentanoic	 acid	 (Ni-(S)-BBA-(S)-MsO	 propyl-
DOPA(OMs)2	 (I)),	 was	 prepared	 from	 the	 corresponding	 NiII	 complex	 of	 BBA	 Schiff	 base	 with	 (S)-
DOPA.18F-fluorination	 efficiency	 of	 I	 was	 15%,	 with	 room	 for	 optimization.	 Acid	 hydrolysis	 of	 the	
intermediate	afforded	protected	derivative	of	(S)-α-[18F]fluoropropyl-L-DOPA,	but	removal	of	the	mesyl	
protective	groups	proved	problematic	 -	use	of	2M	potassium	methylate	 in	MeOH	 (60oC,	10	min)	was	
ineffective.	 	Discussion/conclusion	The	nucleophilic	 fluorination	of	NiII-based	 labeling	precursor	offers	
potential	 novel	 route	 towards	 a	 new	 derivative	 of	 DOPA	with	 18F-label	 in	 the	 α-fluoropropyl	 group.	
Preparation	of	precursor	employing	methoxy	methoxy	(MOM)	protective	groups	instead	of	mesyl	ones,	
something	 that	 should	 resolve	 the	 deprotection	 problem,	 is	 currently	 in	 progress.	 	 This	 study	 was	
supported	by	SNF	grant	IZ73ZO_152360/1.	References:	1	Huang	C	et	al,	[2013],	Nucl	Med	Biol,	40,	498-
506;	2	Krasikova	R	et	al,	[2015],		EJNMMI,	42,	Suppl.1,	S479-480.	 	
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A	convenient	one-pot	synthesis	of	[18F]clofarabine	
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1	Karolinska	Institutet,	Department	of	Clinical	Neuroscience,	Centre	for	Psychiatric	Research,	Stockholm,	
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Introduction:	[18F]Clofarabine	(3,	scheme	1)	has	recently	emerged	as	a	promising	radioligand	for	in	vivo	
imaging	of	deoxycytidine	kinase	activity	using	PET	(1).	In	the	reported	protocols	by	Shu	and	Wu	(1,2),	3	is	
prepared	 in	 a	 two-step	 process	 with	 an	 intermediate	 purification	 that	 proceeds	 with	 10-15%	
radiochemical	yield	(RCY).	We	herein	report	a	simplified	procedure	for	the	preparation	of	3,	in	which	the	
intermediate	purification	was	eliminated.	Materials	&	Methods:	[18F]Fluoride	was	produced	using	a	GE	
PETtrace	cyclotron	and	dried	azeotropically	with	acetonitrile	(MeCN),	potassium	carbonate	and	kryptofix	
(K2.2.2).	Radiofluorination	was	performed	in	MeCN	at	90	oC	for	20	minutes,	after	which	solvents	were	
removed	 in	 vacuo	 and	 deprotection	 was	 performed	 using	 10%	 trifluoroacetic	 acid	 (TFA)	 in	
dichloromethane	(DCM)	at	room	termperature	(rt)	 for	5	min.	Following	an	additional	evaporation,	the	
crude	product	was	dissolved	in	mobile	phase	and	purified	using	semi-preparative	HPLC	(ACE,	C18,	5µm,	
HIL	250×10	mm,	eluted	with	MeCN:	aq.	NH4OH	(0.6%)	90.5:9.5	(v/v)	at	6	mL/min).	3	was	isolated	from	
the	eluent	using	a	C-18	SepPak	cartridge	(Waters)	and	formulated	for	intravenous	injection	in	a	solution	
of	ethanol	and	phosphate	buffered	saline	(10:90).	
	
	Scheme	1.	One-pot,	two-step	radiosynthesis	of	[18F]clofarabine.	
	
Results:	The	radiochemical	conversion	(RCC)	of	18F-fluoride	into	3	was	between	25-30%.	Higher	reaction	
temperatures	or	prolonged	heating	did	not	improve	the	RCC.	Removal	of	MeCN	from	the	reaction	mixture	
prior	to	deprotection	was	found	to	be	essential	and	may	be	ascribed	to	the	known	inhibiting	properties	
of	MeCN	on	trityl-group	hydrolysis	(3).	By-product	formation,	sometimes	observed	when	refluxing	2	with	
aqueous	HCl,	could	be	effectively	eliminated	by	employing	mild	conditions	for	the	deprotection	(10%	TFA	
in	 DCM,	 rt,	 5	min)	 without	 compromising	 the	 RCY.	 No	 intermediate	 purification	was	 required	 in	 the	
process,	that	produced	>99%	radiochemically	pure	3	in	20%	RCY	with	a	specific	activity	>100	GBq/µmol.	
Discussion/Conclusion:	A	simplified	one-pot	 radiosynthesis	of	3	was	developed	 in	which	 intermediate	
purification	 was	 eliminated.	 The	 RCY	 is	 on	 par	 with	 previously	 reported	 protocols	 for	 3	 synthesis.	
References:	1.	Shu	CJ,	Campbell	DO,	Radu	CG,	[2010],	JNM	51(7),	1092-1098.	2.	Wu	C,	Chan	P,	Chang	W,	
Wang	H,	Liu,	R.	[2009],	JNM	Annual	Meeting	Abstracts	50	(2),	1612.	3.	Russell	MA,	Laws	AP,	Atherton	JH,	
Page	MI,	[2009],	Org	Biomol	Chem	7(1),	52-57.	
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BODIPY-estradiol	conjugates	as	multi-modality	tumor	imaging	agents	
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1	Département	 de	médecine	 nucléaire	 et	 radiobiologie,	 Faculté	 de	médecine	 et	 sciences	 de	 la	 santé,	
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Introduction:	 In	vivo	imaging	of	estrogen	receptor	(ER)	densities	 in	human	breast	cancer	is	a	potential	
tool	to	stage	disease,	guide	treatment	protocols	and	follow-up	on	treatment	outcome.	Among	various	
techniques	to	detect	 ligand–ER	interaction	both	positron	emission	tomography	(PET)	and	fluorescence	
imaging	have	received	ample	attention.	Materials	&	Methods:	In	this	study	we	use	4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene	 (BODIPY)	 as	 a	 fluorescent	 probe	 and	 precursor	 for	 18F-labelling	 to	 develop	
estradiol-based	ligands	for	ER.	The	synthesis	involves	attachment	of	a	BODIPY	moiety	to	the	C17α-position	
of	estradiol	using	Sonogashira	cross	coupling	reaction	of	iodo-BODIPY	and	various	17α-ethynyl	estradiol	
(EE2)	 derivatives.	 Confocal	 laser	 scanning	microscopy	was	used	 to	monitor	 cellular	 uptake	of	 the	 EE2	
conjugates	after	1	h	of	treatment	without	and	with	estradiol	to	block	ER.	Flow	cytometric	analysis	was	
performed	 to	 determine	 the	 relative	 fluorescence	 in	 the	 nuclei.	 Results:	 The	 Sonogashira	 coupling	
reaction	 of	 EE2	 derivatives	 with	 iodo-BODIPY(1:1	 molar	 ratio)	 in	 THF/toluene	 (1/2)	 and	 using	
PdCl2(PPh3)2	 as	 catalyst,	 NEt3	 as	 a	 base	 and	 CuI	 at	 room	 temperature	 gave	 the	 desired	 EE2-BODIPY	
conjugates	in	45-86%	yield	(after	purification	by	silica	gel	column	chromatography).	ER-mediated	uptake	
of	 the	 basic	 EE2-BODIPY	 conjugate	 by	 the	 nuclei	 of	 ER-positive	 MC7-L1	 cells	 was	 confirmed	 by	
fluorescence	imaging.	Discussion	&	Conclusion:	The	synthesis	of	a	series	of	EE2-BODIPY	conjugates	was	
achieved	 via	 Sonogashira	 cross-coupling	 in	moderate	 to	 very	 good	 isolated	 yields.	 In	 vitro	 cell	 uptake	
results	 warrant	 further	 studies	 to	 evaluate	 the	 potential	 of	 the	 EE2-BODIPY	 conjugates	 for	
fluorescence/PET	 imaging	of	ER-positive	breast	cancer.	Fluor-18	 labelling	of	 the	BODIPY	moiety	of	 the	
conjugates	as	well	as	fluorescence	and	PET	imaging	in	tumor	bearing	mice	have	been	projected.	
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Easy	and	high	yielding	synthesis	of	68Ga-labelled	HBED-PSMA	and	DOTA-PSMA	by	using	a	Modular-
Lab	Eazy	automatic	synthesizer.		
Di	Iorio	V1,	Iori	M2,	Donati	C1,	Lanzetta	V1,		Capponi	PC2,	Rubagotti	S2,	Dreger	T3,	Kunkel	F3,	Asti	M2.		
(1)	Radiopharmacy	Nuclear	Medicine	Unit,	IRST	IRCCS,	Meldola	(FC),	Italy	
(2)	Nuclear	Medicine	Unit,	IRCCS-Arcispedale	Santa	Maria	Nuova,	Reggio	Emilia,	Italy		
(3)	Eckert	&	Ziegler	Eurotope	GmbH,	Berlin,	Germany	
	
Introduction:	 68Ga-labelled	 PSMA	 inhibitor	 analogues	 are	 one	 the	 most	 important	 class	 of	 new	
radiotracers	under	clinical	observation	and	development	for	the	detection	of	prostate	cancer	lesions	and	
metastases.	 68Ga-	 PSMA-11	 (68Ga-PSMA-HBED-CC)	 has	 already	 attested	 its	 suitability	 in	 the	 clinical	
practice	and	68Ga-PSMA-617	(68Ga-DOTA-PSMA)	has	recently	demonstrated	 its	potential	 in	 individual	
first-in-man	studies	gaining	importance	above	all	in	view	of	its	theranostic	application	as	it	can	be	labelled	
also	with	90-Yttrium	and	177-Lutetium.	In	this	study	the	two	68Ga-labelled	radiotracers	were	synthesized	
using	an	automatic	Modular-Lab	Eazy	synthesizer	(Eckert	&	Ziegler)	and	the	reliability	of	the	system	was	
validated	to	guarantee	preparations	of	pharmaceutical	grade.	Materials	and	Methods:	The	system	was	
assembled	with	a	disposable	cassettes	and	the	vials	were	filled	with	commercial	precursors	and	ready	to	
use	pharmaceutical	grade	reagents.	After	clicking	the	start	button	the	following	steps	were	performed:	a	
1850	MBq	GalliaPharm	68Ge/68Ga	generator	(Eckert	&	Ziegler)	was	eluted	with	0.1	M	HCl	by	a	peristaltic	
pump	by	passing	through	a	cation	exchange	cartridge	into	a	waste	vial.	The	cartridge	was	dried	and	the	
blocked	activity	was	eluted	with	0.55	ml	of	a	5.5	M	HCl	/	5	M	NaCl	solution	into	the	reaction	vial	pre-filled	
with	40	ug	of	precursor	 (PSMA-11	or	PSMA-617)	and	2.6	ml	of	 Sodium	Acetate/HCl/EtOH	buffer.	 The	
reactor	was	heated	at	110°C	for	4	(PSMA-11)	or	8	(PSMA-617)	minutes.	The	mixture	was	diluted	with	7	
ml	of	0.9	%	NaCl	solution	and	transferred	into	the	final	product	vial	by	passing	through	a	light	CM	cartridge	
and	a	sterilizing	filter.	Results:	Both	radiopharmaceuticals	were	produced	in	high	yield.	Starting		from	an	
activity	of	700±20	MBq	the	radiochemical	yield	were	75.6±10	and	75.2±7	%	for	PSMA-11	and	PSMA-617,	
respectively	(n	=	5)	after	15	minutes.	RCP	was	assessed	by	HPLC	and	was	always	>	98	%	(for	68Ga-PSMA-
11	the	sum	of	the	peaks	of	the	two	isomers	was	considered).	All	the	preparations	were	sterile	and	the	
endotoxin	content	was	<	0.5	EU/ml.	Discussion/Conclusions:		The	Modular-Lab	Eazy	synthesizer	works	
with	a	new	technology	which	uses	a	pressure	distribution	system	to	transfer	the	liquid	instead	of	solenoid	
valves	or	stopcocks.	A	disposable,	easy	to	assemble	cassette	allows	the	synthesis	of	68Ga-PSMA-11	and	
68Ga-PSMA-617	in	high	RCY	and	quality.	
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Synthesis	and	Evaluation	of	Fusarinine	C-based	Octadentate	Bifunctional	Chelators	for	Zirconium-89	
Labelling	
Chuangyan	Zhai,1	Christine	Rangger,1	Dominik	Summer,1	Hubertus	Haas,2	Clemens	Decristoforo1	
1Department	of	Nuclear	Medicine,	Medical	University	Innsbruck,	Innsbruck,	Austria	
2Division	of	Molecular	Biology,	Medical	University	Innsbruck,	Innsbruck,	Austria	
	
Introduction:	89Zr	has	received	considerable	interest	as	a	positron	emitting	radionuclide	for	immuno-PET	
imaging	due	to	the	excellent	nuclear	and	physical	properties.	Recently	we	reported	that	fusarinine	C	(FSC)	
is	a	promising	alternative	chelator	for	89Zr-based	PET	 imaging	agents,	exhibiting	superior	stability	and	
kinetic	 inertness	 as	 compared	 to	 89Zr-desferrioxamine	 B	 ([89Zr]DFO).[1]	 Here	 we	 designed	 FSC	
derivatized	chelators	for	89Zr	labeling	which	were	expected	to	on	the	one	hand	improve	the	stability	of	
89Zr-complexes	 by	 saturating	 the	 8	 coordination	 sphere	 of	 89Zr	 and	 on	 the	 other	 hand,	 reduce	 the	
number	of	 functionality	making	 it	 suitable	 for	 the	 conjugation	 to	monoclonal	 antibodies.	Materials	&	
Methods	 FSC(succ)2	 and	 FSC(succ)3	 were	 synthesized	 by	 FSC	 reacting	 with	 succinic	 anhydride,	 and	
FSC(succ)2AA	was	synthesized	by	FSC(succ)2	reacting	with	acetic	anhydride.	The	complexation	properties	
of	FSC(succ)2AA	and		FSC(succ)3	with	Zr4+	were	studied	by	reacting	with	ZrCl4.	For	 in	vitro	evaluation	
partition	 coefficient,	 protein	 binding	 property,	 serum	 stability	 as	 well	 as	 acid	 dissociation	 and	
transchelation	 studies	 of	 89Zr-complexes	 were	 evaluated	 and	 compared	 with	 [89Zr]DFO	 and	 89Zr-
triacetyfusarinine	C	([89Zr]TAFC).	The	in	vivo	properties	of	[89Zr]FSC(succ)3	were	further	compared	with	
[89Zr]TAFC	in	nude	mice.	Results	FSC(succ)2AA	and		FSC(succ)3	were	synthesized	with	satisfying	yield.	
The	 complexation	 with	 ZrCl4	 was	 achieved	 using	 a	 simple	 strategy	 resulting	 in	 high-purity	
[natZr]FSC(succ)2AA	 and	 [natZr]FSC(succ)3	 with	 a	 1:1	 stoichiometry.	 Distribution	 coefficient	 of	 89Zr-
complexes	revealed	improved	hydrophilic	characters	compared	to	[89Zr]TAFC.	All	radioligands	showed	
high	 stability	 in	 PBS	 and	 human	 serum	 and	 low	 protein-bound	 activity	 over	 a	 period	 of	 7	 days.	 Acid	
dissociation	and	transchelation	studies	exhibited	the	different	 in	vitro	stabilities	following	the	order	of	
[89Zr]FSC(succ)3	 >	 [89Zr]TAFC	 >	 [89Zr]FSC(succ)2AA	 >	 [89Zr]DFO.	 Biodistribution	 study	 of	
[89Zr]FSC(succ)3	 exhibited	 a	 slower	 excretion	 compared	 to	 [89Zr]TAFC.	 Conclusion	 [89Zr]FSC(succ)3	
showed	 best	 stability	 and	 inertness	 and	 [89Zr]FSC(succ)2AA	 predicts	 the	 potential	 of	 FSC(succ)2	 as	 a	
monovalent	chelator	for	the	conjugation	to	targeted	biomolecules	in	particular	monoclonal	antibodies.	
Reference:	1.Zhai	C,	Summer	D,	Rangger	C,	et	al.	[2015],	Mol	pharm	12:2142–2150	
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Fully	automated	production	of	[18F]NaF	using	a	re-configuring	FDG	synthesis	module.		
Suphansa	Kijprayoon1,	Ananya	Ruangma2,	Suthatip	Ngokpol3,	Samart	Tuamputsha4	
Oncology	Imaging	&	Nuclear	Medicine	Department,	Wattanosoth	Hospital		
Bangkok	Hospital	at	Headquarter,	Thailand	
	
Introduction:	 We	 modified	 a	 fully	 automated	 method	 for	 [18F]NaF	 synthesis	 by	 re-configuring	 a	
commercial	FDG	synthesis	module	(Single	synthesis	module,	Advanced	Cyclotron	Systems,	Inc.).	Materials	
and	Methods:	The	Lookout	program	was	used	to	sequence	the	steps	for	automated	synthesis	using	excel	
spreadsheet.	 The	 [18F]fluoride	 solution	 is	 transferred	 to	 synthesis	module.	 The	 [18F]fluoride	 ions	 are	
trapped	in	QMA.	The	QMA	cartridge	is	then	washed	with	sterile	water	for	injection	and	eluted	with	0.9%	
NaCl.	The	final	product	was	passed	through	0.22	µm	sterile	filter	to	sterile	product	vial.	Results:	[18F]NaF	
was	successfully	produced	consistently	with	high	yield.	The	non-decay	corrected	yield	after	synthesis	is	at	
least	85%.	Quality	control	of	[18F]NaF	is	performed	according	to	USP	and	EP	requirements.	The	QC	results	
are	passed.	Conclusions:	This	modified	 fully	automated	synthesis	 showed	reproducible	and	very	good	
radiochemical	yields.	This	module	could	be	used	for	[18F]NaF	production	in	our	department.	References:	
C.	Collet	et	al.,	[2015],	Applied	Radiation	and	Isotopes	102:87-92.		
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Extension	of	the	Carbon-11	Small	Labeling	Agents	Toolbox	and	Conjugate	Addition	
Ulrike	Filp	a,	Anna	Pees	a,	Carlotta	Taddei	b,	Aleksandra	Pekošak	a,	Antony	D.	Gee	b,	Alex	J.	Poot	a,	Albert	
D.	Windhorst	a		
a,	Radiology	and	Nuclear	Medicine,	VU	University	Medical	Center,	Amsterdam,	The	Netherlands.	
b,	Division	of	Imaging	Sciences	and	Biomedical	Engineering,	King’s	College,	London,	UK.	
	
Introduction:	 [11C]CO2	and	 [11C]CO	are	undoubtedly	highly	 versatile	 radiolabeling	 agents	with	many	
applications.	The	formation	of	[11C]CO	from	[11C]CO2	has	become	convenient	and	difficulties	have	been	
overcome	for	its	further	implementation	in	radiochemistry.	Likewise,	many	reactions	are	being	explored	
and	many	applications	are	already	possible.[1]	However,	there	is	still	a	need	for	expansion	of	the	carbon-
11	 chemistry	 toolbox	 (Scheme	 1).	 We	 here	 present	 unprecedented	 Michael	 addition	 reactions	 with	
carbon-11	labeled	synthons	1	–	3	as	Michael	donors.Methods:	The	synthesis	of		1		was	performed	with	
[11C]CO2	by	fixation	in	a	Grignard	reaction	with	vinyl	magnesium	bromide	(0.16M	in	THF)	and	subsequent	
Fisher	esterification	under	acidic	conditions.	Alternatively,	a	palladium-mediated	carbonylation	reaction	
with	 [11C]CO	 [2]	 in	 the	 presence	 of	 tert-butanol	 or	 trityl-amine	 with	 vinyl-halides	 afforded	 2	 and	 3.	
Michael	addition	reactions	were	performed	with	4	by	adding	the	synthons	to	the	reaction	solution	using	
TBAF	as	a	base	in	DMSO.	Synthon	1	was	distilled	into	the	reaction	mixture.	Synthons	2	and	3	were	purified	
by	 solid-phase	 extraction	 and	 the	 Michael	 addition	 was	 performed	 at	 100	 ºC	 for	 5	 min,	
respectively.Results:	The	synthesis	of	1	was	successful	with	over	70%	radiochemical	conversion	(RCC)	and	
>95%	radiochemical	purity	determined	by	HPLC.	After	screening	and	optimization	2	was	obtained	in	79	±	
10%	and	3	in	73	±	5%	RCC.	In	Scheme	1	results	are	summarized	for	the	subsequent	conjugate	addition.	
Conclusion:	The	successful	synthesis	of	1	-	3	has	been	achieved	in	good	radiochemical	yields.	Furthermore,	
conjugate	addition	to	5	-	7	is	possible	and	we	are	currently	working	on	expanding	the	variety	of	reactions	
with	these	small	synthons.	Acknowledgements:	RADIOMI	FP7-PEOPLE-2012-ITN;	[11C]CO2	provided	by	
BV	Cyclotron.	References:	[1]	Rahman	O	[2015]	JLCR,	58,	86-98.	[2]	Eriksson	J	et	al.	[2012]	JLCR,	55,	223-
228.	
	
	 	
Scheme	1.	(A)	[11C]acrylate	synthesis:	(i)	Mo,	850	ºC;	(ii)	H2SO4/MeOH,	dist.	90	ºC;	(iii)	[(Cinnamyl)PdCl]2,	
Xanthpos	(7	µmol),	Tert-butanol	(2	mmol),	THF	400	µL;	(iv)	[(Cinnamyl)PdCl]2,	Xanthpos	(7	µmol),	Trityl-
amine	(96	µmol),	THF	400	µL;	(B)	Michael	addition	reactions	with	[11C]acrylates	1	–	3:	(v)	Compound	4	17	
µmol,	TABF	100	µmol,	DMSO	200	µL.	
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In	 Vitro	 Studies	 on	 BBB	 Penetration	 of	 Pramipexole	 Encapsulated	 Theranostic	 Liposomes	 for	 the	
Therapy	of	Parkinson’s	Disease		
Mine	Silindir	Gunay1,	A.	Yekta	Ozer1,	Suna	Erdogan1,	Ipek	Baysal3,	Denis	Guilloteau2,	Sylvie	Chalon2	
1Department	of	Radiopharmacy,	Faculty	of	Pharmacy,	Hacettepe	University,	06100,	Ankara,	Turkey.	
2UMR	INSERM	U930,Université	François	Rabelais	de	Tours,	Tours,	France.	
3Department	of	Biochemistry,	Faculty	of	Pharmacy,	Hacettepe	university,	06100,	Ankara,	Turkey.	
	
Introduction:	Brain	penetration	and	 targeting	 is	hard	due	 to	complex	structure	with	different	barriers	
such	as	blood–brain	barrier	(BBB)	with	blood–cerebrospinal	fluid	(CSF)	interface	and	CSF–blood	interface	
(1,	2).	Although	these	tight	and	rigid	barriers	protect	brain,	they	also	prevent	penetration	of	molecules,	
drugs	 and	 radiopharmaceuticals	 for	 diagnosis	 and	 therapy	 of	 many	 neurodegenerative	 diseases.	
Parkinson’s	disease	(PD)	is	assumed	to	be	one	of	the	most	frequently	observed	neurodegenerative	disease	
among	 geriatric	 disorders.	 PD	 comprises	 motor	 symptoms	 resulting	 from	 the	 death	 of	 dopamine	
generating	cells	in	the	substantia	nigra.	By	using	the	imaging	modalities	such	as	single	photon	emission	
computed	tomography	(SPECT),	the	decline	in	the	accumulation	of	specific	radiotracer	in	the	striatum	can	
be	detected.	For	PD	treatment,	limited	brain	penetration	of	drug	is	a	major	concern.	Passively	or	actively	
targeted,	nanosized	drug	delivery	systems	such	as	liposomes	have	different	interests	for	either	therapy	
or	diagnosis.	Recent	studies	generally	depend	on	the	development	of	new	delivery	systems,	theranostics,	
in	which	diagnosis	can	be	managed	together	with	therapy	by	evaluating	therapeutic	effect.	Materials	and	
Methods:	 Theranostic	 liposomes	 were	 formulated	 by	 polyethylene	 glycole	 (PEG)	 coated,	 nanosized,	
either	neutral	or	positively	charged,	99mTc	labeled	for	SPECT	imaging	and	pramipexole	encapsulated	for	
PD	therapy.	Their	characterization	and	 in	vitro	release	kinetics	were	evaluated.	 In	vitro	penetration	of	
both	 formulations	was	 evaluated	 in	 a	 BBB	 cell	 co-culture	model.	Results:	 Both	 neutral	 and	 positively	
charged	liposomes	showed	proper	characterization	with	about	10%	encapsulation	efficiency	and	around	
100	nm	particle	sizes.	All	formulations	fitted	to	the	first-order	release	kinetics	(3).	Both	formulations	were	
found	BBB	permeable	in	cell	culture	studies	with	fluorescent	images	and	fluorospectroscopy.	Conclusion:	
Promising	 characterization	 and	 release	 profiles	 were	 obtained	 with	 theranostic	 liposomes	 for	 both	
diagnosis	and	therapy	of	PD.	Both	neutral	and	positively	charged	formulations	found	BBB	permeable	in	
vitro.	 In	 vivo	animal	 studies	are	 continuing	 to	obtain	more	accurate	data.	 (The	authors	 thank	 to	Abdi	
Ibrahim	Ilaç	for	Pramipexole.	This	study	was	supported	by	the	grant	of	TUBITAK,	Project	No:	112S244).	
References:	
1.	Choi	YK,	Kim	KW,	[2008],	BMB	Rep	41:	345-52.	2.	Saunders	NR,	et	al.,	[2008],	Trends	Neurosci	31:	279-
86.	3.	Silindir	M,	et	al.,	IPET	[2015],	Proceed.	Book,	IAEA-CN-232/85,	IAEA,	Vienna.	
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Factors	affecting	tumor	uptake	of	99mTc-HYNIC-VEGF165		
Filippo	 Galli1,	 Marco	 Artico2,	 Samanta	 Taurone2,	 Enrica	 Bianchi2,	 Bruce	 D.	 Weintraub3,	 Mariusz	
Skudlinski3,	Alberto	Signore1	
1Nuclear	Medicine	Unit,	Department	of	Medical-Surgical	Sciences	and	of	Translational	Medicine,	Faculty	
of	Medicine	and	Psychology,	“Sapienza”	University	of	Rome,	Rome,	Italy.	
2Department	of	Sensory	Organs,	Sapienza	University	of	Rome,	Rome,	Italy.			
4Trophogen	Inc.,	Rockville,	MD,	USA	
	
Introduction:	Angiogenesis	promotes	tumor	growth	and	metastatization	and	its	principal	effector	is	the	
vascular	 endothelial	 growth	 factor	 (VEGF)	 secreted	 by	 cancer	 cells	 and	 other	 components	 of	 tumor	
microenvironment.	Nowadays,	many	anti-angiogenic	therapies	have	been	developed	and	radiolabelled	
VEGF	analogues	may	provide	a	useful	tool	to	non-invasively	evaluate	the	efficacy	of	such	drugs.	Aim	of	
the	present	study	was	to	radiolabel	the	human	VEGF-A165	analogue	with	99mTechnetium	(99mTc)	and	
evaluate	the	expression	of	VEGFR	in	both	cancer	and	endothelial	cells	in	the	tumor	microenvironment	by	
nuclear	medicine	 imaging	 and	 immunohistochemistry.Material	 and	Methods:	 The	 human	 VEGF-A165	
analogue	 was	 radiolabelled	 with	 99mTc	 using	 succinimidyl-6-hydrazinonicotinate	 hydrochloride	 as	 a	
bifunctional	 chelator.	 In	 vitro	 quality	 controls	 were	 performed	 to	 assess	 its	 retained	 structure	 and	
biological	 activity.	 In	 vivo	 studies	 included	biodistribution	 studies	 and	 tumor	 targeting	experiments	 in	
athymic	 nude	 CD-1	 mice	 bearing	 xenograft	 tumors	 from	 ARO,	 K1	 and	 HT29	 cell	 lines.	
Immunohistochemistry	was	performed	on	excised	tumors	to	evaluate	VEGF	and	VEGF	receptor	(VEGFR)	
expression	 in	 the	 lesion	 and	 endothelial	 cells.Results:	 The	 analogue	 was	 labelled	 with	 high	 labelling	
efficiency	(>95%)	and	high	specific	activity,	with	retained	biological	activity	and	structural	integrity.	Tumor	
targeting	 experiments	 revealed	 a	 focal	 uptake	 of	 radiolabelled	 VEGF165	 in	 tumor	 xenografts	 with	
different	 tumor-to-background	 ratios.	 Immunohistochemical	 analysis	 tumors	 revealed	 an	 inverse	
correlation	 between	 VEGF	 and	 uptake	 of	 the	 radioactive	 hormone.	 A	 positive	 correlation	 between	
radioactive	VEGF165	and	VEGFR1	was	also	observed.	Conclusion:	Radiolabelled	human	VEGF-A165	is	a	
promising	radiopharmaceutical	to	image	angiogenesis	and	evaluate	the	efficacy	of	anti-angiogenic	drugs.	
However,	VEGFR	 imaging	may	suffer	from	quenching	effects	of	endogenous	VEGF	produced	by	cancer	
and	other	cells	of	the	microenvironment.	
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Rhenium-188:	a	suitable	radioisotope	for	targeted	radiotherapy	
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Introduction:	Among	radioisotopes	for	targeted	therapeutic	applications,	188Re	is	very	promising,	thanks	
to	its	suitable	properties	(b-	emitter,	Emax	=	2.12	MeV,	t1/2	=	17	h,	γ-emission	of	155	keV,	conveniently	
obtained	 through	 a	 generator),	 and	 to	 the	 fact	 that	 it	 is	 a	 homologous	 element	 to	 99mTc,	 the	
radioelement	 of	 choice	 in	 nuclear	 medicine.	 Inside	 the	 “Vectorisation	 &	 Radiotherapy”	 Axis	 of	 the	
Canceropole	 Grand	Ouest	 and	 the	 IRON	 Labex,	 our	 teams	 have	 developed	 a	 strong	 expertise	 on	 the	
chemistry	and	targeting	of	rhenium	labelled	radiotracers,	from	bench	to	bedside.	Some	examples	of	what	
we	have	been	developing	are	given	below.	188Re-labelled	Lipiodol:	We	have	developed	a	 stable	and	
efficient	 labelling	 of	 Lipiodol	 with	 188Re	 as	 a	 potential	 treatment	 for	 HCC.	 A	 phase	 1	 clinical	 trial	 is	
currently	 running.	 188Re-labelled	 particles:	 188Re	 has	 been	 used	 to	 label	 micro-	 and	 nanoparticles.	
Radiolabelled	 starch-based	 microspheres	 are	 investigated	 in	 HCC,	 while	 lipid	 nanocapsules,	 also	
investigated	in	HCC	and	adenocarcinoma	models,	gave	prominent	results	in	glioma,	for	which	transfer	to	
clinic	is	underway.	188Re-labelled	peptides:	We	are	also	developing	a	new	bifunctional	chelate	for	the	
Re(I)	tricarbonyl	core,	able	to	link	a	biomolecule	(peptide,	protein…).	Conclusions:	For	more	than	15	years,	
our	teams,	working	closely	together,	have	developed	a	series	of	potential	therapeutic	radiotracers,	some	
of	which	are	now	investigated	in	man,	or	about	to	be.	
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Preparation	of	a	broad	palette	of	68Ga	radiopharmaceuticals	
for	clinical	applications	
Trejo-Ballado	 F,	 Zamora-Romo	 E,	 Manrique-Arias	 JC,	 Gama-Romero	 HM,	 Contreras-Castañon	 G,	
Tecuapetla-Chantes	RG,	Avila-Rodriguez	MA	
Unidad	 Radiofarmacia-Ciclotrón,	 Facultad	 de	 Medicina,	 Universidad	 Nacional	 Autónoma	 de	 México,	
México,	D.F.	04510,	México.	
	
Introduction:	PET	molecular	imaging	and	receptor	binding	peptides	are	emerging	as	powerful	tools	for	
imaging.	Somatostatin	analogues	labeled	with	68Ga	are	the	most	widely	used	and	have	proven	useful	for	
the	management	of	patients	with	neuroendocrine	tumors.	However,	within	the	past	few	years	several	
other	receptor	binding	compounds	labeled	with	68Ga	have	shown	promising	results	with	potential	clinical	
applications	in	PET	centers	that	lack	in	site	cyclotrons.	The	aim	of	this	study	was	to	develop	a	single	vial	
kit	 solution	 for	 the	 production	 of	 68Ga	 radiopharmaceuticals	 for	 clinical	 applications.	 Materials	 &	
Methods:	Chemical	precursors	DOTA-NOC,	DOTA-RGDfK	dimer,	DOTA-Ubiquicidin	(29-41),	and	PSMA-11	
were	acquired	from	ABX.	Gallium-68	was	obtained	from	an	ITG	generator	while	labeling	was	performed	
in	an	 iQS	module	 (ITG	GmbH).	Stock	 solutions	of	different	 concentrations	 (Table	1)	were	prepared	by	
dissolving	the	precursors	 in	0.25M	NaOAc.	Aliquots	of	100	µl	of	the	stock	solutions	were	dispensed	 in	
Eppendorf	vials	and	stored	at	-20°C.	For	labeling,	the	aliquots	were	diluted	with	900	µl	of	0.25M	NaOAc,	
mixed	with	4	ml	of	68GaCl3,	and	incubated	for	10	min.	Purification	was	made	by	SPE	eluting	the	product	
with	1ml	50%	EtOH.	Final	product	was	diluted	with	physiological	saline	and	sterilized	by	filtration	(0.22	
μm,	Millex-GV).	 Radiochemical	 purity	 (RCP)	 was	 determined	 by	 gradient	 HPLC	 using	 a	 Nova-Pak	 C18	
column	(3.9	x	150	mm),	2.5	ml/min	flow	rate.	Eluents	were	A=0.1N	TFA	and	B=MeCN.	Results:	Non-decay-
corrected	yields	are	shown	in	Table	1.	RCP	was	>98%	for	all	 the	radiopharmaceuticals.	HPLC	retention	
times	were	0.5±0.1	min	and	2.5±0.2	min	for	free	68GaCl3	and	labeled	compounds,	respectively.	No	68Ge	
was	detected	in	the	final	product.	
	
Table	1.	Production	information	and	summary	of	results.	
	
	
Conclusion:	This	labeling	method	using	a	single	vial	kit	solution	is	simple,	efficient	and	reliable,	suitable	
to	 be	 used	 for	 the	 production	 of	 a	 variety	 of	 68Ga	 radiopharmaceuticals	 for	 clinical	 diagnostic	
applications.	Acknowledgments:	Research	supported	by	CONACYT	Grant	179218,	and	IAEA	RC16467.	
	
	 	
Radiopharmaceutical	 Concentration	of	
stock	solution	
Incubation	
Temp	
Purification	
cartridge	
Yield	%	
(n=10)	
68Ga-DOTA-NOC	 250	µg/ml	 105°C	 C8	Light	 60±12	
68Ga-DOTA-E-[c(RGDfK)]2	 250		µg/ml	 105°C	 C18	Light	 61±6	
68Ga-DOTA-UBI	 250	µg/ml	 105°C	 C18	Light	 56±10	
68Ga-PSMA	 100	µg/ml	 Room	T	 C18	Light	 70±10	
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68Ga-peptide	preparation	with	the	use	of	two	68Ge/68Ga-generators			
H.	Kvaternik,	D.	Hausberger,	C.	Zink,	B.	Rumpf,	R.	M.	Aigner		
Division	of	Nuclear	Medicine,	Department	of	Radiology,	Medical	University	of	Graz,	Austria.		
	
Introduction:	 The	 clinical	 demand	 for	 68Ga-labelled	 peptides	 is	 constantly	 rising,	 but	 the	 achievable	
radioactivity	per	batch	is	limited	by	the	inventory	of	the	68Ge/68Ga	generator.		One	possible	approach	to	
raising	the	radioactive	yield	is	to	merge	the	radioactive	contents	of	two	68Ge/68Ga	generators	for	one	
batch	 of	 68Ga-peptide.	 The	 key	 to	 this	method	 can	 found	 in	 frame	with	 the	 cationic	 purification	 (1)	
merging	 two	 generator	 eluates.	 Our	 aim	 was	 to	 establish	 this	 method	 in	 the	 synthesis	 of	 68Ga-
DOTANOC.Material	&	Methods:	 The	experimental	 setup	considered	 two	1.85	GBq	 (50	mCi)	 	 iThemba	
68Ge/68Ga-generators	with	calibration	Feb/15	and	Oct/15	and	a	Scintomics	GRP	synthesis	module.	SC-
01	 peptide	 cassettes	 including	 the	 reagents	 were	 applied	 in	 the	 synthesis	 of	 68Ga-DOTANOC.	 The	
automatic	synthesis	sequent	was	modified	by	us	as	followed:		After	the	initial	conditioning	of	the	C18-SPE	
with	ethanol,	water	and	subsequent	drying	with	N2	the	“older”	68Ge/68Ga-generator	was	eluted	with	7	
mL	1M	HCl	by	the	motor	syringe.	10	mL	water	was	added	for	dilution,	and	the	mixture	was	transferred	
over	a	PS-H+	SCX	column	(Machery-Nagel).	The	sequent	stopped	for	the	manual	change	of	the	generator	
tube.	After	continuing	the	sequent,	the	“newer”	Generator	was	eluted	in	the	same	manner	as	described	
above.	Once	washing	and	drying	the	valve	seats,	68Ga	was	delivered	from	PS-H+		into	the	reaction	vessel	
with	a	solution	of	1.4	mL	5M	NaCl	and	0.2	mL	6M	HCl.	The	further	labelling	with	40	µg	precursor	in	HEPES	
were	 performed	 as	 usual.	 Results:	 We	 found	 in	 our	 preliminary	 experiments	 more	 the	 98%	 of	 the	
theoretical	68Ga	radioactivity	after	“double	elution”	adsorbed	on	the	PS-H+	SCX	cartridge.	About	15	%	of	
68Ga	 retained	 on	 the	 PS-H+	 SCX	 after	 transfer	 of	 the	 68GaCl3	 into	 the	 reaction	 vessel.	 The	 followed	
labelling	of	68Ga-DOTANOC	revealed	an	uncorrected	yield	of		>40%.						
68Ga-DOTANOC	
preparation	
Starting	
activity	
68Ga-DOTANOC	
(EOS)	
Synthesis-	
time	
Yield	
(uncorr.)	
Standard	
Single	generator	
1.73	GBq	 0.87	GBq	 32	min	 50	%	
Experimental	
Dual	generator	
2.56	GBq*	 1.10	GBq	 44	min	 43	%	
*Theoretical	starting	activity	of	both	68Ge/68Ga-generator	corrected	to	elution	start	of	the	second	one.		
Conclusion:	The	promising	preliminary	results	with	a	yield	of	1.1	GBq	68Ga-DOTANOC	(EOS)	in	a	merging	
operation	of	an	“old”	and	a	“new”	68Ge/68Ga	generator	indicates	a	high	potential	for	improvement	in	
routine	preparation.	Therefore,	we	extend	our	synthesis	system	with	an	additional	valve	actuator	unit,	
which	should	handle	the	68Ga	elution	from	both	generators	automatically	and	under	GMP	conditions.	
References:	(1)	R.	Mueller,	et	al,	[2012],	Bioconjugate	Chem,	23:1712-1717.		
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Assay	of	HEPES	in	68Ga-peptides	by	HPLC			
H.	Kvaternik,	D.	Hausberger,	B.	Rumpf,	R.	M.	Aigner		
Division	of	Nuclear	Medicine,	Department	of	Radiology,	Medical	University	of	Graz,	Austria.		
	
Introduction:	HEPES	 (2-[4-N-(2-hydroxyethyl)-1-piperazinyl]-N’-ethanesulfonic	acid)	 is	widely	used	as	a	
“good”	reaction	buffer	 in	the	labelling	of	68Ga-peptides.	The	final,	 injectable	solution	of	68Ga-peptide	
may	contain	traces	of	HEPES	as	an	impurity.	The	European	Pharmacopoeia	limited	the	HEPES	content	in	
68Ga-Edotreotide	(68Ga-DOTATOC)	with	200	µg	per	patient	dose	(1).	This	limit	test	is	performed	by	TLC	
and	 developed	 by	 the	 exposing	 to	 iodine	 vapour.	 Alternatively,	 an	HPLC	method	 for	HEPES	 has	 been	
published	(2).	Our	aim	was	to	approve	this	method	of	the	quality	control	of	68Ga-peptides.	Material	&	
Methods:	68Ga-peptides	(68Ga-DOTANOC,	68Ga-DOTATOC,	68Ga-DOTATATE)	were	synthesised	with	a	
Scintomics	GRP	synthesis	module	using	SC-01	cassettes.	The	determination	of	HEPES	was	performed	by	
HPLC	 Agilent	 1260	 equipped	 with	 a	 DAD	 detector	 on	 an	 Obelisc	 N	 column	 (4.6	 x	 150	 mm,	 Sielc	
Technologies):	isocratic	eluent	20%	ACN/	80%	water/	0.05%	phosphoric	acid;	0.8	mL/min;	UV	detection	
at	195	nm.		Results:	Due	to	the	polar	characteristic	of	the	Obelisc	N	column,	a	good	separation	of	the	
sulfonic	acid	HEPES	was	achieved	with	a	retention	time	of	about	9	min.	A	system	suitability	test	with	a	
solution	 of	 100	 µg/mL	 HEPES	 and	 1	 µg/mL	 gentisinic	 acid	 was	 introduced.	 The	 analysis	method	was	
successful	validated	according	to	ICH	in	a	concentration	range	of	HEPES	from	10	µg/mL	to	200	µg/mL.		
This	assay	of	HEPES	was	applied	effectively	in	the	refinement	of	synthesis	sequence	to	the	68Ga-peptides.	
The	 accurate	 measurement	 of	 HEPES	 did	 help	 us	 to	 optimise	 the	 automatic	 workup	 of	 the	 reaction	
mixture	via	C18-SPE,	that	we	reach	an	HEPES	content	in	the	final	solution	below	10	µg/mL	routinely.		A	
disadvantage	of	the	Obelisc	N	is	that	the	HPLC	column	is	very	sensitive	to	alcohol	and	neutral	media.	To	
avoid	damage,	for	the	Obelisc	N	column	an	acid	media	of	about	pH	2	must	use	to	store.	Otherwise	due	to	
irreversible	deactivation	of	groups	on	the	column	material	the	signals	of	NaCl	from	the	sample	will	shift	
in	 the	 retention	 time	and	 interfere	with	 the	 signal	 of	HEPES,	which	disables	 the	 interpretation	of	 the	
analyse	results.	Conclusion:	We	have	demonstrated	that	HEPES	impurities	in	68Ga-peptides	can	analyse	
by	HPLC	with	respect	to	the	limit	of	the	European	Pharmacopoeia.	We	validated	this	analysis	method	and	
used	 it	 in	 the	 development	 of	 the	 preparation	 of	 68Ga-peptides.	 The	 HEPES	 determination	 by	 HPLC	
replaces	in	our	laboratory	the	test	by	TLC	and	is	integrated	into	the	parametric	release	of	our	routinely	
prepared	68Ga-peptides.	References:	(1)	European	Pharmacopeia	8.0	Monograph	01/2013:2482.		(2)	R.	
Sasson,	et	al.,	[2010],	J	Radioanal	Nucl	Chem,	283:753-756.	
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PP27	
Preparation,	in	vitro	and	in	vivo	evaluation	of	a	99mTc(I)-Diethyl	Ester	(S,S)-Ethylenediamine-	N,N´-DI-
2-(3-Cyclohexyl)	Propionic	acid	as	a	target-specific	radiopharmaceutical	
Drina	 Janković1,	 Mladen	 Lakić1,	 	 Aleksandar	 Savić2,	 Slavica	 Ristić3,	 Nadežda	 Nikolić1,	 Aleksandar	
Vukadinović1,	Tibor	J.	Sabo2,	Sanja	Vranješ-Đurić1	
1	Laboratory	for	radioisotopes,	Vinča	Institute	of	Nuclear	Sciences,	University	of	Belgrade,	Serbia	
2	Chair	of	General	and	Inorganic	Chemistry,	Faculty	of	Chemistry,	University	of	Belgrade,	Serbia	
3Biomedical	Research	Center,	R&D	Institute,	Galenika	a.d.,	Belgrade,	Serbia	
	
Introduction:	The	‘‘organometallic’’	complexes	have	been	used	in	the	development	of	new	diagnostic	as	
well	as	therapeutic	radiopharmaceuticals.1	The	organometallic	labeling	approach	has	led	to	the	creation	
of	a	precursor	[M(H2O)3(CO)3]+		(M	=	Tc,	Re),	which	exhibits	several	useful	characteristics.	These	include	
the	small	size	of	the	core,	easy	preparation	with	aqueous-based	precursor	kit	formulations,	and	readily	
substituted	 water	 molecules	 of	 the	 precursor	 fac-[99mTc(H2O)3(CO)3]+	 by	 a	 variety	 of	 functional	
groups.2	 The	 aim	 of	 this	 study	 is	 to	 label	 diethyl	 ester	 (S,S)-ethylenediamine-N,N´-di-2-(3-
cyclohexyl)propionic	acid	(L)	with	99mTc(I)-tricarbonyl	precursor.	The	stability	of	the	formed	complex	and	
its	 in	 vitro	 and	 in	 vivo	 properties	 were	 investigated.Materials	 &	 Methods:	 99mTc(I)-L	 complex	 was	
prepared	 by	 a	 two-step	 procedure	 involving	 the	 preparation	 of	 the	 precursor	 [99mTc(CO)3(H2O)3]+,	
followed	 by	 the	 addition	 of	 L.	 The	 labelling	 efficiency	 and	 challenge	with	 histidine	 and	 cisteine	were	
determined	using	gradient	HLPC.	The	in	vitro	stability	of	the	radiochemical	complex	was	determined	in	
saline	and	human	plasma.	TCA	precipitation	method	for	determining	the	percentage	of	complex	bound	
to	proteins	was	very	useful.	Lipophilicity	measurements	were	done	by	solvent	extraction	method	with	n-
octanol.	The	overall	complex	charge	was	determined	by	electrophoresis	on	paper	strips	(Whatman	no.	1)	
after	 exposure	 to	 a	 constant	 voltage	 (300	V)	 in	 phosphate	buffer	 (pH	7.4)	 for	 1	 h.	Organ	distribution	
studies	were	carried	out	on	normal	and	tumor-bearing	mice	(c57).	Results:	Radiolabeling	yield	was	higher	
than	98%	and	 remained	high	and	practically	unchanged	at	24h	post-labeling.	99mTc(I)-L	 complex	was	
stable	and	resistant	histidine	challenges.	The	percentage	of	protein	binding	was	19.62±2.02%.	It	showed	
a	lipophyilic	character.	Biodistribution	data,	5	min	post	injection,	showed	a	very	high	uptake	in	liver	and	
intestine.	The	majority	of	 the	radioactivity	of	99mTc(I)-L	complex	was	eliminated	via	 the	 liver	 into	the	
intestine.	 The	 organ	 distribution	 in	 B16-melanoma-bearing	 mice	 showed	 increase	 in	 uptake	 by	 the	
tumor.Discussion/Conclusion:	 99mTc(I)-L	 complex	 revealed	 high	 radiochemical	 purity	 and	 stability	 in	
vitro,	 without	 any	 measurable	 decomposition.	 A	 significant	 difference	 of	 99mTc(I)-L	 complex	 uptake	
between	melanoma	model	and	the	normal	mice	was	observed.	Biodistribution	studies	showed	high	tumor	
uptake	in	B16-melanoma-bearing	mice.	This	study	indicates	that	99mTc(I)-L	complex	may	be	a	potential	
agent	for	melanoma	detection.	References:	1.Alberto	R,	Schibli	R,	Egli	A,	Schubiger	AP,	Abram	U,	Kaden	
TA	(1998)	A	novel	organometallic	aqua-complex	of	technetium	for	the	labelling	of	biomolecules:	synthesis	
of	99mTc(OH2)(CO)3]+	from	[99mTcO4]-	in	aqueous	solution	and	its	reaction	with	bifunctional	ligands.	J	
Am	 Chem	 Soc.	 120:7987-88.	 2.	 Alberto	 R	 (2005)	 New	 organometallic	 technetium	 complexes	 for	
radiopharmaceuticals	imaging.	Top.	Curr.	Chem.	252:	1-44.	
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90Y-labeled	magnetite	nanoparticles	for	possible	application	in	cancer	therapy		
S.	Vranješ-Đurić1,	M.	Radović1,	D.	Janković1,	N.	Nikolić1,	G.	F.	Goya2,	P.	Calatayud2,	V.	Spasojević1	and	
B.	Antić1	
1	Laboratory	for	radioisotopes,	“Vinča”	Institute	of	Nuclear	Sciences,	University	of	Belgrade,		Serbia		
2Instituto	de	Nanociencia	de	Aragón	(INA),	University	of	Zaragoza,	Spain	
	
Introduction:	The	synergistic	 interaction	between	hyperthermia	and	radiation	therapy	 is	based	on	the	
heat	effect	that	may	make	some	cancer	cells	more	sensitive	to	radiation	or	harm	other	cancer	cells	that	
radiation	 cannot	 damage	 [1-2].	 	 In	 the	 present	 work	 two	 different	 types	 of	 magnetic	 nanoparticles	
(MNPs),	Fe3O4-Naked	and	polyethylene	glycol	600	diacid	 functionalized	Fe3O4	(Fe3O4-PEG600),	were	
synthetized	 in	order	 to	compare	 their	efficiency	as	 radioactive	vectors.	They	were	90Y-labeled	 for	 the	
potential	 use	 in	 localized	 hyperthermia-radionuclide	 therapy.	 Materials	 &	 Methods:	 MNPs	 were	
synthesized	by	 co-precipitation	of	 ferric	 and	 ferrous	 salts	 in	 a	 basic	 solution	 [3,	 4].	 Radiolabeling	was	
performed	by	mixing	0.5	mL	of	aqueous	Fe3O4-Naked	and	Fe3O4-PEG600	MNPs	suspension	with	37	MBq	
90YCl3	(0.001	mL)	and	incubating	at	room	temperature	on	a	shaker	for	one	hour.	Radiolabeled	particles	
were	 then	 separated	 from	 free	 90Y	 activity	 by	 precipitation	 with	 the	 help	 of	 permanent	 magnet.	
Radiolabeled	MNPs	were	further	used	for	in	vitro	stability	studies	in	saline	and	human	serum,	and	in	vivo	
biodistribution	studies	in	normal	Wistar	rats.	Results	:	
	 	
Discussion/Conclusion:	 The	 Fe3O4-PEG	 diacid	 MNPs	 showed	 high	 phase	 purity	 and	 favorable	
physicochemical	 and	magnetic	 characteristics	 for	 in	 vivo	 use.	 The	 obtained	 SPA	 value	 for	 Fe3O4-PEG	
diacid	MNPs	(200	W/g)	indicates	that	these	MNPs	could	be	used	as	heating	agents	for	in	situ	magnetic	
fluid	hyperthermia	protocols.	Besides,	high	labeling	yield	(97%)	and	in	vitro	and	in	vivo	stability	of	90Y-
labeled-PEGylated	magnetite	 nanoparticles	 create	 opportunities	 for	 their	 use	 in	 the	 combined	 radio-
hyperthermia	cancer	treatment.	References:	1.	Yahara	 K,	 Ohguri	 T,	 Yamaguchi	 S,	 [2015],	 Int	 J	
Hyperthermia	31(	6):600-608.	2.Müller	A.C,	Zips	D,	Heinrich	V,	Lamprecht	U,	Voigt	O,	Burock	S,		Ghadjar	
P,	[2015],	Rad	Oncology	10(1):138.		3.Massart	R,	Cabuil	V,	[1987],	J	Chim	Phys	84:967-973.	4.Radović	M,	
Calatayud	MP,	Goya	G,	Ibarra	MR,	Antic	B,	Spasojević	V,	Nikolić	N,	Janković	D,	Mirković	M,	Vranješ-Đurić	
S,	[2015],	J	Biomed	Mater	Res	Part	A	103A:126–134.	
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Simplified	Automation	of	the	GMP	production	of	68Ga-labelled	peptides		
David	Goblet,	Cristiana	Gameiro,	Neva	Lazarova	
IBA,	Louvain-la-Neuve,	Belgium	
	
Introduction:	Optimized	 automated	 process	 for	 the	 GMP	 production	 of	 68Ga-DOTA-NOC	 and	 68Ga-
PSMA-11	using	a	cassette-based	synthesizer	(Synthera®,	IBA,	Louvain-la-Neuve,	Belgium)	in	combination	
with	a	recently	commercialized	68Ge/68Ga	generator	(Galli	EoTM,	IRE-Elit,	Fleurus,	Belgium)	have	been	
developed	in	this	work.	Materials	&	Methods:	The	generator	outlet	is	connected	to	an	unmodified	FDG-
type	disposable	 cassette	with	 the	appropriate	 reagent	 set	 and	 loaded	onto	 the	 synthesizer.	Once	 the	
automated	process	is	started,	vacuum	elution	takes	place	using	only	1.1	mL	of	a	0.1	M	HCl	solution	from	
the	generator	integrated	reservoir.	No	purification	being	required,	Ga-68	activity	is	directly	sent	to	the	
reaction	vessel.	DOTA-NOC	labeling	is	conducted	as	follows:	a	solution	of	50	µg	peptide	in	1	mL	250	mM	
acetate	buffer	at	pH	5	is	added	and	the	mixture	is	heated	at	120°C	for	5	min.	The	reaction	bulk	is	then	
loaded	on	an	HLB	cartridge	and	washed	with	10	mL	of	water.	68Ga-DOTA-NOC	is	then	eluted	with	1	mL	
of	EtOH/water	65:35	v/v	mix	followed	by	1	mL	of	saline	0.9%	and	collected	through	a	0.22	µM	Millex®-GV	
filter	into	a	sterile	vial	containing	8	mL	of	saline	0.9%.	PSMA-11	labeling	is	conducted	as	follows:	a	solution	
of	10	µg	peptide	in	1	mL	1.5	M	acetate	buffer	at	pH	4.5	is	added	and	the	mixture	is	heated	at	95°C	for	5	
min.	The	reaction	bulk	is	then	loaded	on	a	Sep-pak®	Light	C18	cartridge	and	washed	with	10	mL	of	water.	
68Ga-PSMA-11	is	then	eluted	with	2	mL	of	EtOH/water	1:1	v/v	mixture	followed	by	2	mL	of	phosphate	
buffered	saline	(PBS)	and	collected	through	a	0.22	µM	Millex®-GV	filter	into	a	sterile	vial	containing	6	mL	
of	PBS.	Results:	68Ga-DOTA-NOC	 is	 produced	 in	 r	 <20	min	with	81.5±5.2	%	 radiochemical	 yield	 (RCY)	
(decay-corrected-d.c.)	and	68Ga-PSMA-11	 is	produced	 in	13	min	with	97.4±2.5	%	RCY	 (d.c.).	Reported	
process	 times	 include	 generator	 elution	 and	 formulation.	 In	 both	 cases,	 final	 products	 show	 high	
radiochemical	purity	(TLC	>	97	%	and	99	%	respectively).Discussion/Conclusion:	Automated	processes	for	
the	 production	 of	 both	 68Ga-DOTA-NOC	 and	 68Ga-PSMA-11	 have	 been	 successfully	 achieved	 using	 a	
commercial	 synthesizer	and	a	68Ge/68Ga	generator.	 The	 labeling	procedures	are	 straightforward	and	
efficient,	 thanks	 to	 the	 low	 elution	 volume	 and	 high	 purity	 of	 the	 generator	 eluate	 (no	 need	 for	
fractionation	or	post-elution	purification).		
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Combining	 commercial	 production	 of	 multi-products	 in	 a	 GMP	 environment	 with	 Clinical	 &	 R&D	
activities	
Cristiana	Gameiro1,	Ian	Oxley1,	Antero	Abrunhosa2,	Vasko	Kramer3,	Maria	Vosjan4,	Arnold	Spaans4	
1IBA	SA,	Louvain-La-Neuve/Belgium;	2ICNAS,	University	of	Coimbra,	Coimbra/Portugal;		
3PositronPharma	S.A.,	Santigo/Chile	;	4BV	Cyclotron	VU,	Amsterdam/The	Netherlands,		
	
Introduction:	Mono-product	facilities	are	turning	to	multi-product	to	cope	with	decreasing	prices	of	[18F]-
FDG	 (FDG)	 and	 to	 support	 R&D	 programs.	 The	 aim	 is	 to	 demonstrate	 that	 in	 the	 same	 facility	 and	
equipment,	a	busy	research	program	can	be	safely	integrated	into	commercial	production.	Materials	&	
Methods:	To	be	able	to	safely	combine	both	activities	a	risk-assessment	should	be	designed	to	identify	
key	control	points.	The	use	of	a	fully	automated	platform	(e.g.	IBA	Synthera)	and	its	disposable	cassettes	
can	 prevent	 human	 errors,	 reduce	 risk	 of	 cross-contamination	 and	 improve	 reliability.	 A	 production	
schedule,	training	and	labeling	procedures	should	also	be	considered.	Results:	Positronpharma	in	Chile	
delivers	FDG	daily	to	several	hospitals	and	produced	>	1600	Ci	FDG	in	the	last	3	years.	In	addition,	[18F]-
(FCH,	NaF,	FET,	FLT,	F-MISO,	DMFP),	[68Ga]-DOTA-peptides	and	PSMA-11	have	been	implemented	as	well	
as	two	more	INDs:	[18F]-PR04MZ	and	MHMZ	were	translated	into	clinical	studies.	ICNAS	is	a	research	unit	
of	the	University	of	Coimbra	that	hosts	a	GMP-compliant	PET	production	facility	which	supports	clinical	
and	pre-clinical	R&D	programs	and	supplies	RPs	to	nearby	hospitals.	The	unit	is	in	operation	since	2012	
and	currently	has	five	radiopharmaceuticals	authorized	in	the	market	(18F-:	FDG,	FCH,	NaF)	and	68Ga-
DOTA-NOC.	 All	 are	 produced	 on	 IBA	 Synthera	 and	 together	 represent	 >2000	 production	 cycles.	 An	
extensive	R&D	program	is	in	place	with	plans	for	production	of	other	[18F]-tracers	(F-DOPA	nucleophilic	
route,	FMISO,	FLT,		FES),	[68Ga]-	(PSMA,	DOTA-TOC)	and	[64Cu]-	(ATSM).	BV	Cyclotron	VU	in	Amsterdam	
is	a	private	company	with	a	GMP-compliant	PET	production	facility.	Since	the	90’s	FDG	is	delivered	for	the	
Dutch	hospitals	 (annual	output	of	>	7300	patient	doses	 (11	TBq)).	FCH	and	FBB	(Florbetaben)	are	also	
commercially	 produced	 with	 annual	 output	 >1400	 (1.7	 TBq)	 and	 >340	 patient	 doses	 (1.1	 TBq),	
respectively.	Besides	the	commercial	productions	there	is	also	room	for	an	R&D	program,	e.g.,	currently	
improvement	of	 the	production	of	FCH	 is	examined.	Discussion/Conclusion:	As	a	conclusion,	 the	sites	
described	 have	 been	 functioning	 for	 several	 years	 and	 are	 able	 to	 safely	 combine	 commercial	 daily	
production	while	keeping	a	highly	active	R&D	program	with	more	than	ten	different	tracers	developed	
for	pre-clinical	and	clinical	applications.	
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99mTc-Anidulafungin	a	potential	diagnostic	agent	for	fungal	infections	by	gamma	scintigraphy.	
M.E.	Cardoso,	S.	Aparicio,	L.	Fernández,	M.	Terán.	
	
Introduction:	During	the	last	decades,	an	important	increase	in	the	number	of	patients	with	nosocomial	
fungal	infections,	mainly	due	to	the	higher	number	of	immunocompromised	patients.	Fungal	infections	
in	these	patients	are	severe,	rapidly	progressive,	and	difficult	to	diagnose.	Nuclear	Medicine	may	aid	to	
diagnose	these	illnesses	by	scintigraphic	images.	Anidulafungin	is	an	antifungal	agent	of	the	echinocandin	
class,	which	inhibits	β-1,3-glucan	biosynthesis	that	may	be	radiolabelled	with	tricarbonyl	precursor.		The	
aim	of	this	work	was	to	develop	and	evaluate	99mTc-anidulafungin	as	a	potential	radiopharmaceutical	for	
fungal	infection	detection.	Materials	and	methods:		A	derivative	of	Anidulafungin	was	synthesized	with	
carbon	disulfide	in	order	to	favour	its	conjugation	with	tricarbonyl	precursor.	Chemical	purity	of	the	ligand	
and	 radiochemical	 purity	 of	 the	 complex	 were	 controlled	 by	 HPLC	 in	 both	 cases.	 Stability	 in	 time	 in	
labelling	milieu	was	evaluated	up	to	24	hours	post	labelling,	by	HPLC.	Lipophilicity	was	studied	through	
the	apparent	partition	coefficient	between	n-octanol	and	sodium	phosphate	buffer.		In	vitro	stability	was	
assessed	 incubating	 the	 complex	 with	 human	 plasma	 at	 37ºC,	 by	 protein	 precipitation	 method.	 The	
supernatant	was	analysed	by	HPLC.	
The	 complex	 was	 challenged	 against	 competing	 standard	 ligands	 namely	 hisitidine	 or	 cysteine.	 The	
complex	was	incubated	with	excess	of	histidine/cysteine	at	37ºC	and	samples	were	analysed	by	HPLC	at	
different	times.		Biological	evaluation	was	performed	in	normal	CD1	female	mice	(30+2g);	the	complex	
was	administered	intravenously	 in	the	tail	vein	and	animals	were	sacrificed	three	hours	post	 injection.	
Results:	 99mTc-Tricarbonyl	 and	 the	 anidulafungin	 complex	 were	 obtained	 with	 radiochemical	 purity	
higher	than	95%	in	both	cases.	The	product	was	stable	in	labelling	milieu	for	at	least	24	hours,	and	the	
chromatogram	did	not	show	any	degradation	products	in	that	period.		Partition	coefficient	indicates	the	
complex	has	 good	 lipophilicity	 in	order	 to	 insert	 into	 the	 fungus	membrane	 (Log	P=1.5	±	0.1).	 In	 vivo	
studies	 showed	 that	 the	 complex	 presented	 low	 thyroid	 and	 stomach	 uptake,	 indicating	 no	 “in	 vivo”	
reoxidation.	 Elimination	 paths	 were	 mainly	 hepatobiliar	 (55%)	 and	 urinary	 (25%).	 Discussion	 and	
conclusions	:	In	vitro	studies	show	that	the	complex	has	high	radiochemical	purity,	remarkable	in	milieu	
and	 plasma	 stability	 and	 good	 lipophilicity.	 Preliminar	 in	 vivo	 studies	 indicate	 that	 	 the	 complex	 is	 a	
potential	agent	to	detect	fungal	infections,	nevertheless	further	studies	will	be	performed	in	infection	and	
inflammation	models.		References:	Reyes	A.L,	Fernández	L,	Rey		A,	Terán	M,	[2014],	CRP	7(2):144-150	
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99mTc(CO)3-labeling	and	Comparative	In-Vivo	Evaluation	of	Two	Clicked	cRGDfK	Peptide	Derivatives		
Kusum	Vats1,	Drishty	Satpati1,	Haladhar	D	Sarma2,	Sharmila	Banerjee1	
1Radiopharmaceuticals	Chemistry	Section;	2Radiation	Biology	and	Health	Science	Division,		
Bhabha	Atomic	Research	Centre,	Trombay,	Mumbai	400085	
Introduction:	There	 is	 a	 continued	 interest	 for	development	of	 radiolabeled	RGD	peptides	as	 integrin	
αvβ3	 receptor	 targeted	 molecular	 probes	 possessing	 favorable	 pharmacokinetic	 behavior.1,2	 In	 this	
study,	two	click	chemistry	modified	cRGDfK	peptide	analogues	have	been	synthesized	3	and	radiolabeled	
with	[99mTc(CO)3(H2O)3]+	precursor.	Comparative	in	vivo	evaluation	of	the	two	radiotracers	was	carried	
out	to	determine	the	pharmacokinetics	and	integrin	αvβ3	targeting	potential.		
Materials	 and	Methods:	 cRGDfK	was	 functionalized	with	 N3CH2COOH	 and	N3PEG7COOH	 at	 ε-amino	
group	 of	 lysine.	 The	 two	 azide-modified	 derivatives	 (with	 PEG7and	 without)	 were	 then	 clicked	 with	
propargyl	 glycine	 to	 introduce	a	 tridentate	 chelating	unit	 for	 radiolabeling	with	 [99mTc(CO)3(H2O)3]+	
precursor.	The	radiotracers,	99mTc(CO)3-Pra-Tz-CH2-cRGDfK	and	99mTc(CO)3-Pra-Tz-PEG7-cRGDfK	were	
analyzed	by	HPLC.	Analogous	rhenium	complexes	were	synthesized	for	characterization	of	99mTc(CO)3-
labeled	 radiotracers.	 Biodistribution	 study	 of	 the	 two	 radiotracers	 was	 carried	 out	 in	 C57BL/6	 mice	
bearing	αvβ3-positive	melanoma	 tumors.	 The	 radioactive	preparation	 (~3.7	MBq/animal,	 100	µL)	was	
injected	intravenously	through	the	lateral	tail	vein.	At	different	time	intervals	after	injection	(30,	60,	and	
180	min),	the	animals	(n	=	4/time	point)	were	sacrificed	and	the	relevant	organs	excised	for	measurement	
of	retained	activity.	Results:	The	two	radiotracers,	99mTc(CO)3-Pra-Tz-CH2-cRGDfK	and	99mTc(CO)3-Pra-
Tz-PEG7-cRGDfK	were	prepared	in	>90%	radiochemical	yield	and	exhibited	excellent	stability	in	saline	as	
well	as	in	serum.	Maximum	tumor	uptake	was	observed	at	30	min	p.i.	for	the	two	radiotracers	and	was	
higher	for	99mTc(CO)3-Pra-Tz-PEG7-cRGDfK	(4.11	± 0.51	%ID/g)	as	compared	to	that	for	99mTc(CO)3-Pra-
Tz-CH2-cRGDfK	 (3.01	±	 0.77	%ID/g).	 Tumor	accumulation	of	both	 the	 radiotracers	 reduced	 to	50-60%	
during	blocking	studies	with	cold	cRGDfK	peptide,	suggesting	receptor-mediated	uptake	of	radiotracers.	
Conclusion:	The	two	neutral	99mTc(CO)3	radiotracers	prepared	exhibited	receptor	mediated	uptake	in	
melanoma	 tumor.	 Increased	 tumor	uptake	on	 introduction	of	 PEG7	unit	was	 compromised	with	 slow	
clearance	from	other	organs.	Further	modification	of	the	peptide	with	a	different	spacer	or	a	smaller	PEG	
unit	may	lead	to	more	favorable	pharmacokinetics.	
	
	 	
Comparison	 in	 the	 uptake	 of	 (a)	 99mTc(CO)3-Pra-Tz-CH2-cRGDfK	 and	 (b)	 99mTc(CO)3-Pra-Tz-PEG7-
cRGDfK	in	different	organs/tissue	in	the	absence	and	presence	of	excess	cRGDfK	peptide	at	180	min	p.i.	
References:	 	1.	Gaertner	FC,	Kessler	H,	Wester	HJ	et	al	[2012]	EJNMMI	39:	S126–138.	2.	Hernandez	R,	
Czerwinski	A,	Chakravarty	R	et	al	[2015]	EJNMMI	42:1859–1868.		3.	Zeng	D,	Zeglis	BM,	Lewis	JS	et	al	[2013]	
JNM	54:829–832	
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Application	of		AnaLig	resin	for	99mTc	separation	from	molybdenum	excess	
Wojdowska	W.,	Pawlak	D.W.,	Parus	L.	J.,	Garnuszek	P.,	Mikołajczak	R.	
Radioisotope	 Centre	 POLATOM,	 National	 Centre	 for	 Nuclear	 Research,	 Andrzeja	 Sołtana	 7,	 05-400	
Otwock,	Poland.	
	
Introduction:	 The	 shortage	 of	 99Mo	 (fission)	 has	 renewed	 interest	 in	 alternative	 technetium-99m	
production	methods	either	in	nuclear	reactor	starting	from	98Mo	or	in	accelerator	with	100Mo	as	a	target	
material.	Adsorption	chromatography	on	alumina	is	not	sufficient	for	alternative	production	methods	due	
to	high	amount	of	Mo	in	the	dissolved	target	solution.	Several	chromatographic	resins	were	described	for	
the	separation	of	pertechneate	from	molybdate	including	Dowex	or	ABEC.	Here	we	focused	our	attention	
on	 application	 of	 AnaLigTc-02	 resin	 for	 efficient	 recovery	 of	 99mTc	 from	 large	 molybdenum	 excess.	
Methods:	To	simulate	 	a	target	dissolution	mixture,	10	mL	of	sodium	molybdate	solution	and	 	a	small	
amount	of	Na99mTcO4	in	NaOH	or	(NH4)2CO3	was	delivered	on	the	column	containing	100	mg	of	AnaLig	
resin	using	the	flow	rate	of	0.4	mL/min.	Before	99mTc	elution,	the	column	was	fed	with	3	mL	of	sodium	
hydroxide	 or	 ammonium	 carbonate	 solution	 and	 subsequently	with	 1.5	mL	of	water.	 The	 99mTc	was	
recovered	 in	 5	mL	 of	water.	 The	 eluate	 and	 	 other	 effluents	 activities	 (one	 after	 introduction	 of	Mo	
solution	 and	 two	 after	 rinsing	 columns	 in	 term	 with	 NaOH	 or	 (NH4)2CO3	 solution	 and	 water)	 were	
measured	with	the	dose	calibrator	Capintec	CRC-55tR.	The	sorption	yield	was	studied	as	a	 function	of	
NaOH	and	(NH4)2CO3	for	concentration	of	1.05,	1.4,	2.8	and	4.2	M	for	the	former	and	0.5,	1.5	and	2.5	M	
for	the	latter.	Results:	Best	99mTc	recovery	was	obtained	in	2.8M	NaOH	or	1.5M		(NH4)2CO3	solution.	
Under	 these	 conditions,	 more	 than	 86%	 adsorption	 and	 elution	 were	 achieved.	 Most	 99mTc	 losses	
occurred	during	rinsing	the	column	with	water,	even	approaching	10%	of	activity	and	due	to	rinsing	the	
column	with	NaOH	or	(NH4)2CO3	after	sorption	Tc-99m	on	Analig	resin	(up	to	3.5%).	The	activity	retained	
on	 	 the	 column	 was	 around	 1%	 	 for	 solution	 in	 NaOH	 and	 	 about	 3%	 for	 (NH4)2CO3,	 respectively.	
Acknowledgements:	This	project	was	supported	by	the	grant	ALTECH	PBS1/A9/2/2012	awarded	by	the	
National	 Centre	 for	 Research	 and	 Development	 in	 Poland	 within	 the	 Applied	 Science	 Program.	
References:	 Bénard	 F,	 Buckley	 K.	 R,	 Ruth	 T.	 J,	 Zeisler	 S.	 K,	 et.al.	 [2014],	 J	 Nucl	 Med.	 55:1017-1022.	
Wojdowska	W,	Pawlak	D,	Parus	J,	Mikołajczak	R.	[2015],	Nucl	Med	Rev.	18,	2:65-69	
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Constraints	 for	 selection	of	 suitable	precursor	 for	one-step	automated	 synthesis	of	 [18F]FECNT,	 the	
dopamine	transporter	ligand.	
Pijarowska-Kruszyna	J1,	Jaron	A1,	Kachniarz	A2,	Malkowski	B2,	Garnuszek	P1,		
Mikolajczak	R1	
1	Radioisotope	Centre	POLATOM,	National	Centre	for	Nuclear	Research,	Otwock,	Poland	
2	 Department	 of	 Nuclear	Medicine,	 Oncology	 Centre	 prof.	 Lukaszczyk	Memorial	 Hospital,	 Bydgoszcz,	
Poland	
	
Introduction:	The	fluorine-18	labelled	nortropane	derivative	2β-carbomethoxy-3β-(4-chlorophenyl)-8-(2-
fluoroethyl)-nortropane	([18F]FECNT)	is	a	Positron	Emission	Tomography	(PET)	radioligand	of	reference	
for	imaging	the	dopamine	transporter	(DAT)	[1].	The	use	of	this	radioligand	as	a	clinical	marker	is	highly	
dependent	on	the	robustness	of	the	radiochemical	process	used	for	its	preparation.	[18F]FECNT	has	been	
previously	synthesized	in	a	two-step	chemical	process	with	16%	decay-corrected	yield	in	total	time	of	150	
min	 [2].	 Recently,	 more	 effective	 (25-33%	 decay-corrected	 yield,	 80-90	 min)	 one-step	 synthesis	 of	
[18F]FECNT	by	direct	nucleophilic	[18F]fluorination	from	N-mesyloxy	precursor	was	reported	in	literature	
[3,4].	However,	the	use	of	a	mesylate	as	a	leaving	group	in	such	a	nucleophilic	substitution	reaction	has	
some	drawbacks.	Mesylates	are	rather	hard	to	detect	using	UV-absorption,	which	complicates	the	final	
HPLC	 purification	 of	 the	 radiotracer	 and	 also	 characterized	 by	 higher	 susceptibility	 to	 decomposition.	
Herein,	we	reported	a	fully	automated	synthesis	of	[18F]FECNT	from	the	chlorinated	precursor,	which	was	
earlier	 found	 to	 be	 the	most	 stable	 of	 the	 studied	 halo-	 and	 sulfonyloxy-	 analogues	 [5].	Materials	&	
Methods:	The	commercially	available	SynChrom	[18F]	R&D	synthesis	module	was	readily	configured	for	
the	one-step	synthesis	according	to	conditions	achieved	for	the	fluorination	with	non-radioactive	fluoride	
[5].	 The	 radiolabelling	 process	 involved	 a	 classical	 [18F]fluoride	 nucleophilic	 substitution	 from	 the	
chlorinated	 precursor	 (5mg)	 was	 performed	 at	 110°C	 for	 12	 min.	 Crude	 product	 was	 purified	 using	
preparative	 HPLC	 and	 SPE	 methods.	 Results:	 The	 obtained	 yields	 for	 a	 chlorine-for-[18F]fluorine	
substitution	 of	 59±12%	 (n=5)	 were	 higher	 than	 those	 (45-48%)	 reported	 for	 the	 [18F]FECNT	 batches	
prepared	from	the	N-mesyloxy	precursor	[3,5].	The	total	synthesis	time	was	80-90	min	and	[18F]FECNT	
batches	of	about	2.0±0.5	GBq	(n=3)	with	high	radiochemical	purity	over	than	99%	were	obtained	with	
32±7%	overall	decay-corrected	yields.	These	yields	were	comparable	with	previously	reported	results	for	
the	 one-step	 synthesis	 of	 [18F]FECNT	 [3]	 and	 significantly	 higher	 than	 yields	 obtained	 in	 two-step	
syntheses	[2].	The	specific	activity	of	the	final	[18F]FECNT	product	was	55	GBq/µmol,	which	is	consistent	
with	literature	synthesis	results	(38-72	GBq/µmol)	of	this	radiotracer	[1,2,4]	and	sufficient	for	the	DAT	
density	determination	in	the	human	PET	imaging	studies	[1].	Discussion/Conclusions:	In	this	study,	the	
new	chlorinated	precursor	was	successfully	used	for	one-step	automated	radiosynthesis	of	[18F]FECNT.	
Considering	 these	promising	 results	 as	well	 as	 long-	 term	 storage	 stability	 of	 this	 precursor,	 reported	
procedure	may	provide	a	straightforward	and	reliable	method	for	the	production	of	radiotracer	suitable	
for	human	use.	References:	[1]	Davis	MR	et	al.,	[2003]	J.	Nucl.	Med.,	44:	855-861;	[2]	Voll	RJ	et	al.,	[2005]	
Appl.	Radiat.	Isot.,	63:	353-361;	[3]	Chen	Z	et	al.,	[2008]	Appl.	Rad.	Isot.,	66:	1881-1885;	[4]	Liang	S	et	al.,	
[2013]	 J.	 Radioanal.	 Nucl.	 Chem.,	 298:	 1969-1972;	 [5]	 Pijarowska-Kruszyna	 J,	 et	 al.,	 [2014]	 J	 Labelled	
Compd.	Radiopharm.,	57:	148-157;	
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Gamma	 Scintigraphy	 Studies	 with	 99mTc-	 Amoxicillin	 Sodium	 in	 Bacterially	 Infected	 and	 Sterile	
Inflamed	Rats	
Derya	Ilem-Ozdemir,	Oya	Caglayan-Orumlu,	Makbule	Asikoglu	
Ege	 University,	 Faculty	 of	 Pharmacy,	 Department	 of	 Radiopharmacy,	 Ege	 University,	 Bornova,	 Izmir,	
Turkey.	
	
Introduction:	 The	 in-time	 diagnosis	 of	 bacterial	 infection	 is	 extremely	 significant	 for	 the	 accurate	
treatment.	Nuclear	medicine	scintigraphic	 imaging	 is	an	excellent	non-invasive	method	of	whole-body	
scanning,	 allow	 to	 determinate	 infectious	 foci	 in	 all	 parts	 of	 the	 body,	 based	 on	 pathophysiological	
changes	which	occur	earlier	in	the	infection	process	(1-4).	The	aim	of	this	study	was	to	perform	gamma	
scintigraphy	 studies	 with	 bacterial	 infected	 and	 sterile	 inflamed	 rats	 with	 newly	 developed	
radiopharmaceutical	 99mTc-amoxicillin	 sodium	 (99mTc-AMOX).	 Method:	 E.coli	 suspension	 was	
intramuscularly	injected	into	the	right	thigh	muscle	of	rats	to	create	infection	model.	Turpentine	oil	was	
intramuscularly	injected	into	the	left	thigh	muscle	of	rats	to	create	sterile	inflammation	model.	After	the	
infection	and	sterile	 inflammation	 focus	were	allowed	 to	develop	 for	24	hours	 swelling	appeared	and	
gamma	scintigraphy	studies	were	performed.	99mTc-AMOX	(3.7MBq)	was	intravenously	injected	via	tail	
vein	 to	 the	 rats.	 After	 administration	 of	 radiopharmaceuticals,	 serial	 static	 images	 were	 acquired	 at	
different	time	intervals	(5	minutes,	1,	2,	3,	4	and	5	hours	post	injection).	Results:	The	uptake	of	99mTc-
AMOX	following	intravenous	administrations	was	assessed	on	static	images.	The	images	depicted	rapid	
distribution	throughout	the	body	and	uptake	in	the	bacterial	infected	and	sterile	inflamed	thigh	muscle	
within	one	hour	after	injection.	As	can	be	seen	in	Figure	1	there	was	a	higher	activity	in	both	bacterial	
infected	 and	 sterile	 inflamed	 thigh	 muscle	 as	 compared	 to	 healthy	 thigh	 muscle.	 For	 quantitative	
evaluation,	regions	of	interest	were	drawn	around	the	target	(infected	and	inflamed	thigh	muscle)	and	
non-target	(healthy	thigh	muscle)	regions	of	the	rats.	The	99mTc-AMOX	uptake	was	calculated	by	dividing	
the	average	counts	per	pixel	within	the	region	of	target	to	the	average	counts	per	pixel	within	the	region	
of	 non-target	 (Table	 1).	 Conclusion:	Based	 on	 the	 in	 vivo	 studies,	 99mTc-AMOX	has	 higher	 uptake	 in	
infected	and	inflamed	thigh	muscle	than	healthy	muscle.	The	data	suggest	that	99mTc-AMOX	remained	
at	 the	 infection	 and	 inflammation	 foci	 during	 the	 whole	 experiments,	 there	 being	 no	 statistically	
significant	differences	in	the	ratios	during	the	studied	period	(p≥0.05).		
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Figure	1:	The	scintigrams	of	99mTc-AMOX	injected	bacterial	infected	and	sterile	inflamed	rats	at	different	
time	intervals	(SI=Sterile	Inflamed	Foci,	BI=	Bacterial	Infected	Foci	NT=Non-Target	Extremity,	IS=Injection	
Site).	
	
Table	1:	Target/	Non-Target	Ratios	from	ROI	Analysis	99mTc-AMOX	at	different	time	intervals	
	
References:	1.Das	SS,	Hall	AV,	Wareham	DDW,	Britton	KE.	Infection	imaging	with	radiopharmaceuticals	
in	the	21st	century.	Braz	Arch	Biol	Technol.	2002;45:25–37.	2.	S.	Q.	Shah,	M.	R.	Khanb.	Radiosynthesis	of	
99mTc-Labeled	Novobiocin	Dithiocarbamate	 	Complex	as	a	Potential	 Staphylococcus	aureus	 	 Infection	
Radiotracer.	Radiochemistry.	2012;54:	(3):279–283.		3.	El-Ghany	EA,	El-Kolaly	T,	Amine	AM,	El-Sayed	AS,	
Abdel-Gelil	F.	Synthesis	of	99mTc-peﬂoxacin:	a	new	targeting	agent	for	infectious	foci.	J	Radioanal	Nucl	
Chem.	2005;266:131–139.	4.Peter	H.	Nibbering,	Mick	M.	Welling,	Akke	Paulusma-Annema,	Carlo	P.J.M.	
Brouwer,	Antonella	Lupetti	and	Ernest,	K.J.	Pauwels.	99mTc-Labeled	UBI	29-41	Peptide	for	Monitoring	the	
Efficacy	of	Antibacterial	Agents	in	Mice	Infected	with	Staphylococcus	aureus.	J	Nucl	Med.	2004;45:321-
326	
	 	
Time After Injection 
(h) 
Infected Thigh Muscle 
(Target/Non-Target) 
Inflamed Thigh Muscle 
(Target/Non-Target) 
0 2,35±0,59 1,94±0,09 
1 4,64±1,51 2,94±1,00 
2 2,46±0,19 2,61±0,70 
3 2,33±0,99 2,41±0,12 
4 3,19±1,26 2,73±1,74 
5 4,79±2,82 3,51±1,21 
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PP36	
Preparation	of	99mTc-	Amoxicillin	Sodium	Lyophilized	Kit	
Derya	Ilem-Ozdemir,	Oya	Caglayan-Orumlu,	Makbule	Asikoglu	
Ege	 University,	 Faculty	 of	 Pharmacy,	 Department	 of	 Radiopharmacy,	 Ege	 University,	 Bornova,	 Izmir,	
Turkey.	
	
Introduction:	 Infection	detection	by	nuclear	medicine	imaging	techniques	based	on	pathophysiological	
changes	which	appear	much	earlier	than	anatomical	changes	in	the	infection	process	(1,2).	To	develop	a	
better	 infection	 imaging	 	 which	 will	 accumulate	 efficiently	 to	 inflammatory	 foci,	 clear	 rapidly	 from	
background	 tissue,	 discriminate	 between	 bacterial	 infection	 and	 sterile	 inflammation,	 cost	 low	 and	
prepare	easily	we	 labeled	amoxicillin	sodium	(AMOX)	with	99mTc.	The	aim	of	 this	 study	 is	 to	prepare	
99mTc-AMOX	 in	a	simple	method	with	good	 labeling	efficiency	and	evaluate	the	ready	to	use	cold	kit	
formulation	thus	making	it	available	to	the	other	nuclear	medicine	centers.	The	stability	of	99mTc-AMOX	
in	 human	 serum	was	 identified;	 sterility	 and	 pyrogenicity	 of	 the	 radiopharmaceutical	 was	 estimated.	
Method:	To	 investigate	 the	optimum	radiolabeling	 conditions,	 radiolabeling	was	 tested	with	different	
concentrations	 of	 reducing	 (stannous	 chloride	 and	 stannous	 tartrate)	 and	 antioxidant	 (ascorbic	 acid)	
agent.	Radiochemical	analysis	was	performed	with	Radio	Thin	Layer	Chromatography	(RTLC)	and	Radio	
High	Performance	Liquid	Chromatography	(RHPLC)	studies.	Two	different	freeze	dry	kits	were	formulated	
with	 optimum	 labeling	 conditions	 and	 stability,	 sterility	 and	 pyrogenicity	 of	 the	 kits	were	 performed.	
Results:	 The	 effect	 of	 reducing	 agent	 concentration	 on	 the	 radiochemical	 purity	 was	 evaluated	 and	
optimum	reducing	agent	amount	found	200	µg.	Under	these	conditions	labeling	efficiency	was	around	
90%.	 In	 the	 presence	 of	 ascorbic	 acid,	 stability	 of	 the	 complex	 was	 slightly	 increase	 while	 labeling	
efficiency	for	early	hours	was	not	affected	significantly.	According	to	the	experiments,	the	formation	of	
the	99mTc-AMOX	complex	was	very	fast	and	reached	the	radiochemical	purity	over	95	%	in	15	min	after	
radiolabeling.	While	keeping	other	reaction	conditions	constant	and	varied	the	pH	of	the	reaction	from	
4.8	to	7.4	radiochemical	purity	was	slightly	decreased.	99mTc-	AMOX	was	found	stable	during	to	24	hours	
incubation	 in	 saline	and	human	serum.	Kits	were	 labeled	with	37MBq,	185MBq	and	370	MBq	99mTc.	
Slightly	 decrease	 in	 radiochemical	 purity	 was	 observed	 with	 increasing	 of	 radioactivity.	 According	 to	
sterility	test,	since	there	was	no	growth	in	batches,	kits	were	sterile.	Also	gel	clot	test	showed	that	kits	
were	pyrogen	free.	The	freeze	dry	kits	developed	in	this	study	were	found	to	be	stable	with	a	shelf–life	of	
six	months	when	preserved	at	both	at	+5±3°C	and	+25±2°C/60	±5%	RH.	Conclusion:	Simple	method	for	
radiolabeling	of	AMOX	with	99mTc	has	been	developed	and	standardized.	Labeling	efficiency	of	99mTc-
AMOX	was	assessed	by	both	RTLC	and	RHPLC	and	found	higher	than	90%.	The	resulting	complex	was	quite	
stable	and	labeling	of	˃90%	was	maintained	for	up	to	6	hours.	Two	different	freeze	dry	kits	was	developed	
and	evaluated.	Based	on	the	data	obtained	from	this	study,	both	products	was	stable	for	6	months	with	
high	labeling	efficiency.	
References:	 1.Kaul	 A,	 Hazari	 PP,	 Rawat	 H,	 Singh	 B,	 Kalawat	 TC,	 Sharma	 S,	 Babbar	 AK,	 Mishra	 AK.	
Preliminary	evaluation	of	 technetium-99m-labeled	ceftriaxone:	 infection	 imaging	agent	 for	 the	clinical	
diagnosis	of	orthopedic	infection.	Int	J	Infect	Dis.	2013;17(4):e263-70.	2.	Gemmel	F,	Dumarey	N,	Welling	
M.	Future	diagnostic	agents.	Semin	Nucl	Med	2009;39:11–26.	
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PP37	
Outfits	of	Tracerlan	FXC-PRO	for	11C-Labeling	
Arponen	Eveliina,	Helin	Semi,	Saarinen	Timo,	Vauhkala	Simo,	Kokkomäki	Esa	and	Lehikoinen	Pertti	
Radiopharmaceutical	Chemistry	Laboratory,	Turku	PET	Centre,	University	of	Turku,	Finland	
	
Introduction:	 Commercial	 synthesis	 modules	 for	 11C-labeling	 are	 not	 often	 directly	 suitable	 for	 the	
production	of	different	labeling	agents.	Modification	of	Tracerlab	FXC-Pro	synthesis	module	to	perform	
both	[11C]methylation	and	[11C]carboxylation1	and	the	set-up	of	[11C]radiopharmaceuticals	for	clinical	
use	are	described.	Materials	&	Methods:	Commercial	GE	Tracerlab	FXC-Pro	synthesizer	was	modified	to	
enable	 11C-methylation	with	 both	 [11C]methyl	 iodide	 and	 [11C]methyl	 triflate	 as	well	 as	 direct	 11C-
carboxylation	with	[11C]CO2.	Additional	magnetic	valves	were	installed	to	bypass	the	[11C]methyl	iodide	
recycling	 system	 for	 direct	 use	 of	 [11C]CO2	 and	 to	 bypass	 the	 [11C]methyl	 triflate	 oven	when	 using	
[11C]methyl	 iodide	as	such.	The	valves	are	operated	by	Tracerlab	software.	The	HPLC	operations	were	
modified	by	installing	pneumatic	column	selector	and	a	syringe	operated	loop	injector.	A	sterile	filtration	
unit	(SFU)	was	coupled	with	synthesizer	to	allow	online	filter	integrity	test.	For	monitoring	purposes	more	
GM	tubes	were	also	installed.	[11C]PK11195	was	labeled	with	[11C]methyl	iodide	while	[11C]methionine	
and	[11C]metomidate	were	labeled	with	[11C]methyl	triflate.	[11C]Acetate	was	synthesized	using	direct	
carboxylation	with	[11C]CO2.	Semi-preparative	HPLC	was	used	for	the	purification	of	[11C]PK11195	and	
[11C]methionine.	Solid	phase	extraction	cartridges	were	used	 for	 the	purification	of	 [11C]metomidate	
and	[11C]acetate.	Results:	The	average	synthesis	times	were	30	minutes	for	[11C]methionine,	38	minutes	
for	[11C]PK11195,		20	minutes	for	[11C]metomidate	and	[11C]acetate	including	purification,	formulation	
and	online	sterile	filter	 integrity	test.	[11C]Radiopharmaceuticals	were	obtained	in	good	radiochemical	
yields,	sufficiently	for	several	simultaneous	clinical	doses.	The	radiochemical	purity	exceeded	95%	in	all	
syntheses.	The	use	of	 column	selector	enables	easy	change	of	HPLC	columns	between	syntheses.	The	
filling	of	the	injector	loop	with	pneumatic	syringe	decreases	losses	of	the	injection	solutions	compared	to	
the	inbuilt	fluid	detector.	Due	to	the	limited	number	of	electrical	connections	in	Tracerlab	FXC-Pro	the	
column	selector,	loop	syringe	and	SFU	are	remote	controlled	from	external	touch	screen.	Readings	from	
additional	 GM	 tubes	 are	 also	 shown	 on	 the	 touch	 screen.	 Conclusion:	 Reliable	 and	 robust	 routine	
procedures	for	the	production	of	[11C]methionine,	[11C]PK11195,	 	[11C]metomidate	and	[11C]acetate	
were	developed	using	a	modified	Tracerlab	FXC-Pro	module.		The	synthesis	module	can	be	easily	modified	
and	 re-modified	 for	 production	 of	many	 different	 [11C]radiopharmaceuticals.	References:	 	1.	 Shao	 X,	
Hoareau	R,	Runkle		A	et	al.,	[2011],	J.	Label	Compd.	Radiopharm	54:	819-838	
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PP38	
Microfluidic	synthesis	of	ω-[18F]fluoro-1-alkynes		
Mariarosaria	De	Simone1,	Giancarlo	Pascali2,	Ludovica	Carzoli1,	Mauro	Quaglierini1,	Mauro	Telleschi1,	
Piero	A.	Salvadori1	
1.CNR	Institute	Clinical	Physiology	Pisa,	Italy	
2.Life	 Sciences,	 Australian	 Nuclear	 Science	 and	 Technology	 Organisation,	 New	 Illawarra	 Road,Lucas	
Heights	NSW	2234,	Australia	
	
Introduction:	Cu(I)-catalyzed	 1,3-dipolar	 cycloadditions	 is	 widely	 used	 in	 labeling	 azido-functionalized	
peptides	and	small-molecules	with18F-alkynes.	We	report	on	the	microfluidic	(ADVION)	synthesis	of	5-
[18F]fluoro-1-pentyne	(5-[18F]-FP)	and	6-[18F]fluoro-1-hexyne	(6-[18F]-FH)	and	application	in	labeling	an	
azide-functionalized	 Factor-H.	 Materials	 &	 Methods:	 5-tosyloxy-1-pentyne	 (5-TP)	 and	 6-tosyloxy-1-
hexyne	(6-TH)	were	obtained	from	the	corresponding	alcohols	[1].	[18F]fluoride	(0.3	GBq)	was	produced	
by	irradiation	of	>98%	18O-water	(nyobium	target),	trapped	on	a	trap&release	column	and	eluted	with		
K222/K2CO3	(15mg/3mg)	 in	dry	acetonitrile	 (1ml).	The	K222/K[18F]F	complex	was	dried	by	azeotropic	
distillation	 in	 the	 Concentrator	module,	 	 recovered	 in	 the	 reaction	 solvent	 (600ul)	 and	 uploaded	 in	 a	
storage	 loop	 (P3).	5-TP	or	6-TH	was	dissolved	 in	1	ml	of	 solvent	and	uploaded	 in	a	 storage	 loop	 (P1).	
Boluses	of	precursor	and	K222/K[18F]F	solutions	were	pushed	(total	flow	40μL/min;	P1=P3)	through	the	
reactor	(2m	fused-silica	coil-reactor	i.d.=100µm,	15.6µl)	at	90,	110,	130,	150	and	170°C	Experiments	were	
repeated	in	acetonitrile,	dimethylsulfoxide,	tert-butanol	and	different	P1:P3	ratios	(1:1	and	1:5).	Products	
were	purified	by	distillation	and	analyzed	(radio-TLC,	radio-HPLC).	Factor-H	was	reacted	with	an	azido-
(PEG)4-carboxylate	linker	(azido-PEG)	targeting	protein	amino	groups.	Factor-H	(1.6nmol	in	250µl	of	pH	9	
PBS	 buffer),	 was	 reacted	 (4h	 at	 RT)	 with	 48nmol	 of	 NHS-activated	 azido-PEG.	 The	 azido-protein	 was	
purified	by	ultracentrifugation,	 suspended	 in	water	and	 lyophilized.	5-[18F]-FP	was	distilled	 into	a	vial	
containing	2-6nmol	of	azidoPEG-Factor-H,	1.4	µmol	of	Cu(I),	1.9µmol	of	TBTA	in	150µl	of	THF/H2O	(2:1)	
and	reacted	at	45°C	for	10'.	Unreacted	5-[18F]FP	was	removed	under	nitrogen	flow.	5-[18F]-FP-Factor-H	
was	purified	by	gel	filtration	(RCP>	97%)	and	the	yield	(92±3%	d.c.y.,	n=5)	determined	by	HPLC.	Results:	
Best	 yield	 for	 5-[18F]-FP	 and	 6-[18F]-FH	 (91±6%	 and	 83±5%	 d.c.y,	 n=3)	were	 obtained	 in	 acetonitrile	
(130°C),	P1:P3	1:1.		Reaction	yield	was	lower	in	DMSO	for	both	5-[18F]-FP	and	6-[18F]-FH	(68±11%	and	
71±9%,	d.c.y,	n=3)	and	worse	in	tert-butanol	(33±5%	and	45±2%,	d.c.y,		n=3).	Increasing	P1:P3	ratio	did	
not	influence	yield	and	resulted	in	a	more	frequent	reactor	clogging.	Discussion/Conclusion:	We	describe	
a	microfluidic	approach	for	the	synthesis	of	C5	and	C6	18F-alkynes	and	the	on-line	radiolabelling	of	an	
azido-functionalized	Factor-H	with	5-[18F]-FP.	The	proposed	method	 is	applicable	 to	a	broad	group	of	
compounds	(small	molecules,	peptides	and	nanoparticles	).	References:	1	-	Wang,	Zhe	et	al.,	(2000),	J.	
Org.	Chem.	65(6):1889-1891	
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PP39	
Automated	18F-flumazenil	production	using	chemically	resistant	disposable	cassettes	
Phoebe	Lam,	Martina	Aistleitner,	Reinhard	Eichinger,	Christoph	Artner	
IASON	GmbH,	Feldkirchnerstraße	4,	A-8054	Graz-Seiersberg	
	
Introduction:	 Production	 of	 18F-flumazenil	 from	 2-nitroflumazenil	 under	 GMP	 conditions	 is	 primarily	
performed	with	manipulators	or	custom	built	radiosynthesis	modules	with	fixed	components,	as	the	use	
of	N,N-dimethylformamide	(DMF)	at	160°C	prohibits	the	use	of	commonly	available	disposable	cassettes.	
Cassettes	 for	 the	 GE	 TRACERlab	 MXFDG	 synthesis	 modules	 are	 commercially	 available	 in	 different	
materials.	ROTEM	Industries	and	GE	Healthcare	use	polysulfone	as	the	main	component,	and	it	is	known	
that	this	polymer	is	not	compatible	with	DMF.	Cassettes	from	ABX	are	reportedly	more	chemical	resistant,	
with	polypropylene	as	 its	main	constituent.	The	aim	of	this	work	was	to	establish	a	robust	automated	
radiosynthesis	procedure	for	18F-flumazenil	on	the	GE	TRACERlab	MXFDG,	where	staff	previously	trained	
on	the	same	equipment	can	easily	perform	the	radiosynthesis.	Materials	&	Methods:	Fragments	of	the	
ABX	FDG	cassette	were	exposed	for	1	or	24	h	to	various	solvents	including	acetonitrile	and	DMF	at	room	
temperature	(RT)	or	60°C	to	assess	its	chemical	resistance.	A	new	synthesis	sequence	was	written	for	the	
GE	 TRACERlab	 MXFDG.	 A	 non-radioactive	 test	 run	 was	 performed	 with	 the	 ABX	 FDG	 cassette,	 and	
radiosynthesis	was	carried	out	with	the	cassette	components	replaced	by	chemically	resistance	manifolds	
(ABX).	 Results:	 Incubation	 of	 the	 PP	 ABX	 FDG	 cassette	 fragments	 in	 acetonitrile	 at	 RT	 showed	 no	
macroscopic	influence	on	the	polymer	while	the	fragment	became	soft	and	mouldable	at	60°C.		Visible	
changes	occurred	after	1	h	incubation	with	DMF,	with	the	polymer	having	completely	dissolved	after	24	
h,	regardless	of	temperature.	To	verify	the	implication	of	these	results	on	a	1	h	radiosynthesis,	a	test	run	
was	performed	using	the	same	cassette	material	and	synthesis	conditions	without	radioactivity.	Parts	of	
the	manifold	was	found	to	have	cracked,	and	a	valve	blockade	was	observed	due	to	polymer	melting.	
Radiosynthesis	 was	 carried	 out	 with	 the	 manifolds	 replaced	 by	 chemically	 resistant	 ones,	 and	 18F-
flumazenil	 was	 successfully	 obtained	 in	 4	%	 decay	 corrected	 yield.	Conclusions:	Disposable	 cassettes	
assembled	with	 chemically	 resistant	manifolds	 is	 a	 requirement	 for	 the	 automated	 synthesis	 of	 	 18F-
flumazenil	from	2-nitroflumazenil	using	the	GE	TRACERlab	MXFDG	synthesis	module.	Neither	reagent	kits	
nor	program	sequences	are	hitherto	commercially	available,	but	GMP	grade	production	can	nonetheless	
be	successfully	carried	out	with	modifications	on	existing	equipment.	
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PP40	
The	 effect	 of	 the	 eluent	 solutions	 (TBAHCO3,	 Kryptand	 K2.2.2)	 on	 the	 radiochemical	 yields	 of	 18F-
Fluoromethylcholine	
Surendra	Nakka,	Hemantha	Kumara	MC,	and	Al-Qahtani	Mohammed*	
Cyclotron	 and	Radiopharmaceuticals	Department,	 King	 Faisal	 Specialist	Hospital	 and	Research	Center,	
Riyadh,	Saudi	Arabia	
	
Introduction:	[18F]Fluoromethylcholine	([18F]FCH)	proves	to	be	a	unique	radiotracer	for	the	detection	of	
prostate	cancer	as	well	as	brain	and	lung	tumors	with	Positron	Emission	Tomography	(PET).	The	aim	of	
this	 work	 was	 to	 improve	 radiochemical	 yields	 of	 18F-Fluoromethylcholine	 ([18F]FCH)	 with	 high	
reproducibility.	The	used	eluent	solution	plays	an	important	role	in	production	of	[18F]FCH	radiotracers.	
[18F]FCH	 is	 manufactured	 under	 GMP	 conditions	 using	 one	 of	 two	 eluent	 solutions	 namely	
Tetrabutylammonium	Bicarbonate	 (TBAHCO3)	 and	Kryptand	2.2.2.,	 each	 time.	Method:	 [18F]FCH	was	
radiosynthesized	 using	 a	 fully	 automated	 synthesis	 module	 TRACERlab	 MX.	 Hardware	 cassette	 and	
reagents	 kit	 purchased	 from	 ABX.	 .	 [18F]FCH	 is	 synthesized	 by	 18F-Fluoroalkylation	 of	 N-N-
Dimethylaminoethanol	 (DMAE)	 in	 presence	 of	 Dimethyl	 Sulfoxide	 (DMSO)	 using	 18F-
Fluorobromomethane	[18F]FBM	as	an	alkylating	agent.	Results:	[18F]Fluoromethylcholine	radiosynthesis	
assisted	 by	 Kryptand	 2.2.2	 shown	 irregular	 or	 poor	 distillation	 of	 18F-Fluorobromomethane,	which	 is	
observed	 by	 pressure	 trending	window	 on	 TRACERlab	MX	 during	 distillation	 step	 very	 poor	 gas	 flow	
through	the	four	silica	cartridges	been	observed	which	in	turn	leads	to	production	of	very	less	amounts	
of	 	 [18F]FCH.	 Tetrabutylammonium	Bicarbonate	 (TBAHCO3)	 assisted	18F-FCH	 radiosynthesis	 observed	
with	regular	and	continuous	distillation	of	18F-Fluorobromomethane	through	the	four	silica	cartridges.	
[18F]FCH	 solution	 proved	 high	 radiochemical	 purities	 (>99%),	 Residual	 solvents	 analyzed	 using	 Gas	
Chromatography	 (GC),	 DBM	 &	 DMAE	 is	 not	 identified.	 Conclusion:	 Choice	 of	 Tetrabutylammonium	
Bicarbonate	 (TBAHCO3)	 as	 eluent	 solution	 shown	 very	 consistent	 and	 improved	 radiochemical	 yields	
decay	corrected	20-25%	over	Kryptand	2.2.2	as	eluent	solution.	
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[68Ga]Radiolabeling	of	short	peptide	that	has	a	PET	imaging	potentials	
Al-Qahtani,	Mohammed*,	Al-Malki,	Yousif	
Cyclotron	 and	Radiopharmaceuticals	Department,	 King	 Faisal	 Specialist	Hospital	 and	Research	Center,	
Riyadh,	Saudi	Arabia.	
	
Introduction:		Targeting	short	peptides	are	gaining	interests	in	the	molecular	imaging	field.	Choosing	the	
radioisotope	to	label	those	peptides	is	a	challenging	stage	in	the	process	of	identifying	the	right	imaging	
modality.	Method:		All	needed	reagents	and	solvents	were	used	with	no	further	purifications	unless	it’s	
necessary.	Peptide	used	was	purchased	from	GenScript	and	used	without	further	purifications.	Reaction	
progress	 was	 monitored	 using	 both	 radio-analytical	 thin-layer	 chromatography	 (Radio-TLC)	 and	 high	
pressure	liquid	chromatographic	(Radio-HPLC).	Radio-HPLC	analyses	were	carried	out	on	semi-preparative	
Phenomenex	C-18	(250	mm	x	10	mm).	Radiolabeled	peptide	was	detected	with	the	eluting	of	0.065%	TFA	
in	water	and	0.05%	TFA	in	MeCN	at	2	ml/min	applying	gradient	elution	mode.	Radiochemical	yields	were	
calculated	based	on	the	Radio-HPLC	collections.	Sodium	Citrate	Buffer	(PH=7.5)	wa	the	Radio-TLC	mobile	
phase.	Synthesis	of	DOTA-	Peptide	Conjugate:	9.97	E-7	mol	of	the	intended	peptide	dissolved	in	DMSO	
reacts	with	1.18	E-6	mol	of	(DOTA-NHS-ester)	that	was	prepared	in	MeCN.	The	reaction	was	done	in	a	
phosphate	buffer	with	PH=8	and	heating	at	90ºC	for	30min.	68G	-labeling	of	DOTA-Peptide:	68G	solution	
was	added	to	60	μg	of	conjugated	DOTA-Peptide	in	100	μl	of	HEPES	buffer	(PH=4)	and	the	mixture	allowed	
to	react	for	30	min	at	80°C.	Result:	[68G-DOTA-Peptide]	was	analyzed	on	Radio-HPLC;	the	ration	time	of	
the	product	was	8.4	min	and	Radio-TLC	checks	for	the	collected	product	confirm	the	high	radiochemical	
purity.		
	
	
	
	
	
	
	
	
	
	
	
Discussions:	The	labeled	peptide	is	produce	in	good	radiochemical	yields	and	high	radiochemical	purity.	
Initial	biological	works	are	ongoing	to	evaluate	its	imaging	potential	mainly	on	a	melanoma	cell	line.	The	
findings	will	be	presented.	
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Is	validation	of	radiochemical	purity	analysis	in	a	public	hospital	in	a	developing	country	possible?		
N	Mambilima,	 SM	Rubow,	University	 Teaching	Hospital,	 Lusaka,	 Zambia,	 and	 Stellenbosch	University,	
South	Africa	
	
Introduction:	Pharmacopoeial	 or	manufacturer’s	 radiochemical	 purity	 (RCP)	 analysis	methods	 are	 not	
always	practical	in	a	hospital	setting,	leading	to	modifications	or	substitution	with	quicker,	simplified,	or	
cost	 effective	 analytical	 procedures.	 This	 study	 aimed	 to	 determine	 whether	 appropriate	 validation	
procedures	based	on	ICH	Q2A	and	Q2B	guidelines	are	feasible	in	a	resource	limited	environment,	such	as	
most	hospital	radiopharmacy	settings	in	Southern	Africa.	Materials	and	Methods:	Alternative	RCP	test	
methods	for	Tc-99m	sestamibi	involving	the	use	of	Whatman	31	ET	(Wh)	and	Schleicher	and	Schuell	(SS)	
chromatography	paper	were	used.	Locally	procured	Macherey-Nagel	 (MN)	aluminium	oxide	TLC	strips	
were	intended	as	control	method,	as	strips	described	in	the	manufacturer’s	instructions	were	unavailable.	
All	analyses	were	performed	on	the	3	different	strips	in	parallel,	and	in	triplicate.	In-house	prepared	Tc-
99m	sestamibi,	colloid	and	pertechnetate	were	assumed	to	be	100%	pure.	Samples	containing	mixtures	
of	varying	concentrations	of	the	radiochemical	components	were	analysed.	Results	from	tests	performed	
by	different	operators	were	used	to	judge	intermediate	precision,	and	time	delay	between	spotting	and	
developing	was	used	 to	evaluate	 robustness.	Results:	RCP	of	 sestamibi	without	added	 impurities	was	
99.8%±0.0%	MN,	99.5%±0.1%	for	Wh	and	99.3%±0.2%	for	SS	strips.	Addition	of	pertechnetate	and	colloid	
to	Tc-99m	Sestamibi	after	completion	of	kit	reconstitution,	resulted	in	values	for	sestamibi	higher	than	
the	calculated	RCP	for	all	3	methods.	The	radiochromatogram	scanner’s	 limit	of	detection	and	 limit	of	
quantitation	were	determined.	Discussion	and	Conclusion:	Due	to	the	unexpected	high	RCP	values	after	
addition	of	impurities	to	sestamibi,	all	the	analytical	methods	lacked	specificity	and	accuracy.	The	MN	test	
method	showed	exceptionally	high	values	for	sestamibi	due	to	co-elution	of	the	free	pertechnetate	with	
sestamibi.	 The	MN	 RCP	 test	method	 could	 therefore	 not	 be	 used	 as	 a	 reference	 standard.	 All	 three	
methods	met	the	acceptance	criteria	for	repeatability,	intermediate	precision,	and	robustness.	Validating	
an	analytical	procedure	in	a	hospital	setting	is	only	possible	once	some	important	prerequisites	are	met,	
such	as	availability	of	specified	materials	for	the	reference	procedure,	reliable	reference	standards,	and	
availability	of	HPLC	for	radiopharmaceuticals	that	have	impurities	other	than	pertechnetate	and	colloid.	
A	template	validation	protocol	for	TLC	and	paper	chromatography	was	developed.	
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Improved	automated	radiosynthesis	of	[18F]FEPPA	
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1Division	of	Nuclear	Medicine,	Department	of	Biomedical	Imaging	and	Image-Guided	Therapy,	Medical	
University	of	Vienna	
2Department	of	Inorganic	Chemistry,	University	of	Vienna	
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Introduction:	The	translocator	protein	(TSPO)	has	been	proposed	as	a	biomarker	for	several	conditions,	
including	neurodegenerative	disorders,	cancer	and	non-alcoholic	fatty	liver	disease.	Hence,	a	number	of	
PET	 ligands	 have	 been	 developed	 to	 image	 the	 TSPO,	 including	 the	 aryloxyacetanilide	 derivative	
[18F]FEPPA,	which	is	currently	in	clinical	use	[1].	The	synthesis	of	[18F]FEPPA	was	first	reported	by	Wilson	
et	al.	[2]	and	successively	fully	automated	[3].	Nevertheless	the	purification	of	the	crude	product	by	means	
of	semipreparative	HPLC	is	unsatisfactorily	time	consuming	(retention	time	tR	≈	23	min).	Therefore,	the	
aim	of	this	study	was	to	establish	a	new	set	of	conditions,	which	can	reduce	the	retention	time	of	the	
product	and	consequently	reduce	the	total	time	of	the	synthesis.	Methods:	[18F]FEPPA	was	synthesized	
as	described	elsewhere	[3]	with	minor	modifications	in	a	Nuclear	Interface	synthesizer	(GE	Healthcare,	
Sweden).	Briefly,	the	tosylate	precursor	dissolved	in	acetonitrile	was	added	to	the	azeotropically	dried	
[18F]fluoride	and	the	reactor	was	heated	at	90°	C	for	10	minutes;	after	cooling,	the	reaction	was	quenched	
with	 a	 solution	 50:50	 acetate	 buffer:acetonitrile	 (pH=3,6)	 and	 automatically	 injected	 onto	 a	
semipreparative	 HPLC	 Column	 (Merck	 Chromolith®	 RP-18e,	 100×10	 mm).	 The	 product	 fraction	 was	
collected	in	water	and	the	new	aqueous	solution	was	passed	through	a	pre-conditioned	C-18	plus	SepPak	
cartridge.	Finally,	the	product	was	eluted	with	ethanol	and	formulated	with	saline	and	phosphate	buffer.	
Results:	The	new	procedure	yielded	3.2	±	0.3	GBq	of	 [18F]FEPPA	(27%	±	3%,	not	corrected	for	decay)	
within	17	min	after	the	azeotropic	drying	of	the	[18F]fluoride.	Specific	activity	ranged	from	430	to	600	
GBq/μmol.	 Radiochemical	 purity	 exceeded	 98%.	 Conclusions:	 A	 fast	 and	 reliable	 procedure	 for	 the	
production	 of	 [18F]FEPPA	 was	 successfully	 implemented,	 drastically	 reducing	 the	 total	 time	 of	 the	
radiosynthesis	compared	to	the	previous	published	method	(17	min	compared	to	36	min)	[3].	References:	
[1]Zhang	 J,	 [2015],	 J.	 Neuroinflammation	 12:108.	 [2]Wilson	 A,	 García	 A,	 Parkes	 J,	 McCormick	 P,	
Stephenson	K,	Houle	S,	Vasdev	N,	 [2008],	Nucl	Med	Biol	35:	305-314.	 [3]	Vasdev	N,	Green	D,	Vines	D,	
McLarty	K,	McCormick	P,	Moran	M,	Houle	S,	Wilson	A,	Reilly	R,	[2013],	Cancer	Biother	Radiopharm	28:	
254-259.	
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Synthesis	and	initial	evaluation	of	Al18F-RESCA1-TATE	for	somatostatin	receptor	imaging	with	PET	
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Introduction:	Indium-111	and	gallium-68	labelled	octreotide	derivatives	[1]	are	widely	used	in	SPECT	and	
PET	imaging	of	somatostatin	receptor	expressing	tumours	and	pancreatic	dysfunction.	In	perspective	of	
advantages	of	fluorine-18	(favourable	half-life,	high	production	capacity,	 low	b-energy),	more	recently,	
derivatives	 based	 on	 [18F]aluminium	 fluoride	 complexation	 have	 been	 developed.[2]	 To	 achieve	 high	
labelling	efficiency	at	biomolecule	compatible	conditions	and	improve	radiotracer	properties	in	vivo,	we	
synthesized	an	octreotate	conjugate	with	an	acyclic	trans-cyclohexane	spanned	pentadentate	chelator:	
Restrained	complexing	agent	1,	RESCA1	(Fig.1,	1).	After	low-temperature	Al18F-complexation,	in	vitro	and	
in	 vivo	 characteristics	of	 the	new	 radiotracer	were	 studied.	Materials	&	Methods:	Radiolabelling	was	
achieved	manually	starting	from	50-860	MBq	of	[18F]sodium	fluoride	(Fig.	1).	[Al18F]2	was	purified	by	
SPE	and	analysed	with	iTLC,	LC-MS	and	RP-HPLC.	Stability	of	the	radiotracer	was	investigated	in	vitro	over	
a	period	of	3	h	in	EtOH/Saline	1:9	(RT),	PBS	(37	oC)	and	rat	plasma	(37	oC).	Ex	vivo	biodistribution	data	
were	acquired	at	10	and	60	min	p.i.	of	1.8	MBq	[Al18F]2	in	healthy	male	mice	(Fig.	2,	n=4	per	time	point),	
and	compared	with	those	of	68Ga-DOTA-TATE.	
	
	 	
	
Results:	Complexation	of	{Al18F}2+	with	1	succeeded	with	54-77%	of	product	formation	within	15	min	at	
room	temperature	and	with	85-96	%	after	12	min	at	40	oC.	28-298	MBq	of	[Al18F]2	were	obtained	with	
94-98%	RCP	after	SPE.	After	3	h	of	incubation,	the	content	of	parent	compound	was	99%	in	formulation,	
95%	in	PBS	and	91%	in	plasma.	Distribution	of	[Al18F]2	 in	mice	showed	negligible	bone	uptake,	but	 in	
comparison	with	68Ga-DOTA-TATE	less	binding	in	endocrine	tissues,	4	times	higher	uptake	in	kidneys,	and	
lower	excretion	via	 the	urinary	pathway:	33.2%ID	at	10	min	and	62.2%ID	at	60	min	p.i,,	 compared	 to	
44.1%ID	at	10	min	and	77.9%ID	at	60	min.	p.i.,	respectively.	
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Discussion/Conclusion:	 RESCA1-TATE	 easily	 forms	 a	 chemically	 and	 biologically	 stable	 complex	 with	
{Al18F}2+.	 The	 radiotracer,	 however,	 showed	 lower	 uptake	 in	 organs	 known	 for	 high	 somatostatine	
expression	 in	 comparison	 with	 the	 clinical	 standard.	 This	 could	 be	 caused	 either	 by	 in	 vivo	 binding	
competition	 with	 non-labelled	 RESCA1	 conjugate,	 accelerated	 clearance	 or	 lower	 binding	 affinity	 of	
[Al18F]2.	Future	experiments	with	HPLC	purified	radiotracer	in	competition	binding	studies	in	vitro	and	in	
vivo,	 and	 investigation	 in	 a	 high	 somatostatin	 receptor	 expressing	 tumour	mouse	model	will	 have	 to	
clarify,	whether	 specific	activity,	 receptor	affinity	and/or	 in	vivo	kinetics	of	 [Al18F]2	can	explain	 these	
results.	Research	support:	This	 research	has	 received	support	within	 the	SBO	project	MIRIAD,	 funded	
from	the	IWT	Flanders.	References:	[1]	Breemann	WAP,	de	Blois	E,	Chan	HS	et	al.	[2011],	SNM	41:	314-
321.	[2]	Laverman	P,	McBride	WJ,	Sharkey	RM	et	al.	[2014],	JLCR	57:	219–223	
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Radiolabeling	 and	 SPECT/CT	 imaging	 of	 different	 polymer-decorated	 zein	 nanoparticles	 for	 oral	
administration	
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Verónica	Morán3,	Berta	García-García3,	Juan	Manuel	Irache2,	Iván	Peñuelas1.	
1Radiopharmacy	Unit,	Department	of	Nuclear	Medicine,	University	Clinic	of	Navarra,	Pamplona,	SPAIN,	
2Department	of	Pharmaceutics	and	Pharmaceutical	Technology,	University	of	Navarra,	Pamplona,	SPAIN,	
3Department	of	Nuclear	Medicine,	University	Clinic	of	Navarra,	Pamplona,	SPAIN.	
	
Introduction	&	Aims:	Zein	is	the	major	storage	protein	of	maize,	with	a	“GRAS”	status,	that	can	be	easily	
processed	 to	 form	 nanoparticles.	 Due	 to	 its	 amphiphilic	 character,	 mucoadhesive	 properties	 and	 a	
relatively	 high	 resistance	 to	 the	 effect	 of	 digestive	 enzymes,	 the	 resulting	 nanocarriers	 offer	 great	
potential	for	oral	drug	delivery	purposes	.The	aim	is	optimization	of	99mTc	radiolabelling	of	different	kind	
of	zein	nanoparticles	(ZNP)	and	the	study	by	molecular	imaging	of	their	biodistribution	in	Wistar	rats	after	
oral	 gavage.	 The	 evaluated	 nanoparticles	 were	 bare	 zein	 nanoparticles	 (ZPN)	 and	 decorated	 with	 3	
different	 slippery	 polymers	 (ZNP-A,	 ZNP-B	 and	 ZNP-C).	Materials	 &	Methods:	All	 nanoparticles	 were	
prepared	 by	 a	 desolvation	 technique.	 For	 this	 purpose,	 zein	were	 first	 dissolved	 in	 an	 ethanol:water	
solution,	obtained	by	the	addition	of	an	aqueous	solution	and	spray-dried.		NP	were	pre-tinned	with	SnCl2	
and	labelled	with	99mTcO4-.	Different	SnCl2	concentrations	ranging	from	0.005	to	1.0	mg/mL	were	used	
for	radiolabelling	optimization.	RCP	was	analysed	by	radio-TLC.	For	biodistribution	studies	4	MBq	(0.33mg	
NP)	of	99mTc-nanoparticles	were	used	per	animal	(n=12).	SPECT/CT	studies	were	performed	1,2,4,6	and	
8h	 post-administration.	 SPECT	 acquisition	 protocol	 was	 set	 to	 account	 for	 radionuclide	 decay.	 For	
quantitative	 analysis	 data	 sets	were	 exported	 to	 PMOD	 software	 and	VOIs	 drawn	over	 CT	 images	 on	
stomach	and	 intestine,	count	 ratios	calculated	 in	 respect	 to	 total	animal	counts	and	maximum	counts	
normalized	to	the	last	image	(8h)	for	each	nanoparticle	type.	Results:	Radiochemical	purity	was	>95%	for	
ZNP-A	and	NPZ	using	[SnCl2]=0.5	mg/mL,	while	1.0	mg/mL	was	needed	for	ZNP-B	and	ZNP-C	to	get	similar	
results.	SPECT/CT	 images	showed	that	unmodified	NPZ	had	a	biodistribution	 in	stomach	and	 intestine	
almost	constant	during	the	first	4	hours.	99mTc-NPZ-B	had	a	higher	stomach	mucoadhesion	while	99mTc-
NPZ-A	showed	a	similar	behaviour	but	with	faster	gastric	drainage	and	99mTc-NPZ-C	quickly	moved	to	
intestine.	All	these	results	were	confirmed	by	the	ratios	obtained	from	PMOD	processed	images,	as	shown	
in	Figure	1.	Conclusions:	All	Zein	nanoparticles	could	be	easily	radiolabelled	with	99mTc	with	>95%	RCP.	
The	results	show	a	clear	relationship	between	the	biodistribution	and	the	superficial	properties	which	the	
coating	material	gives	to	the	nanoparticle.	
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Figure	1.	Percentage	activity	(mean+SEM)	for	both	stomach	(black	bars)	and	intestine	(grey	bars)	VOIs	as	
compared	with	the	activity	present	in	the	whole	animal	at	different	times.	
References:	Peñalva	R,	Esparza	I,	Larrañeta	E,	González-Navarro	CJ,	Gamazo	C,	Irache	JM.[2015],	J	Agric	
Food	Chem.;63(23):5603-11	
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An	analysis	of	the	quality	of	68Ga-DOTANOC	radiolabelling	over	a	3	year	period	
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Introduction:	68Ga-DOTANOC	is	an	excellent	radiopharmaceutical	for	imaging	neuroendocrine	tumours	
and	gives	superior	quality	images	to	equivalent	peptides	labelled	with	111In.	For	that	reason,	we	have	
been	developing	our	68Ga-DOTANOC	radiolabelling	service	over	the	past	3	years.	It	is	essential	that	we	
provide	 a	 high	quality	 product	 and	 that	 the	production	 is	 robust,	 reproducible	 and	 in	 line	with	GMP.	
Therefore,	we	have	reviewed	our	quality	data	from	the	production	of	68Ga-DOTANOC			
Materials	and	Methods:	68Ga-DOTANOC	has	been	prepared	using	an	iTG	68Ge/68Ga	generator	and	iQS	
fluidic	labelling	module.	DOTANOC	(ABX)	50-100	mg	was	dissolved	in	0.25M	sodium	acetate	and	heated	
for	5	min	at	110°C	before	elution	of	the	generator	in	4mL	0.05M	HCl.	The	reaction	was	allowed	to	proceed	
for	10	min	before	purification	over	a	Sep-Pak	C8	Plus	cartridge	eluted	with	50%	ethanol	and	washed	with	
0.9%	NaCl.	The	generator	was	flushed	each	day	with	5ml	0.05M	HCl	when	not	used	for	radiolabelling	and	
with	20ml	0.05M	HCl	on	Monday	mornings.	The	68Ga-DOTANOC	product	was	tested	for	free	68Ga	and	
colloids	by	TLC	and	analysed	by	HPLC,	pH	was	measured,	endotoxin	content	assessed	and	radioactivity,	
volume	and	the	presence	of	particles	were	checked	prior	to	release	of	the	product.	68Ge	content	and	
sterility	were	assessed	retrospectively.	Results:	A	total	of	746	elutions	were	carried	out	between	May	
2013	and	December	2015,	the	average	elution	yield	was	85.5%.	The	average	production	yield	(decay	and	
generator	yield	corrected)	was	66.5%.	The	average	68Ge	breakthrough	was	0.0028%	for	the	68Ga	elution	
but	68Ge	was	not	seen	in	the	68Ga-DOTANOC	product.	296	production	batches	were	made	with	7	failures	
(2.4%)	and	these	could	all	be	put	down	to	human	error	(leaks	in	the	fluidic	path,	 incorrect	purification	
method	etc.)	and	so	have	been	minimised	with	training.	No	product	has	failed	quality	control	tests	for	any	
reason.	499	patients	have	been	imaged	with	the	average	number	of	patient’s	per	production	run	being	
1.7.	Discussion/Conclusion:	The	preparation	of	68Ga-DOTANOC	 is	 a	 very	 robust	process	 giving	a	high	
quality	product	in	a	very	reliable	manner.	In	spite	of	high	68Ge	content	in	the	68Ga	elution	with	the	iTG	
generator,	the	product	has	negligible	68Ge	content.	The	product	has	very	low	levels	of	68Ga	colloids	and	
negligible	amounts	of	 free	68Ga	and	gives	a	 very	 clean	HPLC	 trace.	We	conclude	 that	 this	method	of	
production	gives	a	safe,	high	quality	product.	
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In	 vivo	 biodistribution	 of	 adult	 human	 mesenchymal	 stem	 cells	 I	 (MSCS-ah)	 labeled	 with	 99MTC-
HMPAO	administered	via	intravenous	and	intra-articular	in	animal	model.	Preliminary	results.		
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Introduction:	The	application	of	adult	human	mesenchymal	stem	cells	from	bone	marrow	(MSCs-ah)	is	
being	 considered	 a	 promising	 treatment	 of	 musculoeskeletal	 injuries,	 however,	 their	 trafficking	 and	
homing	 are	 still	 controversial	 issues	 with	 further	 studies	 needed.	 Our	 work	 is	 focused	 on	 in	 vivo	
biodistribution	of	99mTc-HMPAO	labelled	MSCs-ah	after	both	intravenous	and	intra-articular	injection	in	
an	animal	model.	Materials	&	Methods:	2	x	106	MSCs-ah	isolated	from	bone	marrow	of	healthy	subjects	
using	SEPAX	system	were	suspended	in	1	ml	of	PBS	and	labeled	with	up	to	9.3	Bq/cel	of		99mTc-HMPAO.	
Radiolabeled	 cell	 suspensions	 were	 administered	 to	 8	 adult	 male	 New	 Zealand	 rabbits	 (3.5-4	 k)	
randomized	in	two	groups.	In	group	A	(n=4),	cell	suspensions	were	administered	via	intravenous	(marginal	
ear	vein)	and	in	group	B	(n=4)	by	intra-articular	injection.	After	dynamic	acquisition	of	images	every	30	s	
for	25	min,	whole	body	static	images	in	anterior	projection	at	1,6	and	24	hours	were	acquired,	previous	
sedation.	 No	 immunosuppressive	 agents	 were	 administered.	 Results:	 Early	 immune	 response	 to	
xenogenic	 MSCs-ah	 was	 not	 detected	 during	 the	 study.	 Neither	 adverse	 reaction	 nor	 technical	
complications	were	 registered,	 so	any	and	every	animal	was	 recruited	 for	 the	 study.	 In	 group	A,	high	
retention	of	the	activity	was	observed	in	lung	parenchyma,	with	kidney	and	bladder	visualization	from	the	
start,	and	biliary	and	abdominal	uptake	from	1h,	maintaining	the	pattern	of	distribution	at	24h,	with	no	
significant	activity	in	liver	and	spleen.	Group	B	show	activity	in	heart,	spleen,	liver,	kidneys	and	bladder	
from	the	start	to	the	late	acquisition	of	24h,	with	biliary	and	intestinal	uptake	from	6	h.	No	activity	was	
observed	in	the	lung	parenchyma	in	this	group.	Discussion/conclusion:	Exogenous	MSCs-ah	administered	
via	 intravenous	are	trapped	mainly	 in	 lungs,	with	slight	posterior	retrafficking	to	other	organs.	On	the	
other	hand,	no	lung	trapping	is	observed	after	intra-articular	injection,	pointing	out	the	suitability	of	this	
route	of	administration	for	the	therapeutic	potencial	of	MSCs-ah	in	musculoskeletal	pathology.	
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Lehtiniemi	P1,	Yim	C2,	Mikkola	K1,	Nuutila	P1,	Solin	O1,2	
1	Turku	PET	Centre,	University	of	Turku,	Kiinamyllynkatu	4-8,	FI-20500	Turku,	Finland	
2	Turku	PET	Centre,	Åbo	Akademi	University,	Porthansgatan	3,	FI-20500	Turku,	Finland	
	
Introduction:	 A	 reliable	 method	 for	 non-invasive	 in	 vivo	 quantification	 of	 beta-cell	 mass	 in	 human	
pancreas	is	needed	to	understand	the	pathophysiology	of	type	1	and	2	diabetes.	Based	on	animal	studies,	
the	[18F]F-exendin-4-peptide	looks	promising	for	imaging	pancreatic	beta	cells	but	further	development	
of	the	tracer	synthesis	is	needed	to	obtain	high	specific	activity	(SA)	and	synthesis	procedures	amendable	
for	GMP	production	[1].	A	proof-of-concept	study	in	type	1	diabetic	patients	and	healthy	subjects	showed	
a	correlation	between	beta	cell	mass	and	uptake	of	111In-exendin-4,	which	could	lead	to	further	insight	
into	the	pathophysiology	of	diabetes	 [2].	Recent	results	with	[18F]F-exendin-4	analogues	demonstrate	
enhanced	 pharmacokinetic	 properties,	 as	 compared	 to	 radiometal-labelled	 counterparts	 [1].	 Here	we	
describe	a	synthesis	of	[18F]F-exendin-4	(Fig.	1)	aiming	at	high	SA	for	the	product.	
	 	
Figure	1.	Synthesis	scheme	of	[18F]F-exendin-4.	
	
Materials	 &	methods:	We	 have	 investigated	 several	 conditions	 and	 solvents	 for	 synthesizing	 [18F]F-
exendin-4.	Alkyne	tosylate	and	a	[18F]fluoride-Kryptofix	complex	were	allowed	to	react	 in	DMSO	for	5	
min	 at	 80	 °C.	 18F-labelled	 tosylate	 precursor	 ([18F]FP)	 was	 isolated	 by	 semi-preparative	 HPLC	 and	
concentrated	with	a	HLB	cartridge,	followed	by	elution	with	THF	from	the	cartridge.	Exendin-4-azide	was	
allowed	to	react	with	[18F]FP	in	presence	of	CuSO4/Na-ascorbate	for	5	min	at	room	temperature	using	
vigorous	mixing.	[18F]F-exendin-4	was	isolated	by	semi-preparative	HPLC	and	concentrated	with	a	Sep-
Pak	C8	cartridge.	[18F]F-exendin-4	was	eluted	with	ethanol	and	PBS.	Radio-TLC	and	radio-HPLC	was	used	
for	 radiochemical	 analysis	 and	 SA	 determination	 of	 the	 [18F]FP	 and	 [18F]F-exendin-4.	 Results:	 18F-
labelling	of	 [18F]FP	proceeded	 in	 an	 50%	 radiochemical	 yield	 (RCY).	 Isolation	of	 [18F]FP	by	HPLC	was	
efficient	and	the	radiochemical	purity	was	>	99%.	The	RCY	of	[18F]F-exendin-4	ranged	between	25-60%	
(calculated	from	[18F]FP,	uncorrected)	and	the	radiochemical	purity	was	>	96%.	The	SA	was	up	to	350	
GBq/µmol	 at	 EOS.	 Discussion/conclusion:	We	 now	 can	 produce	 [18F]F-exendin-4	 with	 a	 SA	 of	 350	
GBq/µmol	for	synthesis	batches	of	>500	MBq.	Our	further	aim	is	to	automate	all	synthesis	procedures	in	
order	to	have	a	GMP-level	production	of	the	tracer,	suitable	for	clinical	evaluation	of	[18F]F-exendin-4.	
References:	[1]	Mikkola	K,	et	al.,	[2013],	Diabetologia	56:211-212	[2]	Brom	M,	et	al.,	[2014],	Diabetologia	
57:	950-959	
18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
 
 
Page 110	
	
PP49	
Experimental	radionuclide	therapy	with	177Lu-labelled	cyclic	minigastrin	and	human	dosimetry	
estimations		
von	Guggenberg	E1,	Rangger	C1,	Mair	C1,	Balogh	L3,	Pöstényi	Z3,	Pawlak	D2,		
Mikołajczak	R2	
1	Department	of	Nuclear	Medicine,	Innsbruck	Medical	University,	Austria	
2	Radioisotope	Centre	POLATOM,	National	Centre	for	Nuclear	Research,	Otwock,	Poland	
3	"Frédéric	Joliot-Curie"	National	Research	Institute	for	Radiobiology	and	Radiohygiene	(NRIRR),	
Budapest,	Hungary	
	
Introduction:	 	Radiolabelled	cyclic	minigastrin-analogues	are	promising	candidates	 for	possible	clinical	
application	in	diagnosis	and	therapy	of	cholecystokinin-2	receptor	(CCK2R)	expressing	tumours,	such	as	
medullary	thyroid	cancer	(MTC)	and	SCLC.	Within	an	international	collaboration	of	the	IAEA	we	performed	
biodistribution	 studies	 and	 an	 experimental	 radionuclide	 therapy	 in	 a	 CCK2R-specific	 mouse	 tumour	
model	 using	 two	 177Lu-labelled	 cyclic	 minigastrin-analogues:	 DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-
Met-Asp-Phe-NH2	 (DOTA-cyclo-MG1)	 and	 DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-NH2	
(DOTA-cyclo-MG2).	Based	on	results	of	biodistribution	studies	dosimetric	considerations	for	humans	were	
extrapolated	 to	 evaluate	 the	 possible	 injected	 activity	 in	 first	 applications	 in	 patients.	 Materials	 &	
Methods:		For	biodistribution	studies	BALB/c	nude	mice	were	xenografted	with	A431	human	epidermoid	
carcinoma	cells	transfected	with	the	human	CCK2R	(A431-CCK2R)	and	transfected	with	the	empty	vector	
alone	(A431-mock)	in	both	flanks.	Tumours	were	allowed	to	grow	for	2	weeks.	Biodistribution	studies	with	
177Lu-DOTA-cyclo-MG1	and	177Lu-DOTA-cyclo-MG2	were	performed	at	an	injected	dose	of	1	MBq	(0.02	
nmol	DOTA-peptide)	at	30min,	4h,	24h,	48h,	72h	and	168h	p.i.	(5	animals/group).	Dose	extrapolation	to	
humans	was	based	on	linear	scaling	of	injected	activity	per	gram	tissue	between	animals	and	humans	and	
computed	using	OLINDA	software.	For	experimental	radionuclide	therapy	the	animals	were	injected	with	
both	177Lu-labelled	DOTA-peptides	at	two	different	dose	levels	of	15	and	30	MBq	corresponding	to	0.6	
and	1.2	nmol	peptide	(6	animals/group).	For	up	to	five	weeks	after	treatment	tumour	volume	and	body	
weight	was	evaluated	 in	comparison	with	a	control	group	 injected	with	physiological	saline.	Results	&	
Conclusion:		Biodistribution	studies	in	tumour-bearing	mice	revealed	an	uptake	of	>3.5%	ID/g	for	both	
177Lu-labelled	DOTA-peptides	in	the	A431-CCK2R-tumour	30min	p.i..	This	uptake	remained	stable	for	4h	
p.i.	and	declined	to	>2%	ID/g	at	24h	p.i..	A	much	lower	uptake	was	observed	in	the	A431-mock	tumour.	
The	tumour-to-kidney	ratio	resulted	to	be	in	the	order	of	3.	In	the	experimental	radionuclide	therapy	a	
clear	therapeutic	effect	could	be	observed.	In	comparison	to	the	control	group	the	mean	tumour	volume	
doubling	time	of	A431-CCK2R-tumours	was	 increased	by	a	factor	of	1.8	and	2.6	 in	the	15	and	30	MBq	
group,	 respectively.	 For	 the	 A431-mock-tumours	 lower	 factors	 of	 1.2	 and	 1.7	were	 observed	 in	 both	
treatment	groups	proving	a	receptor-specific	effect.	On	the	basis	of	dosimetric	extrapolation	to	humans	
first	therapeutic	applications	in	patients	should	start	with	4	repeated	administrations	of	3-5	GBq	to	limit	
the	 cumulative	 kidney	 dose	 to	 <27Gy.	 Based	 on	 patient	 individual	 dosimetry	 accompanying	 the	 first	
therapy	the	injected	activity	may	be	adapted	accordingly.	
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SYNTHESIS	 OF	 RADIOPHARMACEUTICALS	 	 FOR	 CELL	 RADIOLABELLING	 USING	 ANION	 EXCHANGE	
COLUMN	
Socan	A1,	Kolenc	Peitl	P1,	Krošelj	M1,	Rangger	C2,	Decristoforo	C2	
1	Department	of	Nuclear	Medicine,	University	Medical	Centre	Ljubljana	
2	University	Clinic	for	Nuclear	Medicine,	University	for	Medicine,	Innsbruck	
	
Introduction:	111In	labelled	radiopharmaceuticals	are	extensively	used	for	cell	labelling	in	routine	clinical	
practice.	Being	members	of	coordinating	radiometals	group	68Ga	and	89Zr	are	suitable	candidates	for	
synthesis	 of	 radiopharmaceuticals	 used	 for	 cell	 labelling.	 Due	 to	 its	 half	 life	 (78,4h)	 89Zr	 labelled	
radiopharmaceuticals,	 could	 possibly	 enable	 long-term	 “in	 vivo”	 cell	 tracking	 with	 several	 attractive	
clinical	 applications	 (imaging	 of	 infection	 and	 inflammation,	 stem	 cell	 therapy).	 Aim	 of	 study	 was	 to	
develop	a	novel,	versatile	approach	to	prepare	tracers	(oxine,	tropolone)	using	concentration	on	an	anion	
exchange	column.	Materials	&	Methods:	 The	column	 (SepPAK	QME)	was	washed	with	2	ml	of	water.	
Samples	of	68Ga,	111In,	89Zr-HEPES	(0,5M,	1M)	solutions,	samples	varying	in	pH	(3-9)	and	volume	were	
prepared	and	applied	on	column.	Activity	retained	on,	activity	washed	from	column	and	pH	of	the	solution	
were	measured.	Samples	of	0.3	ml	ligand	solution	(tropolone:1mg/ml,	water;	oxine:1mg/ml,	20%,	50%	
EtOH)	were	applied	on	the	column	and	 incubated.	The	column	content	was	washed	with	2	ml	of	PBS.	
Activity	and	pH	measurements	were	performed	as	described	above.	Complex	formations	were	analyzed	
using	extraction	method	into	octanol.	Results:	With	68Ga-HEPES	(1M)	yield	of	activity	retained	on	the	
column	was	above	89%	and	was	not	pH	(3.7-7.3)	and	volume	dependent	(0.5-2.5ml).	Yield	of	68Ga-oxine	
solution	 (20%EtOH)	was	between	43-77%	with	pH	between	6.1-7.4	and	extraction	 into	octanol	above	
96%.	Yield	of	activity	retained	on	column	with	111In-HEPES	(1M)	varied	31–98%	and	was	pH	and	volume	
dependent.	Yield	decreased	with	volumes	applied	greater	than	0.5	ml	and	pH	bellow	4.	Yield	of	111In-
tropolone	solution	was	between	41	-	61%	with	pH	between	6-6.7	and	extraction	into	octanol	above	82%.	
Yield	of	111In-oxine	solution	(20%EtOH)	was	between	41-96%	and	extraction	 into	octanol	above	92%.	
89Zr-HEPES	(0.5M)	yield	of	activity	retained	on	column	was	above	96%	and	was	not	pH	(5.5-9)	and	volume	
dependent	 (0.3-1.5ml).	 	 Yield	 of	 89Zr-tropolone	 solution	was	 above	 85%	with	 pH	 between	 7-7.5	 and	
extraction	into	octanol	above	94%.	Yield	of	89Zr-oxine	solution	(50%EtOH)	was	between	25-71%	with	pH	
between	 7-9	 and	 extraction	 into	 octanol	 above	 86%.	 Conclusion:	 Concentration	 of	 coordinating	
radiometals	111In,	68Ga	and	89Zr	on	an	anion	exchange	column	in	HEPES	allows	on-column	formation	of	
tracers	(oxine,	tropolone)	 in	very	small	volumes	suitable	for	cell	 labelling	with	good	yields	and	quality.	
This	 is	 a	 versatile	 and	 promising	 tool	 to	 prepare	 tracers	 on	 automated	 systems	 further	 used	 for	 cell	
labelling	and	potentially	suitable	for	clinical	practice.	
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[68Ga]peptide	production	on	commercial	synthesiser	mAIO	
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1	Nancyclotep,	Plateforme	d’imagerie	moléculaire	54500	Vandoeuvre	les	Nancy	-	France	
2	Université	de	Lorraine,	F-54500	Vandoeuvre	les	Nancy	-	France	
3	CHRU	de	Nancy-Brabois,	F-54511	Vandoeuvre	les	Nancy	-	France	
4	Trasis	SA,	B-4430	Ans	-	Belgium	
	
Introduction:	Gallium-68	is	a	metallic	positron	emitter	with	a	half-life	of	68	min	that	is	ideal	for	labelling	
small	 peptides	 as	 radiopharmaceuticals	 thanks	 to	 the	 use	 of	 a	 chelating	 agent	 with	 several	 clinical	
applications.	Numerous	gallium-68	labelled	peptides	(eg.	[68Ga]DOTA-TOC/-NOC,	[68Ga]HBED-PSMA-11,	
[68Ga]NODAGA-RGD)	have	shown	their	interest	[1,2].	Developing	an	easy,	rapid	and	performant	labelling	
method	 is	 important.	 Different	 methods	 for	 the	 pre-purification	 of	 the	 generator	 eluate	 have	 been	
explored	 in	 the	 literature,	 although	 recent	 improvement	 on	 some	 generator	 brands	 (i.e.	 low	 68Ge	
breakthrough	 and	 low	 metallic	 impurities	 content),	 makes	 this	 pre-purification	 unnecessary.		
Development	 of	 a	 labelling	 process,	 GMP-compatible	 and	 reproducible,	 using	 a	 commercial	 synthesis	
module	for	every	peptide	labelling	is	a	real	challenge	for	the	nuclear	medicine.	The	method	presented	
herein	uses	a	cassette-based	approach	and	a	MiniAIO	(mAIO,	Trasis®)	module	and	has	been	tested	with	
the	 IGG100	68Ge/68Ga	generators.	Materials	&	Methods:	Preclinical	 IGG100	was	used	as	68Ge/68Ga	
generator.	Precursors	of	radiolabelling	were	bought	from	ABX.	Automated	68Ga-labelling	was	performed	
without	 pre-purification	 in	mAIO	module.	 Optimal	 experimental	 conditions	 (concentration	 of	 sodium	
acetate,	quantity	of	precursor,	temperature	and	duration)	were	determined	for	each	peptide.	Labelling	
efficiency	was	determined	on	Waters	HPLC	system.	Results:	DOTANOC,	DOTATOC,	HBED-PSMA-11	and	
NODAGA-RGD	 were	 tested	 for	 68Ga-labelling	 without	 pre-purification.	 Optimal	 and	 reproducible	
conditions	were	found	for	each	peptide.	68Ga-peptides	were	synthesised	with	excellent	 incorporation	
yields,	 (90-99%)	 and	 good	 synthesis	 yields	 >	 60%	 in	 less	 than	 15	 min.	 Discussion/Conclusion:	 We	
developed	 an	 efficient	 automated	 strategy	 for	 peptide	 labelling	 with	 gallium-68.	 [68Ga]DOTANOC,	
DOTATOC,	[68Ga]HBED-PSMA-11,	[68Ga]NODAGA-RGD	were	obtained	in	good	radiochemical	yield.	Their	
preparation	could	be	performed	with	this	automation	and	their	use	in	human	could	be	done	under	clinical	
trial.	References:	[1]	Breeman	W,	de	Blois	E,	Chan	HS,	et	al.	 [2011],	Semin	Nucl	Med,	41:	314-321.	[2]	
Velikyan	[2014],	Theranostic,	4(1):	47-80	
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Dry	kit	formulation	for	efficient	radiolabeling	of	68Ga-PSMA	
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National	Centre	for	Nuclear	Research	Radioisotope	Centre	POLATOM	
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Introduction:	The	development	of	dry	kits	containing	the	active	ingredient	and	suitable	excipients	permits	
more	 efficient	 use	 of	 68Ge/68Ga	 radionuclide	 generators,	 despite	 the	 limitations	 in	 the	 variety	 of	
generator	 eluent’s	 composition	 and	 pH.	 	 Our	 aim	 was	 to	 develop	 a	 dry	 kit	 formulation	 	 for	 68Ga	
radiolabeling	 of	 the	 PSMA	 inhibitor,	 PSMA-11	 (Glu-CO-Lys(Ahx)-HBED-CC).	 Methods:	 A	 series	 of	
experiments	on	“wet”	labelling	in	the	presence	of	various	amounts	of	sodium	acetate	and	ascorbic	acid	
were	performed	taking	into	consideration	the	challenge	to	find	the	composition	of	buffering	agents	ready	
to	maintain	pH	value	between		4	and	5	after	addition	of		various	volumes	of	68Ga	eluate	(volumes	of	1-
4mL	0.1M	HCl).	 For	 quality	 control	 of	 the	 68Ga–PSMA-11	 the	RP-RadioHPLC	 (Kinetex	 C18	 150mm;	A:	
0.1%TFA/H2O,	 B:	 0.1%TFA/CAN)	 was	 used	 with	 gradient	 conditions	 (according	 to	 M.	 Eder	 et	 al.	
Pharmaceuticals	2014,	7,	779-796)	as	well	as	in	isocratic	elution	(optimally	set	to	17%	B)	which	visualized	
the	 radiolabelled	 and	 non-labelled	 PSMA-11	 in	UV	 chromatogram.	 The	 radiochemical	 purity	 also	was	
tested	by	TLC		(ITLC	SG;	1:	0.9%NaCl/MeOH	80/20	v/v;	2:	0.9%NaCl/MeOH/25%NH3,	80/20/5	v/v/v;	3:	1M	
NH4OAc/MeOH	50/50	v/v).	Results	and	discussion:	Ascorbic	acid	(25mg/mL)	added	to	the	“wet”	labelling	
mixture	increased	the	radiolabeling	yield	(98.8%)	compared	to	the	labelling	performed	in	acetate	buffer	
only	(95.0%).	It	also	increased	the	buffering	capacity	of	the	formulation.	These	results	were	further	used	
to	formulate	the	dry	kit	composition	using	 	30µg	of	PSMA-11,	60mg	of	sodium	acetate	and	12,5mg	of	
ascorbic	 acid.	 The	 yield	 of	 68Ga	 labelling	 of	 PSMA-11	 from	 the	 freeze-dried	 kit	 	 was	 >	 95%.	 	 The	
biodistribution	of	 such	prepared	 	 68Ga-PSMA-11	 	was	 investigated	 in	 healthy	Balb/c	mice	 (n=5)	 after	
intravenous	injection	of	0.1mL	(38	MBq/mL)	(at	15,	30,	60	and	120min).	Comparison	of	uptake	in	main	
organs	and	urine	of	68Ga-PSMA-11,	and	the	68Ga	eluate	in	the	presence	of	acetate	buffer	and	in	presence	
of	mixture	of	sodium	acetate/ascorbic	acid	(t=1h	p.i.)	is	presented	in	the	graph	below.	
	 	
68Ga-PSMA-11	 was	 rapidly	 cleared	 from	 the	 blood	 and	 excreted	 by	 kidney	 route	 with	 >70%	 urine	
elimination	at	1h	p.i.	These	results	confirmed	high	stability	of	the	68Ga-PSMA-11	complex	in	vivo,	with	
low	contribution	of	free	gallium-68,	which	circulates	longer	in	blood	stream.		It	is	worth	noting	that	the	
addition	of	ascorbic	acid	changes	the	biodistribution	of	free	gallium	and	favors	its	blood	clearance.		This	
is	 probably	due	 to	 the	 	 formation	of	week	Ga	 complex	with	 ascorbic	 acid	which	blocks	 	Ga	access	 to		
ferritin,	hence	resulting	in	lower	liver	and	spleen	accumulation.		
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Development	of	an	experimental	method	using	Cs-131	to	evaluate	radiobiological	effects	of	
internalized	Auger-electron	emitters.	
Pil	Fredericia,	Gregory	Severin,	Torsten	Groesser,	Ulli	Köster*	and	Mikael	Jensen	
Hevesy	Laboratory,	DTU-Nutech,	Technical	University	of	Denmark,	Roskilde,	Denmark		and	*Institut	
Laue-Langevin,	Grenoble,	France			
	
Introduction:	The	low	energy	electrons	emitted	in	the	Auger	cascade	of	certain	isotopes	are	expected	to	
have	a	disproportionately	high	 radiobiological	 effect.	 This	 is	 seen	as	 the	effect	of	 the	multiplicity	 and	
predominance	of	very	 low	energy	electrons	 in	dose	delivery.	Despite	many	years	of	research	 in	Auger	
emitters,	only	few	direct	measurements	of	the	radiobiological	effect	of	such	Auger	cascades	have	been	
published.	 	One	problem	 in	making	such	 fundamental	dose-effect	experiments	 is	 the	method	to	bring	
Auger-emitting	isotopes	inside	the	cell	and	close	to	the	nucleus	in	a	predictable	and	quantifiable	manner.	
Only	when	the	location,	activity,	and	time-activity	profile	are	known	it	is	possible	to	compare	the	observed	
damage	with	damage	 induced	by	the	same	dose	and	dose	rate	given	by	external	 irradiation.	We	have	
used	the	biological	uptake	of	the	Auger-emitting	potassium	analogue	Cs-131	(9.7	d)	into	mammalian	cells	
in	culture	as	a	test	system	for	measuring	the	dose-effect	of	Auger	electrons.	Materials	and	Methods:	Cs-
131	was	repeatedly	extracted	from	Ba-131	(11.5	d)	made	by	high	flux	neutron	irradiation	at	ILL	(6	to	10	
days	at	(1.1-1.3)	1015	n.cm-2s-1)	of	either	natural	Ba	(17	mg	as	carbonate)	or	49%	enriched	Ba-130	(0.15	
mg	 as	 nitrate).	 Such	 targets	were	 dissolved	 in	 hydrochloric	 acid,	 and	 re-precipitated	with	 ammonium	
carbonate.	The	supernatant	was	spiked	with	sodium	hydroxide,	then	dried	and	fired,	leaving	cesium-131	
as	a	chloride	salt	with	NaCl	carrier.	The	re-precipitated	targets	were	stored	for	1-2	weeks	for	buildup	of	
Cs-131,	and	then	the	process	can	be	repeated.	We	have	milked	up	to	4	batches	of	useful	Cs-131	activity	
from	a	single	activated	barium	batch	from	ILL.		The	harvested,	131Cs/NaCl	salt	was	dissolved	in	water	to	
reach	isotonicity,	and	was	offered	to	V-79	and	HeLa	cells	in	normal	growth	media.	The	cells	invariantly	
up-concentrated	the	cesium	activity,	reaching	a	plateau	after	8-10	hours.	Results:		Using	enriched	Ba-130,	
higher	activity	 is	obtained,	but	even	with	natural	barium	activities	up	 to	80	MBq	have	been	available	
repeatedly	 for	 the	 uptake	 experiments.	 Under	 optimal	 conditions,	 the	 cells	 in	 culture	 can	 reach	
intracellular	activities	over	1	Bq/cell	during	4	hours	incubation.	The	alkali-metal	nature	of	cesium	gives	us	
reasons	to	assume	a	homogeneous	intracellular	distribution,	allowing	a	first-principles	calculation	of	the	
absorbed	dose.	With	this	method	and	unique	isotope,	we	can	compare	the	effect	of	equivalent	absorbed	
doses	of	external	gamma	and	internal,	predominantly	Auger	delivered	dose.	
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R.	Leonte1,2,	F.	D.	Puicea1,2,	A.	Raicu1,	E.	A.	Min1,	R.	Serban1,	G.	Manda3	and	D.	Niculae1	
1	Horia	Hulubei	National	Institute	for	Physics	and	Nuclear	Engineering,	Radiopharmaceuticals	Research	
Centre,	Magurele,	Romania,	e-mail:	dana.niculae@nipne.ro	
2	Politehnica	University,	Bucharest,	Romania	
3	National	Institute	of	Patology	Victor	Babes,	Bucharest,	Romania	
	
Introduction:	 The	αvβ3	 integrin	 receptors,	 expressed	 on	 tumor	 cell	membranes	 can	 be	 preferentially	
targeted	 by	 peptides	 containing	 the	 RGD	 sequence.	 NOTA-SCN-Bn-E-[c(RGDyK)2],	 NODAGA-RGDfK,	
DOTA-E-[c(RGDfK)2],	and	DOTA-RGDfK	were	labelled	with	Ga-68	and	tested	for	radiolabelling	yield,	purity,	
stability,	 in	 vitro	 binding,	 ex	 vivo	 biodistribution,	 and	 in	 vivo	 imaging.	Materials	 and	 Methods:	 The	
radiolabelling	was	performed	using	an	automated	system	with	inline	quality	control.	Fraction	of	68GaCl3	
eluate	 from	an	organic	matrix	 based	 68Ge/68Ga	 generator,	 400-700	MBq	 in	 2	mL,	was	 used	 to	 label	
NOTA/NODAGA/DOTA-derivatised	 cRGD	 peptides.	 Elution,	 labeling	 and	 purification	 procedures	 were	
performed	in	20-25	min.	The	biodistribution	was	tested	in	tumor	bearing	animal	models	(U87MG,	Walker	
256,	B21	and	AR42J).	The	affinity	of	cyclo-RGD	peptides	to	tumor	cell-surface	receptors	was	determined	
by	real-time	quantification	using	Ligand	Tracer.Results:	Nanomoles	of	peptides	were	labeled	with	high	
yields.	 NOTA-SCN-Bn-E-[c(RGDyK)2]	 and	 NODAGA-cRGDfK	 was	 labelled	 at	 room	 temperature,	 while	
DOTA-cRGDfK,	both	monomer	and	dimer,	were	labeled	at	95°C,	with	over	90%	yield.	The	biodistribution	
pattern	of	68Ga-NOTA/NODAGA/DOTA-cRGD	peptides	shows	high	tumor	uptake,	fast	blood	clearance,	
high	tumor	to	background	ratios	and	renal	elimination.	Up	to	5.3%	ID/g	of	68Ga-DOTA-E-[c(RGDfK)2]	was	
found	on	U87MG	tumor;	the	biological	behavior	of	the	four	tracers	will	be	discussed	in	detail.	Binding	to	
receptors	was	achieved	in	the	first	3	min	of	incubation	of	all	tracers,	however	the	retention	68Ga-DOTA-
E-[c(RGDfK)2]	 on	 both	 AR42J	 and	 U87MG	 was	 the	 highest,	 up	 to	 58%	 from	 activity	 in	 the	 cells.	
Discussion/Conclusions:	The	radiolabelling	with	Ga-68	of	very	promising	candidates	for	imaging	targets	
of	interest	in	cancer	diagnosis	and	therapy	follow-up	such	as	αvβ3	receptors,	were	successfully	adapted	
on	the	automated	module,	reducing	the	reaction	time	and	operator	exposure.	The	preclinical	biological	
evaluation	of	proposed	tracers	show	that	the	uptake	and	retention	on	different	tumor	cells	depends	on	
tumor	type,	receptors	expression	and	dimerization.	Very	good	uptake-retention	profile	of	68Ga-DOTA-E-
[c(RGDfK)2]	 makes	 it	 our	 option	 for	 further	 investigations	 as	 therapeutic	 agent.	 	 Research	 contracts	
CRP16500	IAEA	and	MEN	UEFISCDI,	PN	II	228/2014	are	acknowledged	for	financial	support.		
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Synthesizer-	and	Kit-based	preparation	of	prostate	cancer	imaging	agent	68Ga-RM2	
Marion	Zerna,	Hanno	Schieferstein,	Andre	Müller,	Mathias	Berndt	
Piramal	Imaging,	Berlin,	Germany.		
	
Introduction:	Prostate	cancer	(PCa)	is	the	most	common	cancer	in	men	and	the	second	most	common	
cause	in	cancer-related	deaths.	68Ga-RM2	is	a	nona-peptide	with	optimized	binding	sequence	for	Gastrin	
Releasing	 Peptide	 receptor	 (GRPr)	 which	 is	 overexpressed	 in	 PCa.1	 In	 clinical	 studies	 68Ga-RM2	 has	
demonstrated	its	ability	for	detection	of	primary	prostate	cancer	with	high	specificity	due	to	its	low	uptake	
in	normal	prostate	and	in	benign	hyperplasia.2	Recent	studies	showed	further	potential	of	68Ga-RM2	for	
detection	of	recurrent	PCa	and	for	imaging	of	estrogen	receptor	positive	breast	cancer.3,4.	To	provide	
68Ga-RM2	 for	 further	 clinical	 research,	 robust	 methods	 for	 preparation	 of	 this	 promising	 tracer	 are	
needed.	Herein	we	describe	the	results	of	automated	synthesizer	based	68Ga-radiolabelings	of	RM2	as	
well	as	of	simplified	“shake-and-bake”	kit-preparations.	Materials	and	Methods:	The	automated	68Ga-
radiolabeling	 was	 optimized	 on	 a	 PharmTracer	 module	 (Eckert&Ziegler).	 The	 influence	 of	 several	
scavengers	was	 investigated,	as	well	 as	a	processes	with	and	without	 subsequent	purification	via	C18	
cartridge.	 Optimized	 conditions	 were	 used	 on	 further	 synthesizers	 (Scintomics,	 ITG).	 In	 a	 second	
approach,	a	simplified	kit	preparation	was	established.	The	68Ga-generator	eluate	was	added	directly	into	
a	vial	 containing	RM2-precursor,	buffer	and	scavenger.	The	vial	was	heated	and	optionally	buffer	was	
added	 for	pH-adjustment.	Results:	Automated	procedures	on	various	synthesizers	provided	up	to	850	
MBq	 of	 68Ga-RM2	 in	 >70%	 uncorrected	 yield	 in	 20	 min	 including	 purification	 and	 formulation.	 The	
radiochemical	purity	was	>97%	(HPLC	and	TLC)	 if	ascorbic	acid	was	used	as	scavenger.	The	simple	and	
easy	to	use	kit	preparation	approach	provided	68Ga-RM2	in	90%	uncorrected	yield	and	purity	of	>95%.	
Discussion/Conclusion:	68Ga-RM2	can	be	reliably	obtained	on	automated	synthesizers	as	well	as	by	a	
simple	“shake-and-bake”	kit	preparation	strategy.	Both	methods	provided	68Ga-RM2	in	high	yields	and	
high	radiochemical	purity.References:	1)	Mansi	R,	Wang	X,	Forrer	F,	et	al.,	 [2011],	Eur	J	Nucl	Med	Mol	
Imaging	38:	97-107.	2)	Kähkönen	E,	Jambor	I,	Kemppainen	J,	et	al.,	[2013],	Clin	Cancer	Res.	19:	5434-5443.	
3)	Minamimoto	R,	Hancock	S,	Schneider	B,	et	al.,	J	Nucl	Med:	in	press.	4)	Stoykow	C,	Erbes	T,	Bulla	S,	et	
al.,	[2015],	Eur	J	Nucl	Med	Mol	Imaging	42:	S1	1-924.	
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Synthesis	 of	 pancreatic	 beta	 cell-specific	 [18F]fluoro-exendin-4	 via	 strain-promoted	 aza-
dibenzocyclooctyne/azide	cycloaddition	
Cheng-Bin	Yim,	Kirsi	Mikkola,	Pirjo	Nuutila,	Olof	Solin	
Turku	PET	Centre,	University	of	Turku	and	Åbo	Akademi	University,	Turku,	FINLAND	
	
Introduction:	Diabetes	has	dictated	many	lives,	and	its	lifetime	treatment	has	accumulated	into	one	of	
the	most	costly	medical	conditions,	and	yet,	its	pathophysicology	is	still	undisclosed.	However,	efforts	to	
develop	sensitive	noninvasive	methods	to	quantify	beta	cell	mass,	which	underlies	the	development	of	
diabetes,	have	been	challenged	by	the	 low	abundance	(1-2	%)	and	high	dispersion	of	beta	cells	 in	the	
pancreas	 [1].	 Recent	 preclinical	 studies	 using	 18F-labelled	 exendin-4	 showed	 specific	 targeting	 of	
pancreatic	islets	and	insulinomas	with	favourable	clearance	kinetics	that	would	potentiate	clinical	utility	
[2].	The	focus	of	the	present	study	is	the	radiosynthesis	of	a	novel	18F-labelled	exendin-4	analogue	with	
a	clear	clinical	prospective	for	imaging	pancreatic	beta	cell	mass.	Materials	&	Methods:	The	synthesis	of	
[18F]fluoro-exendin-4	 is	depicted	 in	Scheme	1.	The	dried	 [18F]fluoride-Kryptofix	 complex	was	 reacted	
with	tosylated	prosthetic	compound	1	in	dimethylsulfoxide	at	80	°C.	After	chromatographic	isolation,	the	
18F-labelled	azide	2	was	allowed	to	react	with	cyclooctyne-derivatised	exendin-4	in	ethanol/water	at	60	
°C	 for	30	min.	 Isolation	and	radiochemical	analysis	of	 [18F]fluoro-exendin-4	was	performed	using	high	
performance	 liquid	 chromatography	 (HPLC)	 with	 radiodetector.	 Results:	 Preliminary	 results	 showed	
efficient	reaction	between	prosthetic	reagent	[18F]2	and	exendin-4	precursor	with	a	radiochemical	yield	
of	30	%.	The	absence	of	major	radioactive	by-products	assured	neat	purification	using	HPLC.	The	average	
isolated	 yield	 of	 [18F]exendin-4	 after	 HPLC	 purification	was	 180	MBq	 starting	 from	 3.5	GBq	 aqueous	
[18F]fluoride.	 Discussion:	 Currently,	 the	 scope	 of	 this	 reaction	 is	 being	 explored	 and	 its	 labelling	
conditions	optimized.	Preclinical	studies	with	[18F]fluoro-exendin-4	will	 include	in	vivo	stability,	 in	vivo	
distribution	kinetics,	and	dosimetry	calculations	in	healthy	and	diabetic	animal	models.	References:	[1]	
Andralojc	K,	Srinivas	M,	Brom	M,	et	al.	2012,	Diabetologia,	55,	1247.	[2]	Mikkola	K,	Yim	CB,	Lehtiniemi	P,	
et	al.	2013,	Diabetologia,	56,	S211.	
	 	
Scheme	 1:	 Synthesis	 of	 [18F]fluoro-exendin-4	 via	 strain-promoted	 aza-dibenzocyclooctyne/azide	
cycloaddition.	
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Automated	systems	for	radiopharmacy	
D.	Seifert,	J.	Ráliš,	O.	Lebeda	
Nuclear	Physics	Institute	of	the	CAS,	v.	v.	i.,	Husinec-Řež	130,	250	68	Řež,	Czech	Republic	
	
Introduction:	 Automated	 processing	 modules	 for	 target	 processing	 and	 production	 of	
radiopharmaceuticals	 become	 to	 be	 a	 more	 and	 more	 required	 in	 both	 R&D	 and	 routine	 practice.	
However,	it	turns	out	that	available	systems	for	processing	of	targets	for	radiometal	production	and	for	
labeling	 performed	 via	 microfluidic	 approach	 are	 still	 rather	 limited.	 Our	 aim	 was	 to	 develop	 a	
multipurpose	automated	system	for	processing	solid	state	 targets	and	a	microfluidic	 system	based	on	
PMMA	chip.		Materials	&	Methods:	Stingray	–	Automated	
microfluidic	 system.	 The	 device	 is	 versatile	 automated	
system	 that	allows	 for	 control	of	wide	 range	of	processes	
performed	 on	 a	 microfluidic	 chip.	 The	 system	 makes	
possible	 operations	 like	 precise	 mixing,	 separation,	
extraction	 or	 nanoparticle	 formation	 in	 small-scale.	 The	
system	 consists	 of	 3	 independent	 inlets	 for	 3	 different	
mobile	 phases	 with	 an	 in-built	 degasser,	 4	 peek	 solenoid	
valves,	2	independent	nano	piston	pumps,	2	selectors	(6/7),	
2	manual	inject	valves	with	100	μl	loop	volume	(adjustable),	
2/10	valve,	3	check	valves	and	unique	automated	manifold	
for	inserting	microfluidic	chip.	This	platform	offers	enough	variability	of	reaction	parameters	and	allows	
for	 a	 repeated	 return	 of	 a	 sample	 to	 the	microfluidic	
chip	what	may	enhance	dramatically	the	yield.	CRAB	–	
versatile	 platform	 for	 separation,	 formulation	 and	
simple	labelling	processes		The	main	parts	of	the	system	
are	 two	 reactors,	 two	 selectors,	 peristaltic	 pump,	 3/2	
way	valves,	and	the	column.	Prime	reactor	R1	allows	for	
transport	solid	target	material	from	shielding	container	
to	process	position	and	 for	handling	 liquid	or	 solution	
target	content.	It	is	leak-proof	for	5	bars.	There	is	an	in-
built	solid	phase	extraction	(SPE)	column	for	separation	
processes	driven	by	peristaltic	pump	and	solvents.	Four	
positions	 are	 available	 for	 uploading	 the	 solvents	 into	
the	 reactor	 R1	 or	 on	 the	 SPE	 column.	 Splitting	 the	
separated	radionuclide	from	the	target	matrix,	including	enriched	material,	is	enabled	thanks	to	the	smart	
software	checking	the	activity	coming	out	from	the	column	and	guarding	the	right	position	of	the	splitting	
valves.	Final	activity	concentration	can	be	controlled	via	the	case	software	that	drives	volume	of	eluent	
and	allows	for	setting	the	final	volume	without	losses	on	the	walls	of	reactor	R2.	There	are	3	positions	for	
uploading	the	solvents	to	the	reactor	R2	for	formulation	or	for	simple	labelling	steps	like	chelation.	Results	
and	Conclusion:	Both	automated	platforms	are	versatile,	reliable	tools	that	offer	user-friendly	settings	for	
wide	range	of	processes.	Stingray	is	operable	up	to	200	bar	back	pressure	allowing	thus	the	flow	rate	of	
20	ml/min.	Crab	was	tested	on	separation	of	61Cu	and	64Cu	from	Ni	targets	in	99%	separation	yield	of	
copper	radionuclides	and	almost	quantitative	recovery	of	target	matrix.		
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Simple,	 suitable	 for	 everyday	 routine	 use	 quality	 control	 method	 to	 assess	 radionuclidic	 purity	 of	
cyclotron-produced	99mTc	
Svetlana	V.	Selivanova,	Helena	Senta,	Éric	Lavallée,	Lyne	Caouette,	Éric	Turcotte,	Roger	Lecomte	
Molecular	Imaging	Centre,	CRCHUS,	Université	de	Sherbrooke,	Sherbrooke,	QC,	Canada	
	
Introduction:	 Formulations	 of	 cyclotron-produced	 99mTc	 contain	 trace	 amounts	 of	 other	 Tc	 isotopes	
depending	on	the	isotopic	composition	of	starting	100Mo.	Presence	of	other	nuclides	may	affect	image	
quality	 and	 patient	 dosimetry.	 Therefore,	 quantification	 of	 radioisotopic	 impurities	 is	 very	 important.	
Currently,	radioisotopic	purity	of	cyclotron-produced	99mTc	is	measured	using	gamma-ray	spectrometry	
and	is	time-consuming.	We	sought	to	identify	another	approach	better	suitable	for	quality	control	during	
routine	productions.	Materials	and	methods:	100Mo	targets	(99.815%	enrichment)	were	irradiated	in	a	
cyclotron	at	24	MeV	for	2	h.	The	targets	were	processed	and	radioisotopic	purity	of	resulted	99mTc	was	
evaluated	using	three	different	procedures.	Method	1,	“Dilution”:	An	aliquot	of	diluted	99mTc	solution	
was	 measured	 using	 gamma-ray	 spectrometry.	 Percentage	 of	 each	 radioactive	 contaminant	 was	
calculated	dividing	activity	of	each	isotope	by	total	activity	in	the	sample.	Method	2,	“Shielding”:	A	vial	
containing	formulated	99mTc	was	measured	in	a	calibrated	ionization	chamber.	Then,	it	was	inserted	into	
a	 6	 mm	 thick	 lead	 canister,	 used	 in	 nuclear	 medicine	 for	 99Mo	 breakthrough	 determination,	 and	
measured	using	gamma-ray	spectrometry.	The	activity	of	each	radioactive	contaminant	was	calculated	
and	 divided	 by	 total	 activity	 in	 the	 vial	 as	measured	 in	 ionization	 chamber.	Method	 3,	 “High-energy	
breakthrough”:	A	vial	containing	formulated	99mTc	was	measured	in	a	calibrated	ionization	chamber	as	
is	and	inside	the	lead	canister.	The	ratio	of	two	measurements	gave	relative	proportion	of	high-energy	
gamma-rays.	Results:	There	was	a	tendency	to	slightly	overestimate	the	radioisotopic	purity	of	cyclotron-
produced	 99mTc	 with	 “dilution”	 method	 (99.983±0.007%)	 compared	 to	 “shielding”	 method	
(99.979±0.009%).	Since	both	methods	require	measurements	by	gamma-ray	spectrometry,	they	are	time-
consuming,	involve	elaborate	calculations,	and	demand	specific	expertise.	“High-energy	breakthrough”	
measurements	 showed	 good	 correlation	with	 the	 results	 of	 gamma-spectrometry.	Conclusions:	With	
“shielding”	method,	 lead	canister	attenuated	low-energy	gamma-emission	(including	from	99mTc)	and	
allowed	 detecting	 impurities	 present	 in	 trace	 amounts	 with	 better	 sensitivity.	 While	 “high-energy	
breakthrough”	 measured	 in	 ionization	 chamber	 does	 not	 give	 true	 radioactivity	 values	 for	 each	
contaminant,	it	offers	sufficient	information	about	relative	amount	of	high-energy	radioactive	impurities	
in	the	product.	This	could	serve	as	a	surrogate	test	during	routine	productions	when	cross-calibrated	with	
gamma-spectrometry	data	for	given	isotopic	composition	of	100Mo	targets.	
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Effective	Dose	Estimation	Using	Monte	Carlo	Simulation	for	Patients	Undergoing	Radioiodine	Therapy	
Marina	Zdraveska	Kochovska1,	Emilija	Janjevik	Ivanovska2,	Vesna	Spasic	Jokic3	
1.	 Institute	of	pathophysiology	and	nuclear	medicine,	Medical	faculty,	Skopje,	Macedonia	2.	Faculty	of	
Medical	Sciences,	University	of	“Goce	Delcev”,	Stip,	Macedonia,	3.	Faculty	of	Technical	Sciences,	Universty	
of	Novi	Sad,	Novi	Sad,	Serbia.	
	
Introduction:	Therapeutic	or	diagnostic	radiopharmaceutical	capsule	containing	Na131I	stays	in	stomach	
for	about	15	minutes	before	the	absorption	starts,	long	enough	to	make	possible	risky	exposure.	Material	
and	methods:	Investigations	were	performed	at	Nuclear	medicine	department,	Medical	faculty,	Skopje.	
Eighty	seven	patients	were	reviewed,	age	between	21	and	73.	Patients	were	divided	in	20	groups	receiving	
average	dose	per	 group	1813	MBq	 to	6105	MBq.	 For	 this	 purpose	we	used	Monte	Carlo	4b	 code	 for	
nominal	activity	of	6105	MBq.	The	new	MIRD	phantom	[1-3]	model	was	used	 for	calculation	of	doses	
absorbed	in	specific	organs	due	to	the	presence	of	the	source	in	some	other	organ.	The	stomach	wall	is	
represented	by	the	volume	between	two	concentric	ellipsoids	and	the	contents	within	the	inner	ellipsoid.	
The	 composition	 of	 each	 tissue	 type	 is	 given	 in	 ICRP	 reports	 70	 and	 89	 and	 ICRU	 46	 [4-5].	 Results:	
Calculated	results	are	given	for	imparted	energy	per	transformation	dose	equivalent	and	effective	doses	
for	 different	 organs.	 The	 effective	 doses	 were	 between	 9,17nSv	 for	 bone	 surface	 to	 122.4	 mSv	 for	
stomach.	As	the	total	dose	is	estimated	to	be	126.73	mSv	it	is	obvious	that	the	highest	part	is	received	by	
stomach.	 Discussion	 /Conclusion:	 Capsules	 containing	 Na131I	 are	 widely	 used	 as	 they	 are	 more	
comfortable	for	administration	and	there	is	less	possibility	for	local	contamination	of	patient	and	medical	
staff.	During	the	time	before	absorption	starts	a	large	amount	of	radioactivity	needlessly	expose	a	part	of	
stomach	and	several	surrounding	organs.	Obtained	results	indicate	that	values	of	local	doses	in	stomach	
wall	could	not	be	ignored.	As	it	 is	not	possible	to	measure	these	dose	directly	Monte	Carlo	calculation	
seems	to	be	good	solution	for	this	problem.	References:	1.	Snyder	WS,	Ford	MR,	Warner	GG,	Watson	SB,	
[1975].	MIRD	Pamphlet	No.	11	S”	Absorbed	dose	per	unit	cumulated	activity	for	selected	radionuclide’s	
and	organs”.	Oak	Ridge:	Oak	Ridge	National	Laboratory.	2.		Bolch	W,	Bouchet	L,	Robertson	J,	Wessels	B,	
Siegel	J,	Howell	R,	Erdi	A,	Aydogan	B,	Costes	S,	Watson	E,	[1999].	MIRD	Pamphlet	No.	17,	The	dosimetry	
of	Nonuniform	Activity	Distributions	“Radionuclide	S	Values	at	the	Voxel	Level.	Journal	of	Nucl.	Med.,	40,	
118-368.	3.	Breismeister	JF,	[1997].	A	General	Monte	Carlo	N-	Particle	Transport	Code,	Version	4B.	LA-
12625-M	 report,	 Los	Alamos,	NM:	 Los	Alamos	National	 Laboratory.	 4.	 Zubal	 IG,	Harrell	 CR,	 Smith	 EO,	
Rattner	 Z,	Gindi	G,	Hoffer	 PB,	 [1994].	 Computerized	 3-dimensional	 segmented	 human	 anatomy,	Med	
Phys,	21.299-302.	5.	Eckerman	KF,	Cristy	M,	Rayman	JC,	The	ORNL	Mathematical	Phantom	Series,	Oak	
Ridge	National	Laboratory	Report.[1996].http://homer.hsr.ornl.gov/Vlab/VLabPhan.html.	
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Chemical	 analysis	of	 the	 rituximab	 radioimmunoconjugates	 in	 lyophilized	 formulations	 intended	 for	
oncological	applications	
Darinka	 Gjorgieva	 Ackova1,	 Katarina	 Smilkov1,	 Petre	 Makreski2,	 Trajče	 Stafilov2,	 Emilija	 Janevik-
Ivanovska1	
1Department	of	Pharmacy,	Faculty	of	Medical	Sciences,	University	Goce	Delčev	–	Štip,	R.	Macedonia	
2Department	 of	 Chemistry,	 Faculty	 of	 Natural	 Sciences	 and	 Mathematics,	 University	 “Ss.	 Cyril	 and	
Methodius”-	Skopje,	R.	Macedonia	
	
Introduction:	 Therapeutic	 and	 diagnostic	 antibodies	 have	 become	 the	 fastest	 growing	 class	 of	
biopharmaceutical	drugs	with	more	than	100	antibodies	in	different	phases	of	clinical	trials	today.	For	the	
treatment	 and	 diagnosis	 of	 malignancies,	 various	 radiolabeled	 immunoconjugates	 have	 also	 been	
investigated.	For	efficacy	of	these	drugs,	it	is	important	to	achieve	an	active	conformation	and	stability,	
even	under	unfavorable	conditions	that	may	occur	during	processes	of	conjugation,	purification,	labeling,	
and	also	transport	and	storage.	For	a	protein	based	drug,	a	structural	characterization	is	mandatory	before	
any	possible	start	of	a	clinical	trial.	Vibrational	spectroscopic	techniques,	as	Fourier	transform	infrared	
(FTIR)	 spectroscopy	 and	 Raman	 spectroscopy	 are	 one	 of	 the	 biophysical	 methods	 for	 structural	
characterization	of	proteins	because	of	their	sensitivity	to	the	composition	and	architecture	of	molecules.	
Here	 we	 used	 vibrational	 spectroscopy	 to	 characterize	 the	 physico-chemical	 stability	 and	 structural	
changes	 of	 three	 immunoconjugates	 of	 rituximab,	 intended	 for	 labeling	 with	 radioisotope	 of	 choice	
(177Lu,	 90Y	 and/or	 68Ga),	 relevant	 for	 the	 stability	 of	 therapeutic/diagnostic	 antibodies	 during	
preparation,	 storage	 and/or	 transport.	 Materials	 and	 Methods:	 Rituximab,	 conjugated	 with	 three	
different	 bifunctional	 chelating	 agents	 (BFCAs),	 p-SCN-Bn-DOTA,	 p-SCN-Bn-DTPA	 and	 1B4M-DTPA	 in	 a	
form	of	lyophilized	preparations	non-radioactive	labeled	with	above	mentioned	radioisotope	analogues,	
was	 subjected	 to	 characterization	 and	 determination	 of	 secondary	 structure	 and	 quality	 parameters	
(purity,	 integrity,	 fragmentation	 and	 aggregation	 of	 the	 antibody)	 by	 FT-IR	 and	 Raman	
spectroscopy.Results:	 Based	 on	 the	 frequencies	 assigned	 for	 amide	 I,	 II	 and	 III	 bands,	 the	 studied	
formulations	 contain	 highest	 percentage	 of	 β-sheet	 conformation	 (antiparallel	 and	 parallel)	 in	 the	
structure,	 followed	by	α-helices.	 Significant	 changes	upon	processes	 of	 conjugation	 and	 lyophilization	
were	not	observed	in	comparison	with	spectra	of	native	antibody	(Fig.1).	Vibrational	spectroscopic	data	
allow	 detection	 of	 alterations	 in	 investigated	 protein	 models	 as	 well	 as	 rapid	 assessment	 of	
conformational	 changes	 resulting	 from	 ligand	 binding,	 aggregation	 or	 macromolecular	 interactions.	
Appearance	of	 strong	 absorption	bands	below	1620	 cm–1	 can	be	 correlated	with	 aggregation-usually	
associated	with	the	formation	of	new	strong	β-sheet	structures.	According	to	the	obtained	spectra,	it	is	
important	that	we	observed	retaining	of	native	structure	of	the	antibody	and	no	obvious	aggregation	(the	
lowest	 band	 frequency	 detected	 was	 1620	 cm–1	 with	 weak	 intensity)	 in	 all	 samples	 of	 lyophilizated	
conjugates.	
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Fig.1.	ATR-IR	spectra	of	rituximab	and	p-SCN-Bn-DOTA-rituximab	in	a	form	of	lyophilized	preparations.	
	
Conclusion:	We	investigated	the	application	of	vibrational	spectroscopy	in	assessment	of	conformational	
changes	 during	 stress	 conditions,	 as	 lyophilization	 and	 non-radioactive	 labeling	 are,	 using	 different	
rituximab-conjugates.	The	results	are	a	good	foundation	for	further	radiolabeling	studies	of	the	lyophilized	
formulations	for	possible	therapeutic	application.	
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Serum	 determination	 of	 	 99m	 Technetium	 radiolabeled	 Tirofiban	 using	 high	 performance	 liquid	
chromatography	in	the	animal	rat	model	of	introduced	acute	deep	venous	thrombosis	
Marija	Darkovska	Serafimovska,1	Emilija	Janevik-Ivanovska,	1	Icko	Djorgoski,2	
Zorica	Arsova-Sarafinovska,3,1	Trajan	Balkanov5,	Nenad	Ugresic3	
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Introduction:	 The	 development	 of	 radiolabeled	 small	 peptide	 or	 peptidomimetic	 ligands	 can	 bind	
platelets	and	their	specific	expressed	receptor	have	been	suggested	as	a	new	approach	to	detect	the	clot	
location	and,	more	essentially,	to	determine	the	age	and	morphology	of	the	evolving	thrombus.	This	new	
approach	 is	 focused	 on	 the	 use	 of	 a	 series	 of	 radiolabeled	 platelet	 GPIIb/IIIa	 receptor	 antagonists.	
Tirofiban	N-(butylsulfonyl)-	4-O-(4-(4-piperidyl)-L-tyrosine	is	a	non-peptide	tyrosine	derivate.		The	aim	of	
the	study	was	to	introduce	radioactive-labeled	tirofiban	as	a	specific	imaging	agent	for	acute	DVT	and	to	
determine	 the	 serum	 concentrations	 in	 normotensive	male	Wister	 rats	with	 and	without	 deep	 acute	
venous	 thrombosis	 in	 order	 to	 confirm	 the	 animal	model	 of	 acute	 venous	 thrombosis.	Material	 and	
Methods:	Venous	thrombosis	was	induced	by	ligature	of	the	femoral	vein	in	rats	whose	blood	was	made	
hypercoagulable	by	 intravenous	administration	of	 tissue	 thrombin.	 	 The	determination	of	 Tirofiban	 in	
serum	 was	 performed	 using	 validated	 HPL	 method	 with	 UV	 detection.	 Results:	 The	 labeling	 was	
performed	with	 technetium-99	 in	 the	presence	of	a	 stannous	 reducing	agent	and	 	biodistribution	and	
visualization	of	the	labeled	molecule	was	carried	out	using	the	same	experimental	model	of	DVT.	 	The	
serum	concentrations	of	Tirofiban	measured	after	5,	15,	30,	45	and	60	min	in	the	group	of	rats	with	DVT	
were	lower	as	compared	to	the	serum	concentrations	of	Tirofiban	in	the	control	group	of	rats.	During	the	
determination	 of	 the	 serum	 concentration	 planar	 imaging	 was	 performed	 at	 30	 and	 60	 min	 after	
application.	Sensitivity	and	specificity	were	determined	using	the	ratio	of	‘left	leg	positive	for	DVT’	to	‘right	
leg	negative	for	DVT’.	The	obtained	ratio	was	1.54	after	30	min	and	5.04	after	60	min.		These	values	were	
considered	 positive	 in	 the	 detection	 of	 acute	 DVT	 and	 corresponding	 to	 values	 of	 serum	 application	
obtained	from	the	normal	rat	and	experimental	model.	Conclusion:	The	high	DVT	uptake	and	lower	serum	
concentrations	of	Tirofiban	measured	in	the	group	of	rats	with	DVT	shows	that	radiolabeled	tirofiban	in	
the	introduced	rat	model	can	be	a	promising	agent	for	imaging	the	deep	venous	thrombosis.	
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The	need	and	benefits	of	established	radiopharmacy	in	developing	African	countries	
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1	Faculty	of	Medicine,	Addis	Ababa;	Ethiopia	
2	Ministry	of	Health,	Kenya	
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Introduction:	The	aim	of	our	work	is	to	present	the	current	status,	and	in	the	same	time	the	need	and	
benefit	of	establishment	of	Radiopharmacy	practice	in	Eastern	Africa	using	the	perspective	of	Kenya	and	
Ethiopia.	The	exact	information	on	the	status	and	size	of	Radiopharmacy	units,	regionally,	is	still	not	clearly	
documented,	 as	 well	 human	 resources,	 education,	 suitable	 training	 and	 local	 demand	 for	 the	
Radiopharmacy	and	Nuclear	Medicine	services.		The	Radiopharmacy	Practice	requires	well-defined	and	
controlled	conditions	to	avoid	the	risk	contamination	with	microbes,	pyrogens	and	particulate	matter	as	
well	 as	 cross	 contamination	 with	 other	 radiopharmaceuticals.	 Corresponding	 to	 the	 expected	
improvement,	the	principles	of	Good	Practices	in	all	levels	should	be	planned,	introduced	by	the	planned	
priority	and	strictly	observed	in	the	production,	preparation,	testing	and	the	packaging	of	the	final	product	
ready	for	use.		Because	non-communicable	diseases	(NCDs)	are	a	challenge	of	epidemic	proportion	and	
that	they	will	be	the	commonest	cause	of	mortality	in	Africa	by	2030,	early	detection	and	treatment	can	
significantly	improve	patient	outcomes.	Radiopharmaceuticals	should	have	become	of	invaluable	benefit	
because	they	offer	the	most	sensitive	tools	in	the	detection,	diagnosis	and	targeted	therapy	of	NCDs	and	
also	 infectious	diseases.	 	 In	 light	of	the	foregoing,	therefore,	radiopharmacy	has	a	huge	role	to	play	 in	
responding	 to	 the	 unfolding	 new	 disease	 trends	 in	 sub-Saharan	 Africa.	 The	 preparation	 of	
radiopharmaceuticals	 for	 human	 use	 requires	 that	 it	 is	 carried	 out	 in	 well-defined	 and	 controlled	
conditions	to	avoid	the	risk	contamination	with	microbes,	pyrogens	and	particulate	matter	as	well	as	cross	
contamination	with	other	radiopharmaceuticals.	Accordingly,	principles	of	Good	Manufacturing	Practices	
and	Good	Laboratory	Practices	should	strictly	be	observed	in	the	production,	preparation,	testing	and	the	
packaging	of	the	final	product	ready	for	use.	Most	radiopharmaceuticals	are	parenterally	administered	
and	 must	 therefore	 be	 prepared	 in	 such	 condition,	 and	 using	 such	 techniques	 and	 procedure,	 that	
guarantee	sterility	of	the	product.	Every	procedure	undertaken	should	be	done	according	to	the	clearly	
defined	protocol	and	under	the	right	conditions	so	as	to	build	quality	into	the	product.		Radiopharmacy	
professionals		should	have	adequate	training	in	all	aspects	of	sterile	production,	quality	control,	GMP	,	
GLP,	 radiation	 safety	 and	 radiochemistry	 to	 ensure	 that	 they	 are	 competent	 to	 handle	 radioactive	
materials	and	that	they	can	take	responsibility	for	their	level	of	practice.	Conclusions:	We	are	expecting	
that	the	good	education	and	continuing	training	of	all	professionals	working	in	Radiopharmacy	will	be	the	
key	point	how	to	create	the	network	of	all	professionals	and	state	authorities	for	establishing	and	develop	
Good	Radiopharmacy	Practice,	qualified	personnel	and	appropriate	regulation	according	to	the	local	and	
international	parameters	will	be	step	forward	to	have	advanced	health	care	system	and	confidence	of	the	
patients.	
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University	Master	Program	of	Radiopharmacy	–	step	forward	for	Good	Radiopharmacy	Education	
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Purpose:	The	importance	of	well-established	and	recognized	education	in	Radiopharmacy	became	a	need	
all	around	the	world	as	result	of	different	national	regulation,	different	system	of	education	and	mostly	
of	the	level	of	need,	development	and	investment	in	clinical	and	research	usage	of	radiopharmaceuticals.	
The	 substantial	 confusion	 and	 challenge	 in	 the	 same	 time	 is	 to	 define	 the	 appropriate	 and	 sufficient	
knowledge,	understanding	and	competences	corresponding	to	position	of	professionals	 in	the	working	
place,	 including	 the	 type	 and	 level	 of	 formal	 education.	Methods:	 The	 goal	 of	 the	 Academic	Master	
program	for	Radiopharmacy	in	English,	with	the	recognized	accreditation	from	the	National	Body	in	2014	
and	 recommended	by	 the	Ministry	of	Education	and	Science	 in	our	 country	according	 to	 the	Bologna	
system	 with	 120	 ECTS	 credits	 is	 to	 give	 the	 opportunity	 for	 all	 students	 with	 finished	 academic	
undergraduate	 program	 (at	 least	 240	 ECTS)	 to	 follow	 it	 and	 to	 receive	 academic	 title	 Master	 of	
Radiopharmacy.	The	Radiopharmacy	Education	Program	is	organized	according	to	the	University	model	
including	Obligatory	and	Optional	Theoretical	Courses,	Obligatory	Practices	and	Master	Thesis	on	the	end	
of	the	second	year	using	the	University	laboratory	of	Radiopharmacy,	that	is	under	ISO	accreditation,	new	
PET	 facilities	 and	 all	 other	 corresponding	 facilities	 available	 in	 the	 university	 and	 in	 the	 country.	 The	
program	use	e-learning	platform	from	the	University	and	IAEA	contribution	and	collaboration	related	to	
the	education	and	training	of	the	students	from	developing	countries.	The	result	of	that	collaboration	is	
already	inscribed	students	from	Kenya	and	Ethyopia.	Results:	The	syllabus	include	knowledge	and	skills	in	
three	 categories:	1.	 Specific	 knowledge	and	 skills:Design	of	Radiopharmacy	 facilities	and	QA	program,	
Production	 and	 synthesis	 of	 radionuclides	 and	 radiopharmaceuticals,	 Quality	 control	 of	
radiopharmaceuticals	 2.	 Basic	 knowledge	 and	 skills:	 Leadership	 and	 collaboration,	 Communication,	
Negotiations,	 Analytical	 and	 critical	 thinking	 skills	 including	 creativity	 and	 ethical	 considerations,	
Pharmaceutical	and	chemistry	knowledge	 	3.	Fundamentals	of	Radiopharmacy:	General	models	of	 the	
area	,	Key	specializations	within	the	field,	Evaluation	of	performance	within	the	area	Conclusions:	The	
program	creates	academic	staff	able	to	work	in	all	spheres	of	the	modern	Radiopharmacy,	conventional	
hospital	Radiopharmacy	and	with	 the	option	of	continuing	 their	education	 in	some	PhD	program.	The	
program	can	be	also	a	basic	platform	for	the	more	advanced	courses	available	for	the	professionals	from	
the	European	and	world	recognized	associations.		
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Synthesis	and	preclinical	validations	of	a	novel	18F-labelled	RGD	peptide	prepared	by	ligation	of	a	2-
cyanobenzothiazole	with	1,2-aminothiol	to	image	angiogenesis.	
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Introduction:	 The	 RGD-recognising	 αVβ3,	 αVβ5	 and	 α5β1	 integrins	 are	 known	 to	 be	 involved	 in	
carcinogenesis	and	are	overexpressed	in	many	types	of	tumours	compared	to	healthy	tissues;	thereby	
they	 have	 been	 selected	 as	 promising	 therapeutic	 targets.	 Positron	 emission	 tomography	 (PET)	 is	
providing	a	unique	non-invasive	screening	assay	to	discriminate	which	patient	is	more	prone	to	benefit	
from	 antiangiogenic	 therapies,	 and	 extensive	 research	 has	 been	 carried	 out	 to	 develop	 a	 clinical	
radiopharmaceutical	 that	 bind	 specifically	 to	 integrin	 receptors.	 However,	 despite	 promising	 clinical	
results,	one	still	needs	to	identify	an	integrin	radioligand	that	could	be	easily	deployed.	We	herein	report	
the	synthesis	of	a	18F-labelled	RGD	peptide,	namely	[18F]FPyPEGCBT-c(RGDfK),	by	condensation	of	a	2-
cyanobenzothiazole	prosthetic	group	to	a	cysteine-modified	cyclic	RGD	peptide	and	the	characterisation	
of	 its	 preclinical	 biologic	 properties.	 Materials	 &	 Methods:	 A	 novel	 bifunctional	 synthon	
([18F]FPyPEGCBT)	has	been	developed	to	accommodate:	i)	an	efficient	[18F]F-	incorporation	and	ii)	a	mild	
conjugation	to	biomolecules.	Then,	[18F]FPyPEGCBT	has	been	conjugated	to	a	cyclic	RGD	peptide	known	
for	 its	 high	 binding	 affinity	 and	 selectivity	 for	 integrin	 αVβ3.	 The	 in	 vitro	 binding	 characteristics	 of	
FPyPEGCBT-c(RGDfK)	were	analysed	by	standard	binding	assay	 in	U-87	MG	and	SKOV-3	cancer	models	
and	 its	 selectivity	 towards	 integrins	 by	 siRNA	 depletions.	 Its	 preclinical	 potential	was	 studied	 in	mice	
bearing	 subcutaneous	 tumours	 by	 ex	 vivo	 biodistribution	 studies	 and	 in	 vivo	 microPET/CT	 imaging.	
Results:	[18F]FPyPEGCBT	was	prepared	from	its	corresponding	2-trimethylammonium	triflate	precursor	
and	purified	by	solid-phase	extraction.	Ligation	of	[18F]FPyPEGCBT	to	the	cysteine-modified	cyclo-(RGDfK)	
peptide	was	 carried	out	 in	DMF	at	 43	oC.	 The	18F-peptide	was	obtained,	 after	HPLC	purification	 and	
reformulation,	in	124–132	min	from	the	end	of	bombardment	with	a	final	decay-corrected	yield	of	7%	±	
1.	In	vitro,	FPyPEGCBT-c(RGDfK)	bound	efficiently	to	RGD-recognising	integrins	as	compared	to	a	control	
c(RGDfV)	peptide	(IC50	=	30.8	×	10-7	M	vs.	6.0	×	10-7	M).	In	vivo,	this	new	tracer	demonstrated	specific	
tumour	uptake	with	%ID/g	of	2.9	and	2.4	in	U-87	MG	and	SKOV-3	tumours	1	h	after	injection.	Tumour-to-
muscle	ratios	of	4	after	1	h	of	uptake	allowed	good	visualisation	of	the	tumours.	However,	unfavourable	
background	 accumulation	 and	 high	 hepatobiliary	 excretion	 were	 noticed.	 Discussion/Conclusion:	
[18F]FPyPEGCBT-c(RGDfK)	specifically	detects	tumours	expressing	RGD-recognising	integrin	receptors	in	
preclinical	studies.	Further	optimisation	of	this	radioligand	may	yield	candidates	with	improved	imaging	
properties	and	would	warrant	the	further	use	of	this	efficient	labelling	technique	for	alternative	targeting	
vectors.	References	 :	1.Jeon	 J,	 Shen	 B,	 Xiong	 L,	Miao	 Z,	 Lee	 KH,	 Rao	 J,	 Chin	 FT,	 [2012],	 Bioconjugate	
Chemistry	23:	1902–1908.	2.	Su	X,	Cheng	K,	Jeon	J,	Shen	B,	Venturin	GT,	Hu	X,	Rao	J,	Chin	FT,	Wu	H,	Cheng	
Z,	[2014],	Molecular	Pharmaceutics	11:	3947-3956.3.	Inkster	JAH,	Colin	DJ,	Seimbille	Y,	[2015],	Organic	
&	Biomolecular	Chemistry,	13:	3667-3676.	
	
